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Abstract of a thesis submitted in partial fulfilment of the 
requirements for the Degree of Doctor of Philosophy. 
Abstract 
The Health Effects of Intermittent Hypoxic Exposure in a sedentary population 
 
by 
Catherine Anne Lizamore 
 
The use of simulated altitude is frequently used in an attempt to enhance athletic performance. 
Similar techniques have also recently been used in a clinical population to improve cardiovascular 
risk. However, the effects of different frequencies of simulated altitude per week, follow up 
assessments and the effects of passive simulated altitude in addition to exercise (rather than 
exercising in hypoxia) has not been tested in a sedentary, middle-aged population.  
To simulate altitude, an intermittent hypoxic exposure (IHE) protocol was used whereby 5-min of 
hypoxia was alternated with  5-min of normoxia for 1 hour. Heart rate variability (HRV), i.e. the beat-
to-beat fluctuations between R-peaks, cardiovascular fitness (V˙ O2peak), systolic blood presssure (SBP), 
highly-sensitive C-Reactive protein (hs-CRP, indicative of systemic inflammation associated with 
athlersclerosis), high density lipoprotein, total cholesterol, and arterial stiffness were used to assess 
cardiovascular health during 3 IHE studies.   
In the first study, 4 IHE sessions/week for 4 weeks resulted in increased HRV compared to a placebo 
treatment (71.6 ± 52.5%, mean between-group change from the natural logarithm  90% confidence 
interval), indicating increased parasympathetic activity. The second study assessed the effects of IHE 
frequency on selected risk factors. Following the 5-week intervention, HRV (during paced breathing) 
increased in participants given both 2-3 (IHE3) and 5 (IHE5) IHE sessions per week (IHE5: 47.3  
41.6%; IHE3: 6.2  6.9%), thereby confirming the changes in HRV reported in Study 1. In addition, 
haemoglobin concentration (2.7 ± 2.8%), time taken to complete the maximal fitness assessment 
(34.5 ± 36.8%), and maximal workload (14.4 ± 14.9%) were increased in IHE5 compared to the 
control group, while changes in hs-CRP (12.7 ± 48.7%) were trivial. None of these changes were seen 
in IHE3. There was an increased V˙ O2peak (12.6 ± 9.3%) in IHE3 compared to the Control, but not IHE5.  
Due to the benefical effects on V˙ O2peak and HRV, 2-3 IHE sessions/week were used together with 3 
exercise sessions/week (IHE3+Ex), and compared to exercise only (Ex) in the third study. Immediately 
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post intervention, 4- and 8-wk follow up measurements  were taken. Both groups showed a tendency 
to decrease total cholesterol, improve arterial compliance (pulse wave velocity) and increase V˙ O2peak 
and HRV, but these changes were unclear. High density lipoprotein (Post: 8.0  8.0%; 8-wk: 10.0  
8.5%), SBP (Post: -3.4  3.4%; -3.5  3.7%) improved in IHE3+Ex more than Ex, and while V˙ O2peak was 
qualitatively unclear at Post it was increased at the 4-wk (9.4  8.0%) and 8-wk (7.9  8.3) follow-up 
sessions. While differences in systemic arterial stiffness (augmentation index) was unclear between 
groups at Post, the augmentation index increased at 4- and 8-wk (4-wk: 11.8  18.4%; 8-wk: 24.8  
19.7%) in the IHE3+Ex group compared to Ex.  
Overall, IHE appears to increase the parasympathetic contribution to the sympathovagal balance of 
the heart at rest in sedentary middle-aged participants, and may improve SBP and some fitness 
parameters, particularly with 4–5 IHE sessions/week. While the short-term effects of IHE on arterial 
health are promising, more research on the long-term effects of IHE treatments is needed before IHE 
can conclusively be considered ‘safe’.  
Keywords: Intermittent hypoxic exposure,  heart rate variability, exercise, sedentary, health, 
cardiovascular risk, systolic blood pressure, total cholesterol, high density lipoprotein, highly 
sensitive C-Reactive protein, arterial stiffness 
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 Chapter 1
Introduction 
“If exercise could be purchased in a pill, it would be the single most widely prescribed and 
beneficial medicine in the nation.”  
Robert H. Butler 
 
Atherosclerotic cardiovascular disease is the leading cause of death worldwide (Gersh et al., 2010, Perk et 
al., 2012), and is responsible for approximately 40% of all deaths in Europe and America (Heidenreich et al., 
2011, Perk et al., 2012). New Zealand citizens are no exception to these trends, with cardiovascular disease 
and cancer listed as the joint leading causes of death nationwide (Ministry of Health, 2013). Aside from 
premature death, the steady decline in health attributed to cardiovascular disease results in an increase in 
disability restricted years (Perk et al., 2012), and a substantial economic burden related to health care (Leal 
et al., 2006). However, as cardiovascular disease is progressive in nature (Dzau et al., 2006), the pathway to 
full cardiovascular disease can be disrupted by early detection and treatment of identified risk factors (Perk 
et al., 2012). For example, there are a number of health conditions such as hypertension, diabetes, elevated 
cholesterol and obesity, or lifestyle influences such as physical inactivity, or cigarette smoking that have 
been identified as pre-cursors to cardiovascular disease (Dzau et al., 2006, Chobanian et al., 2003).  
In terms of health improvement and maintenance, exercise is widely regarded as one of the best and most 
cost effective means of interrupting the pathway to full cardiovascular disease. Indeed, given the low cost 
and cardioprotective benefits conferred by regular physical activity, in 1998 New Zealand established 
“Green Prescription” whereby a doctor can ‘prescribe’ physical activity to their patient (Ministry of Health, 
2012). If the patient chooses to enrol in the Green Prescription programme, they are offered nutritional 
advice, discuss physical activity goals and receive follow up support (Ministry of Health, 2012). In a similar 
spirit to the Green Prescription programme, a new initiative, “Exercise is Medicine” has been established in 
association with the American College of Sports Medicine and the American Medical Association (Sallis, 
2009). The purpose of this initiative is to encourage medical practitioners to view physical activity as a 
prescription that can be given to patients requiring the medical benefit of exercise.  
While exercise is the best option for most people, there are many people who cannot exercise or who can 
only exercise in limited amounts. Such people include those who are confined to bed-rest and those with 
spinal injuries, patients with chronic diseases such as arthritis, multiple sclerosis and patients undergoing 
muscular rehabilitative therapy following a sports injury or surgery. For this population, an intervention 
14 
 
that may afford some of the cardiovascular benefit of exercise, but without physical activity, would be very 
valuable indeed. 
Interestingly, research in the Former Soviet Union has long recommended the use of simulated altitude 
training (as is used in many athletic protocols) to improve the outcome of a number of different diseases 
such as hypertension, diabetes mellitus and respiratory disease (Serebrovskaya, 2002). However, much of 
this research is written in Russian and warrants further investigation. In ‘Western’ countries, the majority of 
the research regarding altitude training has been focussed on elite athletes and is directed at improving 
performance (Millet et al., 2010). Still, there are some simulated altitude exposure interventions that have 
been conducted in a clinical population with the aim of improving exercise tolerance and thereby improving 
cardiovascular health (Burtscher et al., 2009, Burtsher et al., 2004). While the available literature regarding 
the use of simulated altitude in a sedentary or clinical population has demonstrated beneficial responses, 
both with and without concurrent exercise, there are still a number of questions that warrant further 
investigation.  
The purpose of this thesis is to determine the effects of intermittent hypoxic exposure on cardiovascular 
risk factors in a sedentary population. 
1.1 Thesis statement and aims  
The purpose of this thesis is to determine the effects of intermittent hypoxic exposure on cardiovascular 
risk factors in a sedentary population. In order to achieve this, the following aims have been outlined: 
1) Identify gaps in the literature regarding the use of simulated altitude for health improvement. 
2) Informed by findings in the literature review, determine the effects of simulated altitude (without 
the use of exercise) on selected risk factors in a sedentary population 
3) Informed by findings in the literature review, determine the effects of simulated altitude (with the 
use of exercise) on selected risk factors in a sedentary population 
As this research is based at a university rather than at a medical school, we have elected to use sedentary 
participants as the target research population, rather than clinical or acutely unwell participants.  
To guide the progression of the research, a decision tree was used (see Figure 1). 
15 
 
 
Figure 1: Decision making process for research progression 
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1.2 Thesis format 
The best means of testing these hypotheses was to run successive studies, each developing the learnings 
from the previous one. Therefore, the nature of this research lends itself to a ‘thesis by papers’ approach, 
whereby each chapter of the thesis is written in the format of an academic journal article. It follows then, 
that each paper is self-contained, including an introduction and background section to the research 
covered in that chapter, as well as a discussion of the results. Additionally, a brief description of the 
‘learnings’ from the previous study and how they relate to the following study has been included between 
chapters to improve readability and the flow between chapters. All references are listed in the reference 
list at the end of the thesis. 
Early on in the research planning, we realised that heart rate variability (HRV), which is both a predictor of 
cardiovascular health, and reflects instantaneous alterations in the autonomic control of the heart (Task 
Force of The European Society of Cardiology and The North American Society of Pacing and 
Electrophysiology, 1996) would be a useful tool in all three studies. Accordingly, the assessment of HRV in 
each of the 3 studies has become a sub-theme that has been threaded through each of the studies. 
However, while the assessment of HRV is inexpensive, non-invasive, and time-efficient, there are various 
methodological caveats (such as data capture techniques, how the data are filtered, and the presentation 
of the final HRV results) that need to be addressed. An introduction to HRV and it’s measurement, and a 
draft paper on the repeatability of HRV are included in the Appendix A and B respectively. 
1.3 An overview of the following thesis chapters 
1.3.1 Chapter 2: Literature Review on the effects of simulated altitude 
To fully understand the research to date a comprehensive literature review was undertaken. While the 
primary focus of this thesis is on a clinical or sedentary population, the review did include literature on 
athletic and well trained populations. The decision to include literature focussed on athletic populations 
was due to the large amount of research that has already been conducted in this population. The findings 
from these studies could provide insight into any physiological changes observed in an unwell or sedentary 
population or help to generate ideas for protocol development. The review includes a quantitative 
assessment of the currently available literature including a profile of the research (sex and ages of 
participants, types of training programmes used and physical abilities of participants), and an in-depth 
discussion relating to studies that have investigated the use of simulated altitude exposure in either a 
clinical or sedentary population. Tables summarising the literature relating to healthy/active, and well 
trained/athletic populations are also included, but are not extensively discussed. Directions for future 
research are recommended. The literature review did not include extended hypoxic exposure such as long 
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sojourns at altitude (including native mountain dwellers, or mountaineering expeditions) and disease-
related hypoxic exposure (such as in obstructive sleep apnoea, or ischemic heart disease). Several key areas 
for future research include: 
I. The effects of simulated altitude, particularly an intermittent hypoxic exposure (IHE) protocol which 
alternates several minutes of severe hypoxia with several minutes of normoxic recovery cycled for 
an hour, on cardiac autonomic modulation, vascular health, blood lipid profile, and cardiovascular 
risk profile in addition to conventional cardiovascular fitness assessments is needed. 
II.  The need to report the participant’s subjective response to the simulated altitude treatments.  
III. A greater emphasis is needed on research in a clinical or sedentary population. These population 
groups appear to demonstrate promising improvements to simulated altitude.  
IV. Research regarding the effects of different frequencies of simulated altitude sessions per week on 
health (assessed via modulation of cardiovascular risk factors) is missing. 
V. One study has reported beneficial responses of the effect of IHE in conjunction with exercise on 
cardiovascular risk factors in a sedentary, overweight population of 18 – 20 year old men. More 
research should be conducted on the effects of passive simulated altitude in conjunction with 
exercise (versus exercise alone or exercise in hypoxia) in a sedentary, middle-aged group who are 
likely to demonstrate greater cardiovascular risk factors. 
To address these gaps in the literature, three different studies were undertaken. 
1.3.2 Chapter 3: Study 1: The effect of intermittent hypoxic exposure on heart rate 
variability in a sedentary population 
While meeting the aim and purpose outlined in Figure 1, this research also sought to determine both the 
response in the autonomic control of the heart rate during an IHE session and the adaptive response to 4 
weeks of 4 IHE sessions per week. As HRV is both an indicator for cardiovascular risk, and provides an 
instantaneous reflection of parasympathetic and sympathetic activity on the heart rhythm, this was used as 
the central measure in this study. The results of this study indicated an improvement in parasympathetic 
activity during rest in response to the 4-week intervention. We also indicate substantive parasympathetic 
withdrawal and reactivation between hypoxic and rest intervals respectively which was not present in the 
control group. 
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1.3.3  Chapter 4: Study 2: The minimum dosage of intermittent hypoxic exposure per 
week for health improvement in sedentary, middle-aged individuals 
The aim of this study was to build on from Study 1’s findings and determine whether there is a dose 
response to the frequency of IHE treatments per week, and if so, what the minimum number of IHE 
sessions per week is to elicit a health benefit. To achieve this, participants were divided into groups 
receiving 2 – 3 IHE sessions per week and 5 IHE sessions per week (with one group as a control group) for 5 
weeks. By using these frequencies, we have effectively gathered data from the effects of 2, 3, 4 and 5 IHE 
sessions per week in a sedentary population.  
Along with HRV, other independent risk factors for CVD, including highly sensitive C-Reactive protein, 
cardiorespiratory fitness, and systolic blood pressure (SBP) were included in this study to give a more 
comprehensive overview of the effect of IHE on CVD risk factors in a sedentary population.  
The results of Study 2 indicated that while cardiovascular benefit associated with 5 IHE sessions per week 
demonstrated enhanced HRV and exercise tolerance, there was some improvement in HRV and possible 
improvement in V˙ O2peak in the group receiving IHE 2 - 3 times per week. 
1.3.4 Chapter 5: Study 3: Does intermittent hypoxic exposure enhance the effect of an 
exercise intervention on overall cardiovascular risk profile? 
The aim of the final study was to assess whether IHE has an additive health benefit when used in 
conjunction with an exercise training programme. To test this, one group received 2 – 3 IHE sessions per 
week in conjunction with 3 supervised exercise sessions while another attended only exercise training.  
This study included independent risk factors and a full cardiovascular risk profile. Independent risk factors 
included arterial stiffness, HRV and cardiovascular fitness, while the overall cardiovascular risk was assessed 
using the New Zealand Cardiovascular Risk Chart. This risk profile uses a compilation of risk factors 
including systolic blood pressure, total cholesterol: high density lipoprotein level, age, smoking and 
diabetes status to determine an overall 5-year risk of fatal or non-fatal cardiovascular disease (New Zealand 
Guidelines Group, 2009). See Figure 31 in Appendix E for a copy of the NZ Guidelines risk assessment chart. 
While the group receiving the IHE and exercise treatment demonstrated slightly superior results in 
independent risk markers, the cardiovascular risk profile was unchanged in both groups. When weighed 
against the time commitment of the three IHE sessions per week for only a marginal improvement in 
health, it is likely that an individual’s time would be better spent exercising one or two addition days. 
Additionally, more research is needed on the long-term (greater than 2 months) effects of IHE on vascular 
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health. However, for those who are restricted to a limited amount of exercise, IHE may be worthwhile. In 
this case 4 or 5 IHE sessions per week should be considered.  
1.3.5 Chapter 6: Overall discussion and conclusion 
The findings from each of the three studies are analysed collectively, final recommendations for the use of 
IHE in a sedentary, middle-aged population, and projections for future research are discussed. 
1.3.6 Appendices  
Supplementary material has been included in the appendices. Appendices A and B include an overview of 
HRV and how it was interpreted in this thesis. Appendices C and D report the raw data for studies 2 and 3 
(raw data for Study 1 are included in Chapter 3). Appendix E contains the chart used to assess overall 5-year 
cardiovascular risk used in Study 3. Finally, Appendix F explains how the qualitative outcomes are assessed 
using the spreadsheets designed by Will Hopkins. Appendix G contains a paper that was based on the 
baseline results of Study 3. 
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 Chapter 2
Literature Review: The use of simulated altitude techniques for 
beneficial physiological adaptation. 
2.1 Introduction 
Altitude training has long been used in athletic populations in an attempt to improve competitive 
performance. However, while there is potential for improved performance following altitude training, it is 
also expensive, time consuming and disruptive to family and work life. For example, it is recommended that 
athletes reside at 2000 – 2500 m for greater than 3 -  4 weeks, for more than 12 - 22 hours/day (Wilber et 
al., 2007, Rusko et al., 2004, Duke et al., 2012). Clark et al. (2009) specify that for improvements in 
haemoglobin mass (Hbmass) at least 100 hours of hypoxic exposure at between 2200 – 3000 m for at least 12 
hours/day are required for every 1% increase in Hbmass. In addition to the long duration required, the 
currently recommended best practice for altitude training is to use a “live high train low” model (Millet et 
al., 2010) which involves living at altitude while driving to and from lower altitude for exercise training. The 
time, inconvenience and expense associated with real altitude training has resulted in the development of 
several simulated altitude protocols which aim to provide a convenient method of achieving the benefits of 
altitude training but without the disruption and financial costs associated with real altitude training.  
To simulate altitude, researchers (and coaches/athletes) either employ the use of hypobaric chambers or 
create a normobaric hypoxic environment. The latter is achieved by either diluting the ambient air with 
nitrogen (Wilber, 2001), using re-breathers which recycle expired air (Sausen et al., 2003), or ‘hypoxicators’ 
which extract oxygen from the air through the use of a polymeric membrane air separation process 
(Serebrovskaya et al., 2003). The relevance of differences between the hypo- and normobaric techniques 
have been the heart of a recent debate (Millet et al., 2012b), with most agreeing that hypobaric hypoxia 
provides a different and far more complex network of stresses (Millet et al., 2012a); for example, greater 
susceptibility of acute mountain sickness (Roach et al., 1996). However, this is also debated by Schommer 
and Bartsch who point out only a negligible difference in acute mountain sickness (50% in real altitude 
versus 58% in normobaric hypoxia)  following 18 h of exposure (Bailey et al., 2005, Schommer et al., 2011). 
Taylor, Snyder and Johnson as well as Guenette and Koehle have also suggested that there is a greater risk 
of pulmonary oedema with hypobaric hypoxia via increased pulmonary fluid flux in lower barometric 
pressure (Levine et al., 1988, Snyder et al., 2006). Other differences reported were the lower air resistance 
in hypobaric hypoxia (Girard), quality of sleep (Nespoulet, Wuyam, Tamisier, Verges, and Levy), and greater 
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respiratory muscle energy cost in normobaric hypoxia (For all points and counterpoints, see Girard et al., 
2012). 
However, it is the reduction of oxygen that is the trigger for adaptations associated with the oxygen-sensing 
transcription factor, the α-subunit of Hypoxic Inducible Factor – 1 (HIF-1α). Indeed, the oxygen sensing 
pathway is the central argument in Mounier and Brugniaux’s counter-point to the non-importance of 
hypobaric pressure in altitude adaptation (Mounier and Brugniaux, 2012a, Mounier and Brugniaux, 2012b).  
On arrival in an oxygen reduced environment (in real or simulated altitude) there is a spontaneous increase 
in ventilation known as the hypoxic ventilatory response. This increase in ventilation includes an increase in 
tidal volume and respiratory frequency (Powell et al., 1998) and is essential in maintaining adequate tissue 
oxygenation. The hypoxic ventilatory response is activated primarily via the carotid body peripheral 
chemoreceptors (Prabhakar and Peng, 2004) and can be up-regulated within one breath of oxygen reduced 
air (Powell et al., 1998). Other researchers have also observed increases in heart rate, cardiac output and 
left ventricular ejection fraction (Huez et al., 2009) with hypoxia. The concurrent activation of HIF-1α up-
regulates genes responsible for angiogenesis, erythropoiesis (Semenza, 2009) iron homeostasis (observed 
as an increase in haemoglobin (Clark et al., 2009, Saunders et al., 2009)) and altered glucose metabolism 
(Semenza, 2001) which are important for long-term adaptation and maintenance of tissue and organ 
oxygenation in a low oxygen environment.  In addition to these adaptations, physiological changes such as 
increased chemoreflex sensitivity to hypoxia (Bernardi et al., 2001), increased pulmonary arterial pressure 
(Zhao et al., 2001) and increased subsarcolemmal mitochondrial expression (Schmutz et al., 2010) which is 
a subgroup of mitochondria which appears to be most responsive to endurance training (Koves et al., 2005) 
are observed.  
It is the influence of these adaptations that are thought responsible for increased maximal oxygen 
consumption (Robertson et al., 2010c) and improved exercise economy following altitude training. The 
haematological adaptations (red blood cells and haemoglobin in particular) have typically thought to be the 
primary adaptation responsible for improved athletic performance (Levine and Stray-Gundersen, 2005). 
However, a study by Garvican et al. (2011) suggests that other non-haematological adaptation to hypoxia 
may be responsible for improvements in performance. To isolate the role of Hb in exercise performance, 
Garvican et al. (2011) allowed one group of sub elite cyclists to adapt normally to a simulated live high train 
low protocol, and withdrew a proportion of blood in a matched control group to negate any gains in Hb. 
These researchers found that despite no net increase in Hbmass following blood removal, the control group 
still improved V˙ O2peak similar to that of the test group which suggest that the ‘upstream changes’ and 
triggers leading to the increase in Hb mass may also be important in the adaptation to exercise. Some 
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examples of non-haematological adaptation include improved muscle buffering capacity, lactic acid 
tolerance, and greater mitochondrial efficiency (Gore et al., 2007).   
While the physiological adaptation to real or simulated altitude training are promising, in reality, the 
training response can be quite varied, with some athletes demonstrating considerable improvements 
(Saunders et al., 2009, Beidleman et al., 2003), and others showing either no change (Taylor et al., 2011, 
Aulin et al., 1998, Siebenmann et al., 2012) and in ‘non-responders’ a drop in performance (Chapman et al., 
1998) following altitude training.  Additionally, even if the individuals indicate HIF-1α -related physiological 
adaptation, such as increased erythropoeitin and haemoglobin mass, or demonstrate enhanced laboratory 
assessments of fitness such as improved running economy or V˙ O2peak, these do not always transfer into 
improved competitive or time trial performance (Robertson et al., 2010c). However, the chance of 
beneficial athletic performance has generally out-weighed the risk of either no improvement or a small 
decline. As such a number of real and simulated altitude training protocols have been suggested.  
All altitude and simulated altitude training protocols assume the return of the individual to sea level. As 
such, the hypoxic exposure is ‘intermittent’. However, the ‘intermittent’ nature of the hypoxic dosage is 
highly varied and can be broken into several training models such as Live High Train High (LHTH), Live High 
Train Low (LHTL), intermittent hypoxic training (IHT) and intermittent hypoxic exposure (IHE). Refer to Table 
1 for a description of these techniques. Typically, prolonged hypoxic exposure such as the LHTH and LHTL 
models, or hypoxic exposure during exercise, such as in LHTH and IHT protocols, use lower hypoxic dosages 
(equivalent to 2,000 – 3,000 m), while shorter hypoxic exposures, as is used in passive IHE models, use a 
higher hypoxic dosage (equivalent to 4,000 m). At times, a combination of these techniques is used. For 
example, IHT may be used in conjunction with IHE whereby a participants initially performs 30 – 60 min 
exercise in hypoxia followed by another 3 h of passive hypoxic exposure. Alternatively, additional IHT may 
be performed in conjunction with the LHTL model (also referred to as “live high train low and high”).  
Interestingly, it is not only athletes and coaches who are interested in simulated altitude training devices. 
The overlap between convenience and potential for physiological improvement and exercise-enhancing 
adaptations has meant that the use of simulated altitude has also become a point of interest in clinical 
cohorts (Burtscher et al., 2010). In most cases, patients with cardiovascular disease exhibit poor exercise 
tolerance which makes any sort of physical activity difficult and short lived. Additionally, sedentary 
individuals who typically suffer from poor exercise tolerance and fitness levels would also stand to benefit 
from such treatments. For clinicians and exercise professionals, an intervention that promises to improve 
the exercise tolerance of their patients and clients prior to, or in conjunction with an exercise programme 
would be widely beneficial.  
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The purpose of this review is to determine the extent to which simulated altitude has been investigated in 
sedentary or clinical populations, and to examine the treatments used and findings from the retrieved 
papers. Furthermore, a summary of the literature pertaining to well-trained and athletic populations is also 
provided. 
Table 1: Hypoxic exposure training methods 
IHE IHT  LHTH LHTL 
 
 
  
 
    
   
    
 
 
 
 
    
 
IHE: intermittent hypoxic exposure, IHT: intermittent hypoxic training, LHTL: live high train low, LHTL: Live 
high train low. IHE is usually achieved using hypobaric chambers, altitude tents, or by delivering a lower 
fraction of inspired oxygen (FiO2) through a hand held face mask. This method of simulated altitude 
exposure is distinct from the others in that there is no physical training performed within or alongside the 
altitude exposure. Hypoxic exposure can range from several repeated doses of a few minutes of hypoxic 
exposure interrupted by several minutes of ambient air over 40 – 90 min, or a single dose of several hours. 
IHT requires that the individual either travels to real altitude for their training programme or trains within a 
hypobaric chamber (hypobaric hypoxia) or altitude tent (normobaric hypoxia), or while inspiring a hypoxic 
gas delivered through a face mask. The individual then returns to sea level following the exercise. During 
LHTH, the individual either resides at and trains in real altitude, in a hypobaric chamber (hypobaric 
hypoxia), or in an ‘altitude apartment’ (normobaric hypoxia). The hypoxic exposure is uninterrupted, and 
can range in time from several days to several weeks. However, with LHTL the individual either resides at 
real altitude, in a hypobaric chamber, in an ‘altitude apartment’, or in an ‘altitude tent’, but returns to a 
normoxic environment for training. The hypoxic exposure usually ranges from 8 h (in the case of altitude 
tents), to 18 – 20 hours (in altitude apartments, real altitude or hypobaric chambers).  
2.2 Search methods  
Google Scholar, Science Direct and PubMed (via Medline) were searched using a combination of “include” 
and “excluding” terms. In addition to these databases, all APS journals and the “High Altitude Medicine and 
Biology” journals were searched individually. The focus of this literature review is on the adaptive response 
to short term, simulated altitude in un-acclimatized humans. Therefore, any long-term hypoxic exposure 
associated with extended exposure to high altitude (such as high altitude residents and mountain tribes or 
mountaineering expeditions) or as a consequence of disease states (such as obstructive sleep apnoea, 
> 4,000 m 
2,000 – 3,000 m 
< 1,000 m 
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ischemic heart disease or neonatal hypoxia) were also excluded. While a wealth of research conducted on 
rats, mice and dogs has investigated the role of hypoxia in gene expression and molecular pathways, the 
focus of this review is on intervention-based research in humans and therefore all animal studies were 
excluded from this review. Given the focus on the adaptive response to the simulated altitude, only 
research examining a training response to the simulated altitude was accepted, and therefore studies 
examining an ‘instantaneous’ physiological response to a single dose of hypoxia were excluded. Finally, only 
English-speaking, full text, peer reviewed academic journal articles were accepted in this review. 
In an attempt to balance the number of articles between people of different health states, the descriptors 
“Sedentary” OR “untrained” OR “Inactive” were included in the Google Scholar and Science Direct search 
terms (anywhere in article). A subsequent Google Scholar search which included the terms, “well trained”, 
“active”, “athlete” and “simulated altitude”, “interval hypoxia” and “normobaric hypoxia” was also 
included. After reviewing the first 100 articles in the second Google Scholar search, the remainder of the 
2390 search results were restricted to those published after 2009. Refer to Figure 2 for a full description of 
the inclusion and exclusion terms used, and the number of articles accepted at each filtering stage. 
Following the searching process, the reference lists of selected review articles (Burtscher et al., 2010, 
Bärtsch et al., 2008, Muza, 2007, Wilber, 2007) were reviewed and any additional articles were added.  
It is important to note that while this is an extensive review of the literature, and is likely to contain the 
majority of hypoxia-related interventions performed in sedentary individuals, it is likely that research 
regarding athletic populations published before 2009 has not been included. Additionally, given the 
specificity of populations in the search terms (“Sedentary” OR “untrained” OR “Inactive” OR “well trained” 
OR “active” OR “athlete”), it is possible that relevant research that has not specified the training status of 
their population was not captured in the search process. After all articles were retrieved and documented, 
they were then sorted into one of 4 participant categories: 
 Well-trained / athlete 
 Healthy / active 
 Sedentary / untrained  
 Clinical.  
Regarding the grouping of participants, the distinction between healthy/ active groups and sedentary / 
untrained were, at times, blurred. For example, if participants were described as healthy but not involved in 
exercise or physical activity, or untrained, they were included in the “sedentary/ untrained”. In cases where 
participants were described as healthy but no indication of level of physical activity was recorded, but 
included a description akin to “healthy lowlanders, not taking medications and without disease” the study 
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was included in the “healthy/ active” category. Therefore there is a possibility that some studies have been 
misclassified.  The details of the training protocols and key outcomes of the studies were also noted. 
 
Figure 2: Database and journal search procedure 
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2.3 Results and discussion  
There were 1464 articles returned from the searching process, and 213 were accepted based on their titles. 
Of these 213 articles, 94 articles were focussed on intervention style studies in humans. In the rejected 
articles, 16 were focussed on real altitude only with no simulated altitude content, 40 were reviews, 
commentaries or debates, 57 were ‘instantaneous’ or non-intervention based and 6 were either duplicates, 
animal studies or irrelevant. An additional 39 articles were added after reviewing the reference lists of 
selected articles, all of which were published before 2009 (one was in 2009). Articles ranged in date from 
1992 to 2013. 
Of the retrieved articles, 85% were focussed on healthy, physically active participants of which 52.6% of the 
articles were based on “well-trained / athlete” cohorts and 32.4 % were in “healthy / active” participants. In 
the remaining 15% of the retrieved articles, 12% were in “sedentary / untrained” populations and 3% 
investigated the response of simulated altitude in a clinical population, see Figure 3.  
 
Figure 3: Proportion of studies focussing on different populations, and within those portions, the 
methods used to simulate altitude 
See Table 3 - Table 6 for the studies included in this Pie Diagram.  
 
Figure 4 at the end of this chapter represents the prevalence of the authors cited in this literature review. 
Altitude simulation methods were grouped into 3 main training modalities, namely LHTL (n = 41), IHT (n = 
44) and IHE (n = 68), refer to Table 1 for a description of these protocols. (If a research article used two or 
more types of simulated altitude protocol, these were counted separately). Eight articles made use of a 
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combination of techniques: 7 combined IHE+IHT (5 in the healthy / active population, and 2 in the well 
trained / athlete population) and 1 combined LHTL with IHE. Twenty one studies used hypobaric hypoxia to 
simulate altitude: 13 in IHE protocols (2 in Clinical, 2 in sedentary / untrained, 1 in healthy / active, and 8 in 
well trained / athletes), 6 in IHT (2 in sedentary / untrained, 2 in healthy / active, and 2 in well trained / 
athlete), and 2 in IHE+IHT combinations (1 in healthy / active, and 1 in well trained / athlete).  
Within the IHE protocol, there were two distinct techniques: Those that included one continuous, passive 
exposure of simulated altitude, usually over 3 – 4 h, and those that included short (several minutes) of 
severe hypoxic exposure, usually around an FiO2 of 12%, alternated with a similar duration of ambient air, 
and repeated for 40 – 90 min. For the sake of clarity, for the remainder of this discussion, repeated, short 
intervals of hypoxic alternated with short periods of normoxic breathing will be referred to as intermittent 
hypoxic exposure (IHE), while the sustained periods of passive hypoxic exposure will be referred to as 
prolonged hypoxic exposure (PHE).  
Traditionally, male participants have been recruited more frequently than female participants into 
simulated altitude research, at ratios of approximately 7:1; 6:1; 17:1 and 5:1 in the clinical; sedentary / 
untrained; healthy/active; and well-trained / athlete groups respectively. Studies focussing on active 
participants have typically recruited younger participants; while in the sedentary cohorts, the participants 
have generally been older (see Table 2). In the sedentary / untrained group however, there seemed to be 
specific groupings regarding participant age. That is, 18 studies ranged in age from 19 – 28 years, and the 
participants in the 6 remaining studies were between 42 – 64 years old (which accounts for the much larger 
standard deviation in the age of this group). 
Table 2: Overview of participant profiles in simulated altitude research 
Participant group Number of 
studies 
Male 
n 
Female 
n 
Approximate average  
age (years  SD) 
Clinical 4 71 11 54.6  8.2 
Sedentary / untrained 16 339 55 29.9  14.4 
Healthy / active 43 529 32 24.5  3.1 
Well trained / athlete 70 1037 201 24.5  4.3 
 
Given the vested interest in athletic performance by the coaches, athletes and even government, and the 
very small differences in performance between the top elite athletes, it makes sense that most research 
regarding the use of simulated altitude has been centred on athletic performance. Indeed, numerous 
recent review articles on the effects of simulated altitude on athletic performance have already been 
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published (Bärtsch et al., 2008, Bonetti and Hopkins, 2009, de Paula and Niebauer, 2012, Wilber, 2011). 
However, the smaller branch of the research that has focussed on sedentary participants and those with 
cardiovascular disease may have more potential for health improvement than for athletic improvement, 
and has typically received a lot less attention than its athletic counterpart. In response to this, the first part 
of this discussion will review the available literature on the use of simulated altitude in “clinical” and 
“sedentary/ untrained” population groups, with a closer look at the effectiveness of each simulated altitude 
technique in each group. The key outcomes following the examination of this literature will then be 
compared to findings observed in the wider population. The literature review will conclude with 
recommendations for future research directions. 
2.3.1 Clinical populations 
There were only 4 articles examining the effect of IHE in a clinical population, all of which used passive 
hypoxic exposure (see Table 3). Within the IHE protocols, one article focussed on interval IHE (Haider et al., 
2009) and 3 focussed on PHE (del Pilar Valle et al., 2006, Tin'kov and Aksenov, 2002, Saeed et al., 2012).  
Intermittent hypoxic exposure  
The aim of Haider et al. (2009) was to assess whether short intervals of hypoxic exposure would influence 
the cardiovascular autonomic dysfunction associated with chronic obstructive pulmonary disease. To assess 
functional respiratory control, Haider et al. (2009) reported the ventilatory response to normocapnic 
normoxia (control), normocapnic hypoxia (index of peripheral chemoreflex), and hyperoxic hypercapnia 
(index of central chemoreflex). Baroreflex sensitivity was estimated using autoregressive power spectral 
analysis of the interval between R- R peaks in heart rate data, and systolic blood pressure (SBP).  
Following the 3-week trial, participants receiving IHE demonstrated improved baroreflex sensitivity and a 
slight (non-statistically significant) decrease in SBP. The RR interval also increased, suggesting improved 
vagal activity. However, the increase in RR interval could also have been related to the tendency for 
participants in the IHE group to breathe slower and more deeply following the intervention. Additionally, 
Haider et al. (2009) did not report how well the participants tolerated the hypoxic intervals, only that no 
clinical problems arose. Therefore future research in this population, using this technique should monitor 
changes in RR interval under controlled breathing, and monitor tolerance to the hypoxic dosage. 
Prolonged hypoxic exposure  
The reports of improved exercise tolerance (Saeed et al., 2012), myocardial perfusion (del Pilar Valle et al., 
2006) and blood lipid profile (Tin'kov and Aksenov, 2002) in a clinical population following PHE are 
promising. However, the small number of studies in this population and the different focus in each of the 
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studies makes it difficult to assess the repeatability of the respective findings. There are also limitations in 
each of these studies that cloud the clarity of the outcomes in these trials.  
The major limitation in these studies has been the lack of a control group. For example, despite a relatively 
large number of participants recruited into the study by Tin'kov and Aksenov (2002), particularly when 
compared to other studies of this nature (n = 46 in Tin’kov and Aksenov (2002), versus 18, 12 and 6 by 
Haider et al. (2009), Saeed et al. (2012), and del Pilar Valle et al. (2006) respectively), Tin’kov and Aksenov 
(2002) did not include a group receiving a normoxic placebo. The absence of a control group makes it 
difficult to conclusively pinpoint the alteration of the blood lipid profile to the intermittent hypobaric 
hypoxic exposure. For example, it is possible that the change in the blood lipid profile over the course of 
the study could have been attributed to the participant’s ongoing use of medication over the course of the 
3-week intervention period and the 10-month follow up, or indeed a change in season (Ockene et al., 2004) 
or physical activity levels. Similarly, oral acetazolamide (a carbonic anhydrase inhibitor which acts as a 
diuretic) was administered to 11 of the 12 participants in the study by Saeed et al. (2012) prior to the PHE 
treatment to prevent altitude sickness. While all of the participants tolerated the hypoxia well, there is also 
a small possibility that the ingestion of the acetazolamide could have augmented some of the training 
responses. As the time course of the changes in the blood profile variables almost perfectly matches the 
changes in the intervention, particularly immediately following the intervention period, and the 3 month 
follow up, it is likely that the hypobaric hypoxic treatment was indeed responsible for this change. 
The small sample size in del Pilar Valle’s study was possibly the largest limitation in their study. However, 
given the high risk population used in their trial, and the absence in participant motivation required for 
their measurements, their results are likely reliable. The improvement in myocardial perfusion was 
attributed to improved blood flow due to an increase in angiogenesis, and an improvement in vasodilation 
due to improved serum nitric oxide following the PHE protocol (del Pilar Valle et al., 2006). 
Overall, 3 – 4 h episodes of PHE at a simulated altitude of 2,700 – 4,200 m for 2 – 3 weeks in patients with 
stable chronic heart failure or coronary heart disease appears to have beneficial effects on blood lipid 
profile, myocardial perfusion and exercise capacity. While there appears to be high potential for PHE to 
improve health outcomes in this population, further placebo-controlled (or randomised crossover), double 
blind studies are required before conclusive statements can be made regarding the effectiveness of PHE in 
this population.  
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Table 3: Studies researching simulated altitude training in a clinical population 
Authors Participant 
description (cohort, 
MF, Age 
Group 
treatment 
Hypoxia frequency 
(sessions, per week, 
weeks) 
Hypoxic severity Main Outcome 
Intermittent hypoxic exposure (n=1) 
  Haider et 
al. (2009) 
Patients with mild 
COPD symptoms; 
10M8F; 51.5 y 
IHE 3-5 min hypoxia: 3 min 
recovery cycled for 3 - 5 
rotations; 5 sessions / 
wk, 3 wks.  
FiO2: 15, 13, 12 in wk 1, 2, 3 
respectively 
(2600 m, 3750 m, 4400 m)
ɣ
  
 Baroreflex sensitivity & RR interval, 
slight  in SBP but NS.  HCVR but not 
HVR 
As above, 5M4F, 
52 y 
C: (sham) As above but with 
normoxic placebo 
FiO2: 21 in wk 1 – 3  
(SL) 
Slight  baroreflex sensitivity & RR 
interval (NS),  SBP 
Age matched 
healthy, 5M9F, 47 y 
Healthy 
comparison 
Baseline data only No treatment   
Prolonged hypoxic exposure (n=3) 
del Pilar 
Valle et al. 
(2006)  
Severe stable CHD, 
6M, 66.5 y 
PHE* 4 h / session, 1 session / 
wk, 14 sessions  
2 h acclimatizing to target, 1 h 
at target, 1 h descent. Starting 
target 2400 m,  by 250 - 300 
m each following session until 
4200 m 
Improved myocardial perfusion, no 
evidence of impairment 
Saeed et 
al. (2012)  
Patients with stable 
chronic heart failure, 
9M3F, 52.5 y 
PHE 3-4 h / session, 10 
sessions over 22 d 
Started at 1500 m,  by 300 m 
every session until 2700 m. 
 V˙ O2max (up to 4 wk post),  exercise 
time,  6 min walk distance,  skeletal 
muscle strength. Trend to improved left 
ventricular ejection fraction 
Tin'kov 
and 
Aksenov 
(2002)  
Coronary heart 
disease patients (30 
with myocardial 
infarction, 16 
ischemic heart 
disease); 46M, 48 y 
PHE* 3 h / session, 22 sessions 
in 22 d 
3500 m Total cholesterol & low density 
lipoprotein,  high density lipoprotein 
(up to 6 months post).  coefficient of 
atherogenity  
*hypobaric hypoxia; PHE: prolonged hypoxic exposure; IHE: intermittent hypoxic exposure; C: control; sham: normoxic placebo; ɣ estimated using altitude conversion chart 
by www.higherpeak.com; FiO2: fraction of inspired oxygen;  increase;  decrease;  no change; SL: sea level; COPD: Chronic obstructive pulmonary disease; RR interval: 
average distance between RR peaks; SBP: systolic blood pressure; HCVR: hypocapnic ventilatory response; HVR: hypoxic ventilatory response; M: male; F: female.  
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2.3.2 IHT and IHE in sedentary / untrained populations 
The results of the studies utilising sedentary / untrained, but otherwise relatively healthy individuals 
are summarised in Table 4. The research involving this cohort focussed exclusively on IHE and IHT 
training modalities, with 4 articles using IHE (Balykin et al., 2004, Burtscher et al., 2009, Burtsher et 
al., 2004, Shatilo et al., 2008), 3 using normobaric, PHE (Wang et al., 2007a, Wang et al., 2007b, 
Wang et al., 2010), 2 using hypobaric PHE (Katayama et al., 1998, Ricart et al., 2000), 8 using 
normoxic IHT (Balykin et al., 2004, Friedmann et al., 2003, Geiser et al., 2001, Mao et al., 2011, Vogt 
et al., 2001, Wang et al., 2010, Wiesner et al., 2010, Pesta et al., 2011), and 2 using hypobaric IHT 
(Katayama et al., 1998, Nishiwaki et al., 2011). Balykin et al. (2004) and Wang et al. (2010) tested 
both IHE and IHT groups. Overall, the quality of these studies were better, with more researchers 
reporting comparisons relative to control groups. 
Intermittent hypoxic exposure  
The population used in these studies included people with mild COPD (or at risk for COPD), who 
were overweight, or who were healthy and active but elderly (60 – 74 y). Most studies reported an 
improvement in exercise tolerance during a submaximal workload (Burtscher et al., 2009, Burtsher 
et al., 2004, Shatilo et al., 2008), particularly in those with greater disease  (Burtsher et al., 2004) or a 
sedentary nature (Shatilo et al., 2008). Changes in maximal capacity were somewhat harder to 
detect. Only the elderly men in the study by Burtsher et al. (2004) demonstrated a clear increase in  
V˙ O2peak compared to the control group. While the later study by Burtscher et al. (2009) and the study 
by Balykin et al. (2004) both noted a small increase in V˙ O2peak following IHE, neither increase was 
statistically significant (despite an increase in time to exhaustion reported by Burtscher et al. (2009)).  
There were several conflicting adaptations in response to the IHE protocol. For example, while some 
studies report an increase in red blood cells (Burtsher et al., 2004) and haemoglobin (Burtscher et 
al., 2009, Burtsher et al., 2004), others have noticed no meaningful increase (Shatilo et al., 2008). 
Interestingly, both Shatilo et al. (2008) and Burtscher et al. (2009) reported small, but not 
statistically significant decreases in total cholesterol which is in line with the improvement in blood 
lipid profile following PHE in a clinical population (Tin'kov and Aksenov, 2002). However, the 
decrease in cholesterol in the test group in the study by Burtscher et al. (2009) was similar to the 
decrease in the control group and therefore these results were equivocal.  
The study by Balykin et al. (2004) primarily investigated the effectiveness of different IHE protocols 
with, and without the use of exercise. The IHE protocols used in conjunction with exercise training 
(either simultaneously, or sequentially) were more effective regarding exercise capability, and these 
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results are discussed under the “Intermittent hypoxic training” heading. One particularly interesting 
outcome of the IHE group was the decrease in sympathetic and increase in parasympathetic activity 
in the autonomic control of the heart following the hypoxic exposure intervention, resulting in a 
reduced strain index (regarding cardiac autonomic regulation). This was also reflected in the reduced 
resting heart rate and systolic blood pressure.  Unfortunately neither the frequency nor the duration 
of the hypoxic stimulus was clearly reported, and therefore such variables warrant further 
investigation. 
Participants in these studies appear to have tolerated the hypoxia well. Prior to the IHE intervention, 
the elderly participants in the study by Shatilo et al. (2008) underwent a sustained 10 min exposure 
at an FiO2 of 12 % to test hypoxic tolerance. Of the 36 participants who participated in the sustained 
hypoxia, 1 was excluded due to a SBP increase of more than 30% between minutes 3 – 5 of the 
exposure (and was excluded from the study), and 4 participants voluntarily stopped the sustained 
exposure due to dizziness, shortness of breath or weakness. These symptoms occurred 
approximately 7 min into the hypoxic interval. After the first IHE session of the 10 d intervention, 3 
participants reported mild chest discomfort, dizziness and tinnitus. No further distress was reported 
during the IHE intervention periods of 5 min. In Burtscher et al.’s studies, participants (in both the 
control and in the test groups) reported feeling dizzy or sleepy during the hypoxic exposure 
(Burtscher et al., 2009, Burtsher et al., 2004)  
In general, all of the IHE studies made use of a control group of sorts (while Shatilo et al. (2008) and 
Balykin et al. (2004) did not use a placebo group, they did examine the intervention in different 
population groups).  Of note is that while some of the haematological parameters are unclear, there 
were no negative health outcomes attributed to the IHE interventions (such as increased SBP, or a 
decline in exercise tolerance).  
Therefore, for those who are unable to exercise, the possibility of health benefit compared to the 
seemingly absent risk of harm would make this intervention worthwhile, particularly regarding the 
positive effects regarding submaximal exercise tolerance. The potential for IHE to reduce 
sympathetic dominance and improve the strain index of autonomic control of the heart, as reported 
by Balykin et al. (2004), is also intriguing, and should be explored further in a clinical or sedentary 
population. 
Prolonged hypoxic exposure 
The research regarding normobaric PHE has been conducted by one research group who have 
focussed primarily on the differences in the hypoxic severity (FiO2 of 12% vs 15%) on haemodynamic 
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control (Wang et al., 2007a, Wang et al., 2010), eosinophil- and neutrophil- platelet aggregation, 
cytokine response to  strenuous exercise (Wang et al., 2007b), as well as exercise tolerance and 
ability. The results of these studies indicate a large variation in physiological response depending on 
both the time and severity of the hypoxic dosage. For example, 4 or 8 weeks of PHE, for 1 h, 5 
times/week using an FiO2 of 15% resulted in improved pulmonary ventilation, and submaximal and 
maximal exercise performance, as evidenced by an approximately 9% change in V˙ O2peak from 
baseline (Wang et al., 2007a, Wang et al., 2007b), which were not statistically significant following 
30 minutes of the same PHE protocol (Wang et al., 2010). Additionally, while the arterial hyperaemic 
response (an indication of vascular haemodynamic function) following occlusion remained largely 
unchanged following 4 weeks of 30 min or 60 min PHE, at an FiO2 of 15%, the hyperaemic response 
tended to worsen after 4 weeks of 60 min PHE at an FiO2 of 12% (Wang et al., 2007a). In addition to 
the reduced hyperaemic response, the group receiving an FiO2 of 12% demonstrated an increase in 
lipid peroxidation, decrease in vitamin E levels and a decrease in vascular endothelial function which 
was attributed to a decrease in antioxidative capacity (Wang et al., 2007a). Contrastingly, 8 weeks of 
the same PHE protocol at an FiO2 of 12 or 15% resulted in a reduction in the pro-inflammatory 
cytokine and thrombo-inflammatory responses to strenuous exercise, but only the group receiving 
an FiO2 of 12% demonstrated a substantial increase in circulatory anti-inflammatory cytokines  IL-6 
and IL-10 during hypoxia, exercise, and at rest (Wang et al., 2007b).  
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Table 4: Studies relating to simulated altitude in a sedentary / untrained population 
Authors Participant description 
(cohort, MF, Age) 
Group Frequency (sessions, per 
week, weeks) 
Hypoxic 
severity 
Main Outcome 
Intermittent hypoxic exposure 
Balykin et 
al. (2004)  
Healthy, sedentary, 
overweight, no disease, 
11M, 18 - 20 y 
C:  Cycling (100W) 30 min/d, 3 d/week, 4 wk Sea level Very small changes, only resting V
˙
O2 & V
˙
CO2 
worthwhile,  strain index of ANS (not 
significant) 
  As above; 9M; 18-20 y IHE 5 min hypoxia alternated with 
5 min recovery, 10 sessions, 
over 22 d 
FiO2: 10  SNS,  PNS,  strain index of ANS,  physical 
work capacity 
  As above; 9M; 18 - 20 y IHE before exercise As above followed by C 
exercise. 10 IHE and 10 C 
exercise sessions 
FiO2: 10  SNS,  PNS, strain index of ANS,  physical 
work capacity, better  than IHE alone 
  As above; 10M; 18 - 20 y IHT: cycling (100 W) 30 min/d, 3d/week, 10 
sessions 
FiO2: 10  ANS changes between IHE + Exercise and IHE 
only, but greater  in physical work capacity 
  As above; 8M; 18 - 20 y IHE alternated with IHT IHE and IHT protocols 
alternated, as described 
above 
FiO2: 10 Improved ANS balance & physical work capacity 
(less than combination groups). Greater 
improvement in anthropometric data. 
Burtsher et 
al. (2004)  
Normally active, half 
with & half without prior 
MI, 8M, 59 y  
IHE 3 - 5 minutes hypoxia cycled 
with 3 min normoxia repeated  
for 3 -5 cycles, 5 d / wk, 3 wk 
FiO2: 14, 12 10 
in wk 1, 2, 3 
RBC & Hb, submaximal efficiency & tolerance. 
 peak workload, but  efficiency 
  As above, 8M, 61 y C As above but normoxic 
placebo 
FiO2: 21 RBC,  other bloods, small changes in 
submaximal & maximal exercise 
Burtscher 
et al. 
(2009)  
Normally active (2 h / 
wk), with chronic 
obstructive pulmonary 
symptoms, 5M4F, 51 y 
IHE 3-5 min hypoxia alternated 
with 3 min normoxia, cycled 
for 3-5 repetitions, 5 d/ wk, 3 
wk 
FiO2: 15, 13, 
12, in wk 1, 2, 
3 
SBP, DBP, forced expiratory volume, Hb, & 
plasma volume, exercise time compared to C 
  As above, 5M4F, 52 y C: As above but normoxic 
placebo 
 
FiO2: 21   SBP, DBP, arterial O2 saturation, triglycerides 
      
35 
 
Authors Participant description 
(cohort, MF, Age) 
Group Frequency (sessions, per 
week, weeks) 
Hypoxic 
severity 
Main Outcome 
Shatilo et 
al. (2008)  
Healthy active seniors; 
14M; 67 y 
IHE 5 min hypoxia alternated with 
5 min normoxia cycled 4 
times, for 10 d 
FiO2: 12%  Haemodynamic indices or work capacity.  
skin blood flow during submaximal exercise & 
hyperaemic recovery time 
  Sedentary seniors; 21M; 
61 y 
IHE As above As above   exercising blood pressure,  submaximal work, 
& anaerobic threshold.  HR & BP during 
submaximal exercise.  skin blood flow.  
improvements compared to active group 
Prolonged hypoxic exposure 
Katayama 
et al. 
(1998)  
Healthy, no regular 
physical activity, no 
cardiorespiratory disease 
or medication; 7M; 19 y 
IHT*: 2 X 15 min cycling 
(5 min recovery 
between) at 40 % sea 
level max; remainder as 
PHE* 
2 h/d, 6 sessions in 6 d 30 min up  to 
4500 m; 1 h at 
4500 m, 15 
min back to 
sea level 
 HVR or HCVR,  V˙ O2peak  
  As above; 6M; 19.5 y PHE* (rest) As above As above   HVR but HCVR or V˙ O2peak  
Ricart et al. 
(2000)  
4WD members; 5M4F; 
45 y 
PHE*  2 h/d, 7 d/wk, 2 wk 5000 m   SaO2 & expired minute volume ( tidal 
volume).  Resting variables, packed cell volume 
or Hb after 2 wks. 
Wang et al. 
(2007b)  
healthy, non-smokers, 
no medications, disease 
free; 10M; 24 y 
PHE: Moderate (15%) 1 h/d, 5 d/wk, 8wk FiO2: 15%;  
2733 m 
Lower  in hypoxia & exercise induced eosinophil 
& neutrophil platelet-aggregation, interleukin-1ß 
& malondialdehyde levels 
  As above; 10M, 23 y PHE: Severe (12%)  As above FiO2: 12% As above, but also  plasma interleukin 6 & 
interleukin 10 
Wang et al. 
(2007a) 
Healthy, non-smokers, 
no medications, disease 
free; 10M; 24 y 
PHE: Moderate (15%) 1 h/d, 5 d/wk, 4 wk FiO2: 15%;  
2733 m  
 pulmonary ventilation & oxygen uptake  
  As above; 10M, 23 y PHE: severe (12%)  As above FiO2: 12% As above, but also  exercising BP  Plasma 
malondialdenhyde & nitric oxide, hyperaemic 
arterial response (haemodynamic function), 
venous compliance & endothelium-dependant 
vasodilation.  Plasma antioxidant & Vitamin E 
 As above, 10M, 24 y C As above FiO2: 21% No change 
. 
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Authors Participant description 
(cohort, MF, Age) 
Group Frequency (sessions, per 
week, weeks) 
Hypoxic 
severity 
Main Outcome 
Wang et al. 
(2010)  
Healthy, non-smokers, 
no medications, disease 
free; 12M; 23 y 
IHT: cycling 50% 
maximal heart rate 
reserve  
30 min/d, 5 d/wk, 4 wk FiO2: 15%;  
2733 m 
 Stroke volume, hyperaemic & re-oxygenation 
suppression induced by FiO2: 12%. perfusion & 
O2 extraction in FiO2: 12% exercise 
 As above; 12M; 23 y IHT: 50% max work at 
FiO2: 15% 
As above FiO2: 15%;  
2733 m 
As above but also better improvement in aerobic 
capacity than normoxic exercise.  
  As above; 12M; 23 y C: sedentary normoxic As above Sea level  No worthwhile change 
  As above; 12M; 21 y C: normoxic cycling 
(50% maximal work 
rate) 
As above Sea level  No worthwhile change 
  As above; 12M; 21 y PHE As above FiO2: 15%;  
2733 m 
No worthwhile change 
Intermittent hypoxic training 
Balykin et 
al. (2004)  
Healthy, sedentary, 
overweight, no disease, 
11M, 18 - 20 y 
C:  Cycling (100W) 30 min/d, 3 d/week, 4 wk Sea level Very small changes all NS except resting vo2 & 
VCO2, in strain index of ANS (NS) 
  As above; 9M; 18-20 y IHE 5 min hypoxia alternated with 
5 min recovery, 10 sessions, 
over 22 d 
FiO2: 10  SNS,  PNS,  strain index of ANS,  physical 
work capacity 
  As above; 9M; 18 - 20 y IHE before exercise As above followed by C 
exercise. 10 IHE and 10 C 
exercise sessions 
FiO2: 10  SNS,  PNS, strain index of ANS,  physical 
work capacity, better  than IHE alone 
  As above; 10M; 18 - 20 y IHT: cycling (100 W) 30 min/d, 3d/week, 10 
sessions 
FiO2: 10 ANS changes between IHE + Exercise and IHE 
only, but greater  in physical work capacity 
  As above; 8M; 18 - 20 y IHE alternated with IHT IHE and IHT protocols 
alternated, as described 
above 
FiO2: 10 Improved ANS balance & physical work capacity 
(less than combination groups). Improvement in 
anthropometric data. 
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Authors Participant description 
(cohort, MF, Age) 
Group Frequency (sessions, per 
week, weeks) 
Hypoxic 
severity 
Main Outcome 
Friedmann 
et al. 
(2003)  
Recreationally active or 
untrained, 10M, 25 y 
IHT: Low resistance, 
high repetition leg 
strength training 
40 min/d, 3 d/wk, 4 wk FiO2: 12  
4500 m 
As below, but also correlation between hypoxic 
markers & glycolytic enzyme mRNA linked to 
hypoxic specific adaptation. 
No practical benefit of IHT 
  As above, 9M, 24 y C: normoxic low 
resistance, high 
repetition leg strength 
training 
As above but normoxic 
placebo 
Sea level  Strength endurance capacity, but  muscle 
cross sectional area, fibre type distribution or 
fibre cross sectional area. High inter-individual 
variation in mRNA analyses.  
Geiser et 
al. (2001)  
Healthy untrained, 10M, 
23 y 
IHT: high intensity  
(80% V
˙
O2peak) hypoxia 
30 min/d, 5 d / wk, 6 wk 3850 m   V˙ O2peak & maximal power tested in hypoxia 
and normoxia.  mitochondrial volume density. 
 knee extensor muscle volume & capillary 
length density (length of capillary in 1 mm
3
) 
  As above, 8M, 23 y IHT: low intensity (67%  
V
˙
O2peak) hypoxia 
30 min/d, 5 d/wk, 6 wk 3850 m  V˙ O2peak.  maximal power, but less so than high 
intensity groups.  mitochondrial volume density 
  As above, 8M, 25 y C: high intensity (80%  
V
˙
O2peak)  in normoxia 
As above but normoxic 
placebo 
600 m  V˙ O2peak.  maximal power (more so than low 
intensity.)  mitochondrial volume density  
  As above, 7M, 29 y C: low intensity (67%  
V
˙
O2peak) normoxia 
As above but normoxic 
placebo 
600 m  V˙ O2peak.  maximal power, but less so than high 
intensity groups;  mitochondrial volume density 
Katayama 
et al. 
(1998)  
Healthy, no regular 
physical activity, no 
cardiorespiratory disease 
or medication; 7M; 19 y 
IHT*: 2 X 15 min cycling 
(5 min recovery 
between) at 40 % sea 
level max; remainder 
PHE* 
2 h/d, 6 sessions in 6 d 30 min up to 
4500 m; 1 h at 
4500 m, 15 
min back to 
sea level 
HVR or HCVR,  V˙ O2peak  
  As above; 6M; 19.5 y PHE*  As above As above  HVR but HCVR or V˙ O2peak  
Mao et al. 
(2011)  
Healthy, non-smoker, no 
medication or history of 
disease: 12 M; 22 y 
IHT: cycling at 60% 
work rate  
30 min/d, 5 d/wk, 5 wk FiO2: 15%;  
2733 m 
 Erythrocyte health and durability under shear 
stress. eryptotic response to hydrogen peroxide 
  As above; 12M; 22 y C: cycling at 60% work 
rate  
As above FiO2: 21%  
(sea level) 
 Erythrocyte rheological properties under rest 
or exercise. 
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Authors Participant description 
(cohort, MF, Age) 
Group Frequency (sessions, per 
week, weeks) 
Hypoxic 
severity 
Main Outcome 
Nishiwaki 
et al. 
(2011)  
Postmenopausal women,  
sedentary/ recreationally 
active, no hormone 
replacement therapy; 8F; 
56 y 
IHT*: 30 min swimming 
50 % V
˙
O2peak, PHE 
remainder 
2 h/d, 4 d/wk, 8 wk 2000 m   Brachial pulse wave velocity;  
 Flow mediated dilation & peak diameter 
  As above; 8F; 56 y C: 30 min swimming 30 min/d, 4 d/wk, 8 wk Sea level  No worthwhile changes 
Pesta et al. 
(2011)  
Healthy sedentary: 7M; 
29 y 
IHT: endurance training 35-55 min/d, 3 d/wk, 10 wk FiO2: 13.5%,  
4000 m  
 Fatty acid oxidation capacity per muscle mass 
mainly due to qualitative mitochondrial change, 
& partly due to tissue density. 
  As above; 8M; 28 y C: endurance training, 
normoxia 
As above, normoxic placebo Sea level   Physiological oxidative phosphorylation & key 
mitochondrial changes. 
  Healthy sedentary; 7M; 
24 y 
IHT: strength training 12 - 17 min/d, 3 d/wk, 10 wk FiO2: 13.5%,  
4000 m  
 As above 
  As above; 3M; 24y C: strength training As above,  normoxic placebo Sea level  As above.  
Vogt et al. 
(2001)  
Untrained, 7M, 23 y IHT: high intensity (4 - 6 
mmol blood lactate) 
30 min/d, 5 d/wk, 6 wk 3850 m   V˙ O2peak & maximal power output; HIF-1α & 
splice variant HIF-1α
736
;  myoglobin & vascular 
endothelial growth factor mRNA. 
  Untrained, 8M, 25 y C: High intensity as 
above 
As above but normoxic 
placebo 
Sea level   V˙ O2peak & maximal power output 
  Untrained, 7M, 23 y IHT: low intensity (2 - 3 
mmol blood lactate) 
30 min/d, 5 d/wk, 6 wk 3850 m   V˙ O2peak & maximal power output HIF-1α & 
splice variant HIF-1α
736
 
  Untrained, 8M, 29 y C: Low intensity as 
above 
 
 
 
 
 
As above, normoxic placebo Sea level   V˙ O2peak & maximal power output 
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Authors Participant description 
(cohort, MF, Age) 
Group Frequency (sessions, per 
week, weeks) 
Hypoxic 
severity 
Main Outcome 
Wang et al. 
(2010) 
Healthy, non-smokers, 
no medications, disease 
free; 12M; 23 y 
IHT: cycling 50% 
maximal heart rate 
reserve  
30 min/d, 5 d/wk, 4 wk FiO2: 15%;  
2733 m 
 Stroke volume, hyperaemic & reoxygenation 
suppression induced by FiO2: 12%. perfusion 
and O2 extraction in FiO2: 12% exercise 
  As above; 12M; 23 y? IHT: 50% max work at 
FiO2: 15% 
As above FiO2: 15%;  
2733 m 
As above; also more aerobic capacity than 
normoxic exercise.  
  As above; 12M; 23 y C: sedentary normoxic As above Sea level  No worthwhile change 
  As above; 12M; 21 y C: normoxic cycling 
(50% maximal work 
rate) 
As above Sea level  No worthwhile change 
  As above; 12M; 21 y PHE As above FiO2: 15%;  
2733 m 
No worthwhile change 
Wiesner et 
al. (2010)  
Sedentary, overweight, 
healthy, 10M14F; 42 y 
IHT: Treadmill (65% 
maximal HR) 
1 h/d, 3 d/wk, 4 wk 2740 m   Workload during training;  
 V˙ O2peak & time to exhaustion; greater 
improvement in respiratory quotient & lactate at 
anaerobic threshold & body composition. 
  As above, 8M13F, 42 y C: Treadmill (65% 
maximal heart rate) 
As above, normoxic placebo Sea level   V˙ O2peak and time to exhaustion 
*hypobaric hypoxia; IHE: intermittent hypoxic exposure; M: male; F: female; PHE: prolonged hypoxic exposure; IHT: intermittent hypoxic training; C: control; ɣ estimated 
using altitude conversion chart by www.higherpeak.com; FiO2: fraction of inspired oxygen;  increase;  decrease;  no change; V
˙
O2: oxygen uptake; V
˙
CO2: volume of 
carbon dioxide; ANS: autonomic nervous system; PNS: parasympathetic nervous system; SNS; Sympathetic nervous system; Hb: haemoglobin; RBC: red blood cells; HR: 
heart rate; BP: Blood pressure; NS: not significant SBP: systolic blood pressure; HCVR: hypocapnic ventilatory response; HVR: hypoxic ventilatory response; HIF-1α: the 
alpha subunit of the hypoxic inducible factor transcription factor. 
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Regarding the studies utilising hypobaric hypoxia in a sedentary population, one was focussed on the 
acclimatization potential of hypobaric PHE, and was assessed using rest and exercising parameters in 
hypobaric hypoxia (Ricart et al., 2000). The results of this study demonstrated no change in RBC or 
Hb (however, given the 2-week duration of this study, this was not unexpected). On the other hand 
exercising ventilation and SpO2 both improved while cycling at an estimated 30% of V
˙ O2peak following 
14 PHE sessions in the hypobaric chamber (Ricart et al., 2000). The increase in both SpO2 and 
ventilation was interpreted as beneficial altitude acclimatization. Similarly, Katayama et al. (1998) 
reported an increase in the hypoxic ventilatory response, but after a much shorter intervention (1 h 
/ d for 6 d at 4500 m, compared to 2 h / d for 14 d at 5000 m in the Ricart et al. (2000) study). 
Overall, while the effects of hypobaric PHE are likely to improve hypoxic sensitivity and 
acclimatization through increased ventilation in hypoxia, there is insufficient literature available to 
comment on its effectiveness as a means of improving exercise tolerance or health in a sedentary 
population. Conversely, the use of normobaric PHE in this population appears to consistently 
improve exercise tolerance and capacity following > 4 weeks of 5 PHE sessions/ week for at least 60 
min. Given the similarity between the physiological responses to an FiO2 of 12 and 15% regarding 
improvements in exercise parameters and a resistance to pro-inflammatory cytokine and thrombotic 
responses to strenuous exercise, the added potential of PHE at an FiO2 of 12% to increase circulatory 
IL-6 and IL-10 (Wang et al., 2007b) seems offset by the possibility of an increase in lipid peroxidation 
and a decrease in vascular endothelial function (Wang et al., 2007a). Therefore, based on the limited 
available research, a PHE protocol of >4 weeks for 1 h/ d, 5 d / week at an FiO2 of 15 % should be 
recommended in this population.  
Intermittent hypoxic training  
When researchers have used identical exercise intensity protocols in hypoxic, compared to normoxic 
conditions, the participants training in hypoxia have demonstrated superior aerobic capacity 
following as little as 6 – 10 IHT sessions (Katayama et al., 1998, Balykin et al., 2004) or as long as 4 – 
5 weeks (Wang et al., 2010, Mao et al., 2011) of IHT (30 min/d, 5 d/ week). However, other 
researchers have demonstrated no improvement in sea level performance compared to the control 
group following 6 weeks of high (80% V˙ O2peak) or low (67% V
˙ O2peak) intensity IHT for 30 min/d, 
5d/week (Geiser et al., 2001, Vogt et al., 2001) and no clear advantage following 10 weeks of IHT 
(Pesta et al., 2011).  
Interestingly, even when there is little change in exercise performance, there are likely to be 
hypoxic-related adaptations at the cellular level (Friedmann et al., 2003, Geiser et al., 2001, Vogt et 
al., 2001). For example, despite positive correlations between mRNA levels of vascular endothelial 
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growth factor (VEGF) and myoglobin, and between phosphofructokinase and lactate dehydrogenate 
following IHT (but not before), there was no additional advantage of strength training in hypoxia 
compared to normoxia  (Friedmann et al., 2003). Other structural alterations reported as a 
consequence of IHT include significant increases in muscle volume of knee-extensors, capillary 
length density, which is the capillary length in 1 mm3 (Tomanek, 2013), and mitochondrial volume 
density (Geiser et al., 2001, Vogt et al., 2001) and elevated mRNA concentrations of  the alpha 
subunit of hypoxic inducible factor – 1 (HIF-1 α) (Vogt et al., 2001).   
None of the studies reported any beneficial erythropoietic responses as a consequence of 4 – 6 
weeks of IHT (Wang et al., 2010, Geiser et al., 2001, Mao et al., 2011). Indeed, Mao et al. (2011) 
demonstrated accelerated aging, decreased size, a reduction in the ability of erythrocytes to deform 
under stress, and increased eryptotic (or suicidal cell death) response to hydrogen peroxide, 
following IHT. 
However, potentially valuable adaptations for a sedentary population that were reported following 
IHT include improvements in the cardiac autonomic balance between sympathetic and 
parasympathetic contributions to the heart period, and increased lipid metabolism as evidenced by a 
lower RER  during exercise (Balykin et al., 2004) which was possibly responsible for the 13% decrease 
in body fat weight compared to little change following normoxic exercise (Balykin et al., 2004). 
Additionally, Nishiwaki et al. (2011) reported improvements in vascular health (decreased pulse 
wave velocity and improved flow-mediated vasodilation) following IHT, but not normoxic exercise 
following hypobaric IHT. Further research should examine whether these improvements in vascular 
health can be repeated following normobaric hypoxia. 
2.3.3 Simulated altitude in an active cohort 
There have been numerous literature reviews that have already been published on the effectiveness 
of simulated altitude training on an active / athletic population. Therefore, a literature review, per se 
will not be discussed here and instead, a brief overview of some of the already published literature 
reviews will be provided. For the reader’s interest, Table 5 and Table 6 provide a summary of 
research investigating the role of simulated altitude in an active / well-trained population.  
The reviews have included general overviews (de Paula and Niebauer, 2012, Wilber, 2007, Levine, 
2002) or meta-analyses (Bonetti and Hopkins, 2009, Lancaster and Smart, 2012) of simulated 
altitude techniques. (The meta-analysis by  Lancaster and Smart (2012) has been criticised by Duke 
et al. (2012) for an inappropriate use of meta-analyses as the studies included were too dissimilar to 
draw generalisations). Others have examined the effectiveness of specific protocols such as IHE and 
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PHE (Bärtsch et al., 2008, Muza, 2007), IHT (Vogt and Hoppeler, 2010), or LHTL (Wilber, 2007). 
Physiological mechanisms have also been reviewed (Bailey and Davies, 1997). However, the key 
drivers for improved performance are still widely debated (See Point: Counter Point debate between 
Levine and Stray-Gundersen (2005), Gore and Hopkins (2005), and others (Noakes, 2005)). For 
example, some posit that the central modifier of performance is in adaptation of haemodynamic 
parameters such as erythropoietin or haemoglobin concentrations which increases V˙ O2peak (Levine, 
2002, Rusko et al., 2004, Levine and Stray-Gundersen, 2005), while others argue that improved 
muscle efficiency, mitochondrial function, buffering and lactate tolerance (Gore et al., 2007), or even 
placebo/nocebo effects (Bonetti and Hopkins, 2009) are more likely to be responsible.   
Regardless of which mechanisms are ‘most important’, one of the conflicting features regarding 
simulated (or real) altitude training is the lack of performance despite hypoxic-specific 
haemodynamic or cellular adaptation (Fudge et al., 2012, Vogt and Hoppeler, 2010, Clanton and 
Klawitter, 2001). Vogt and Hoppeler (2010), argue that the absence of observed improvements in 
performance despite gene expression changes may simply be due to a lack of sensitivity in V˙ O2peak or 
power output testing. Indeed, the variation in those who benefit from or do not benefit from 
simulated (or real) altitude training has led to the discussion of the possibility of ‘responders’ and 
‘non-responders’ to altitude training (Gardner, 2009, Levine, 2002). However, others argue that the 
notion of responders and non-responders may simply represent a normal distribution of responses 
and therefore question the success of such interventions (de Paula and Niebauer, 2012). 
Overall, the effects of simulated altitude in an athletic population has received mixed outcomes, 
with some researchers arguing against (Bärtsch et al., 2008, de Paula and Niebauer, 2012), and 
others supporting the use of simulated altitude (particularly IHE or PHE) for athletic enhancement 
(Hamlin and Hellemans, 2007, Bonetti et al., 2006, Wood et al., 2006), or for improving 
acclimatization prior to performance at altitude (Muza, 2007, Vogt and Hoppeler, 2010). For athletes 
and well trained individuals, the most widely supported model of simulated altitude for 
improvement in performance is the LHTL (Bonetti and Hopkins, 2009, Levine, 2002, Loffredo and 
Glazer, 2006, Rusko et al., 2004). 
2.3.4 Key areas for future research in a sedentary or clinical population 
In the sedentary and clinical populations, IHT does not appear to be particularly more effective than 
normoxic training in improving exercise capacity (Friedmann et al., 2003, Pesta et al., 2011, Vogt et 
al., 2001). However, the effects on vascular health are promising (Nishiwaki et al., 2011, Shi et al., 
2013). Contrastingly IHE appeared to be effective in inducing beneficial adaptation in this cohort, 
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particularly regarding aerobic fitness and exercise tolerance (Burtscher et al., 2009, Burtsher et al., 
2004, Shatilo et al., 2008), restoring cardiac autonomic balance between parasympathetic and 
sympathetic activity (Balykin et al., 2004), and blood lipid profiles (Tin'kov and Aksenov, 2002). 
Further research regarding the hypoxic dosage required for beneficial adaptation in required. 
Cardiac autonomic modulation and systolic blood pressure 
During hypoxia there is an increase in the sympathetic activity of the autonomic nervous system as 
evidenced by an increase in systolic blood pressure and heart rate with hypoxia (Rodway et al., 
2007). However, while systolic blood pressure may remain elevated following PHE, there was no 
such increase following 10 IHE sessions (Foster et al., 2005) in an active population. Indeed, a 
decrease in resting (Shatilo et al., 2008) and exercising (Burtsher et al., 2004) systolic blood pressure 
has been observed following an IHE protocol at an FiO2 of 12% (particularly in a sedentary 
population), but there was an increase in exercising SBP following a similar dose of PHE (Wang et al., 
2007a). Therefore, when selecting a mode of treatment for a sedentary cohort an IHE protocol 
(rather than PHE) may be preferential in a population who may be at risk of high BP. 
Interestingly, some authors have reported a shift towards increased parasympathetic activity in 
cardiac autonomic control following an IHE intervention period (Balykin et al., 2004, Haider et al., 
2009), particularly in an unhealthy population (overweight and at risk of or with mild chronic 
obstructive pulmonary disease). However, while there was reduced parasympathetic withdrawal 
during the hypoxic exposure, no further changes in resting HRV were found in a healthy population 
(Bernardi et al., 2001). The greater sympathovagal improvement via increased parasympathetic 
activity in the autonomic control of the heart in the sedentary population, compared to the fit 
cohort suggests that there is greater potential for improvement following an IHE intervention in a 
less healthy population. As a decrease in vagal activity in cardiac control may be linked to numerous 
risk factors for cardiovascular disease, and indeed even precede the risk factors themselves (Thayer 
and Lane, 2007), the potential for IHE to improve HRV in a sedentary population and potentially 
reduce the risk for future disease warrants further investigation.  
Blood lipid profile  
High density lipoprotein (HDL), low density lipoprotein (LDL) and total cholesterol are important 
considerations in the assessment of a person’s overall cardiovascular risk (New Zealand Guidelines 
Group, 2003). Therefore, the reports of decreased total cholesterol and LDL and a corresponding 
increase in HDL following PHE (Tin'kov and Aksenov, 2002) warrants further investigation. It is 
important that future research makes use of a control group to cater for seasonal or biological 
variation in these measures.  
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Vascular health 
Two recent studies have demonstrated an improvement in vascular health following IHT protocols in 
both postmenopausal women and healthy young men (Nishiwaki et al., 2011, Shi et al., 2013). 
However, Wang et al. (2007a) has reported a decrease in haemodynamic function following a PHE of 
60 min (FiO2 of 12% ) but not following 60 min at an FiO2 of 15% (Wang et al., 2007a, Wang et al., 
2010) which suggests that the severity of the hypoxic stimulus should pass a minimum threshold, but 
not be excessive. That is, there was no change in haemodynamic function following 30 or 60 min of 
PHE at 15%. An improvement in flow mediated dilation and arterial compliance was noted following 
2 h of IHT+PHE at a simulated altitude of 2000 m (IHT: 30 min of swimming at 50% V˙ O2peak +90 min 
PHE) (Nishiwaki et al., 2011) or 50 min IHT (60% HRmax) +30 min PHE at a simulated altitude at 
approximately 2400 m or an FiO2 of 15.5% (Shi et al., 2013). However, 60 min of PHE at an FiO2 of 
12% had a detrimental effect on haemodynamic function (Wang et al., 2007a). An IHE protocol may 
provide a good balance between short intervals of severe hypoxia sufficient to improve arterial 
function, but regular alternation with ambient air may prevent distress or maladaptation.  
 Dosage 
Katayama and colleagues have investigated various alterations and adjustments between the 
different hypoxic delivery modalities. In doing so, Katayama’s research group have established that, 
there is no added advantage to using a 3 h exposure compared to 1 h of hypoxia, that 14 d are 
better than 7 d, and that an FiO2 of 12.3% is better than 15% (Katayama et al., 2009, Katayama et al., 
2007, Katayama et al., 2005). However, most of these studies have been conducted in well trained 
cohorts, using the PHE model, and were focussed on acclimatization. Further research regarding 
dosage should be conducted in a sedentary population. Furthermore, no researchers have 
investigated the differences in the frequency of hypoxic exposures per week. As there are no 
additional advantages to a longer session, compared to a shorter session (1 h compared 3 h), or IHE 
to PHE (Koehle et al., 2007), a 60 min IHE session may prove most beneficial for a sedentary 
population. Additionally, IHE is unlikely to cause any increases in systolic blood pressure (Foster et 
al., 2005), and may avoid the reduction in haemodynamic function with 60 min of PHE at an FiO2 of 
12%. Further research should investigate the frequency of IHE sessions per week necessary for an 
improvement in health in a sedentary population. 
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2.4 Key points and further research from literature review: 
 Simulated altitude seems more likely to be beneficial in a health context, but only 15% of the 
retrieved articles examined the health response to simulated altitude in a sedentary 
population.  
 Based on the current literature, 1 h of IHE to an FiO2 of 12% for at least 2 weeks is likely to 
be most worthwhile for health adaptation. However, more research is needed on the 
frequency of IHE per week for beneficial adaptation. 
 The effects of simulated altitude on the sympathovagal balance in cardiac autonomic 
modulation, vascular health, blood lipid profile as well as cardiovascular fitness should be 
further investigated. 
 While the assessment of specific variables is useful, the effect of simulated altitude on an 
overall cardiovascular risk profile should be pursued.  
 More information regarding the tolerance to hypoxia is desirable. 
 
 
 
Figure 4: The size of each author's surname represents their contribution to the overall literature 
analysed in Tables 3 – 6 
(www.wordle.net, accessed on the 17 November 2013)  
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Table 5: Literature summary of the use of simulated altitude in a healthy / active population (Listed alphabetically) 
 
Authors Participant description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per week, 
weeks) 
Hypoxic 
severity 
Overall Main Outcome(s) 
Ainslie et 
al. (2003)  
Healthy, non-smoker, no 
medication or history of 
disease, 12M, 27 y 
PHE 9 h / d, 5 sessions in 5 d 4300 m  Hypoxic ventilator response 
  Hypoxic & hypercapnic ventilatory 
response 
Ainslie et 
al. (2007)  
Healthy, non-smoker, no 
medication or history of 
disease, 3M4F, 25 y 
IHE then real 5 min hypoxia alternated with 5 
min normoxia for 90 min, 10 - 
12 sessions in 12 d 
SpO2: 82 - 75%   HVR during hypoxic interval (related 
to associated  BP &  middle cerebral 
artery blood flow velocity) following 
IHE. 
 Response in IHE & 12 d real altitude 
(1560 m) 
  As above, 4M3F, 25 y C then real As above, normoxic placebo SpO2: >95% 
Ainslie et 
al. (2008)  
Healthy, non-smoker, no 
medication or history of 
disease, 6M5F, 26 y 
11 IHE + real altitude;  5 min hypoxia alternated with 5 
min normoxia for 90 min, 10 - 
12 sessions in 15 d; followed by 
12 d real altitude (1560 m) 
SaO2: 82 - 75% 
during IHE,  
1560 m at real 
altitude 
  Change to cerebral auto-regulation 
in hypoxia,  
 Muscle oxygenation in hypoxia  
Real altitude   IHE 
  As above, 4M3F, 26 y C then real No treatment followed by 12 d 
at real altitude 
1560 m   
  As above, 6M4F, 26 y Intermittent 
hypercapnia 
As IHE + real, but with FiCO2: 
5% 
FiCO2: 5%, then 
1560 m real 
  
47 
 
Authors Participant description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per week, 
weeks) 
Hypoxic 
severity 
Overall Main Outcome(s) 
Aulin et al. 
(1998)  
Cross country skiers, middle 
and long distance runners, 
road cyclists, rowers and 
triathletes,  
5M1F, 22 y 
LHTL   12 h/d, 10 sessions in 10 d 2000 m  Initial Hb after 2 d but returned to 
baseline.  
 EPO in 3 -5 d and  reticulocyte 
during 7 d LHTL.  
 V˙ O2submax or V
˙ O2peak, BP (rest or 
exercise) or mood states. 
  As above,  
8M1F, 27 y 
LHTL 12 h/d, 10 sessions in 10 d 2700 m 
  As above, 
4M1F, 32 y 
C no treatment sea level 
Bailey et 
al. (2000)  
University students, 2 - 4 h 
exercise/wk, no smoking or 
medications,18 M, 22 y 
IHT: Cycling at 70 - 
85% HR  maximum 
for 20 - 30 min 
20 min/d in wk 1&2; 30 min/d 
in wk 3&4, 3d/wk, 4wk 
FiO2: 16%  IHT:  Lean mass & V
˙ O2peak  SBP & 
exercisesubmax lactate concentration.  
 homocystein  
Both:  nonesterified fatty acids, total 
cholesterol, HDL & LDL &  power 
outputmax 
C: Apolipoproteins AI & B 
  As above, 14 M, 22 y C (sham): as above As above, normoxic placebo FiO2: 21% 
Bailey et 
al. (2001a)  
University students, 2 - 4 h 
exercise/wk, no smoking or 
medications, 18M, 22 y 
IHT: Cycling at 70 - 
85% HR  maximum 
for 20 - 30 min 
20 min/d in wk 1&2; 30 min/d 
in wk 3&4, 3d/wk, 4wk 
FiO2: 16%   Peripheral cholecystokinin (CCK) 
during IHT (correlated to SpO2)  
 CCK at rest or exercise. 
    As above, 14 M, 22 y C (sham): cycling at 
70 - 85% HR for 20-
30 min 
As above, normoxic placebo FiO2: 21% 
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Authors Participant description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per week, 
weeks) 
Hypoxic 
severity 
Overall Main Outcome(s) 
Bailey et 
al. (2001b)  
University students, 2 - 4 h 
exercise/wk, no smoking or 
medications, 18M, 22 y 
IHT: Cycling at 70 - 
85% HR  maximum 
for 20 - 30 min 
20 min/d in wk 1&2; 30 min/d 
in wk 3&4, 3d/wk, 4wk 
FiO2: 16%  In hypoxia: exercise induces  
hydroperoxide & malondialdehyde at 
 V˙ O2peak; increases correlated with  
Hb saturation. 
After IHT: Greater  in exercise-
induced increase in lipid 
hydroperoxides & malondialdehyde in 
IHT  
(through selective mobilization of α-
tocopherol.) 
  As above, 14 M, 22 y C (sham): cycling at 
70 - 85% HR 
maximum for 20 - 30 
min 
As above, normoxic placebo FiO2: 21% 
Bakkman 
et al. 
(2007)  
Used to regular bicycling, no 
endurance training. Healthy, 
no smoking, disease or 
medication, 5M3F, 27 y 
IHT*: 1 leg 30 min at 
65% of maximal 
power output  
45 min/d, 4d/wk, 4 wk 3000 m  Both:  max power output 
C:  citrate synthase,  
 cytochrome C oxidase 
    As above C: Other leg 30 min 
at 65% of maximal 
power output  
As above sea level 
Beidleman 
et al. 
(2003)  
healthy, active no disease or 
smoking, 3 participants, 23 y 
PHE* 4 h/d, 5d/wk, 3wk 4300 m   PHE vs IHT+PHE: data pooled  
 TT performance (22 %)  
 Adductor pollicis endurance,  
 Resting SpO2  
  
  As above, 3 participants, 23 
y 
IHT*: Cycling 45 - 60 
min, 70 - 85% 
maximal HR; 
remainder PHE* 
4 h/d, 5d/wk, 3wk (exercise 
during first h PHE*) 
4300 m 
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Authors Participant description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per week, 
weeks) 
Hypoxic 
severity 
Overall Main Outcome(s) 
Beidleman 
et al. 
(2004)  
healthy, no disease smoking, 
1-2h exercise/wk, 3 
participants, 23 y  
(Total participants: 5M1F) 
PHE* 4 h/d, 5d/wk, 3wk 4300 m   PHE vs IHT+IPE: data pooled  
In 24 h hypoxia:  acute mountain 
sickness & PETCO2 via  ventilation 
after training 
  
  As above,  
3 participants, 23 y 
IHT*: Cycling 45 - 60 
min, 70 - 85% 
maximal HR; 
remainder PHE* 
4 h/d, 5d/wk, 3wk (exercise 
during first h PHE*) 
4300 m 
Beidleman 
et al. 
(2008)  
Healthy, no disease 
smoking, 1-2h exercise/wk, 
5 participants 26 y  
(Total participants: 8M2F) 
5 PHE* 4h/d, 7 sessions in 9 d 4300 m  Both:  time trial performance & SS 
work rate. Data pooled:  
16 % improvement in time trial 
performance 
 SaO2 ,  HR & RPE during steady 
state exercise   As above, 5 participants, 26 
y 
5 IHT* 4h/d, 7 sessions in 9 d, exercise 
in first h PHE* 
4300 m 
Beidleman 
et al. 
(2009)  
Healthy lowlanders, non-
smoking,  
11M, 22 y 
PHE & IHT: 2 X 25 
min cycling at 80% 
peak HR 
2h/day, 7 consecutive sessions 4500 m for PHE, 
3000 m for IHT 
  Time trial  
 HR, SaO2, or RPE during steady 
state exercise in either group 
 
 
 
 
As above,  
6M, 20 y 
C: 6 As above, normoxic placebo Normoxia 
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Authors Participant description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per week, 
weeks) 
Hypoxic 
severity 
Overall Main Outcome(s) 
Berglund 
et al. 
(2002)  
Healthy, 3M, 20-23 y PHE&IHT: 10 min 
cycling at 50 W 
24 h/d, 10 consecutive d SpO2: 91%,  
14 kPa 
  EPO  
(especially after 2 d hypoxia, still 
elevated after 10 d) 
 Hb & Hct 
 Ferritin 
  
  As above, 4M, 20-23y PHE&IHT: as above 
but also 45 min 
cycling at 75 % 
maximum HR every 
other d 
24 h/d, 10 consecutive d SpO2: 91%,  
14 kPa 
Bernardi 
et al. 
(2001)  
Ukrainian soldiers,  
12M, 26 y 
IHE 5-7 min rebreathing alternated 
with 5-7 min normoxia for 1h, 
7d /wk, 2wk 
PETO2: 35 - 40 
mmHg 
  Resting respiration,  HVR,  vagal 
withdrawal in hypoxia, trend to  Hb & 
RBC,  resting HRV 
    As above,  
6M, 27 y 
C As above Sham 
Debevec 
et al. 
(2010)  
Moderately active, healthy, 
9M, 20 y 
IHT: Cycling at HR 
corresponding to 
50% hypoxic peak 
power output 
70 min/d, 5 d/wk, 4 wk FiO2: 12%  C:  V
˙
O2peak, peak power output and 
time to exhaustion 
IHT:  Time to exhaustion  
hypoxic V˙ O2peak, pulmonary function 
or haematological variables 
  
  As above, 9M, 22 y C: Cycling as above at 
50% normoxic peak 
power output 
70 min/d, 5 d/wk, 4 wk FiO2: 21% 
Debevec 
and 
Mekjavic 
(2012)  
Active, healthy, non-smoker, 
10 M, 23 y 
PHE 4h/d, 4 consecutive d 4200 m  
FiO2: 12%  
 In hypoxia:  SpO2 & Ventilation  
 Constant power test or oxygenation 
(cerebral, vastus lateralis, or serratus 
anterior). As above, 9M, 22 y C 4h/d, 4 consecutive d Sham 
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Authors Participant description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per week, 
weeks) 
Hypoxic 
severity 
Overall Main Outcome(s) 
Faulhaber 
et al. 
(2010)  
Cyclists, 6M, 40 y PHE 1h/d, 7 sessions over 9 d FiO2: 12.5%   Mean power output in hypoxia 
PHE  C.  
 Time trial As above, 6M, 34 y C As above FiO2: 21% 
Foster et 
al. (2009)  
Healthy, no confounding 
medical condition, 10M, 21 -
36 y 
IHE  4 d sham, 10 d IHE: 2 min 
hypoxia (or placebo) cycled 
with 2 min normoxia for 6 h 
PETO2: 45 
mmHg 
 MAP 
 Nitric oxide derivatives 
In hypoxia:  pressor response 
 cerebrovascular resistance 
Foster et 
al. (2005)  
Recreationally active, 
healthy, 9M, 26 y 
IHE 5 min hypoxia cycled with 5 min 
normoxia for 1 h, 10 sessions in 
12 d 
FiO2: 12%  HVR (baseline after 17 d),  
 SBP in PHE but not in IHE.  
 In hypoxia: IHE  PHE regarding 
ventilatory & cardiovascular response;  
 cerebral oxygenation.   As above, 9M, 26 y PHE 30 min/d, 10 sessions in 12 d FiO2: 12% 
Foster et 
al. (2006)  
Recreationally active, 
healthy, 9M, 26 y 
IHE 5 min hypoxia cycled with 5 min 
normoxia for 1 h, 10 sessions in 
12 d 
FiO2: 12%   Maximal exercise or ventilatory 
responses during exercise (no 
relationship).  
 
 HVR in IHE and PHE.   As above, 9M, 26 y PHE 30 min/d, 10 sessions in 12 d FiO2: 12% 
Garcia et 
al. (2000)  
Healthy, non-smokers, 9M, 
29.3 y 
PHE 2h/d, 12 consecutive d 3800 m  
FiO2 : 13%  
  Hct or Hb,  
 Ret count to d 5.  
 HVR in hypoxia to d 5, then  to 
lower value on d 12,  
 Ventilatory data (normoxia or 
poikilocapnic hypoxia). 
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Authors Participant description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per week, 
weeks) 
Hypoxic 
severity 
Overall Main Outcome(s) 
Green et 
al. (1999)  
Active, but not endurance 
trained, healthy, 9M, 19 - 27 
y 
IHT: 30 min of 1 leg 
cycling at 75% 
maximal mechanical 
power of weaker leg. 
First 6 wk continuous 
Last 2 wk interval 
30 min/d, 3d/wk, 8 wk FiO2: 13.5% In hypoxia: Mitochondrial potential 
up-regulated  
Na
+
 -K
+
 -ATPase pump expression 
down-regulated.  
Normoxic training  both. 
  
  As above C: as above, but 30 
min on other leg in 
normoxia 
As above FiO2: 21% 
Holliss et 
al. (2013)  
Physically active, healthy, 
9M, 22 y 
IHT: single leg high 
intensity interval 
training 
25 min/d, 5 d/wk, 3wk FiO2: 14.5%   Muscle metabolism between legs 
after training 
  
  As above As above, other leg As above FiO2: 21% 
Katayama 
et al. 
(1999)  
Healthy, no medication, 7M, 
21 y 
IHT*: cycling at 70% 
altitude V
˙
O2peak  
30 min/d, 5d/wk, 2 wk 4500 m  Both groups  V˙ O2peak after training, 
&  after detraining. 
 HVR in IHT (not sig),  C. 
 HVR after detraining As above, 7M, 22 y C: cycling at 70% sea 
level V
˙
O2peak  
30 min/d, 5d/wk, 2 wk Sea level 
Katayama 
et al. 
(2000)  
Healthy, no medication, 7M, 
21 y 
IHT*: cycling at 70% 
altitude V
˙
O2peak  
30 min/d, 5d/wk, 2 wk 4500 m  SBP changes in parallel with HVR in 
progressive hypoxia,  
 DBP & HR. sig correlation between 
change in HVR and change in 
SBP/change in SaO2 
As above, 7M, 22 y C: cycling at 70% sea 
level V
˙
O2peak  
30 min/d, 5d/wk, 2 wk Sea level 
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Authors Participant description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per week, 
weeks) 
Hypoxic 
severity 
Overall Main Outcome(s) 
Katayama 
et al. 
(2001)  
Healthy, no cardiovascular 
disease, 6M, 21 y 
PHE* 30 min ascending, 60 min at 
target/d, 7 consecutive d 
4500 m   HVR (rest) &  ventilatory equivalent 
for O2, and SaO2 in submaximal 
exercise for 7 d.  
Koehle et 
al. (2007)  
University students 
(mountaineering and 
endurance backgrounds), 10 
M, 26 y 
PHE 1 h/d, 7 consecutive d 4200 m 
FiO2: 12% 
  HVR (plateau after 3 d). HVR 
returned to baseline within a week. 
PHE  IHE 
  As above (crossover) IHE 5 min of hypoxia alternated 
with 5 min normoxia, for 2 h; 7 
consecutive d 
4400 m   
Kolb et al. 
(2004)  
Healthy, no smoking, 
mediation or disease, 12 M, 
26 y 
PHE 8 h/d, 5 consecutive d 4300 m  
FiO2: 13.8% 
 PETCO2 &  SaO2 as night 
progressed.  
 AMS on 1st & 2nd night.  
 Cerebral blood flow sensitivity to 
change in O2 & CO2. Regional cerebral 
O2 saturation correlated with SpO2 
Kounalakis 
et al. 
(2013)  
 
 
 
Healthy, active, 8M, 20 y PHE 24 h/d, 10 consecutive d 3400 m  
FiO2: 15.4%  
 C in any measure 
 PHE NIRS in cerebral, serratus 
anterior, V
˙
O2peak or peak work rate 
 ventilation after PHE, & lower  in 
VL Hb dissociation 
As above (crossover) C 24 h/d, 10 consecutive d Sham 
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Authors Participant description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per week, 
weeks) 
Hypoxic 
severity 
Overall Main Outcome(s) 
Levine et 
al. (1992)  
Recreationally active, 7 
participants, 27 y 
IHT*: cycling at 70% 
sea level V
˙
O2peak  
45 min/d, 5 d/wk, 5 wk 2500 m  C:  V˙ O2peak C,  HVR,  
IHT:  V˙ O2peak,  HVR, (possibly  
chemoreceptor sensitivity) 
  
  
  As above, 7 participants, 27 
y 
IHT*: cycling at 70% 
altitude V
˙
O2peak  
As above 2500 m 
  As above, 7 participants, 26 
y 
C: cycling at 70% sea 
level V
˙
O2peak  
As above sea level 
Lundby et 
al. (2005)  
Healthy, moderate-well 
trained, 8M, 24 y 
PHE* 2 h/d, 7 d/wk, 2 wk 4100 m   Hb, HCT, Ret, serum transferrin, 
EPO, or exercise capacity 
Lusina et 
al. (2006)  
Healthy, no smoking, 
mediation or disease, 11 M, 
25 y 
PHE 1 h/d, 10 consecutive d SpO2: 80 %   HVR following IH.  
 SNS during hypoxia & stayed  after 
SpO2 normalised.  
Correlation: MSNA& HVR (SNS & HVR 
centrally controlled.) 
McLean et 
al. (2006)  
Healthy, non-smokers, 6M, 
26.5 y 
PHE 8h/d, 3 consecutive d FiO2: 12.9   EPO & Hct, Hb & RBC (likely natural 
variation or dehydration as  markers 
for EPO such as ret counts or serum 
ferritin concentration   As above, 5M, 26 y 5 C As above FiO2: 20.4% 
Melissa et 
al. (1997)  
Recreational activity, 10 M, 
19 - 25 y 
IHT: 30 min unilateral 
cycling at 75%  
maximal power 
output of weaker leg 
for first 6 wk, interval 
training in last 2 wk 
30 min/d, 3d/wk, 8 wk FiO2: 13.5%   Both legs: V
˙ O2peak, time to 
exhaustion, citrate synthase, succinate 
dehydrogenase & 
phosphofructokinase.  
IHT:  Citrate synthase 
 As above (crossover) As above , other leg As above FiO2: 21% 
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Authors Participant description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per week, 
weeks) 
Hypoxic 
severity 
Overall Main Outcome(s) 
Morton 
and Cable 
(2005)  
Healthy, active in team 
sports, 8M, 21 y 
IHT: moderate - high 
intensity interval 
training 
30 min/d, 3d/wk, 4 wk 2750 m  
FiO2: 15% 
 Both:  V˙ O2peak, Maximum work rate, 
onset of blood lactic accumulation, 
mean & peak power. IHT  C  
 Hb & Hct 
  As above, 8M, 20 y C: as above As above Sea level 
Querido et 
al. (2008)  
Healthy, normal pulmonary 
function, 8M, 41 y 
IHE 5 min hypoxia alternated with 5 
min normoxia for 1h, 10 
consecutive d 
FiO2: 12%   Cerebrovascular sensitivity to 
hypoxia,  
 Ventilatory, BP or HR sensitivity 
change 
Querido et 
al. (2009)  
Healthy, normal pulmonary 
function, 9M, 24 y 
PHE 1 h/d, 10 consecutive d SpO2: 80%   Minute ventilation in hypoxia. 
 Exercise ventilation, middle 
cerebral artery mean velocity & MAP 
Querido et 
al. (2012)  
Healthy, normal pulmonary 
function & no breath 
holding activities, 9M, 24 y 
PHE 1 h/d, 10 consecutive d SpO2: 80%   Cytokines / markers of 
inflammation 
Rodway et 
al. (2007)  
Healthy (not obese, smoking 
or medicated), not training, 
10 M, 20 - 35 y 
IHE 10 min hypoxia alternated with 
10 min normoxia for 1 h, 3 
consecutive d 
FiO2: 13.5%  In hypoxia:  HR, SBP, DBP  
 Nitric oxide synthase mRNA 
correlated to nitric oxide synthase 
mRNA & average end exposure DBP & 
MAP during d 1 - 3 in IHE  As above PHE 1 h/d, 3 consecutive d FiO2: 13.5% 
Shi et al. 
(2013)  
Healthy, no smoking or 
disease, 8M, 26 y 
IHT: Treadmill 
exercise at HR 
corresponding to 
60% V
˙
O2peak 
50 min IHT followed by 30 min 
PHE, 3 d/wk, 4 wk 
FiO2: 15.4%, 
2500 m 
 Improved brachial PWV &  
V
˙ O2peak after IHT, not C 
  
  As above (crossover) C: As above As above, normoxic placebo Fio2: 21% 
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Authors Participant description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per week, 
weeks) 
Hypoxic 
severity 
Overall Main Outcome(s) 
Shin et al. 
(2013)  
Healthy, 9M, 23 y IHT: Treadmill, 60% 
Vo2peak for 40 min 
(5 min warm 
up/down) followed 
by 30 min PHE 
80 min/d, 3d/wk, 4 wk 2500 m   
FiO2: 15.4% 
 V˙ O2peak & HR after training, “Fairly 
Light” corresponded to higher loads.  
Taylor et 
al. (2011)  
Healthy, recreationally 
active, 8M, 20 y 
PHE 75 min/d, 10 consecutive d 2980 m   V˙ O2peak or time to exhaustion 
 Monocyte expressed heat shock 
protein 72 (day 2 - 2 d post-
intervention. 
 Daily elevations in oxidative stress 
markers & sustained  in EPO. 
Tonini et 
al. (2011)  
Active healthy volunteers, 
10M2F, 23 y 
PHE 30 desaturations/h for 8 h, 7 
d/wk, 2 wk 
FiO2: 13%   Exercise capacity,  
 PETCO2 &  VE/VCO2 
(hyperventilation during exercise) 
 HRmax,  DBP, after 1 min of 
submaximal exercise recovery 
 Lactate & RER < 1 at higher power 
output  
*: Hypobaric hypoxia;  Increased;  Decreased;  No change, or no difference; AMS: Acute mountain sickness; BP: Blood pressure; C: Control group; CO2: Carbon dioxide; 
DBP: diastolic blood pressure; EPO: Erythropoeitin; F: Females; FiCO2: fraction of inspired carbon dioxide; FiO2: Fraction of inspired oxygen; Hct: Haematocrit; Hb: 
Haemoglobin; HR: heart rate; HRsubmax: heart rate measured during submaximal exercise; HRR: heart rate reserve; HDL: High density lipoprotein; HIIT: High intensity interval 
training; HVR: hypoxic ventilatory response; IHE: passive intermittent hypoxic exposure;  IHT: intermittent hypoxic training (exercise in hypoxia); LDL: Low density 
lipoprotein; LHTL:Live high train low; LMTM: Live moderate train moderate; M: Males; MAP: Mean arterial pressure; MSNA: Muscle sympathetic nervous activity; O2: 
Oxygen; PETCO2: Partial pressure of end-tidal carbon dioxide; PHE: Prolonged hypoxic exposure; PWV: Pulse wave velocity; RPE: Rating of perceived exertion; RBC: Red 
blood cells; Ret: Reticulocytes; RER: Respiratory exchange ratio sEPO: serum erythropoeitin; SaO2: arterial oxygen saturation; SpO2: peripheral oxygen saturation; SBP: 
Systolic blood pressure; SNS: Sympathetic nervous system; TT: Time trial; V
˙
O2: oxygen uptake; V
˙
O2peak: peak oxygen uptake; V
˙
O2submax: submaximal exercising oxygen 
uptake; VE: expired volume; VCO2: volume of carbon dioxide. 
.
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Table 6: Summary of the literature examining simulated altitude exposure in a well-trained / athletic cohort 
Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Abellan et al. 
(2005)  
Triathlete,  
8M 
PHE* 3h/d, 5d/wk, 4 wk 4000 – 5500 m  Serum erythropoietin, 
 Reticulocytes or RBC. 
  As above,  
8M 
C As above, normoxic placebo Sea level 
Ashenden et al. 
(1999a)  
Triathletes, 
cyclists, cross 
country skiers, 
6M, 25 y 
LHTL 8 - 10 h/d, 23 consecutive d 3000 m  
FiO2: 15.5% 
 Hb, Reticulocyte parameters. 
  As above, 7M, 25 
y 
C Slept at home Sea level 
Ashenden et al. 
(1999b)  
Road cyclists,  
5F, 26 y 
LHTL 8-10 h/d, 12 consecutive d 2650 m  
FiO2: 16% 
 Hb, Reticulocytes or any 
reticulocyte related variables. 
  As above,  
6F, 26 y 
C Slept in dormitories Sea level 
Ashenden et al. 
(2000)  
Middle distance 
runners,  
6 athletes, 22 y 
LHTL 8 - 11h, 5 d LHTL, 3 d recovery 
for 24 d 
2650 m  
FiO2: 16% 
 EPO (after 5 d), but not after 2nd & 
3
rd
 'block' of 5 d.  
 Reticulocyte production. 
 As above,  
6 athletes, 22 y 
 
 
C Slept in dormitories Sea level 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Aughey et al. 
(2005)  
Triathletes, cross 
country skiers, 
road cyclists, 6M, 
25 y 
LHTL 9.5 h/d, 23 consecutive d 3000 m  
FiO2: 15.5% 
LHTL:  3-O-methylfluorescein 
phosphatase (also depressed after 
exercise in C & LHTL).  
 Plasma K+ & [3H]ouabain binding.  
LHTL:  V˙ O2peak but   work. 
 
  As above,  
7M, 25 y 
C Slept at home   
Aughey et al. 
(2006)  
Cyclists & 
triathletes,  
12M, 27 y 
LHTL continuous 8 - 10 h/d, 20 consecutive d 2650 m  
FiO2: 16.3% 
LHTL continuous:  3-O-
methylfluorescein phosphatase (after 
5 d), below pre after 20 d.   
 
LHTL interspersed: Initial  reversed 
itself &  after 20 d.  plasma K+ 
  As above,  
10M, 26 y 
LHTL interspersed 8 - 10 h/d, 5 d LHTL, 2 d 
recovery for 26 d 
2650 m  
FiO2: 16.3% 
  
As above,  
11M, 26 y 
C Slept in dormitories or own 
homes 
 
Sea level 
Bonetti et al. 
(2006)  
Sub-elite sprint 
kayak paddlers, 
10M, 23 y 
IHE 5 min hypoxia alternated with 
5 min normoxia for  1 h, 
5d/wk, 3wk 
FiO2: 12 – 10%  Peak power, repeated sprint power, 
& Hb after IHE.  
 lactate, time trial, V˙ O2peak  & 
exercise economy 
  As above 
(crossover) 
 
 
C Placebo Sea level 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Brugniaux et al. 
(2006b)  
Elite middle 
distance runners,  
5M, 24y 
LHTL 14 h/d, 18 consecutive d 2500 - 3000 m 
FiO2: 16.4% 
LHTL: V˙ O2peak, maximal aerobic 
power, V
˙
O2 and ventilation at 
ventilatory threshold.  
 HRsubmax in 10 min run 
 serum transferrin receptor 
 Hb mass 
 red cell volume 
  As above,  
6M, 23 y 
C As above, normoxic placebo Sea level 
Brugniaux et al. 
(2006a) 
Cross country 
skiers,  
3M3F, 23 y 
LHTL 11 h/d, 18 d 2500 m for 6 d, 
3000 m for 6 d, 
3500 m for 6 d 
AMS,  
SaO2 in hypoxia to 90% at 3500 m.  
 SaO2 after acclimatization, (except at 
3500).  
 leukocyte, or heart function.  
 HVR & smaller change in SpO2) but 
 after 15 d. 
 
 As above,  
2M3F, 20 y 
C 24 h/ d, 18 d 1200 m 
 Swimmers,  
8M,1F, 20 y 
LHTL 16 h/d, 13d 2500 m for 5 d, 
3000 for 8 d 
 As above, 
 8M1F, 17 y 
C 24 h/d, 13 d 1200 m 
 Runners,  
6M, 25 y 
LHTL 14 h/d, 18 d 2500 m for 6 d, 
3000 m for 12 d 
 As above,  
6M, 23 y 
 
 
 
C 24 h/d, 18 d 1200 m 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Casas et al. (2000)  Elite climbers, 
5M1F, 28 y 
IHT*: 15 min / h at a 
HR of 120 - 130 
beatmin-1 (based on 
100W HR at sea level) 
3 - 5 h/d, 17 d 4000 - 5500 m  Packed cell volume, red blood cell & 
Hb concentration  
 HR & Lactate vs exercise load curve  
shifted right ( aerobic endurance).  
 Anaerobic ventilatory threshold, 
pulmonary ventilation, tidal volume, 
respiration frequency, V
˙
O2 CO2 output 
& ventilatory equivalent to O2 & Co2 at 
ventilator threshold. 
Clark et al. (2009)  Cyclists,  
12 M, 22 y 
LHTL 14 h /d, 3 wks 3000 m,  
FiO2: 15.5% 
 Hb mass (3 %),  
 V˙ O2peak,  
1% Hb /week 
EPO peaked on day 2 
Clark et al. (2004)  Triathletes and 
cyclists,  
9 M, 27 y 
LHTL continuous 9-10 h/3, 20 d 2650 m  
FiO2: 16.3% 
 Lactate appearance in first 1 h 
exercise between groups.  
After 25 min at 85% V
˙
O2peak , lactate 
accumulation > 65%.  
V
˙
O2peak (continuous less high).  
Lactate disappearance similar to 
lactate accumulation.  
 Buffering capacity in either. 
  As above, 
10M, 26 y 
C As above, normoxic placebo Sea level 
  As above,  
10M, 27 y 
LHTL interspersed 9-10h /d, 5 consecutive d / 
wk, 4 wk 
 
2650 m  
FiO2: 16.3% 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Czuba et al. (2011)  Elite cyclists,  
10 M, 22 y 
IHT: 15 min: warm up / 
down.  30 - 40 min: 
95% lactate threshold  
60 - 70 min/d, 3 d/wk, 3 wk 2500 - 2600 m  
FiO2: 15.2% 
IHT:  V˙ O2peak, V
˙
O2 lactate threshold, 
work ratemax, work rate at lactate 
threshold &  lactate concentration. 
Improved time trial.  
 Haematological variables. 
  As above,  
10 M, 24 y 
C As above Sea level 
Dufour et al. 
(2006)  
Highly trained 
distance runners,  
9 M, 30 y 
IHT: 1 X moderate, 1 X 
high intensity (with 
normal training) + 3 
normoxic sessions 
24 - 40 min/d, 2 d/wk, 6 wk 3000 m  
FiO2: 14.5% 
IHT:  V˙ O2peak & time to exhaustion.  
 Haemodynamic.  
C:  any parameter 
  As above,  
9 M, 30 y 
C As above Sea level 
Fu et al. (2007)  Collegiate Runners 
and Swimmers, 
4M6F, 23 y 
PHE* 3 h/d, 5 d/wk, 4 wk 4000 - 5000 m  HR, BP, cardiac output, stroke 
volume, total peripheral resistance, 
heart rate variability or cardiac vagal 
baroreflex action 
  As above,  
7M5F, 23 y 
C As above Sea level 
Gore et al. (2006)  Swimmers and 
runners,  
5M6F, 16 - 35 y 
PHE* 3 h/d, 5 d/wk, 4 wk 4000 - 5000 m  erythropoietin 
 Red cell volume, Hb, soluble 
transferrin receptor, or reticulocytes 
  As above,  
6M6F, 16 - 48 y 
 
 
 
C As above Sea level 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Gore et al. (2001)  Triathletes, cross 
country skiers, 
road cyclists,  
6M, 25 y 
LHTL 9.5 h/d, 23 consecutive d 3000 m   
FiO2: 15.5% 
 muscle capacity  
 V˙ O2peak  (but work maintained) 
 V˙ O2submax and  efficiency 
  
As above,  
7M, 25 y 
C Normal accommodation Sea level 
Hamlin and 
Hellemans (2007)  
Cyclists, runners, 
swimmers and 
kayakers,  
5M7F, 32 
IHE 5 min hypoxia: 5 min 
normoxia for 90 min, 5 d/wk, 
3 wk 
FiO2: 10 - 12%  3km run time (-1.7% 2 d & 2.3% 17 d 
after IHE).  
 reticulocytes (23.5% 2 d & 14.6 % 12 
d later) in IHE vs C. 
  
As above,  
8M2F, 32 y 
C Placebo Sea level 
Hamlin et al. 
(2008)  
Rugby Union 
players,  
9MF, 22 y 
IHE - tested at altitude 6 min IHE: 4 min normoxia for 
1 h, 11 sessions in 15 d 
3750 - 5000 m  
FiO2: 10 - 13%  
Improved HRsubmax & Lactate speed  
 Other parameters.  
In hypoxia:  Performance in all 
athletes  
 IHE effect. 
  As above,  
6MF, 26 y 
C - tested at altitude As above Sea level 
  As above,  
7MF, 21 y 
C - Tested at SL As above Sea level 
Hamlin et al. 
(2010)  
Cyclists (road, 
mountain bike, 
triathlete, and 
multisport 
athletes), 
 8M1F, 30 y 
IHT: 60-70 HRR for 90 
min followed by 2 
Wingate tests  
(5 min recovery). 
Logged training 
90 min / d, 10 consecutive d SpO2: 88 - 82% IHT:  Mean power  
 30s peak power, 20km mean power, 
& 20 km oxygen cost.  
 Lactate, RER & SPO2 2 d post IHT. 
  As above,  
6M1F, 39 y 
C Placebo   
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Hendriksen and 
Meeuwsen (2003)  
Triathlete, 
12M, 30 y 
IHT*: 105 min training 
on a cycle ergometer 
at 60 - 70% HRR 
2 h/d, 10 consecutive d 2500 m IHT:  Maximal power output, 
anaerobic mean power, & anaerobic 
peak power& non-significant  V˙ O2peak.  
C:  Maximal power output, V˙ O2peak, 
anaerobic mean power, or peak power 
at sea level. 
  Crossover  C Placebo Sea level 
Hinckson and 
Hopkins (2005)  
Runners and 
Triathletes,  
11M, 31 y 
LHTL 8 h/d, 7d/wk, 4 wk 2500 - 3000 m  Running time, (1%, 1.4% & 1.9 % for 
800 m, 1500 m & 3000 m),  especially 
in athletes with I allele for angiotensin 
converting enzyme  
 Hb. 
 
  Crossover  C no altitude tents Sea level 
Hinckson et al. 
(2006)  
Elite rowers, 
2M5F, 23 y 
IHE 6 min IHE: 4 min normoxia for 
90 min, 7d/wk, 3 wk 
SpO2: 88 - 80% IHE:  5000 m but  mean power for 
500 m time trial  
Major benefits unlikely 
  Elite rowers, 
1M4F, 20 y 
C Placebo Normoxic placebo 
Hinckson et al. 
(2007)  
Rugby players, 
5M, 23 y 
IHE 6 min IHE: 4 min normoxia for 
1 h, 7d/wk, 2 wk 
FiO2: 10 - 15%  Maximum sprint time or speed.  
 Peak power during scrum, offensive 
sprint & tackle 
  Rugby players, 
5M, 23 y 
 
 
C Placebo Normoxic placebo 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Hinckson et al. 
(2005)  
Competitive 
runners,  
8M2F, 25 y 
LHTL 10 h/d, 7 d/wk, 24 - 30 d 2500 - 3000 m LHTL:  Time to exhaustion (16 %).  
 Effect on genotype for angiotensin 
converting enzyme & change in Hb 
  Competitive 
runners,  
8M2F, 37 
C Normal accommodation Sea level 
Julian et al. (2004)  Highly trained 
distance runners,  
14M3F total, 25 y 
(groups not 
distinguished) 
IHE 5 min hypoxia alternated with 
5 min normoxia for 70 min, 
5d/wk, 4wk 
FiO2: 10 - 12%  V
˙
O2peak, 3000 m time trial, EPO 
soluble transferrin receptors, or 
reticulocytes 
  As above C Placebo Normoxic placebo 
Katayama et al. 
(2003)  
Endurance 
runners,  
6M, 21 y 
PHE* 90 min/d, 3d/wk, 3wk 4500 m PHE:  3000 m running time.  
V˙ O2submax  
 Time to exhaustion in maximal test. 
Both:  cardiorespiratory parameters 
in exercise or resting haematological 
parameters  
 After 3-wk recovery. 
  As above,  
6M, 23 y 
C No treatment Sea level 
Katayama et al. 
(2004)  
Endurance 
runners,  
8M, 22 y 
PHE: 8 3 h/d, 7 d/wk, 2 wk FiO2: 12.3%  V
˙
O2submax & 3000 m time tended to 
improve 
 V˙ O2peak or resting haematological 
parameters. 
  As above,  
7M, 20 y 
C: 7 No treatment Sea level 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Katayama et al. 
(2005)  
endurance 
runners,  
7M, 20 y 
PHE 3 h/d, 7 d/wk, 1 wk FiO2: 12.3%  Hypercapnic ventilatory slope after 
7 d,  after 14 d 
BOTH:  Hypercapnic ventilatory 
intercept &  hypoxic ventilatory 
slope.  
 After 2 wk recovery 
  As above,  
7M, 22 y 
C No treatment Sea level 
  As above,  
8M, 22 y 
PHE 3 h/d, 7 d/wk, 2 wk FiO2: 12.3% 
  As above,  
8M, 20 y 
C No treatment Sea level 
Katayama et al. 
(2007)  
Endurance 
runners,  
6M, 20y 
PHE 1 h/d, 7 d/wk, 1 wk 2500 m  
FiO2: 15.5% 
 Any parameter at FiO2 15.5%.  
 HVR at FiO2 12.3% 
 HVR or SpO2 during exercise. 
  As above,  
6M, 20 y 
PHE 1 h/d, 7 d/wk, 1 wk FiO2: 12.3% 
  As above,  
6M, 21 y 
C No treatment Sea level 
  
  
      
Katayama et al. 
(2009)  
Distance runners,   
10M, 26 y 
PHE 1 h/d, 7 d/wk, 1 wk 4300 m  
FiO2: 12% 
Both:  HVR  
 Hypocapnic ventilatory response 
  Crossover study PHE 3 h/d, 7 d/wk, 1wk 4300 m  
FiO2: 12%  
  Crossover study C No treatment Sea level 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Kinsman et al. 
(2005)  
endurance 
runners,  
7M, 26 y 
LHTL continuous 6 h/d, 7 d/wk, 15 d 2650 m  Between groups. Highly varied 
arousal response & respiratory 
disturbance (not significant).  
 SpO2 during hypoxic sleep.  
 Number of arousals at 1 & 2 wk into 
study,  
 REM 1 wk into study. 
  As above  
7M, 26 y 
LHTL interspersed  6 h/d, 5d/wk, 3 wk 2650 m 
Lecoultre et al. 
(2010)  
Competitive 
cyclists,  
7M, 29 y 
IHT: 2 X HIIT + 15 min 
warm up/down; 
1 X 100 min endurance  
46 - 105 min/d, 3d/wk, 4 wk 3000 m  Endurance performance but  
IHT  C  
 Lactate turnover C & IHT.  
 Glucose metabolism in IHT   As above  
7M, 26 y 
C normoxic training Sea level 
Maciejczyk et al. 
(2012)  
Elite Polish race 
walker,  
1M, 30 y 
C; LHTL; Real LHTL: 8 h/d, 7 d/wk, 4 wk; 
Real 26 d continuous 
LHTL: 2133 m,  
Real: 1800 m 
LHTL:  Haematological parameters & 
 Ventilatory threshold 
V˙ O2peak.  
Real altitude: V˙ O2peak,  
 Ventilatory threshold 
 Haematological measures.  
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Manimmanakorn 
et al. (2012)  
Well trained 
netball players, 
10F, 20 y 
Occlusion: As IHT 12 - 13 min/d, 5 d/wk, 5 wk Kaatsu   Maximal voluntary contraction, area 
under 20s force curve & number of 
20% 1RM.  
 Cross sectional area in Kaatsu & IHT 
groups.  
 Gains in Kaatsu vs IHT (except 
number of 20% 1RM). 
  As above,  
10F, 20 y 
IHT: 3 sets of knee 
extension & flexion to 
exhaustion (20% 1RM) 
As above SpO2: 80% 
  As above,  
10F, 20 y 
C: As IHT As above Normal 
Manimmanakorn 
et al. (2013)  
Well trained 
netball players,  
10F, 20 y 
Occlusion  12 - 13 min/d, 5 d/wk, 5 wk Kaatsu   Electromyographic activity after 
Kaatsu vs to IHT and C 
  As above, 
10F, 20 y 
IHT: 3 sets of knee 
extension & flexion to 
exhaustion (20% 1RM) 
As above SpO2: 80% 
  As above,  
10F, 20 y 
C As above Normal 
Mounier et al. 
(2009)  
Cyclists and 
triathletes,  
10M, 24 y 
IHT: 2 X interval, 3 X 
continuous:  
1 h 60% V
˙
O2peak  
26 - 60 min/d, 5d/wk, 3 wk 3000 m  HIF-1a mRNA in skeletal muscle but 
 leukocytes 
  As above  
9M, 24 y 
C As above Sea level 
Muza et al. (2009)  US Military 
personnel,  
11M, 22 y 
PHE + IHT; 2 h PHE 
followed by: 2 x 25 min 
cycling at 80% peak HR 
2 h PHE & 1 h IHT, 7 d/wk, 1 
wk 
PHE: 4500 m 
IHT: 3000 m 
IHT+PHE  all variables.  
Real altitude: improved time trial, 
RPE  
HR & SaO2. 
  As above,  
10M, 21 y 
Real 24 h/d, 6 d 2200 m 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Neya et al. (2007)  Collegiate middle 
and long distance 
runners,  
10M, 21 y 
LHTL 10 - 12 h/d, 7 d/wk, 4 wk 3000 m  
FiO2: 14.5% 
 Total Hb, V˙ O2peak, or time to 
exhaustion (any group) 
LHTL: Running economy (5%) 
  As above,  
9M, 20 y 
IHT: 30 min treadmill 
running for 12 of the 
31 d intervention 
30 min/d, 12 consecutive d 3000 m  
FiO2: 14.5% 
  As above,  
6M, 21 y 
C No treatment Sea level 
Nordsborg et al. 
(2012)  
Road cycling, 
triathlons, cycle 
cross, mountain 
biking,  
15M1F, 39 y 
(groups not 
specified) 
LHTL 16 h/d, 7 d/wk, 4 wk 3000 m LHTL  C groups.  
 Mean power, arterial plasma pH, 
lactate, K+ & muscle buffer capacity, 
sarcolemmal H
+
 transporters & NA
+
K
+
 
pump subunits a1, a2 & b1 in 
submaximal or maximal exercise. 
  As above C As above, normoxic placebo Normoxic placebo 
Nummela and 
Rusko (2000)  
400 m runners 
(Finnish national 
team),  
6M2F, 22 y 
LHTL 16.5 h/d, 10 consecutive d 2200 m  
FiO2: 15.8%  
LHTL:  400 m race time  
 Speed at onset of blood lactate 
accumulation.  
 Resting blood pH ( 6/ 8 LHTL 
participants) 
 As above,  
10 M, 22 y 
C 
 
 
Sea level Sea level 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Pedlar et al. (2008)  Runners and 
Triathletes,  
6M, 30 y 
IHT: Treadmill running  
75 min / d, below 2 
mmol/L lactate 
75 min / d, 8 consecutive d 2500 m  
FiO2: 14.9% 
In hypoxia:  TT time  
Both: improved TT performance but 
not sig; better in IHT.  
 Individual variability   As above,  
6M, 29 y 
C Normoxic training Normoxic placebo 
Ponsot et al. 
(2006)  
Distance runners,  
8M, 30 y 
IHT: 2 x 12 min at 
beginning up to 2 x 20 
min intervals at the 
second ventilatory 
threshold 
24 - 40 min/d, 2 d/wk, 6 wk 3000 m  
FiO2: 14.5% 
 
IHT:  Time to exhaustion, V˙ O2 at the 
second ventilatory threshold & 
 V
˙
O2peak;  
 muscle oxidative capacity  
IHT: Mitochondria shifted to a more 
oxidative profile  
 
  As above,  
7M, 31 y 
C: as above, in 
normoxia 
Normoxic training Normoxic placebo 
Povea et al. (2005)  Swimmers and 
middle distance 
runners,  
8M, 21 y  
LHTL 11 - 16 h/d,  
13 consecutive d 
2500 - 3000 m  
FiO2: 15.7-14.5%  
 Ventilation & SNS in subsequent 
hypoxic exposures in the Hyp groups 
  As above, 
12M, 22 y 
LLTL No treatment 1200 m 
Pupiš and Čillík 
(2008)  
Race walker, 1M, 
28 y 
IHE 6 min hypoxia alternated with 
3 min normoxia for 90 min, 21 
sessions over 14 d 
FiO2: 14 - 8% 
SpO2: 90 - 70% 
 3km walk time after IHE  
 Haematological variables. 
Ramos Campo et 
al. (2011)  
Elite cyclists,  
8 cyclists, 23 y 
PHE 40 - 60 min/d, 4 d/wk, 8 wk FiO2: 14 - 11%; 
SpO2: 90 - 85% 
 Haematological variables, no 
suggestion of erythropoiesis. 
  As above,  
8 cyclists, 27 y 
C Normoxia Sea level 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Robach et al. 
(2006a)  
Nordic skiers,  
3M3F, 23 y 
LHTL 11 h/d, 18 consecutive d 6 d 2500 m 
6 d 3000 m 
6 d 3500 m 
 EPO & Soluble transferrin receptor 
response.  
 Reticulocytes or any haematological 
parameters.  
 V˙ O2peak, time to exhaustion.   
No advantage of altitude > 3500 m 
  As above,  
2M3F, 21 y 
C Normoxic placebo 1200 m 
Robach et al. 
(2006b)  
Swimmers,  
8M1F, 20 y 
LHTL 16 h/d, 13 consecutive d 5 d 2500 m  
8 d 3000 m 
LHTL: Ret, sEPO, & Soluble 
transferring receptor;  
 Red blood cells.  
 V˙ O2peak (not sig).  
 2000 m time.  
C:  Reticulocytes.  
 Performance/ haematological 
parameters after 2 wks. 
  As above, 
 8M1F, 17 y 
C No treatment 1200 m 
Roberts et al. 
(2003)  
Cyclists,  
14M5F, 28 y 
groups not 
specified 
  
  
LHTL: 5 d 8 - 10 h/d, 5 consecutive d 2650 m  
FiO2: 16.3% 
 Groups so data pooled.  
 Average maximal power output in 4 
min, & maximum accumulated oxygen 
deficit ( C). 
 Both:  V˙ O2peak 
  LHTL: 10 d 8 - 10 h/d, 10 consecutive d 2650 m  
FiO2: 16.3%  
  LHTL: 15 d 8 - 10 h/d, 15 consecutive d 2650 m  
FiO2: 16.3% 
  
  
C No treatment Sea level 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Robertson et al. 
(2010a)  
Elite swimmers,  
11M7F, 21 y 
Either 10 d of LHTL, or 
5 d LHTL + 5 d LMTM 
for each 'block'. 4 
blocks over 21 wks. 
Real: LMTM 
9-10 h/d, 4 X 10 nights 2600 m Large individual variation, Some 
physiological adaptation to altitude 
training but transfer into improved 
competitive performance. Evidence of 
responders & non-responders. 
Robertson et al. 
(2010b)  
Middle distance 
and distance 
runners,  
6M2F, 30 y 
LHTL 14 h/d, 21 consecutive d; 5 wk 
wash out, repeated 
3000 m LHTL:  V˙ O2peak  & Hb,  
 Time trial response.   
 Variability in the altitude blocks in 
time trial performance (LHTL C) 
LHTL: Reproducible in V˙ O2peak  (2.1%) 
& Hb (2.8%).  
 LHTL > C after 1st block & Hb > C in 
second block. 
  As above,  
5M3F, 30 y 
C Normoxia Sea level 
Robertson et al. 
(2010c) 
 
Middle distance 
runners,  
6M2F 
LHTL+H: Treadmill: 1 X 
moderate, 1 X long, 2X 
high intensity interval 
training.  
LHTL: 14 h/d; 7 d/wk, 3 wk; 
IHT: 60 - 75 min/d; 4 d/wk, 3 
wk 
3000 m (living); 
2200 m (IHT) 
LHTL + IHT:  V˙ O2peak , Hb, & 3km time 
trial but  after 2 wks.  
IHT: Only  V˙ O2peak 
  
Middle distance 
runners,  
7M2F 
IHT: Treadmill: 1 
moderate, 1 long, and 
2 interval 
IHT: 60 - 75 min/d; 4 d/wk, 3 
wk 
2200 m 
Rodríguez et al. 
(2000)  
Well trained,  
8M, 24 y 
PHE* 90 min/d, 3d/wk, 3 wk Started 4000 m,  
 500 m each day 
to 5500 m, 5500 
m to end. 
 All haematological indicators of red 
cells: packed cell volume, RBC count, 
reticulocytes, and Hb.  
 
 
   SpO2 from 60 to 78 % 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Rodríguez et al. 
(2007)  
Runners and 
Swimmers,  
5M6F, 2 y 
PHE* 3 h/d, 5 d/ wk, 4 wk Started 4000 m,  
500 m every 
second day to 
5500 m,  
5500 m to end 
Both:  Time trial, V˙ O2peak, ventilation, 
HR, ventilation, or V
˙
O2 at ventilatory 
threshold.  
 Swimmers. V˙ O2peak & V
˙
O2 at 
ventilatory threshold 
  As above,  
6M6F, 23 y 
C As above, normoxic placebo Normoxic placebo 
Rodriguez et al. 
(1999)  
High altitude 
expedition 
members,  
1M6F, 28 y 
PHE*+IHT*; IHT*: 3 – 5 
X 10 – 15 min light 
cycling (HR 120 - 130) + 
PHE for remainder 
3 -5 h/d, 9 consecutive d 4000 m -5500 m IHT+PHE  PHE  
 Exercise time & maximal pulmonary 
ventilation during exercisemax,  
lactate velocity curved to the right 
(aerobic endurance),  
 packed cell volume, RBC, Hb 
concentration & Reticulocytes 
  As above,  
8M2F, 28 y 
PHE* As above 4000 m -5500 m 
Roels et al. (2007a)  Cyclists and 
triathletes,  
10M, 24 y 
IHT: 3 X continuous: 
60% V
˙
O2peak for 1h. 2 X 
interval 
56 - 90 min/d, 5 d/wk, 3 wk 3000 m Both:  Peak power output,  
V˙ O2peak  
In hypoxia:  Peak power output after 
IHT.  
 Average power output in the time 
trial in C 
  As above,  
8M, 24 y 
C Normoxic training Sea level 
Roels et al. 
(2007b)  
Cyclists and 
triathletes,  
10M, 24 y 
IHT: 3 X continuous: 
60% V
˙
O2peak for 1h.  
2 X interval 
56 - 90 min/d, 5 d/wk, 3 wk 3000 m Both:  Peak power output  
 V˙ O2peak   
IHT: changed mitochondrial substrate 
preference ( glutamate + malate &  
 palmitate +malate during maximal 
ADP stimulated mitochondrial 
respiration 
 As above,  
9M, 24 y 
C Normoxic training Sea level 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Roels et al. (2005)  Cyclists and 
triathletes,  
11M, 22 y 
IHT: 2 high intensity 
interval training 
sessions/wk 
57 - 85 min/d, 2 d/wk, 7 wk 3000 m Both:  mean power output (not sig) 
 after 3 wks.  
IHT during warm up/ down + recovery: 
 V˙ O2peak.  
 Haematological variables 
  Cyclists and 
triathletes,  
11M, 23 y 
IHT: (hypoxia during 
warm up and cool 
down but intervals in 
normoxia) 
37 - 52 min/d, 2 d/wk, 7 wk 3000 m 
  Cyclists and 
triathletes,  
11M, 33 y 
C Normoxic training Sea level 
Saunders et al. 
(2004)  
Elite distance 
runners,  
10M, 25 y 
LHTL 9 - 12 h/d, 5 d/wk, 4 w 2000 m -3100 m LHTL:  V˙ O2submax, ventilation, 
respiratory exchange ratio, HR, Hbmass, 
(not significant). 
 As above,  
10M, 24 y 
LMTM 20 d real altitude 1570 m  
  As above,  
13M, 25 y 
LLTL Sea level Sea level 
Saunders et al. 
(2009)  
Elite middle 
distance runners, 
 9 runners, 24 y 
LHTL 9 h/d, 5 d/wk, 12 wk 2860 m LHTL: V˙ O2submax, Hbmass, HRsubmax & 
trivial  V˙ O2peak 
 
  As above, 
 9 runners, 27 y 
C 
 
 
 
Normal residence Sea level 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Schmitt et al. 
(2006)  
Cross country 
skiers,  
3M3F, 23 y 
LHTL 11 h/d, 18 consecutive d 6 d 2500 m 
6 d 3000 m 
6 d 3500 m 
 V˙ O2peak LHTL & C groups  
 Peak power LHTL > C.   
 V˙ O2peak  after 15 d LHTL: 
 peak power output & power at 
respiratory compensation point 
 As above,  
2M3F, 21 y 
C Sea level Sea level 
 Swimmers, 8M1F, 
20 y 
LHTL 16 h/d, 13 consecutive d 5 d 2500 m 
8 d 3000 m 
  As above,  
8M1F, 17 y 
C Sea level Sea level 
 Runners, 
 5M, 24 y 
LHTL 14 h/d, 18 consecutive d 6 d 2500 m 
12 d 3000 m 
  As above,  
6M, 23 y 
C Sea level Sea level 
Siebenmann et al. 
(2012)  
Road cycling, 
triathlon, cycle 
cross, mountain 
bike, 10 cyclists 
(15M1F, 29 y 
overall) 
LHTL 16 h/d, 28 consecutive d 3000 m  V˙ O2peak (in normoxia & hypoxia).  
 Hb, mean power output & exercise 
economy in groups 
  6 Cyclists C Sea level Sea level 
Tadibi et al. (2007)  Endurance trained 
athletes 10M, 27 y 
IHE 6 min hypoxia alternated with 
4 min normoxia for 1 h, for 15 
consecutive d 
FiO2: 10 - 11%  Peak power, mean power, V
˙
O2peak, 
lactate threshold, HR, ventilation, or 
submaximal variables. 
  As above,  
10M, 29 y 
C Normoxic placebo Normoxic placebo 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Tiollier et al. 
(2005)  
Cross country 
skiers,  
3M3F, 23 y 
LHTL 11 h/d, 18 consecutive d 6 d 2500 m  
6 d 3000 m,  
6 d 3500 m 
 Secretory immunoglobin A (sIgA) 
significant in LHTL but not in C 
LHTL:  Protein concentration negative 
correlation with sIgA at 3000 & 3500. 
 Cortisol   
As above,  
2M3F, 21 y 
C Sea level Sea level 
Townsend et al. 
(2002)  
Cyclists and 
triathletes,  
12M, 27 y 
LHTL consecutive 8 - 10 h/d, 20 consecutive d 2650 m  HVR LHTLcontinuous than C  
PETCO2 in LHTL groups 
  Cyclists and 
triathletes,  
10M, 27 y 
LHTL interspersed 8 - 10 h/d, 5 d/wk, 4wk 2650 m 
  As above,  
11M, 26 y 
C Sea level Sea level 
Townsend et al. 
(2005)  
Triathletes and 
cyclists, 
11M, 26 y 
LHTL continuous 8 - 10 h/d, 20 consecutive d  Submaximal exercise ventilation in 
both LHTL groups, (not C).  
HVR correlated with exercisesubmax 
ventilation after LHTL   Triathletes and 
cyclists,  
9M, 26 y 
LHTL interspersed 8 - 10 h/d, 5 d/wk, 4wk 
  
As above,  
11M, 26 y 
C Sea level   
Truijens et al. 
(2008)  
Runners and 
Swimmers,  
6M5F, 22 y 
PHE* 3 h/d, 5 d/ wk, 4 wk 4000 m +  500 m 
every second day 
to 5500 m; 5500 
m until end 
 Exercise economy,  HRsubmax, lactate, 
ventilation or velocity at V
˙
O2peak 
  As above,  
6M6F, 23 y 
C As above Normoxic placebo 
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Authors Participant 
description 
(cohort, MF, Age) 
Group treatment Frequency (sessions, per 
week, weeks) 
Hypoxic severity Overall outcome(s) 
Truijens et al. 
(2003)  
Swimmers,  
3M5F, 29 y 
IHT: 3 X High intensity 
training  
3 X low / moderate 
normoxic training  
3 h/d, 5 d/ wk, 4 wk FiO2: 15.3% Both:  100 & 400 m freestyle;  
 V˙ O2peak 
  As above,  
3M5F, 29 y 
C normoxic training Normoxic placebo 
Ventura et al. 
(2003)  
Cyclists, 7 
participants 
(11M1F, 25 y, 
groups not 
specified) 
IHT: 30 min / session, 
Borg values > 15 & 
exercise HR recovery > 
45 s 
30 min/d, 3 d/wk 6 wk 3200 m  V˙ O2peak, maximal power output (in 
hypoxia / normoxia) or hypoxic work 
capacity.  
In hypoxia:  SpO2 & blood lactate in 
IHT.  
In hypoxia both:  Ferritin in (sig IHT); 
 reticulocytes 
  As above, 5 
participants 
C As above 560 m 
Wood et al. (2006)  Hockey and 
Soccer players,  
15M, 24 y 
IHE 6 min hypoxia alternated with 
4 min normoxia for 1 h, for 15 
consecutive d 
3600 – 6000 m  Speedmax & sprint speed ( last 
sprint),  
 Lactate concentration, resting & 
exercising HR.  
 Performance 9 d later. 
  
As above,  
14M, 23 y 
C normoxic placebo Sea level 
*: Hypobaric hypoxia;  Increased;  Decreased;  No change, or no difference; BP: Blood pressure; C: Control group; CO2: Carbon dioxide; DBP: diastolic blood pressure; 
EPO: Erythropoeitin; F: Females; FiO2: Fraction of inspired oxygen; Hb: Haemoglobin; HR: heart rate; HRsubmax: heart rate measured during submaximal exercise; HRR: heart 
rate reserve; HDL: High density lipoprotein; HIIT: High intensity interval training; HVR: hypoxic ventilatory response; IHE: passive intermittent hypoxic exposure;  IHT: 
intermittent hypoxic training (exercise in hypoxia); LDL: Low density lipoprotein; LHTL: Live high train low; LMTM: Live moderate train moderate; M: Males; O2: Oxygen; 
PHE: Prolonged hypoxic exposure; RPE: Rating of perceived exertion; RBC: Red blood cells; Ret: Reticulocytes; RER: Respiratory exchange ratio; sEPO: Serum erythropoeitin 
SpO2: peripheral oxygen saturation; SBP: Systolic blood pressure; SNS: Sympathetic nervous system; V
˙
O2: oxygen uptake; V
˙
O2peak: peak oxygen uptake; V
˙
O2submax: 
submaximal exercising oxygen uptake. 
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 Chapter 3
Preface to Study 1: The effect of short term intermittent hypoxic 
exposure on heart rate variability in a sedentary population 
The first study includes both a practical and academic purpose: from a practical point of view, the 
reasonably small study served to trial the recruitment protocols, participant management systems, 
testing and IHE and HRV protocols. The second purpose was to address some of the issues identified 
in the literature review. Specifically, regarding Research Gap I: The effect of IHE on cardiovascular 
fitness and the parasympathetic and sympathetic responses to simulated altitude; Research Gap II: A 
detailed assessment of the participant’s subjective response to the IHE protocol; and by selecting 
sedentary, middle-aged participants, Research Gap III will also be addressed. The low cost, non-
invasive and time efficient nature of heart rate variability (HRV) assessment made this measurement 
technique ideal for the purpose of the first study.  
Authorship:  
Catherine Lizamore1, Yasotha Kathiravel2, John  Elliott3, John Hellemans4 & Michael Hamlin1 
1Department of Social Science, Parks, Recreation, Tourism and Sport, Lincoln University, Christchurch, 
New Zealand, 2Sports Doctors, Christchurch, New Zealand,  3Department of Medicine, University of 
Otago, Christchurch, New Zealand,  4Sportsmed, Christchurch, New Zealand 
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study, primary feedback on draft documents.   
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3.1 Abstract 
While the effects of instantaneous, single-bout exposure to hypoxia have been well researched, little 
is known about the heart rate variability (HRV) responses during or as an adaptation to repeated, 
short-term, high intensity intermittent hypoxic exposure (IHE) in a sedentary population. Resting HRV 
and exercise capacity was assessed in 16 participants (8 receiving IHE, (IHE) and 8 receiving placebo 
(C)) before and after a 4-week IHE intervention. Heart rate variability was also measured during an 
IHE session in the last week of the intervention. Post-intervention, the root mean squared successive 
difference (rMSSD) increased substantially in IHE (71.6 ± 52.5%, mean change ± 90% confidence 
limits) compared to C suggesting an increase in parasympathetic activity. However, aside from a 
likely decrease in submaximal exercise heart rate in the IHE group (-5.0  6.4%) there was little 
evidence of improved exercise capacity. During the 4-week IHE measurement, there was a decline in 
parasympathetic activity during the hypoxic exposure (reduced R-R interval: –7.5 ± 3.2%; and rMSSD: 
-24.7 ± 17.3%), and reactivation during ambient breathing. It is possible that parasympathetic 
withdrawal and reactivation associated with the repeated hypoxic exposure  and ambient air 
intervals was responsible for the increased rMSSD during rest. In summary, while 4 weeks of IHE is 
unlikely to improve maximal exercise capacity, it may be a useful means of increasing HRV in people 
unable to exercise. 
 Keywords: Autonomic nervous system, sedentary lifestyle, interval hypoxia, simulated altitude, 
physical fitness, health 
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3.2 Introduction  
Heart rate variability (HRV) is the analysis of the variation in the beat-to-beat intervals in the heart 
rhythm, which reflects parasympathetic (vagal) and sympathetic actions on the sinus node (Stein and 
Kleiger, 1999). Typically, a lower resting HRV (or lower variation in RR intervals or cyclic oscillations in 
the beat-to-beat intervals) is associated with poorer health and cardiovascular disease (Dekker et al., 
2000) while an increase in HRV  is associated with improved health (Felber Dietrich et al., 2008, 
Rennie et al., 2003). Based on these associations, the assessment of HRV has provided a reasonably 
simple, non-invasive and cost effective means of assessing the sympathovagal balance in the 
autonomic control of the heart. 
Heart rate variability is also responsive to the changes in the ANS associated with external stimuli 
such as real or simulated altitude (Saito et al., 2005). For example, an initially sharp increase in 
sympathetic activity is observed upon arrival at altitude (Guger et al., 2008, Vigo et al., 2010), which 
gradually declines through the acclimatization process (Jun et al., 2008, Sevre et al., 2001). The 
recovery of HRV to baseline levels upon return to normoxic ambient air depends on the length and 
severity of the initial exposure. That is, after 12 hours of continuous hypoxic exposure, a dampened 
effect on HRV is still evident an hour after returning to normoxic ambient air (Guger et al., 2008), but 
after a brief hypoxic exposure of 15 min, recovery is almost immediate (Roche et al., 2002).  
While the acute effects of single or continuous hypoxic exposures have been well-documented, the 
HRV response during repeated bouts of intermittent hypoxic exposure (IHE), such as is used in 
simulated altitude procedures for athletes (Bonetti and Hopkins, 2009, Hamlin et al., 2009) and non-
athletes (Burtsher et al., 2004, Haider et al., 2009) has received little attention. In addition, while IHE 
has been suggested as a safe means of improving exercise economy (Burtsher et al., 2004) and 
baroreflex sensitivity (Haider et al., 2009) in participants with cardiovascular disease, little is known 
about the training effect of IHE on HRV in a sedentary, middle-aged population. The aim of this 
research was to investigate the instantaneous and adaptive effects of 4 weeks of IHE on HRV in a 
sedentary, middle-aged population. 
3.3 Methods 
3.3.1 Participants and overview of the experimental procedure 
Relatively inactive individuals who participated in less than 30 min of physical activity on most days 
of the week (Garber et al., 2011), who were generally healthy, aged between 45 – 60 years were 
eligible to participate. Exclusion criteria included: uncontrolled hypertension or cholesteraemia, any 
condition where SpO2 is already compromised, melanoma, pregnancy, or by their own or the 
screening physician’s discretion.  
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Following a health assessment, all participants completed a baseline assessment during which HRV, 
BP and fitness were assessed. The 16 participants were then randomly selected into either a group 
receiving IHE treatments (IHE) (n=8;  5 females, 3 males; age: 56.5 ± 5.50 years; height: 171.0 ± 10.1 
cm; weight: 82.3 ± 13.5 kg; body fat: 33.5 ± 4.5%; mean ± s)  or a placebo (C) (n=8; 6 females, 2 
males; age: 56.1 ± 5.1 years; height: 164.6 ± 8.4 cm; weight: 81.3 ± 27.2 kg; body fat: 35.2 ± 12.9%). 
During week 4 of the intervention, HRV was measured during the IHE and placebo treatments in 
order to measure the effects of hypoxia and the normoxic placebo against ambient air conditions. 
The week 4 measurements were not compared to baseline or post-intervention recordings as the 
recording durations and conditions were different. Following the conclusion of the 4-week 
intervention, a post-intervention assessment was conducted where the measurements taken at the 
baseline assessment were repeated. (See Figure 5 for a visual representation of the testing 
procedure). Participants remained blind to their groups throughout the study. All participants signed 
a written informed consent prior to participation. This study was approved by the local University 
Human Ethics Committee. 
3.3.2 Baseline and post-intervention testing 
Quantification of physical activity at baseline and post-intervention was completed using the 
International Physical Activity Questionnaire, long-format (IPAQ-LF), and a 4–day diary detailing 
nutritional intake, sleep, mood, medicine and physical activity. Participants were asked to replicate 
these on subsequent testing days. At baseline, participants were familiarised with the testing 
equipment and procedures, and anthropometric data were collected including body composition and 
weight (InBody230, Biospace Co. Ltd., Seoul, South Korea), height and age. An overview of the full 
experimental procedure is outlined in Figure 5. 
 
Figure 5: Experimental procedure including Baseline and Post-intervention, and the Week 4 HRV 
assessment 
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Heart rate variabilty. 
 Resting heart rate (HR), HRV and systolic blood pressure (SBP) were measured for 5 min following 5 
min of supine rest in a quiet, semi-dark room. Heart rate variability was detected using a heart rate 
monitor (RS800CX, Polar Electro Oy, Kempele, Finland) and belt (Wearlink W.I.N.D, Polar Electro Oy, 
Kempele, Finland). The detection of RR intervals using similar Polar heart rate technology has been 
validated against 12-lead ECGs (Porto and Junqueira Jr, 2009). Following detection of the RR 
intervals, data were filtered and analysed using Polar software (Polar ProTrainer 5, Version 5.41.000) 
with the default settings of moderate filter power and minimum protection zone of 6 beatmin-1. 
Data were then visually inspected and any remaining ‘spikes’ in the HR trace were removed and 
replaced with the next appropriate RR interval. Finally, some researchers have reported uncertainty 
regarding the ability of the Polar ProTrainer5 software’s error correction function to detect non-sinus 
originating beats, which can result in inflated results (Wallén et al., 2012). Therefore, all data were 
screened for inflated values using the Median Absolute Deviation (Wilcox, 2010) method for outlier 
detection. Participants with greater or less than 2.5 x the population standard deviation as estimated 
by the median (Leys et al., 2013) were excluded from the dataset. The data were all log transformed 
prior to analysis to reduce skewness associated with HRV measurements and ensure a normal 
distribution for the statistical analyses. 
The root mean square of successive differences in the RR interval (rMSSD) provides an indication of 
vagal stimulation from short term recordings, and is more resistant to breathing artefact than 
alternative analyses (Penttilä et al., 2001). Therefore, the rMSSD was used as the primary indicator of 
parasympathetic alteration. However, in order to present a more complete picture of any potential 
change in HRV, the standard deviation of normal to normal intervals (SDNN), as well as alterations in 
the high (HF, 0.15 – 0.4 Hz) and low frequency (LF, 0.04 – 0.15 Hz) bands, which were generated 
using autoregressive modelling in the respective bandwidths, are also reported.   
The analysis of HRV can be unreliable during exercise due to non-neural influences associated with 
increased respiratory effort (Sandercock and Brodie, 2006), therefore no exercise-related HRV was 
analysed. Additionally, meaningfulness of the very low and ultra-low frequency in short term (5 min) 
HRV analysis is unclear (Task Force of The European Society of Cardiology and The North American 
Society of Pacing and Electrophysiology, 1996), and therefore these measurements have not been 
included. 
Two participants in the IHE group were excluded from the resting HRV analyses due to equipment 
malfunction (n = 1), and an rMSSD outlier (n = 1).   
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Blood pressure. 
 Blood pressure was measured continuously throughout rest and exercise using plethysmography to 
detect brachial arterial pressure in the finger (MLE1054-V Finometer MIDI, Finapres Medical Systems, 
The Netherlands). Data were recorded using BeatScope Easy® software (Finapres Medical Systems, 
The Netherlands). The average of the last 5 min of the 10 min rest period was recorded as resting 
blood pressure. 
Oxygen consumption during rest and exercise.  
Respiration gases were collected through a facemask that allowed simultaneous respiration via the 
nose and mouth (Hans Rudolph, Kansas City, MO, USA), and measured using a breath-by-breath 
analysis system (MetaMax® 3B; Cortex Biophysik, Leipzig, Germany). Prior to each battery of tests, 
the gas analyser was calibrated against 15% oxygen and 5% carbon dioxide. Volume was calibrated 
daily (Hans Rudolph 5530 3 L syringe; Kansas City, MO, USA).  
A modified submaximal Astrand protocol (Siconolfi et al., 1982) was used to measure submaximal 
oxygen uptake (V˙ O2submax) and to predict V
˙ O2peak. Participants started pedalling at 50 rpm on a cycle 
ergometer starting at a workload of 25 W (Monark Ergomedic 818E, Sweden). Resistance increased 
by 25 W every 2 min until the participant reached 70% of their age predicted maximum heart rate 
((220 – age)*0.7) (Siconolfi et al., 1982). Participants then continued to cycle at the same workload 
for an additional 2 min, and then until steady state (≤ 5 beatmin-1 between consecutive min) was 
achieved. See Figure 6 for a diagram of the exercise testing protocol.  
Breath-by-breath data were exported to an Excel spreadsheet for visual inspection and any outlying 
data points were removed. The last 5 min of the 10 min resting interval, and the last 30 s of the 2 min 
50 W exercise stage were selected, averaged and reported as oxygen consumption per min, per kg of 
body mass (ml·min-1·kg-1) for resting and V˙ O2submax measures respectively. Heart rate and RPE were 
measured at the end of each min during the 50W stage, and were used to indicate submaximal heart 
rate (HRsubmax) and rating of exertion (RPE50w) respectively. The mean of the 70% age-predicted 
steady state HR recordings and the final workload were used to predict V˙ O2peak using the Astrand-
Rhyming nomogram and age correction factor. Steady state heart rates of  112 beatmin-1 were 
excluded from the analysis as their predicted V˙ O2peak could not be accurately measured using the 
Astrand nomogram.  
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Figure 6: Exercise testing protocol 
 
Intermittent hypoxic exposure.  
During the 4-week intervention, participants received six 5-min intervals of hypoxic (or placebo) air 
delivered through a face mask (QuadraLite Facemask, Intersurgical, Intermed, Auckland, New 
Zealand) interspersed with six 5-min periods of breathing normoxic ambient air, 4 times per week 
during seated rest. Hypoxic air (Compressor Twin, GO2Altitude, Biomedtech, Victoria, Australia) was 
controlled such that: IHE: Week 1: SpO2 = 95% (fraction of inspired oxygen (FiO2) ~ 0.18); Week 2: 
90% (FiO2 ~0.16); week 3: 85% (FiO2 ~ 0.13); and Week 4: 80 - 85% (FiO2 ~ 0.10 – 0.12); C: SpO2 > 95% 
in Weeks 1 – 4. The slow progressive decline in SpO2 in the test group was implemented to improve 
blinding of the participants in the test group to the hypoxic stimulus. SpO2 was monitored using 
finger pulse oximetry (Nonin Pulse Oximeter, Plymouth, Minnesota). During Week 4, HRV and HR 
were recorded during each participant’s intervention session to determine the parasympathetic and 
sympathetic interactions in response to a full IHE (or placebo) session. While 5 min recordings for the 
assessment of short-duration oscillations are recommended, we prioritised stationarity of the HR 
recordings and therefore elected to use the last 2 min of each 5 min hypoxic and normoxic interval 
where the participant was most likely to have stabilised to the new condition. The average of the 6 
hypoxic (or normoxic) intervals and the average of the 6 ambient air intervals were then compared.  
Throughout the intervention period participants kept a diary to record any intervention-related 
comments. Recurring comments between participants were identified and the total number of 
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referrals to the ‘captured’ comment was counted, as was the greatest contribution made by one 
participant. This was done to identify where repetitive comments by one participant could have 
skewed the data.  
3.3.3 Statistical analyses 
Statistical analysis was performed using a baseline – post parallel groups spreadsheet designed to 
compute the magnitude of the smallest worthwhile change between groups using a 90% confidence 
interval (Hopkins, 2006). The smallest worthwhile change was determined using Cohen’s value of 0.2 
(i.e. the difference between means is at least greater than the between-participant standard 
deviation at baseline, divided by 0.2) to indicate that the true effect is at least small. The confidence 
interval indicates the range of uncertainty of the true value. For a mechanistic inference (in the case 
of IPAQ-LF, HRV and HR) if the confidence interval overlaps both substantially increased and 
substantially decreased values, the effect is ‘unclear’. In all other cases, the outcome is ‘clear’ and 
statement based on the percent chance of the outcomes is given (increased/trivial/decreased). 
Probabilistic inferences for the qualitative outcome were assigned using the following criteria: <0.5% 
= most unlikely; 0.5 – 5% = very unlikely; 5 – 25% = Unlikely; 25 – 75% = possibly; 75 – 95% = likely, or 
95 – 99.5% = very likely, >99.5% = most likely (Hopkins et al., 2009).  
For variables directly affecting health or performance (exercise economy, SBP and predicted V˙ O2peak), 
a clinical analysis was performed. In this analysis, if the potential for benefit was acceptable but the 
risk of harm was too high, the effect is ‘unclear’. An odds ratio of benefit: harm was accepted if the 
ratio was > 66%. In the case of a clear outcome, a statement of the likelihood that the changes were 
beneficial/ trivial/ harmful was made. In this way, the risk of making a Type 1 clinical error (using a 
harmful effect) is prioritised over a Type 2 error (not using a beneficial effect). 
Data were log transformed prior to analysis to reduce non-uniformity of error. Baseline values were 
used as a covariate in all analyses to avoid the effect of regression to the mean, and bias associated 
with uneven baseline averages (Hopkins, 2006). Unless otherwise specified, all results are expressed 
as mean change (%) ± 90% confidence interval. The raw baseline and post-intervention values, as 
well as the qualitative outcome and the percent chances that the change has substantially increased/ 
is trivial/ has substantially decreased (in the case of the mechanistic analyses) or is beneficial/ trivial/ 
harmful (in the case of clinical analyses) are reported in Table 7.  
3.4 Results 
Raw data are presented in Table 7. 
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3.4.1 Differences between baseline and post-intervention measurements 
Resting HR in the IHE group decreased compared to the C group, (-10.4 ± 8.7%, mean change  90% 
confidence interval) and the RR interval increased (7.8 ± 8.1%) when Post-intervention data were 
compared to baseline values. (However, when looking at the raw data, there was only a 1 beat.min-1 
decrease in resting HR in the IHE group, compared to a 2 beat.min-1 increase in the C group. 
Therefore, the statistically worthwhile effect in this measure may have limited practical value.)  
Additionally, markers of parasympathetic contribution to HRV increased substantially in the IHE 
group compared to the C group (rMSSD: 71.6 ± 52.5% (See Figure 7); and HF: 242.1 ± 147.2%) 
following the 4 weeks of IHE treatment. There were no clear changes in SDNN (11.8 ± 41.9%), LF (-7.1 
± 127.4%), SBP (-3.4 ± 8.4%) or resting oxygen consumption (-0.7 ± 16.9%) between the groups 
following the 4-week intervention.  
 
Figure 7: Root mean square of successive differences (rMSSD) at baseline and post-intervention 
Thin lines indicate individual responses; thicker lines indicate the group average (which is also 
indicated numerically on either end of the mean line). IHE: group receiving hypoxic air during 
intermittent hypoxic treatments; C: Control Group receiving normoxic (placebo) air during 
intermittent hypoxic treatment; rMSSD: root mean square successive difference. 
 
One participant in the IHE group was excluded from all exercising oxygen consumption 
measurements due to missing post-intervention data. All participants completed the 50 W 
submaximal stage. There were no clear changes in V˙ O2submax (-0.1  13.9%) or RPE50W (-5.0  13.0%) 
between groups at a 50 W workload. However, the IHE group demonstrated a likely decrease in 
HRsubmax (-5.0  6.4%) compared to the C group. Two participants in each group were excluded from 
the peak oxygen uptake (V˙ O2peak) predictions as their steady state heart rates were less than 112 
Baseline Post Baseline Post 
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beatsmin-1. Changes in estimated V˙ O2peak between groups as a result of IHE training were trivial (0.8 
± 7.0%).  
3.4.2 Week 4 assessment of 2 min HRV during IHE or placebo treatments. 
During the hypoxic exposure there was a decrease in rMSSD (30.0 ± 2.6 ms to 25.4 ± 1.8 ms) and the 
RR-interval (976 ± 20 ms to 883 ± 16 ms), and an increase in HR (62.4 ± 1.5 beatmin-1 to 68.2 ± 1.3 
beatmin-1) compared to ambient air. The C group remained relatively stable when alternating 
between placebo and ambient air (rMSSD: 18.2 ± 1.5 ms to 20.3 ± 2.1 ms; RR-interval: 970 ± 16  ms 
to 950 ± 35 ms; HR: 62.4 ±  1.2 beatmin-1 to 63.6 ±  2.6 beatmin-1). When the hypoxic interval was 
compared to the placebo, there was a very likely decrease in rMSSD (-24.7 ± 17.3%, 1/1/98, mean 
change (%)  90% confidence interval, % chances of increase/trivial/decrease) and RR-interval: -7.5 ± 
3.2%, 0/0/100) and a most likely increase in HR (8.8 ± 3.4%, 100/0/0), see Figure 8. 
 
Figure 8: Heart rate and rMSSD responses during a typical Week 4 IHE session. 
IHE: group receiving hypoxic air during intermittent hypoxic treatments; C: Group receiving normoxic 
(placebo) air during intermittent hypoxic treatment. rMSSD: Root mean square successive difference; 
HR: Heart rate; HE: 5-min hypoxic exposure interval; Rest: 5-min ambient air interval; NE: 5-min 
normoxic (placebo) interval. Shaded bars indicate the hypoxic or placebo intervals. Thin grey lines 
indicate individual participant results, whereas the thicker black lines indicate the group mean.  
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Table 7: Raw Baseline and post-intervention resting and exercising data, including mechanistic and clinical outcomes 
 IHE baseline IHE post C baseline C post Qualitative outcome 
Rest 
 Mechanistic variables 
HR (beatmin-1) 59.2 ± 7.4 57.8 ± 6.2 66.7 ± 9.8 67.4 ± 8.2 Likely decreased (1/6/94) 
RR-interval (ms) 1029 ± 135 1049 ± 118 955 ± 164 921 ± 116 Likely increased (83/16/2) 
rMSSD (ms) 30.7 ± 11.9 35.6 ± 8.1 23.1 ± 10.9 21.8 ± 11.0 Very likely increased (95/3/1) 
SDNN (ms) 39.2  11.0 45.0  13.5 30.0  11.0 35.1  15.9 Unclear (56/27/17) 
HF (ms2) 325.2  263.5 467.6  242.7 234.1  150.7 235.6  255.4 Very likely increased (97/2/1) 
LF  (ms2) 251.3  87.8 380.7  167.8 355.1  261.2 492.1  491.7 Unclear (25/39/36) 
 Clinical variables 
SBP (mmHg) 120.7 ± 19.5 122.6 ± 21.0 109.4 ± 12.7 117.0 ± 11.8 Unclear (9/37/54) 
V˙ O2rest  (ml·min
-1
·kg
-1
) 3.1 ± 1.1 3.3 ± 0.5 2.9 ± 0.7 3.4 ± 0.7 Unclear (24/46/30) 
Fat mass (kg) 27.5  5.3 28.7  7 31.1  21.2 31.4  21.0 Very likely trivial (1/99/0) 
Muscle mass (kg) 30.7  6.6 30.2  5.9 28.1  5.3 28.1  28.1 Very likely trivial (1/95/3) 
Exercise 
V˙ O2submax   
(ml·min
-1
·kg
-1
) 
10.0  1.8 11.0  1.7 11.3  1.8 12.1  2.2 Unclear (31/38/32) 
HRsubmax   90.3  8.7 86.3  7.9 90.8  14.0 91.0  12.7 Likely decreased (2/23/75) 
RPE50W 10.5  1.3 10.0  1.3  10.0  1.9 10.3  1.6 Unclear (12/29/60) 
Predicted  
V˙ O2peak (ml·min
-1
·kg
-1
) 
23.6 ± 2.5 23.5 ± 2.6 25.0 ± 10.0 24.9 ± 10.8 Likely trivial (9/86/5) 
Data are mean ± SD, outcomes are expressed as: % chance of increase/trivial/decrease for mechanistic variables, and % chances of beneficial/trivial/harmful in 
clinical variables. IHE: Intermittent hypoxic exposure group; C: control group; baseline: recording prior to intervention; Post; 1 – 3 days post-intervention; HR: 
Heart rate; RR- interval: Average interval between R to R peaks in the HR trace; rMSSD: Root mean square successive difference; SDNN: Standard deviation of 
normal to normal R-peak intervals; HF: high frequency; LF: low frequency; SBP: Resting Systolic blood pressure; V˙ O2rest : Oxygen uptake during rest; V
˙ O2submax: 
oxygen uptake during the last 30 s of the 50W interval; HRsubmax: average heart rate taken at the end of each min during the 50W exercise interval; RPE50W: average 
rating of perceived exertion taken that the end of the 50W exercise interval; predicted V˙ O2peak : peak oxygen uptake predicted using Astrand nomogram 
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The most frequently reported comments relating to the IHE sessions were “fine” and “tired”. More 
participants in Hyp than C reported breathing discomfort (usually regarding an absence of “enough 
air”) or headaches (Figure 9). 
 
Figure 9: Frequencies of recurring comments from participants regarding the hypoxic/normoxic 
exposure recorded in notebooks over the course of the 4-week intervention period. 
Black and white bars on the left represent proportions from the control group, while lined and 
crossed bars on the right represent proportions from the hypoxic group. As these bars indicate the 
total number of times the comment was made over the 4-week intervention, irrespective of whether 
it was from 1 person repeatedly, or many people once, the value of the highest contribution by one 
person has been indicated (black and crossed sections respectively). C: control group receiving 
normoxic (placebo) air during intermittent hypoxic treatments. Hyp: group receiving hypoxic air 
during intermittent hypoxic exposure  
 
There were no clear changes in physical activity (total METS) between groups over the course of the 
study. Food and activity diaries indicated that participants had not deviated substantially in their day-
to-day nutrition, medication or physical activity habits. 
3.5 Discussion 
 
The results of this study indicate that although the typical response to breathing hypoxic air is 
associated with a decrease in HRV, the subsequent adaptation following 4 weeks of IHE is associated 
with increased HRV. As lower HRV is associated with impaired health (Stein and Kleiger, 1999), the 
results of this study would indicate an improvement in parasympathetic activity during rest and 
possibly improved health in the IHE group. While some studies have invesigated the immediate 
response of hypoxic intervals on HRV in a young healthy population (Wadhwa et al., 2008), to our 
knowedge, this is the first study to look at both the instantaneous and adaptive response of the ANS 
to repeated hypoxic exposure intervals in a sedentary, middle-aged population. 
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The overall increase in resting HRV following 4 weeks of IHE (post-intervention compared to the 
baseline measurement) is possibly the result of an adaptive response to the sympathetic and 
parasympathetic alterations observed during the Week 4 hypoxic intervals. That is, during the 
hypoxic intervals there was a decrease in rMSSD and an increase in HR suggesting parasypathetic 
withdrawal and an increase in the proportion of sympathetic activity. This was followed by an 
increase in rMSSD and a decrease in HR with return to ambient air, suggesting sympathetic 
withdrawal and the return of parasympathetic activity. While a substantial vagal withdrawal during 
hypoxic exposure has been noted in several studies (Guger et al., 2008, Kanai et al., 2001, Koelwyn et 
al., 2013, Saito et al., 2005), there is only one other study (to our knowledge) that has investigated 
the actions of repeated hypoxic intervals on HRV. Wadhwa et al. (2008) monitored the interaction 
between hypoxic and normoxic interventions between eight 4-min hypoxic intervals separated by a 
5-min normoxic recovery in young males and females (24 years). As in our study, Wadhwa et al. 
(2008) reported a decrease in parasympathetic activity during hypoxia. However, Wadhwa and 
colleagues also observed a progressively greater decline in parasympathetic contribution with 
sucessive hypoxic intervals. We did not detect a similar progressive decline with sucessive hypoxic 
exposures, but the inter-individual variation in the IHE group in our study was high, and therefore we 
may have missed finer HRV patterns. Alternatively, fitter individuals have reported greater sensitivity 
to hypoxia (Woorons et al., 2007), which may infer that although participants in our study and in 
Wadwha et al. (2008) received a similar hypoxic dosage, the younger cohort may have reacted more 
severely to the hypoxic dosage. Finally, aside from a brief familiarization the day before the data 
collection, participants in Wadhwa and colleagues’s study were not experienced with the hypoxic 
intervention. Therefore, it is possible that the 3 weeks of hypoxic treatments prior to the Week 4 
measurement could have inferred a level of resistance to the hypoxic stimulus. Indeed, in a similar 
study in healthy army recruits  2 weeks of IHE resulted in reduced vagal withdrawal during the 
hypoxic exposure suggesting that repeated, short term hypoxic exposure can develop tolerance to 
future hypoxic episodes (Bernardi et al., 2001).  
Balykin et al. (2004) also reported a reduction in the strain index of autonomic regulation (a 
reduction in markers of sympathetic activity and an increased parasympathetic activity) in young 
adult males following 10 IHE sessions, but no comments regarding possible mechanisms for this 
adaptation were discussed. In contrast, Bernardi and colleagues’ (2001) study showed no overall 
changes in resting HRV between baseline and post-intervention. Unfortunately Balykin et al. (2004) 
did not specify whether the 10 sessions were on consecutive days, or whether they were spread over 
1 month as some of the other groups in their study were. If the 10 IHE sessions were indeed spread 
over 1 month, it is possible that the absence in a change in HRV at post-intervention in Bernardi et 
al.’s (2001) study could be due to the comparatively shorter short 2-week intervention.   
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There were no worthwhile changes in SDNN or LF in the post-intervention compared to the baseline 
in the IHE compared to the C group. As the LF reflects both sympathetic and parasympathetic activity 
(and is therefore difficult to interpret), and the SDNN is an assessment of all long- and short-term 
HRV components (which may be limited by the 5 min recording), conclusions drawn from these 
variables are limited. 
While we did not detect any improvement in estimated V˙ O2peak or V
˙ O2submax, we did notice lower HR 
during submaximal (50 W) exercise. This finding is supported by Burtscher et al. (2009) who, in 
addition to improved HRsubmax, also reported significantly lower SBP, HR, and RPE in the group 
receiving IHE following his 3-week intervention. The greater improvement in V˙ O2submax  in Burtscher et 
al.’s (2009) participants compared to our participants may be attributed to the lower baseline health 
of the individuals in their study. Similarly to Burtscher et al. (2009), despite the improvement in 
HRsubmax, we did not detect any change in V
˙ O2submax  between the groups. These findings suggest that 
IHE seems to improve submaximal HR but has an unclear effect on oxygen efficiency. The decreased 
HRsubmax may be associated with the increased parasympathetic activity at rest. Alternatively, 
haemodynamic adaptation to the hypoxic exposure may account for the reduction in HRsubmax. For 
example, Burtscher et al. (2009) detected a significant increase in total haemoglobin (Hb) mass in his 
participants following 5 IHE sessions per week for 3 weeks. It is possible that an increase in Hb mass 
in our participants would allow sustained oxygen delivery at a reduced HRsubmax. However, it would be 
expected that with improved oxygen-carrying capacity, improvement in both V˙ O2submax and V
˙ O2peak 
would result (Calbet et al., 2006). Therefore, in our participants, it is possible that the reduced 
HRsubmax with no apparent change in V
˙ O2submax or V
˙ O2peak is as a result of greater vagal preservation 
during light or moderate exercise. 
There was wide variation in the subjective reponse of the participants to the IHE treatment. For 
example, while most of the participants tolerated the hypoxic intervals well (see “fine” or “no 
comment” in Figure 9), a number of the Hyp group detailed mild side effects during the hypoxic 
interval (such as having an urge to breath faster or more deeply, see “breathing” in Figure 9). One 
participant noted headaches, chest pain and blurry vision during the hypoxic exposure interval (note 
the much higher “highest contributor” portion in the “headache” and “other” bars in Figure 9). On 
the advice of the physician, the participant in question stopped the hypoxic interval at the onset of 
any of these symptoms and only continued with the IHE session  following full recovery, and if so 
desired by the participant. On all occasions, the symptoms abated following a short return to 
ambient air and the participant was happy to continue the session. The session was continued at a 
previously well-tolerated FiO2. 
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The absense in any meaningful changes in body composition supports the absence of a change in 
body composition noted by Balykin et al. (2004). It is likely that the frequency and the duration of the 
hypoxic stimulus would need to be greater than the mild dose administered to participants in this 
study before any changes in body composition were to be observed.  
3.5.1 Limitations 
The measurement of rMSSD reflects vagal modulation, which is largely related to the respiratory 
sinus arrhythmia and, therefore, can be influenced by breathing frequency (Hirsch and Bishop, 1981). 
Given that there can be substantial individual variation in the hypoxic ventilatory response (Hirshman 
et al., 1975), the change in breathing frequency with hypoxic exposure may be responsible for the 
decrease in rMSSD. However, while Penttilä et al. (2001) did note a decrease in rMSSD with increased 
breathing frequency, the change in rMSSD was not statistically significant compared to paced 
breathing conditions. Therefore the decrease in rMSSD during hypoxic exposure in our study is likely 
to predominantly reflect vagal withdrawal, rather than change in respiration.  
There was reasonably high intra-individual variation in the HRV measurements, particularly in the 
control group, which suggest that some individuals decreased their HRV following the intervention 
period. The higher level of intra-individual variation in the control group suggests that a high level of 
day-to-day variation in this measurement and that cautiousness would be appropriate when drawing 
meaning from the present findings. 
The small sample sizes (Hyp: n = 8, and C: n = 8), and the necessity to exclude some of the data due 
to erronous or incomplete datasets increase the risk of Type 1 errors, and reduce the extent to which 
these results can be applied to other populations. Therefore, caution should be used when 
interpreting these results until the findings can be repeated in a larger population. 
Participants were encouraged to be as inclusive as possible when using their comment books, but 
this notetaking was not monitored. Consequentially, some participants may have recorded data 
unrelated to the hypoxic exposure, while others neglected to complete the comment books 
altogether. A focus group debriefing session or individual open-ended interview would provide more 
structured feedback.  
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3.6 Conclusion 
Four IHE sessions per week for 4 weeks had a positive response on the parasympathetic contribution 
to HRV in sedentary, middle-aged adults, and lowered their submaximal exercising HR. However, the 
IHE intervention did not demonstrate any beneficial effect on aerobic efficiency or capacity as there 
were no substantial changes in V˙ O2submax or estimated V
˙ O2peak in the Hyp group. If these findings are 
confirmed in a larger cohort, IHE may prove to be a useful technique for improving HRV in people 
who are unable to exercise, such as those confined to bed rest, but 4 IHE sessions per week are 
unlikely to improve oxygen uptake characteristics in a sedentary middle-aged population.  Our study 
demonstrated a high level of variation in the participant’s physiological and subjective response to 
the hypoxic exposure session which may suggest that some participants may have adapted better to 
hypoxic exposure than others.  
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 Chapter 4
Preface to Study 2: The minimum dosage of intermittent hypoxic 
exposure per week for health improvement in sedentary, middle-
aged individuals. 
The results from the previous study indicated a beneficial effect of IHE on HRV. However, changes in 
predicted V˙ O2peak and rating of perceived exertion were unclear. There are two reasons for the 
absence in any change in cardiovascular fitness (aside from lower submaximal exercising heart rate). 
The first reason could be associated with the choice of measurement techniques. That is, the 
estimated V˙ O2peak may not have been sensitive enough to detect subtle improvements in 
cardiovascular function. In addition, there are also inherent inaccuracies with estimation of V˙ O2peak 
compared to maximal testing. The following studies have, accordingly, used a maximal 
(contraindication-free) fitness assessment in the assessment of cardiovascular fitness. Furthermore, 
a more sensitive cardiovascular risk factor (highly sensitive C-reactive protein) has been included. The 
second reason could lie with the treatment. In the 4-week intervention, only the last 2 weeks were 
designed to yield an oxygen saturation below 90% which may have been insufficient time for 
meaningful HIF-1α related adaptations to have taken place. The following study has been designed as 
a 5-week intervention to allow further time for adaptation. Finally, this study seeks, primarily, to 
address Research Gap IV: the effect of different frequencies of IHE per week on cardiovascular risk 
factors. And, as a sedentary middle-aged population were recruited for this study, Research Gap III is 
also touched on. 
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4.1 Abstract 
Objectives: Determine the effect of different frequencies of IHE per week on novel (HRV and hs-CRP) 
and traditional (fitness and systolic blood pressure) cardiovascular risk factors in a sedentary 
population. Method: Twenty nine untrained participants (12 male; aged: 55.9 ± 5.0; BMI: 28.0 ± 4.9, 
mean ± SD) were randomly allocated to groups receiving intermittent hypoxic exposure (IHE) 
treatments 2-3 times/week (IHE3); IHE treatments 5 times/week (IHE5) or a control group receiving 
normoxic placebo 2-3 times/week (C). Prior to the fitness assessments, highly sensitive C-Reactive 
Protein (hs-CRP) and Haemoglobin concentration (Hb) were collected. During baseline and post-
intervention assessments, participants rested for 16 minutes in a quiet, semi-dark room. Between 
minutes 5 – 10 heart rate variability (HRV) was recorded under spontaneous breathing conditions. 
The participants then breathed in time to a metronome set to 12 breathes per minute for the last 6 
minutes while HRV was recorded under controlled respiration. The average of 2 systolic blood 
pressure (SBP) measurements (immediately following spontaneous and controlled breathing periods 
respectively) were recorded as resting SBP. Following the resting measurements, participants 
completed a modified Astrand protocol on a stationary bicycle. Participants pedalled at a set cadence 
of 50rpm, while resistance increased every 2 minutes. At 40 – 50% heart rate reserve, participants 
maintained the workload for 6 minutes while submaximal oxygen uptake (V˙ O2submax) was measured. 
The protocol was then resumed and resistance increased every 2 minutes until a pre-defined cut off 
criteria was reached. The time between the steady state exercise and the maximal exertion (timeex), 
the maximum resistance achieved for a minimum of 30 seconds (resmax), and maximal oxygen uptake 
(V˙ O2peak) were measured. During 5 weeks of treatment, IHE participants breathed hypoxic air through 
a nose and mouth mask connected to hypoxicators to slowly reduce peripheral blood oxygen 
saturation (SpO2) from > 95 % in week 1 to 80 % in weeks 4 – 5. The control participants breathed 
normoxic placebo air through identical nose and mouth masks also connected to the hypoxicators, 
but such that week 1 - 5: SpO2 > 95 %. All sessions included alternating intervals of 5 minutes hypoxia 
/placebo with 5 minutes of ambient air intervals for 1 hour while seated at rest. Magnitude based 
inferences were used to analyse the data for practical significance, using the mean change ± 90 % 
confidence interval. Results:  Following 5 weeks of IHE, participants in the IHE5 group demonstrated 
improved rMSSD under both spontaneous and controlled breathing conditions (36.7  42.7% and 
47.3  41.6% respectively, mean change  90% confidence interval) but the RR-interval was only 
likely increased under controlled breathing (6.2  6.9%). The IHE3 group demonstrated no clear 
changes in HRV parameters under spontaneous breathing, but both RR-interval (4.6  5.7%) and 
rMSSD (30.3  39.2%) were increased when breathing was controlled at 12 breaths per minute. 
Regarding hs-CRP, there were no clear change IHE3 (7.6  58.6%) following the intervention. 
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However, the IHE5 group demonstrated a possibly trivial increase in the inflammation marker (12.7 ± 
48.7%).   
The participants in the IHE5 group improved their timeex (34.5 ± 36.8%) and their resmax (14.4 ± 
14.9%) compared to the control group, and despite an increase in Hb (2.7 ± 2.8%) there were only 
trivial changes in V˙ O2submax (0.0 ± 8.0%) and no clear changes in V
˙ O2peak in this group. Conversely, the 
IHE3 group demonstrated no clear change in timeex or resex but did demonstrate a likely increase in 
both   V˙ O2submax (5.5 ± 6.8%) and V
˙ O2peak (12.6 ± 9.3%), despite no clear change in Hb.  
Both IHE3 and IHE5 demonstrated possibly decreased SBP (IHE3: -5.4 ± 8.1 %; IHE5: -4.0 ± 7.0 %) at 
rest compared to the control group, however the clinical outcome was unclear for both groups.  
Conclusions:  Attending 5 IHE sessions per week for 5 weeks resulted in greater benefit in novel and 
traditional risk factors (primarily regarding improved exercise tolerance and HRV). However, 
participants with already high hs-CRP should be restricted to 2 – 3 IHE sessions per week until more 
research is conducted concerning the effects of IHE on inflammation. Interestingly, 2 – 3 IHE sessions 
per week for 5 weeks were also associated with an improvement in V˙ O2peak, and possibly HRV. IHE 
may be a useful in preparing inactive participants for exercise, and may reduce some cardiovascular 
disease risk factors.  
Keywords: heart rate variability; intermittent hypoxic exposure; sedentary; heart disease risk factors 
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4.2 Introduction  
Cardiovascular disease has long been a major cause of death and disability worldwide (Kannel et al., 
1976, Perk et al., 2012). Given the severity of this disease, a number of atherogenic (such as 
cholesteraemia, hypertension, glucose intolerance) and lifestyle (physical inactivity, poor diet or 
cigarette smoking) risk factors for heart disease have been identified (Conen et al., 2009, Chobanian 
et al., 2003, Myers et al., 2004, Kannel et al., 1976) in the hopes of interrupting the progression of 
cardiovascular disease (Dzau et al., 2006). More recently, additional risk factors such as reduced 
heart rate variability (HRV) and elevated highly sensitive C-Reactive protein (hs-CRP) have been 
highlighted as independent predictors of heart disease and mortality (Rifai and Ridker, 2001, Ridker, 
2001, Dekker et al., 2000, Tsuji et al., 1996). An increase in the basal level of hs-CRP, a sensitive 
marker of inflammation, can indicate the presence of atherosclerosis which is an inflammatory 
process which results in the formation of atherosclerotic plaques in the arterial wall (Ross, 1999). 
Therefore, an increase in hs-CRP can indicate reduced arterial health and a higher risk of an 
atherosclerotic event.  
Heart rate variability (HRV) measures the variance in the beat-to-beat intervals of the heart rhythm 
which provides insight into the sympathovagal balance of the autonomic nervous system (Task Force 
of The European Society of Cardiology and The North American Society of Pacing and 
Electrophysiology, 1996). An increase in sympathetic activity as indicated by lower HRV is generally 
associated with poorer health outcomes, while higher HRV is associated with improved autonomic 
function (either through increased parasympathetic contribution or reduced sympathetic 
innervation) and improved health (Felber Dietrich et al., 2008). 
Evidence suggests that physical activity plays an important role in maintaining lower basal hs-CRP 
(Lavoie et al., 2010) and higher HRV (Rennie et al., 2003). However, exercise tolerance is often 
reduced in those at risk for, or with, cardiovascular disease. This can limit the effectiveness of 
exercise-based interventions. In an attempt to improve exercise tolerance, several researchers have 
investigated the use of simulated altitude techniques. It is hypothesised that the improved oxygen 
delivery and stress tolerance inferred by adaptation to the hypoxic stimulus will result in improved 
exercise tolerance in a population with compromised health (Burtscher et al., 2009, Burtsher et al., 
2004, Meerson, 1993). For example, passive intermittent hypoxic exposure (IHE; Haider et al., 2009, 
Saeed et al., 2012), and hypoxic exposure during exercise, also known as intermittent hypoxic 
training (IHT; Bailey et al., 2000), have both been used to improve the cardiovascular health of both 
asymptomatic individuals (Bailey et al., 2000) and patients with cardiovascular disease (Haider et al., 
2009, Saeed et al., 2012). Indeed, the results of a recent review of the literature suggest that IHE and 
IHT interventions demonstrate greater improvements in exercise tolerance in participants with 
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compromised health, such as those with COPD, compared with healthy participants (Burtscher et al., 
2010).  
Despite the increasing use of IHE and IHT in both asymptomatic and higher risk participants, little is 
known about the minimum required frequency of intermittent hypoxic exposure per week for health 
benefit, and, to date, there has been no guidance on the minimum appropriate length or intensity of 
each IHE session. For example, while the intervention durations for Saeed et al. (2012) and Haider et 
al.’s (2009) participants were a similar length (approximately 3 weeks), and both adopted the IHE 
approach, the severity of the hypoxic exposure intervals were quite different. That is, Saeed et al.’s 
(2012) participants underwent 10 X 3 – 4 hour continuous hypoxic exposure sessions at a simulated 
height of 2700 m (SpO2 average at Week 4 = 91.1 %), while Haider et al.’s (2009)  participants were 
exposed to 15 X 18 – 40 minute IHE sessions (SpO2 = 80% at Week 4). To date, no research has been 
conducted investigating the minimum number of IHE sessions per week for improvement in 
cardiovascular risk factors. Therefore, the aim of this study was to determine the effects of different 
frequencies of IHE per week (either 2-3 times per week, or 5 times per week) on traditional (physical 
fitness and systolic blood pressure) and novel (HRV and hs-CRP) risk factors for cardiovascular 
disease in a sedentary population.  
4.3 Methods 
4.3.1 Participants.  
Forty-nine volunteers from the local communities surrounding the host university responded to the 
recruitment material. After learning more about the study, 19 decided not to participate, and 1 male 
participant in the C group withdrew their participation from the study in the third week of the 
intervention due to the time commitment. Only the data for the 29 participants who completed the 
study have been reported (see Table 8 for baseline characteristics).  All participants were medically 
assessed prior to enrolment in the study. Participants were sedentary (did not undertake any regular, 
or planned physical activity) and were free of any medication or illness that could be compromised 
by the intervention. Prescription to any medication was sufficiently stable such that the dosage was 
unlikely to change over the course of the intervention. Exclusion criteria included the presence of any 
melanoma, unstable medical condition, or if the participant was advised against participation by their 
medical practitioner for any other reason. All participants provided written informed consent. This 
study was approved by the local University Human Ethics Committee.  
4.3.2 Experimental design. 
 This was a randomized placebo controlled single-blind study. (While participants were aware of how 
many times per week they were attending sessions, they were unaware of whether or not they were 
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receiving hypoxic or placebo treatments).  All individuals expressing interest in the study were 
medically assessed prior to inclusion. If the individual was suitable, and had no contra-indications to 
participation, they proceeded with the baseline blood sample. Participants then underwent a 
familiarisation session, followed one week later by a maximal baseline assessment. Following the 
fitness assessment, the participant was then randomly assigned into either a group receiving 5 IHE 
sessions per week (IHE5, n = 10); 2 - 3 IHE sessions per week (IHE3, n = 10), or 2 - 3 normoxic placebo 
sessions per week (C, n = 9). The total hypoxic dosage per session was 30 min of hypoxic at a targeted 
SpO2 of 80%.  
Table 8: Physical characteristics of groups 
 C (n=9) IHE3 (n=10) IHE5 (n=10) 
Age (yr) 54.8 ± 5.4 57.0 ± 5.9 55.7 ± 5.0 
Males/females 3M/6F 4M/6F 5M/5F 
Body mass (kg) 79.5 ± 11.5 81.6 ± 20.0 76.2 ± 13.7 
Height (cm) 168.7 ± 3.5 171.4 ± 10.2 163.7 ± 6.8 
BMI (kg.m-2) 27.9 ± 4.1 27.6 ± 5.2 28.5 ± 5.6 
V˙ O2peak (mlmin
-1kg-1) 26.8 ± 3.3 23.7 ± 6.0 27.2 ± 7.5 
SBP (mmHg) 107.5 ± 17.9 118.8 ± 17.7 111.7 ± 22.8 
On permanent medication † 6 (66.7%) 7 (70%) 5 (50%) 
Values are mean ± SD, except for permanent medication: n (% of group). 
†Excluding supplements and occasional medication (e.g. for migraines). 
All participants completed 5 weeks of the intervention treatment. The post-intervention venous 
blood sample was collected within 7 days of the final IHE/placebo session, and was taken at any time 
before or at least 1 day after the post – intervention fitness assessment (this was to ensure an 
adequate time for re-hydration prior to the blood sample). All measurements were taken at the same 
time of day ± 2 hours as the baseline assessment to reduce biological variation (Huikuri et al., 1994). 
Prior to all blood samples and fitness assessments, participants were asked to record their physical 
activity and dietary intake for the day before and the day of the measurement, and were asked to 
match their routines and caloric intake prior to each assessment as closely as possible. Participants 
were also advised to avoid any strenuous exercise, caffeine or alcohol for at least 12 hours prior to 
their assessments. See Figure 10 for a diagram of the order of testing. 
4.3.3 Food and activity monitoring 
During the baseline and post-intervention testing weeks, the participants were given a pedometer to 
wear, and were instructed to log their steps over 3 typical days. The average of the 3 day recordings 
was used as the baseline and post-intervention record of habitual daily activity. Similarly, participants 
were asked to record all food and medicine ingested, and to describe any physical activity for 2 days 
prior to measurement sessions.   
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Figure 10: Study timeframe 
The familiarisation, baseline and post-intervention fitness assessments included resting 
anthropometric measurements, resting heart rate, heart rate variability and blood pressure. This was 
followed by a maximal fitness assessment conducted on a cycle ergometer 
4.3.4 Venous blood samples. 
All blood samples were taken in a rested state and in a seated position. Samples were drawn from 
the antecubital vein at a local medical facility by a trained phlebotomist.  Venous blood samples were 
then analysed at an accredited laboratory (Canterbury Health Laboratories, Christchurch). High 
sensitivity C-reactive protein (hs-CRP) was measured using CardioPhase® hs-CRP (Siemens Healthcare 
Diagnostics, Marburg, Germany). As hs-CRP is sensitive to inflammation or infection (Chambers et al., 
1991), participants were also asked to postpone the blood sample collection if they were feeling 
unwell or had sustained any injuries within 7 days (Pearson et al., 2003). All hs-CRP measurements 
>10 gm/L were excluded, as were results consistent with acute inflammation or infection based on 
the medical doctor’s opinion. Each participant’s hs-CRP results were classified into risk-stratified 
quintiles defined by Ridker (2001), (1: 0.1 – 07 gm/L low; 2: 0.7 - 1.1 gm/L mild; 3: 1.2 - 1.9 gm/L 
moderate; 4: 2 - 3.8 gm/L high; 5: 3.8 – 15 gm/L highest) and then averaged into a group mean to 
reduce the effects of normal within subject variability and to provide greater risk stratification 
(Ridker, 2001). 
Haemoglobin was also drawn to help explain any exercise-related improvements (or lack thereof) 
following the intervention.  Haemoglobin was estimated using the SLS-Hb method (Sulfolyer reagent 
system, Sysmex XE-2100, Kobe, Japan). Two participants in C were excluded from the Hb analysis 
(blood sample taken > 7days after last IHE session (n=1); and no post-intervention measurement (n = 
1)) and 1 participant in IHE3 opted out of the blood sample collection. 
No participants had hs-CRP > 10 mg/L. However, 3 participants in C, 1 participant in IHE3 and 2 
participants in IHE5 were removed from the dataset for reasons unrelated to the study. Reasons 
included: dentistry or migraines earlier in the week, blood samples taken > 7 days following final IHE 
session, or missing post intervention samples. 
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4.3.5  Resting anthropometric and cardiovascular data.  
Following explanation of the testing procedure and familiarisation with the equipment, height 
(Mechanical Stadiometer, Surgical & Medical Products, Mentone, Australia) and body composition 
(InBody230, Biospace Co. Ltd., Seoul, South Korea) were measured. Resting heart rate and heart rate 
variability were measured continuously over a 10 minute supine resting period in a semi-dark room 
(Polar RS800CX and Polar WearLink® Transmitter, Kempele, Finland). Immediately following this 10-
minute resting interval, blood pressure (described below) and instantaneous heart rate (HR) were 
recorded. Participants remained supine and were instructed to breathe in time to a metronome at 12 
breaths.min-1 for an additional 6 minutes while HRV and HR rate were measured. (Refer to “4.3.7 
Heart rate variability analysis” for more detail regarding breathing frequency). No attempt was made 
to control tidal volume, participants were simply asked to breathe as normally as possible. Systolic 
blood pressure was measured again at the end of the controlled breathing interval. Throughout the 
16-minute resting period, breath by breath analysis of respiration rate and gaseous exchange was 
monitored using a calibrated metabolic cart (MetaMax®3B, Cortex Biophysik, Leipzig, Germany). The 
controlled breathing period was later reviewed, and any participant who had a breathing frequency 
of > 12 ± 0.5 breaths.min-1, or a SD of > 1.0 over the selected 5 minute interval was excluded from the 
HRV analysis. Based on these criteria, 1 participant in C and 1 participant in IHE3 were excluded from 
the controlled breathing dataset due to non-conformity with the controlled breathing requirements. 
An additional 2 participants in IHE3 and 1 participant in IHE5 were excluded from all HRV analyses 
due to unclear recordings. The last 5 minutes of the 10 minute spontaneous breathing interval and 
the last 5 minutes of the 6-minute controlled breathing interval were selected for HRV analysis. 
4.3.6 Blood pressure.  
Resting and exercising systolic blood pressure was measured using a sphygmomanometer coupled 
with a pressure transducer that converts the applied pressure to an electronic signal (MLT1100/D, 
ADInstruments, Dunedin, New Zealand). A piezoelectric element was used to detect finger pulse 
(MLT1010/D Pulse Transducer, ADInstruments, Dunedin, New Zealand). The finger pulse and 
sphygmomanometer readings were recorded via a data acquisition unit (ML856 PowerLab 26T, 
Dunedin, New Zealand) and displayed concurrently on graphical recordings (LabChart®, 
ADInstruments, Dunedin, New Zealand). The blood pressure cuff was manually calibrated before 
each session. The cuff was inflated until the finger pulse was no longer detected by the Pulse 
Transducer, and thereafter an additional 20 mmHg was applied. Pressure was slowly released from 
the cuff, and the SBP was read off the sphygmomanometer graph at the point where the finger pulse 
returned. This technique was used to avoid bias associated with manual blood pressure recordings, 
particularly in single-blind studies, and to improve accuracy. To further improve the accuracy of the 
baseline and post-intervention blood pressure recordings the average of 2 blood pressure readings, 
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separated by 5 minutes, were taken during the rest interval. The first was taken immediately 
following the spontaneous breathing interval, and the second was taken immediately following the 
controlled breathing interval. Controlled breathing has no statistically relevant effect on SBP (Pinna 
et al., 2006). The average of these values was used as the baseline and post-intervention resting 
blood pressure.  
4.3.7 Heart rate variability analysis.  
Heart rate variability was measured during the supine rest period, under spontaneous and 
controlled-breathing conditions. A breathing frequency of 12 breaths per minute (or 0.2 Hz) was 
selected for the controlled breathing as this is comfortably within the range of the HF band (0.15 – 
0.4 Hz), but may prevent the mild hyperventilation observed by Pinna et al. (2006) when respiration 
was paced at 15 breaths / minute (or 0.25 Hz). Along with the average time between the R to R peaks 
(RR interval), the root mean square of successive differences in the R to R peaks (rMSSD) was used as 
the primary measurement of HRV as it is highly correlated to the high frequency measurement in the 
spectral domain (Tsuji et al., 1996, Sinnreich et al., 1998) but is more resistant to the effect of 
alterations in respiration on HRV (Penttilä et al., 2001). However, for greater comparability with 
other studies, the standard deviation of normal to normal R peak intervals (SDNN) and the high 
frequency (0.15 – 0.4 Hz) and low frequency (0.04 – 0.15 Hz) in the spectral domain are also 
reported. The rMSSD and HF are used to estimate the short term components, or parasympathetic 
modulation of the HRV analysis, while the SDNN represents overall HRV. The interpretation of the LF 
measurement is more difficult as it is thought to reflect both sympathetic and parasympathetic 
interactions (Task Force of The European Society of Cardiology and The North American Society of 
Pacing and Electrophysiology, 1996).  
Heart rate variability was detected using a transmitter belt (Wearlink W.I.N.D, Polar Electro Oy, 
Kempele, Finland) and recorded on a Polar heart rate watch (RS800CX, Polar Electro Oy, Kempele, 
Finland) set to capture RR interval data within an accuracy of 1 ms. A contact electrode gel (Sigma 
Crème®, Clectrode cream, Parker Laboratories Inc. Fairfield, New Jersey, USA) was used to optimise 
the contact between the electrodes of the transmitter belt and the skin. Heart rate data were saved 
on the watch until it could be uploaded (external IrDA USB 2.0) to the Polar ProTrainer5™ software 
(Version 5.40.172) onto a laptop. HR data were automatically filtered for ectopic beats using the 
“error correction” function in the Polar ProTrainer5™ software. Filters were set to the default 
‘Moderate’ filter power and Minimum Protection Zone of 6 beatmin-1. Following the filtering 
process, any remaining ‘spikes’ in the data were manually removed prior to analysis. Spontaneous HR 
data were selected from the last 5 minutes of the 10 minute spontaneous breathing rest period. Data 
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for the controlled breathing interval were selected using the 5-minute portion of the 6 minute 
controlled breathing period, starting 30 seconds into the paced breathing. 
 To avoid including erroneous data in the final dataset, participants with particularly high HRV 
recordings (which can occur when non-sinus originating beats go undetected by the error correction 
software (Wallén et al., 2012)) were excluded from the analysis. The median absolute deviation 
(MAD) method was used to detect outliers (Leys et al., 2013) from the combined groups. This 
method is far less sensitive to the effect of outliers  than protocols relying on the mean  SD (Wilcox, 
2010). A moderately conservative approach was used (Leys et al., 2013) and all data 2.5 X the SD as 
estimated from the median were considered outliers and were removed from the dataset. See Table 
9 for the number of participant data excluded at each stage of the data filtering process. 
Table 9: HRV data filtering process 
Total data collected 
IHE3: n =  10 IHE5: n =  10 C: n = 9 
   
Excluded due to: Equipment / measurement error 
IHE3: n =  10 IHE5: n = 9 C: n = 8 
   
Excluded due to: Outlying data (2.5*MAD) 
IHE3: n = 8 IHE5: n = 8 C: n = 8 
   
Excluded due to: Non-compliance with controlled 
breathing 
IHE3: n = 7 IHE5: n = 8 C: n = 7 
 
  
Data for Spontaneous 
breathing dataset: 
Data for Controlled 
breathing dataset: 
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4.3.8 Fitness assessments.  
A modified Astrand protocol performed on a manually calibrated cycle ergometer (Monark 
Ergomedic 818E, Sweden) was used to estimate oxygen consumption and fitness level during 
moderate and high intensity exercise during familiarization, baseline and post-intervention 
assessments. Cadence was displayed between the handle bars of the cycle ergometer and 
participants were instructed to maintain a cadence of 50 rpm throughout the assessment. 
Participants initially pedalled at a resistance of 25 W. After 2 minutes, blood pressure and 
instantaneous heart rate were recorded while participants continued to pedal. Every second minute, 
resistance was increased by 25W until a target heart rate of 40 – 50% heart rate reserve (HRR), or a 
rating of perceived exertion (RPE) of 13-14 on the 20-point Borg RPE Scale was achieved. Participants 
continued for 5 minutes at the targeted ‘moderate’ intensity workload while heart rate and oxygen 
consumption were recorded. Following this, the workload increased by 25 W every second minute 
until one of the following cut off criteria were achieved: HR within 10 beats of age predicted heart 
rate maximum; RPE of ≥ 19; participant’s volitional exhaustion; or an inability to maintain the 
required cadence (Siconolfi et al., 1982). The test was abandoned if any of the following occurred: 
SBP ≥ 210 mmHg; cramp; chest pain; dizziness or light headedness; signs of poor perfusion; or any 
other pain. A recovery interval of 5 minutes pedalling at a workload of 25 W and 50 rpm followed. 
See Figure 11 for a description of the baseline and post-intervention testing protocols.  
Three participants were restricted to submaximal fitness assessments due to high blood pressure (n = 
2) and a back injury (n = 1). Submaximal data were reported as an average of all data recorded during 
the 5 minute moderate intensity interval. A change in submaximal fitness was assessed using the 
change in submaximal exercise heart rate (HRsubmax), systolic blood pressure (SBPsubmax), and oxygen 
uptake (V˙ O2submax) in IHE3 and IHE5 compared to C.  
Maximal fitness capacity was determined using maximum oxygen consumption (V˙ O2peak) measured 
over the last 30 seconds of maximal exertion, the time from the end of the moderate intensity steady 
state period to maximal exertion (Timeex), and the resistance of the last complete minute (Resmax). 
Refer to Figure 11 for a diagrammatic representation of the fitness assessment. 
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Figure 11: Protocol for baseline and post-intervention fitness assessment 
4.3.9 5 week intermittent hypoxic exposure treatment.  
Participants received 5 minute intervals of either normoxic placebo air (C) or hypoxic air (IHE3 and 
IHE5) delivered through their own hand held face mask (QuadraLite Facemask, Intersurgical, 
Intermed, Auckland, New Zealand) fitted with an antibacterial filter (HMEF Clear-therm, Intersurgical, 
Intermed, Auckland, New Zealand) which was connected to a Hypoxicator System (GO2Altitude, 
Biomedtech, Victoria, Australia). The 5-minute normoxic/hypoxic intervals were separated by 5-
minute ambient air intervals, repeated for 1 hour (total of 30 minutes of hypoxic/placebo exposure 
per session). Heart rate and peripheral oxygen saturation (SpO2) were monitored continuously 
throughout the IHE session using fingertip pulse oximeters (Nonin Pulse Oximeter, Plymouth, 
Minnesota) built into the hypoxicators. Participants in the IHE3 and IHE5 groups received a fraction 
of inspired oxygen (FiO2) to yield weekly SpO2 values as follows: Week 1: 95%, Week 2: 90%, Week 3: 
85%, and weeks 4 and 5: 80%. The C participants received a normoxic FiO2 such that during all weeks 
SpO2 > 95%. Participants were blinded to their SpO2 and HR data during the breathing sessions.  
4.3.10 Statistical analyses.  
Any changes in pre- and post-intervention measurements in the IHE3 and IHE5 groups were 
compared to changes in C. Magnitude based inferences were used to assess the change in pre- and 
post-intervention variables. A spreadsheet (Hopkins, 2007) which analyses the magnitude of the 
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change in means against a smallest worthwhile change was used to provide a quantitative and 
qualitative assessment of the changes in the test groups (IHE3 and IHE5) against the control. Cohen’s 
smallest worthwhile change of 0.20 standardised units, that is, the inter-individual standard 
deviation (SD) between all participants at baseline divided by 0.2 (Cohen, 1988), was applied to test 
whether the true changes in variables were at least small. To reduce the effects of non-uniformity of 
error, and non-normal distributions (which are particularly prevalent in HRV analyses), the natural 
logarithm of the dependent variables was used in the statistical analysis (Hopkins et al., 2009).  
The practical significance of the results were reported using mechanistic and clinical inferences. The 
mechanistic inference relates to where the likely range of the true value lies relative to the smallest 
worthwhile change (Batterham and Hopkins, 2006). The likely range of the true value is expressed 
using the percentage change (from the natural logarithm) ± 90 % confidence interval, and the 
percent chances for substantially increased / trivial / substantially decreased outcomes (Hopkins, 
2007).  Where the confidence interval spans all three possibilities (increased, trivial and decreased), 
the result was deemed unclear. In all other cases, a mechanistically clear outcome is achieved (i.e. 
the confidence interval spans either 1, or a maximum of 2 possibilities, i.e. beneficial/trivial, or 
harmful/trivial) and a qualitative assessment of the magnitude of the change can be given. To 
determine the qualitative outcome the following scale was used: < 0.5 % = most unlikely; 0.5 – 5 % = 
very unlikely; 5 – 25 % = unlikely; 25 – 75 % = possibly; 75 – 95 % = likely, or 95 – 99.5 % = very likely, 
> 99.5 % = most likely).  
In cases where the variable has a direct effect on health or performance a clinical analysis was 
performed (these included SBP, hs-CRP, exercise efficiency and maximal oxygen uptake in the 
present study). In clinical analysis, the risk of harm is also included in the analysis, and results are 
only considered acceptable for use when the potential for benefit is substantially greater than the 
risk of harm. In this way avoiding harm is prioritised over neglecting to use a beneficial effect 
(Hopkins et al., 2009, Hopkins, 2007). For this study the benefit: harm ratio was considered 
acceptable if it was greater than 66 %.  
In all cases the baseline measurement was included as a covariate to reduce the impact of regression 
to the mean, and neutralise uneven starting values between groups (Hopkins, 2006). Results are 
presented as the % change in the mean from the natural log  90% confidence interval; % chance 
that the change substantially increased/trivial/decreased; followed by the qualitative outcome.  
4.4 Results 
All raw baseline and post-intervention testing data are presented in Table 23 in Appendix C.  
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4.4.1 Resting heart rate variability  
The HRV results are presented in Table 10. Refer to Table 9 for the filtering process and final number 
of participant data included for each group.  
Table 10: Baseline and post-intervention resting HR and HRV results 
 Mean change (%) and 
90% confidence interval 
Chances of increase/ 
trivial /decrease 
Qualitative outcome 
Spontaneous breathing 
RR interval (ms)    
IHE3 – Control -1.6  7.5  19 / 35 / 46 Unclear 
IHE5 – Control 2.1  8.1 50 / 33 / 18 Unclear 
rMSSD (ms)    
IHE3 – Control 13.5  49.8 52 / 32 / 16 Unclear 
IHE5 – Control 36.7  42.7 86 / 11 / 3 Likely increased 
SDNN (ms)    
IHE3 – Control -1.9  36.9 32 / 29 / 39 Unclear 
IHE5 – Control 5.3  41.1 49 / 21 / 29 Unclear 
HF (ms2)    
IHE3 – Control 58.2  123.9 70 / 22 / 8 Unclear 
IHE5 – Control 101.5  95.0 91 / 7 / 2 Likely increased 
LF (ms2)    
IHE3 – Control  74.0  76.2  89 / 8 / 3 Likely increased 
IHE5 – Control 55.0  67.9 86 / 10 / 4 Likely increased 
Controlled breathing 
RR interval (ms)    
IHE3 – Control 4.6  5.7 77 / 20 / 3 Likely increased 
IHE5 – Control 6.2  6.9 84 / 13 / 3 Likely increased 
rMSSD (ms)    
IHE3 – Control 30.3  39.2 81 / 15 / 4 Likely increased 
IHE5 – Control 47.3  41.6 93 / 5 / 2 Likely increased 
SDNN (ms)    
IHE3 – Control 15.3  23.2 73 / 22 / 5 Possibly increased 
IHE5 – Control 22.2  26.7 86 / 10 / 4 Likely increased 
HF (ms2)    
IHE3 – Control 46.4  96.8 67 / 26 / 7 Unclear 
IHE5 – Control 62.3  104.3 78 / 15 / 7 Unclear 
LF (ms2)    
IHE3 – Control 222.5  228.2 93 / 2 / 4 Likely increased 
IHE5 – Control 39.3  633.7 58 / 11 / 31 Unclear 
Spontaneous breathing: Participants were instructed to breathe as normally as possible for 10 
minutes, the last 5 minutes of this 10 minute interval were used to assess heart rate variability 
measures; Controlled breathing: participants breathed in time to a metronome which controlled 
respiration at 12 breaths per minute for 6 minutes. Heart rate variability was measured for 5 minutes 
starting 30 seconds after the start of the metronome. RR Interval: time interval between R – R peaks 
of the QRS complex; IHE3 and IHE5: Groups receiving intermittent hypoxic exposure treatments 2 – 3 
or 5 times per week respectively; rMSSD: root mean square successive difference; SDNN: standard 
deviation of normal to normal beats; HF: high frequency; LF: low frequency 
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4.4.2 Fitness  
Submaximal and maximal results are presented in Table 11. 
Table 11: Differences in submaximal and maximal exercise as a result of the 5 week intervention 
 Mean change (%) and 
90% confidence interval 
Chances of increase/ 
trivial /decrease 
Qualitative outcome 
Submaximal exercise 
V˙ O2submax  
 (mlmin-1kg-1) 
   
IHE3 – Control 5.5 ± 6.8 68 / 29 / 2 Clinically possibly harmful 
IHE5 – Control 0.0  8.0 17 / 65 / 18 Clinically possibly trivial 
    
SBP (mmHg)    
IHE3 – Control 3.6  6.1 53 / 44 / 3 Clinically possibly harmful 
IHE5 – Control - 1.7  6.2  8 / 61 / 31 Unclear 
    
HRsubmax (beatmin
-1)    
IHE3 – Control - 0.9  5.8 26 / 28 / 46 Unclear 
IHE5 – Control - 0.3  5.5 30 / 32 / 38 Unclear 
 
Maximal exercise 
V˙ O2peak (mlmin
-1kg-1)   
IHE3 – Control 12.6  9.3  92 / 7 / 0 Clinically likely beneficial 
IHE5 – Control 0.1  11.0  20 / 58 / 20 Clinically possibly trivial 
    
Resmax (watts)    
IHE3 – Control 4.4  16.1   52 / 30 / 18 Unclear 
IHE5 – Control 14.4  14.9  88 / 9 / 3 Likely increased 
    
Timeex (sec)    
IHE3 – Control 16.6  48.1  63 / 21 / 16 Unclear 
IHE5 – Control 34.5  36.8  91 / 5 / 4 Likely increased 
Submaximal exercise: Participants were instructed to maintain a ‘moderate’ workload for 5 minutes 
while submaximal variables were recorded; V˙ O2submax : average oxygen uptake over the 5 minutes of 
moderate exercise; SBPsubmax: average of all systolic blood pressure recordings taken during the 5 
minute moderate workload interval; submaximal oxygen uptake; HRsubmax: average heart rate during 
the 5 minute moderate workload interval; Maximal exercise: workload increased every 2 minutes 
until any of the pre-defined criteria for maximal exertion were achieved; V˙ O2peak: maximal oxygen 
uptake during last 30 seconds of peak exercise; Resmax: Maximum resistance tolerated for at least 30 
seconds; Timeex: Time from the end of the 5 minute moderate workload to maximal exertion; IHE3: 
Group receiving intermittent hypoxic exposure treatments 2 - 3 times per week; IHE5: Group 
receiving intermittent hypoxic exposure 5 times per week; rMSSD: root mean square successive 
difference. 
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4.4.3 Blood samples:  
hs-CRP. 
There were no clear changes in hs-CRP between IHE3 and C (7.6  58.6 %; 24/65/11; unclear). The 
IHE5 group demonstrated possibly trivial clinical changes when compared to C (12.7 ± 48.7 %; 
23/72/5; possibly trivial). When the participants’ hs-CRP results were divided into the quintiles 
defined by Ridker (2001), there were no differences between the groups. 
Hb.  
There were no clear changes in Hb in the IHE3 group compared to the C group (0.8  3.3 %; 
33/58/10, unclear). However, the IHE5 group demonstrated a possible increase in Hb compared to 
the C group (2.7 ± 2.8 %; 68/32/1; possibly increased). 
4.4.4 Resting blood pressure  
Both the IHE3 group and the IHE5 groups demonstrated a clinically unclear change in blood pressure 
from baseline to post-intervention measurements (IHE3 vs C: -5.4 ± 8.1 %; 4/27/69; unclear; IHE5 vs 
C: -4.0 ± 7.0 %; 3/44/53; unclear). 
4.4.5 Muscle mass and fat mass 
There were no meaningful changes between groups regarding fat mass or muscle mass as a result of 
the intervention. (Fat mass: IHE3 vs C: -3.1  3.1 %; 0/100/0; most likely trivial; IHE5 vs C: 4.3  6.0 %; 
13/87/0; likely trivial. Similarly for muscle mass:  IHE3 vs C: -0.2  1.7 %; 0/100/0; most likely trivial; 
IHE5 vs C: -1.5  2.8 %; 0/88/12; likely trivial). 
4.4.6 Pedometer and food diaries 
There were no clear differences between groups on steps taken before and after the intervention in 
any group. 
Food and activity diaries were inspected and none of the participants varied substantially in their 
daily routines pre- and post- intervention. 
4.5 Discussion 
The purpose of this study was to determine the effect of different frequencies of IHE on traditional 
and novel cardiovascular risk factors in a sedentary, but otherwise health population. The key finding 
of the study is that while there were a greater number of beneficial adaptations associated with the 
IHE5 group (greater increases in the parasympathetic components of HRV, improved time to 
exhaustion in the maximal fitness assessment, increased maximum workload, and improved Hb) 
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there was also evidence of improved HRV and fitness measurements in the IHE3 group (improved 
HRV under controlled conditions, and increased V˙ O2peak). To our knowledge, this is the first time that 
the effect of the number of IHE sessions per week has been tested on selected cardiovascular risk 
factors in a sedentary population. 
4.5.1 Novel risk factors 
HRV 
As rMSSD and the RR interval were the primary measures of HRV in this study, the results of this 
study suggest a more prominent HRV response to IHE in the group receiving more frequent hypoxic 
stimulus. Indeed, the results of this study support the findings of an earlier study run by our research 
lab which demonstrated an increase in rMSSD following a 4-week intervention of 4 IHE sessions / 
week (see Study 1, Chapter 3). In this earlier study, the improvement in HRV at rest was attributed to 
an adaptive response to the repeated parasympathetic withdrawal and reactivation during hypoxic 
exposure. The results of the present study develop this finding further in that it appears that a 
minimum number of hypoxic exposure sessions per week are necessary before increases in HRV 
become clear. That is, there were small increases in rMSSD in IHE3 (compared to the control group, 
and only under controlled breathing conditions), and a clear increase in rMSSD in IHE5 under both 
spontaneous and controlled breathing conditions. Taken with the findings from the 4-week 2010 
study, our results suggest that a minimum of 4 – 5 IHE sessions per week for at least 4 weeks are 
required before an increase in resting parasympathetic activity is detected in a sedentary, middle-
aged population.  
The rMSSD in our participants was just within the normal range outlined by Nunan et al. (2010), 
which likely reflects the healthy but sedentary nature of the middle-aged participants in this study, 
compared to the ‘healthy adults’ in their meta-analysis.  However, the controlled breathing interval 
in our study did not produce increased HRV values as reported in the aforementioned article (See 
raw values presented in Table 23 in Appendix C). Rather, our outcomes are similar to those of Pinna 
et al. (2006) who noted very little difference in markers of parasympathetic and sympathetic activity 
between spontaneous or controlled breathing frequencies in their middle-aged participants. There 
are some notable differences between the study by Pinna et al. (2006) and our study. The first 
difference is that we controlled breathing at a frequency at 0.2 Hz to reduce any hyperventilation, 
compared to Pinna et al. (2006) who used 0.25 Hz which is more comfortably within the high 
frequency bandwidth of 0.15 – 0.4 Hz (Task Force of The European Society of Cardiology and The 
North American Society of Pacing and Electrophysiology, 1996). Secondly, the time domain (rMSSD) 
was the primary indicator of parasympathetic activity in the present study, rather than the spectral 
domain (high and low frequency). The rMSSD reported in the present study supports the findings of 
 111 
Pinna et al. (2006) in that the controlled breathing did not appear to have a substantial effect on 
rMSSD. However, the HF reported in the present study was substantially higher than Pinna et al.’s 
(2006) study, and did appear to increase with paced breathing. For example, group means of 278, 
238, and 234 Hz under spontaneous breathing conditions, and 282, 313, and 391 Hz (C, IHE3, IHE5 
respectively) under controlled conditions were reported at the baseline recordings of the present 
study. Pinna et al. (2006) reported group means of 90 Hz (range: 46 – 145 Hz) under spontaneous 
and 70 Hz (35 – 170 Hz) under controlled conditions. Using data gleaned from the practice and 
baseline assessments of the present study, we found HF and LF measurements to be the least 
reliable measures of HRV in this cohort (see draft paper in Appendix B), and therefore would urge 
caution in drawing conclusions from the spectral components of HRV reported in this study. 
The high variation in the HF and LF reported in the present study is not unique. In the current 
literature, there is a wide range of reported HRV recordings, particularly regarding spectral analyses. 
For example, in Nunan et al. (2010) systematic review to determine normative values for HRV 
measures, high frequency reports ranged from 98 Hz (Notarius et al., 1999) to 1246 Hz (Sandercock 
et al., 2004) under spontaneous breathing, and from 82 Hz (Piccirillo et al., 2004) to 1506 Hz 
(Sandercock et al., 2004) under controlled breathing, refer to Supplementary table in Nunan et al. 
(2010). This high variation in reported HRV may depend on the equipment used to capture the RR 
intervals, the orientation of the participant during the measurement, the length of the HRV 
recordings, the population under investigation, and the level of the participant’s familiarity with the 
equipment, researchers and procedures (and therefore anxiety). Therefore, in assessing the 
differences between paced and spontaneous breathing, it is important that the measurements being 
compared are from the same participants, measured under the same conditions and ideally, by the 
same researchers. Unfortunately there were only two such studies that measured both paced and 
spontaneous breathing in the review by Nunan et al. (2010). Of these two studies, one reported an 
increase in HF and rMSSD values with paced breathing (Sandercock et al., 2004), while the other 
reported little difference between the paced and spontaneous breathing (Sinnreich et al., 1998). The 
systematic review for normal values of HRV by Nunan et al. (2010) is an important and long overdue 
‘puzzle piece’ in the understanding of HRV, and indeed is useful in detecting where one’s participants 
fit in the greater scheme of the reported research. However, the methodological causes of variation 
discussed above, and the restricted number of large population studies meeting the requirements for 
inclusion in the review may limit the more specific generalisations that can be drawn from the 
findings. 
  
 112 
Hs-CRP 
While the hs-CRP in the IHE3 group remained relatively consistent throughout the trial, the hs-CRP 
demonstrated a small increase in the IHE5 group. While this increase was trivial, and not sufficient to 
increase the IHE5 group from the 4th  into the 5th quintile of ‘highest relative risk’ for  future 
cardiovascular disease as defined by Ridker (2001), it is important to address the possible causes of 
this increase. As mentioned earlier, highly sensitive C-reactive protein is a sensitive marker of 
inflammation that has become useful in the detection and monitoring of the early atherosclerotic 
stages of cardiovascular disease (Koening et al., 1999). However, an increase in C-reactive protein 
(CRP) has also been associated with hypoxic exposure, both in disease, such as in patients with 
Obstructive Sleep Apnoea (Yokoe et al., 2003), and environmentally such as during sojourns to high 
altitude (Hartmann et al., 2000). The inflammation response to the hypoxic environment is delayed, 
with very little increase in CRP in the first  (Pavlicek et al., 2000) or second (Hartmann et al., 2000) 
days at high altitude, but is substantially increased on days 3 and day 4 (Hartmann et al., 2000). The 
participants in the IHE5 group were exposed to daily doses of hypoxia to a target SpO2 of 80%, which 
is approximately equivalent to 4,500 m (Hartmann et al., 2000). While these intervals were brief 
(total of 30 minutes of hypoxic exposure), the additive effect of the daily exposure may have slowly 
increased systemic inflammation. While Hartmann et al. (2000) did not present any data regarding 
the recovery time of the elevated hs-CRP to normal resting values following the return to sea level, 
when the patients with obstructive sleep apnoea syndrome were given continuous positive airway 
pressure devices to eliminate the hypoxic episodes during sleep, the C-reactive protein was 
decreased substantially (Yokoe et al., 2003). Therefore, it is unlikely that the marginally elevated hs-
CRP will persist for any extended period of time following cessation of the hypoxic training sessions. 
However, as C-reactive protein may propagate cardiovascular disease rather than just indicate its 
presence (Li and Fang, 2004) caution should be used when recommending IHE to participants who 
might already have elevated levels of hs-CRP. 
4.5.2 Traditional risk factors 
Exercise tolerance 
As the submaximal workload was controlled using HR, the uniformity of the submaximal exercise 
heart rate between baseline and post-intervention measurements in all three groups indicates good 
consistency in the exercise test between baseline and post-intervention trials. The within group 
differences between baseline and post-intervention oxygen efficiency, as assessed by V˙ O2submax, 
suggested that the IHE3 remained largely unchanged following the 5-week intervention, and the IHE5 
group improved efficiency (see Table 23 in Appendix C). As the decrease in V˙ O2submax in IHE5 (-1.2 
mlmin-1kg-1) was similar to the change in the control group (-0.8 mlmin-1kg-1), it is unlikely that the 
improved oxygen efficiency could be attributable to the intermittent hypoxic exposure. Despite 
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including a familiarization session, the improvements in the Control group could be attributed to 
improved familiarity with the researchers and exercise testing protocols. Thus, neither group (IHE3 
nor IHE5) demonstrated any advantage attributable to the IHE treatment over the control group 
during submaximal exercise.  
During the maximal assessment, the results were somewhat conflicting. The IHE3 group likely 
improved V˙ O2peak but did not demonstrate any other improvement to support an improvement in 
exercise tolerance (such as improved timeex, or resmax). Conversely, the IHE5 group did demonstrate 
increased timeex and resmax but did not demonstrate any improvement in V
˙ O2peak, despite an increase 
in Hb. The findings from the IHE5 group are similar to those of Burtscher et al. (2009) who reported 
improved exercise time, time to anaerobic threshold, and increased total haemoglobin mass, but no 
clear improvement in V˙ O2peak in his population of patients at risk for coronary pulmonary obstructive 
disease. Burtscher et al. (2009) suggests, that the exercise time reflects greater sensitivity to training 
effects than V˙ O2peak. So, while participants in the IHE5 group did not improve exercise tolerance to the 
point of improving V˙ O2peak, exercise capacity was improved sufficiently to alter more sensitive 
markers of exercise tolerance. Contrary to the findings of other researchers (Calbet et al., 2006), the 
1.75% increase (within group) in Hb in the IHE5 group following the 5 weeks of IHE treatment was 
not sufficient to alter the V˙ O2peak of our participants in a meaningful way. Similarly, Clark et al. (2009) 
reported no change in  V˙ O2peak in their cohort of well-trained male cyclists following an increase of 
3.3% Hbmass, and only a trivial correlation (r = 0.09) between the change in Hbmass and V
˙ O2peak. Our 
research supports the idea of a minimum dose required in a hypoxic environment for an increase in 
haemoglobin (the Control and IHE3 groups exhibited no change, but there was a clear, possible 
increase in Hbmass in IHE5). However, it does not support an automatic improvement in V
˙ O2peak with 
an increase in Hbmass. The question arises of whether in addition to recommendations for a minimum 
time spent in hypoxic exposure for an increase in Hbmass (Rusko et al., 2004), there is also a minimum 
worthwhile increase in Hbmass required before a practical increase in V
˙ O2peak is achieved. 
 Alternatively, the increased workload and higher time to exhaustion in the IHE5 group may indicate 
a greater anaerobic tolerance. Findings such as these have also been observed by other researchers 
(Hamlin et al., 2010) who posit that mechanisms such a shift to glycolytic energy pathways (Hamlin et 
al., 2010), and improved skeletal muscle buffer capacity (Mizuno et al., 1990) are responsible for the 
improvements in anaerobic performance. 
The improvement of V˙ O2peak in the IHE3 group without any other supporting evidence of improved 
exercise tolerance is confusing. It is possible that ‘upstream changes’ in response to hypoxic 
exposure (Garvican et al., 2011) may be responsible for the increase in V˙ O2peak in the IHE3 group in 
the current study. That is, while 2-3 IHE sessions per week are insufficient to simulate an increase in 
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Hb, they may be sufficient to stimulate other, non-haematologically based adaptations, such as the 
adaptations associated with an up regulation of HIF-1α and an adaptation of the hypoxic sensing 
system (Vogt et al., 2001, Hoppeler et al., 2003). However, if this were the case, it is unlikely that 
these adaptations would occur in the group receiving 2 – 3 IHE sessions per week, and not in the 
group receiving 5 IHE sessions per week.  
 Blood pressure 
Resting systolic blood pressure decreased in both the IHE3 (9.6 mmHg) and IHE5 (5.2 mmHg) groups 
compared to negligible change in the control group (0.2 mmHg). However, when the baseline was 
added as a covariate the changes between groups were unclear. The improved HRV as indicated by 
increased parasympathetic activity (rMSSD) in IHE3 (small) and IHE5 (moderate – large) following the 
5 weeks of IHE may be linked to the improved resting SBP in the IHE3 and IHE5 groups. However, as 
the SBP at baseline in the IHE3 and IHE5 groups was substantially higher than the C group, it is 
possible that the improvements reflect a regression to the mean, as opposed to a true change 
(Hopkins, 2006). Therefore, the ‘unclear’ outcome is appropriate in this regard, and more 
information is needed before a confident statement can be made regarding the effect of IHE on SBP.  
Muscle mass and fat mass 
There were no meaningful differences between groups in either the fat mass or muscle mass 
measurements following the intervention when compared to the control group. The absence in any 
notable changes between groups pre- and post-intervention supports both the study by Balykin et al. 
(2004) and our earlier study (see Chapter 3) and suggests that an IHE protocol in this format, without 
an additional exercise component, is insufficient to induce any beneficial alteration in muscle mass or 
fat mass.  
4.5.3 Dosage 
As with real altitude exposure, the frequency, and length of the IHE intervention are important for 
altitude related adaptations. However, in both studies run by our research group, the IHE sessions 
were fixed at 5-minute hypoxic exposure intervals separated by 5 minutes of ambient air for one 
hour and the intervention period ran for a period of 4 - 5 weeks. As different intervention lengths or 
hypoxic exposure intervals were not assessed, the minimum hypoxic exposure or intervention length 
is still unknown.  
Our research protocol was similar to that of Tadibi et al. (2007) but we used a lower frequency of 
hypoxic exposure intervals per week (3 and 5 in our study, compared to 7 in Tadibi et al.’s (2007) 
protocol), but longer intervention length (5 weeks in our study compared to 2 weeks in Tadibi et al.’s 
(2007) protocol). This suggests that the length of the intervention may be as important as the 
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frequency or intensity of IHE. For example, in Beidleman et al.’s (2009) study, 1 week of severe 
hypoxic exposure and hypoxic training did not yield any meaningful change in the hypoxic group 
when compared to the placebo in submaximal or maximal exercise parameters (Beidleman et al., 
2009). While this is by no means a full review of the literature, and there are some exceptions 
(Beidleman et al., 2008), it is likely that an intervention of greater than 3 weeks in duration will be 
beneficial for improvement associated with IHE (Haider et al., 2009, Saeed et al., 2012).  
The results from this study and our earlier 2010 study suggest that a minimum IHE frequency of 4 - 5 
times per week are required before clear physiological changes take place. However, as little as 2 – 3 
sessions per week may result in small increases in parasympathetic activity at rest, but these 
responses are likely to be of a smaller magnitude than more frequent exposures per week. 
4.5.4 Limitations 
The nature of this study lends itself to Type 1 errors, or declaring that an effect is worthwhile, when 
it is in reality a product of chance. Both the small group sizes and the large number of variables are 
important factors when considering the chances of a false positive (Hopkins, 2000a). This increase in 
the risk of Type 1 errors may account for the unexpected improvements in the V˙ O2peak data in the 
IHE3 group. No attempt was made to correct for these potential errors as all measurements were 
pre-planned and have been openly reported. 
This study was a single blind, randomised control trial. Strictly speaking however, there was no 
control for the group coming 5 times per week, as the control participants in this study all came 3 
times per week. Following the recruitment period, and after all recruitment strategies had been 
exhausted, there were not enough participants to divide into 4 groups, as the group sizes would have 
been too small to make meaningful inferences (Pyne and Hopkins (2012) suggest a minimum of 10 
individuals per group). Thus, when deciding between whether to assign a control group to the IHE3 
or IHE5 group, the researchers felt the best participant retention would be in the IHE3 group.  
Iron is an important part of haemoglobin production, and to ensure anaemia does not interfere with 
aerobic adaptation some researchers recommend the inclusion of iron supplementation during 
altitude training (Brownlie et al., 2002, Maughan, 1999). Unfortunately, due to budgetary constraints 
we were unable to provide iron supplementation to the participants in this study.  However, none of 
the participants presented with low Hbmass at baseline, and as none of them were participating in 
strenuous exercise at the time, it is unlikely that the participants would have been iron deficient. 
Some of the studies used in the introduction and discussion are specific to well-trained individuals, 
and/or are focussed on real rather than simulated altitude. These techniques and populations may 
well respond differently to the sedentary cohort in this study. However, the inclusion of these studies 
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in the discussion and introduction of this chapter help to understand the mechanisms behind some 
of the adaptations reported in the current investigation. 
In any exercise assessment, motivation will play a large role in the extent to which a participant is 
willing to endure the exercise load. Furthermore, ratings such as the Borg Rating of Perceived 
Exertion scale are subjective and require the participant to assess themselves. To reduce the effects 
of variations in extrinsic motivation, the researcher leading the fitness assessment paid attention to 
maintain a similar level of verbal encouragement between all participants at all measurement 
sessions. However, some variations in the level of encouragement supplied the motivation of the 
participant on the day and the participant’s subjective rating of their exertion could have confounded 
the results of the fitness assessment. 
4.6 Conclusion 
Intermittent hypoxic exposure appears to have a beneficial effect on both novel and traditional 
cardiovascular risk factors in a sedentary population. Greater improvements in HRV and exercise 
tolerance were observed in the IHE5 group (improved timeex, resmax, Hb and HRV) than the IHE3 
group; however the IHE3 group did demonstrate improvement in V˙ O2peak and a small increase in HRV 
(only when compared to the control and under controlled conditions only). While within group 
change suggested a decrease in SBP with IHE, there were no clear changes in SBP compared to C. 
Caution is recommended when advising participants with high levels of hs-CRP to engage in more 
than 3 IHE sessions per week. Intermittent hypoxic exposure sessions at least 4 – 5 times per week 
are recommended.   
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 Chapter 5
Preface to Study 3: Does IHE enhance the cardioprotective effect of 
exercise in a sedentary population? 
The previous two studies have demonstrated improvements in both novel and traditional 
cardiovascular risk factors with IHE. While Study 2 demonstrated greatest improvement in 
cardiovascular risk factors with 5 IHE sessions per week, there was some health benefit in the group 
attending 2 – 3 IHE sessions per week. Therefore, the aim of the following study was to determine 
whether 2 – 3 IHE sessions per week in addition to 3 exercise training sessions per week would result 
in greater improvement in cardiovascular risk profile than exercise only. The time frame of the 
exercise intervention was extended to 10 weeks as this is the time frame used in the government 
funded “Green Prescription” programme. The advantage of aligning the time frame of the current 
research programme to the Green Prescription time frame is that it opens the door to future 
comparisons between ‘real world’ interventions. Additional risk factors, such as arterial stiffness, 
total cholesterol and high density lipoprotein were selected for greater risk assessment profiling. 
Additionally, the findings in Study 2 indicated a possibly trivial increase in hs-CRP following 5 IHE 
sessions per week. Typically, an increase in basal hs-CRP indicates systemic inflammation which is 
usually associated with atherosclerosis. By including an assessment of arterial stiffness, we can better 
understand the effects of IHE on immediate and longer-term vascular health. Finally, as walking / 
jogging formed the majority of the aerobic component in the exercise training, a treadmill fitness 
assessment, rather than the bicycle assessment was used to improve the testing protocol with the 
functional adaptation to the exercise intervention. 
This study has been written in research paper format but it has not been submitted to a journal. It is 
likely that this research will be divided into 2 research papers (one focussing on arterial stiffness and 
the other focussing on the cardiovascular risk profile). However, in the interests of avoiding 
unnecessary repetition (particularly in the methods section), all information has been included into 
one paper. 
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5.1 Abstract 
Exercise is one of the best means of reducing cardiovascular disease risk in a sedentary population. 
As simulated (or real) altitude training is thought to improve exercise capacity in an athletic cohort, 
several health-focussed researchers have investigated whether simulated altitude would improve the 
effectiveness of a traditional exercise programme in reducing cardiovascular risk factors. However, 
most research has focussed on individual risk factors, rather than overall cardiovascular risk profile. 
In addition to this, research has largely focussed on exercise training in hypoxia, rather than training 
in normoxia and receiving an additional passive hypoxic stimulus. Objectives: Determine the effects 
of exercise supplemented with passive intermittent hypoxic exposure (IHE) on individual risk factors, 
and overall cardiovascular disease risk profile compared to exercise alone. Methods: All participants 
were medically screened prior to inclusion in the study. Following acceptance, 34 participants were 
divided into either a group receiving exercise and IHE (IHE3 + Ex, n = 16; 6 males, 10 females; Age: 
56.7  6.4 years; weight: 78.6  12.4 kg; height: 168.0  8.8 cm) or exercise alone (Ex, n = 18, 5 males, 
13 females; Age: 56.4  6.5 years; weight: 81.2  15.9; height: 167.3  8.42). Both groups received 
exercise training 3 d/ week for 10 weeks. Training was for an hour and included, a 10 min light 
aerobic warm up, 20 min aerobic (walking/ jogging outdoors), 15 min strength (including all major 
leg, core and arm muscle groups) and a 15 min warm down comprising light aerobic cool down and 
stretching. All participants trained with heart rate monitors and aimed for a an intensity of 70 – 75% 
of their heart rate maximum in Week 1 and 75 – 80% heart rate maximum for weeks 2 – 10. In 
addition to the exercise training, the IHE3 + Ex group also received IHE sessions for 2 – 3 d/ week, 
which involved breathing 5 min hypoxic air alternated with 5 min ambient air for 1 h while seated 
comfortably. The fraction of inspired oxygen (FiO2) was controlled by the researcher to yield an SpO2 
of 90%, 85%, and 80% in weeks 1, 2 and 3 – 10 respectively. Testing took place before (Baseline), 
after (Post) and at 4 and 8 weeks following the intervention. Each testing period included: a blood 
sample (high density lipoprotein, HDL, and total cholesterol, TC). Blood samples were not collected at 
the 4-week follow up.; An arterial stiffness assessment (pulse wave velocity, PWV, and pulse wave 
analysis, PWA using the augmentation index, AIx); and a fitness assessment (including resting heart 
rate variability (HRV) and systolic blood pressure (SBP) and a maximal treadmill test to exhaustion). 
Heart rate variability was measured using the average R peak to R peak (RR) interval and the root 
mean square of the successive difference (rMSSD) between beats. Overall 5-year risk of 
cardiovascular disease was assessed using the New Zealand Guidelines Chart which combines SBP, 
age, sex, TC:HDL ratio, and diabetic status to assess an overall risk. Additionally, 10-year 
cardiovascular risk was assessed using the Framingham risk stratification process. Results: In all 
analyses, the mean change from the baseline measurement between IHE3 + Ex and Ex was assessed. 
Therefore, a negative result represents a decrease in the IHE3 + Ex compared the Ex group in the 
 120 
change score from baseline. Following 10 weeks of IHE, TC decreased in both groups, but was higher 
in the IHE3 + Ex group than the Ex (Post: 4.4  6.5%, possibly harmful; and 8-wk: 6.5  7.2% likely 
harmful, mean change  90% confidence interval, qualitative outcome). The higher TC in IHE3 + Ex 
was due to a likely beneficial increase in HDL in the IHE3 + Ex group compared to Ex at Post and 8-wk 
(Post: 8.0  8.0%; 8-wk: 10.0  8.5%). Accordingly, the ratio between TC and HDL was likely beneficial 
at Post (-77.2  50.5%) but unclear at 8-wk (-24.7  52.4%). Systolic blood pressure decreased more 
so in the IHE3 + Ex group immediately following the intervention (Post: -3.4  3.4%, possibly 
beneficial), was possibly trivial at 4-wk (0.5  3.5%), and possibly beneficial at 8-wk (-3.5  3.7%). 
Overall cardiovascular risk using the New Zealand Guidelines Chart for risk assessment demonstrated 
subtle improvements between risk categories in both groups. There were no clear changes in PWV at 
any time point (Post: -0.3  11.2%; 4-wk: -4.2  11.5%; 8-wk: -8.1  9.3%), however PWA 
demonstrated an unclear decrease in AIx at Post (-6.1  18.4%), and a likely and very likely harmful 
increase at 4-wk and 8-wk respectively (4-wk: 11.8  18.4%; 8-wk: 24.8  19.7%) compared to Ex. 
Both groups showed increased RR interval and rMSSD as a result of the 10-week intervention, but 
the changes between groups were most likely trivial at all test periods in the RR interval (Post: 3.1  
5.1%; 4-wk: 0.0  5.3%; 8-wk: 3.4  5.4%) and unclear in rMSSD (Post: 18.0  24.0%; 4-wk: 14.0  
25.2%; 8-wk: 13.0  25.6%). Changes in cardiovascular fitness showed different, but beneficial 
responses in both groups. While the differences between groups in V˙ O2peak remained unclear at post 
(3.1  7.7%) there was a likely beneficial response in the IHE +Ex group at 4 and 8-wk follow up (4-wk: 
9.4  8.0%, 8-wk: 7.9  8.3) suggesting improved aerobic capacity. Time to exhaustion (measured as 
the time taken from the beginning of Stage 1 to voluntary exhaustion) was similar in both groups 
(Post: 3.8  6.3%; 4-wk: -1.3  6.5%; 8-wk: 5.0  6.8%). Conclusion: Exercise with IHE resulted in 
greater reduction in individual risk factors (improved SBP, V˙ O2peak, HDL, and a tendency towards 
increased HRV) but showed no substantial benefit in 5- or 10 year risk of cardiovascular disease. 
Changes in cardiovascular fitness were more difficult to interpret. There was an unclear decrease in 
PWV in the IHE3 + Ex group, but the AIx measurements demonstrated an unclear decrease at Post, 
but then a likely and very likely increase at the 4- and 8-wk assessments respectively. The increase in 
AIx could be accounted for by an increase in the pulse pressure with little change in the 
augmentation pressure, or from a down-regulation of the endothelial nitric oxide synthase following 
cessation of the hypoxic exposures (resulting in increased vascular tone and more intense reflection 
waves).  More research is needed regarding the long-term effects of IHE on vascular health before 
IHE can be considered a safe intervention. Whether a less severe dose of hypoxia would generate the 
cardio-protective adaptations without the apparent increase in arterial stiffness should be explored 
in either a healthy, younger cohort or in animal models.  
Keywords: heart rate variability; intermittent hypoxic exposure; sedentary; heart disease risk factors  
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5.2 Introduction  
It has been well established that exercise is a highly effective means of reducing cardiovascular 
disease and its risk factors (Garber et al., 2011). In an attempt to enhance the health benefits of 
exercise, some researchers have investigated the use of either exercise supplemented with passive 
simulated altitude exposure (Balykin et al., 2004) or exercise in a hypoxic environment (Friedmann et 
al., 2003, Geiser et al., 2001). The motivation behind the inclusion of a hypoxic stimulus to the 
exercise training is related to the adaptations associated with the actions of the alpha subunit of the 
transcription factor, Hypoxic Inducible Factor – 1 (HIF-1α). In hypoxia, HIF-1α acts to stimulate genes 
responsible for adaptations such as angiogenesis and erythropoiesis (Semenza, 2009), adaptations 
which are thought to have a beneficial effect on exercise, resulting in greater improvements in 
exercise capacity than when training in normoxia. 
Indeed, previous research conducted in a sedentary middle-aged population by our research group 
has demonstrated improved HRV, time to exhaustion in a maximal exercise test on a cycle ergometer 
test, and increased haemoglobin following 5 weeks of passive simulated altitude exposure. These 
outcomes support the cross-adaptive effects of hypoxia (without concurrent exercise training) to 
exercise capacity.  However, research regarding exercise training in hypoxia in a sedentary 
population has returned mixed findings. For example, some studies have reported improved muscle 
and mitochondrial volume and greater capillary length density (Geiser et al., 2001), improved 
vascular health (Nishiwaki et al., 2011), and greater V˙ O2peak (Katayama et al., 1998). Other studies 
have reported either no worthwhile effect of training in hypoxia compared to normoxic training on 
strength  (Friedmann et al., 2003) or mitochondrial function (Pesta et al., 2011). Some research has 
even reported a detrimental effect  on erythrocytes structure and stress tolerance immediately 
following an exercise intervention in hypoxia (Mao et al., 2011). Others have found that although the 
hypoxic stimulus resulted in adjustment at the molecular level, this did not transfer into a functional 
improvement in exercise capacity more so than that of exercise in normoxia (Vogt et al., 2001).  
To our knowledge, there has only been one study which has compared the effect of passive hypoxic 
exposure as a supplement to exercise training in a sedentary population. Balykin et al. (2004) 
examined the effects of an intermittent hypoxic exposure (IHE) technique to simulate altitude in a 
population of overweight, sedentary males. In this protocol, the participants were seated and 
passively inhaled 5 min of hypoxic air alternated with 5 min of normoxic air, for 1 h for a total of 10 
IHE sessions. The groups receiving IHE in conjunction with 30 min of aerobic exercise on a cycle 
ergometer at a resistance of 100 W (either immediately following IHE or on alternative days) 
demonstrated increased parasympathetic and decreased sympathetic activity in the autonomic 
control of the heart and greater improvements aerobic capacity compared to either exercise training 
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or IHE on its own. Given the promising results from this study, further research using IHE as a 
supplement to exercise should be investigated in a sedentary population who may already exhibit 
autonomic dysfunction and poor cardiovascular fitness. 
There are several limitations in the literature investigating the potential health benefits of IHE. For 
example, most studies, including Balykin’s (2004) study, have examined the effects of IHE on specific 
risk factors. While this is useful in that it allows the researcher to pinpoint specific responses as a 
result of adaptation to the hypoxic stimulus, cardiovascular disease is the result of combination of 
several risk factors, rather than just one (Dahlöf, 2010). Therefore, when assessing the effects of IHE 
and exercise on cardiovascular health it is useful to examine the overall cardiovascular profile of the 
participant in addition to individual risk factors. Additionally, most research on altitude training has 
been conducted in healthy, fit individuals (for example, the participants in the Balykin et al. (2004) 
study were healthy men between the ages of 18 – 20 years). As sedentary, middle-aged participants 
have a higher cardiovascular risk than a healthy young cohort, and therefore have more to benefit 
from such a treatment than a healthy young cohort, more research regarding the effects of IHE on 
health in an older, inactive population is warranted. Finally, the long-term effects of IHE 
interventions are seldom measured, and therefore it is unknown how long any potential adaptation 
associated with hypoxic exposure will last.  
In response to these limitations in the literature, the purpose of this investigation is to determine the 
effect of adding IHE to a standard exercise programme on cardiovascular health in sedentary, middle-
aged participants. This will be assessed using both individual risk factors for heart disease such as 
arterial health (pulse wave analysis, PWA and pulse wave velocity, PWV), heart rate variability (HRV), 
cardiovascular fitness (time to exhaustion and peak oxygen uptake, V˙ O2peak), and an overall 5 – year, 
and 10 -year risk of cardiovascular disease as estimated using the New Zealand Guidelines Group 
(2009) year risk assessment chart, and Framingham 10 year risk assessment (D’Agostino et al., 2008). 
See Figure 31 in Appendix E for a copy of the New Zealand Guideline’s 5 – year cardiovascular risk 
assessment chart. 
5.3 Methods 
5.3.1 Participants.  
Men and women who were doing less than NZ physical activity guidelines of 30 minutes of moderate 
physical activity on most (<5) days of the week (Ministry of Health, 2008), and who were between 
the ages of 45 – 70 were recruited from the local community. All interested candidates were 
required to undergo a medical screening prior to inclusion. Participants were excluded if they had an 
uncontrolled medical condition (uncontrolled hypertension, hypercholesterolemia etc.) were 
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smokers, had any melanoma, cardiovascular disease or were recommended against participation by 
the assessing medical practitioner or their general practitioner. Participants on medication were 
included provided the condition was stable and the medication dose was unlikely to change over the 
course of the trial.  
As outlined in Figure 12, two participants in Ex (n=18) and three participants in IHE3 + Ex (n=16) 
withdrew their participation in the first week of the training programme, and have been excluded 
from the group descriptions and analyses. Participant descriptions can be found in Table 12. All 
participants were informed of the procedures and risks and provided written informed consent.  
Human Ethics approval was granted by the Lincoln University Human Ethics Committee. 
 
Figure 12: Participant recruitment process 
5.3.2 Experimental design. 
Following inclusion into the study, participants underwent a baseline testing period followed by a 10-
week intervention period. Testing periods then took place within 3 days of the conclusion of the 10-
week interval (Post) and 4- and 8-weeks (4-wk and 8-wk respectively) following the conclusion of the 
intervention.  
Each testing period required the participants to attend 3 separate appointments.  The first 
assessment was to collect a blood sample, from which total cholesterol (TC) and high density 
lipoprotein (HDL) were measured (but not at 4-wk follow up). The second assessment was an arterial 
health assessment and included PWV and PWA analyses. The last assessment was a fitness 
assessment which included anthropometric, HRV, and exercise (V˙ O2peak and time to exhaustion) 
measurements. Arterial stiffness assessments were completed within 1 weekend, and all fitness 
assessments were completed within the adjacent following week (participants attended sessions at 
the same time of day for each returning assessment), see Figure 13. Following baseline assessments, 
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participants were matched for age and sex and were then allocated into 1 of 2 groups. (The 
allocation of participants to groups was random except for 3 participants who specifically requested 
the exercise only group due to the time commitment associated with the exercise and simulated 
altitude group). One group received 3 exercise sessions per week (Ex) while the second group 
received 3 IHE sessions per week in addition to 2-3 of sessions (IHE3 + Ex) per week. Participants in 
the IHE3 + Ex and Ex groups all trained together. After the 10-week intervention, all the baseline 
assessments were repeated immediately and at 4 and 8-wk follow up assessments. See Figure 13 for 
the research timeframe. 
Table 12: Anthropometric data of participants 
IHE3 + Ex: Group receiving intermittent hypoxic exposure in addition to exercise during the 
intervention period. Ex: Group receiving exercise only during the intervention period. SBP: Systolic 
blood pressure; DBP: Diastolic blood pressure; TC: Total cholesterol; HDL: High density lipoprotein; 
TC: HDL: Total cholesterol to high density lipoprotein ratio; V˙ O2peak: peak oxygen uptake during 
exercise to exhaustion. 
 
 IHE3 + Ex (n=16) Ex (n=18) 
 Female (n=10) Male (n=6) Female (n=13) Male (n=5) 
Age (years) 56.9 ± 5.8 56.3 ± 7.9 55.4 ± 6.2 59.0 ± 7.3 
Weight (kg) 74.0 ± 12.5 86.1 ±8.5 79.2 ± 17.7 86.5 ± 8.8 
Height (cm) 163.6 ± 6.3 175.3 ± 7.5 164.6 ± 8.1 174.2 ± 4.7 
Body fat (%) 37.5 ± 7.2 23.6 ± 1.2 39.5 ± 5.8 26.4 ± 4.2 
Resting heart rate 
(beatsmin-1) 
65.4 ± 10.0 63.8 ± 8.9 62.0 ± 10.3 58.8 ± 14.4 
SBP (mmHg) 124 ± 11.0 126.9 ± 14.1 125.7 ± 17.6 119.1 ± 29.7 
DBP (mmHg) 71.1 ± 7.6 73.6 ± 3.7 72.3 ± 8.0 69.0 ± 16.5 
TC 5.3 ± 1.1 5.7 ± 0.5 5.9 ± 0.5 5.9 ± 1.1 
TC:HDL 3.8 ± 1.3 5.1 ± 1.1 4.3 ± 0.7 5.4 ± 2.1 
V˙ O2peak (mLmin
-1kg-1) 26.8 ± 6.0 34.8 ± 5.0 25.0 ± 3.9 25.4 ± 7.7 
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Figure 13: IHE3 + Ex versus Ex only research timeframe 
The bars indicate where various measurements took place, and the interval for measurement. Open 
bars indicate the period for blood collection, solid bars indicate where arterial stiffness 
measurements were taken (over 1 weekend), and striped bars outline where fitness assessments 
were measured (over 1 week, immediately following the arterial stiffness assessment. 
 
5.3.3 Food and activity monitoring 
Participants were asked to record all food and medicine ingested, and to describe any physical 
activity for 2 days prior to measurement sessions.  
5.3.4 Assessment 1: Venous blood samples. 
All blood samples were taken following an overnight fast. Participants reported to a participating 
local medical facility, were seated and had their blood drawn from the antecubital vein by a trained 
phlebotomist. Venous blood samples were then analysed at an accredited laboratory (Canterbury 
Health Laboratories, Christchurch). High density lipoprotein (HDL) and total cholesterol (TC) were 
analysed using an enzymatic essay performed using the Abbott c8000 analyser (Abbott Laboratories. 
Abbott Park, Illinois, U.S.A ) with Abbott reagents.  
5.3.5 Assessment 2: Arterial stiffness 
There are several different ways of monitoring or assessing arterial health. Two of the most 
convenient, non-invasive, and well-validated methods are the assessment of pulse wave velocity and 
pulse wave analysis. 
Pulse wave analysis 
Pulse wave analysis (PWA) provides a systemic appraisal of vascular health, including the ventricular-
vascular interaction and an assessment of endothelial function (Stoner et al., 2012). The 
augmentation index (AIx) is a PWA assessment which indicates arterial stiffness based on the 
augmentation of the pressure wave generated during systole (Stoner et al., 2012), and is also an 
independent risk factor for coronary artery disease (Weber et al., 2004). Following ejection of the 
ventricular load, the forward moving pressure wave (incident wave) travels through the low-
resistance aorta and arteries towards the periphery. When the incident wave reaches the highly 
Arterial stiffness  
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resistant arterioles, a reflection wave is generated that travels back up along the arteries and aorta 
towards the heart (Vlachopoulos and O'Rourke, 2000). A fast travelling pulse wave (associated with 
stiffer arteries) will arrive back at the heart during systole, which in turn will have two important 
effects on the vascular-ventricular interaction. First, by interacting with the incident wave earlier on 
during systole where the pressure is higher, an even higher second systolic peak is created. And 
second, by arriving back at the heart during systole (rather than diastole) both ventricular ejection 
and coronary blood flow are inhibited (Vlachopoulos and O'Rourke, 2000). The amount of pressure 
added to the incident wave by the reflected wave is known as the augmentation pressure (derived 
using maximum systolic peak of the pulse wave minus the pressure at the inflection point where the 
forward and reflected waves interact). The augmentation index is the augmentation pressure 
expressed as a percentage of the pulse pressure (Stoner et al., 2012), see Figure 14. 
Pulse wave analysis was assessed using a SphygmoCor device (SphygmoCor, AtCor Medical, Sydney, 
Australia) and integrated software (SCOR Px 7.1, AtCor Medical, Sydney, Australia) which 
automatically interprets and displays the AIx. Measurements were taken on the radial artery, with 
the arm fully supported and following a minimum of 20 min undisturbed rest in the supine position 
(Stoner et al., 2013). To reduce the impact of heart rate on the AIx (Wilkinson et al., 2000), all data 
were normalised to a heart rate of 75 beats per minute prior to analysis. A minimum of two 
recordings were taken. If AIx differed by 4% between the two recordings a third recording was taken, 
and the average of the closest two measurements were used. The quality of the recordings was 
assessed using the default setting specifications (average pulse height: 80 units, pulse height 
variation: 5 %, Diastolic variation: 5 %, and quality index: >80 %) and recordings were only accepted if 
they fell within these limits. 
Pulse wave velocity 
The carotid – femoral pulse wave velocity is considered the gold standard in the measurement of 
arterial stiffness (Laurent et al., 2007), as it reflects the velocity of the pulse wave down the aorta 
(regional aortic pressure). The velocity of the pulse wave is determined by the stiffness of the aorta, 
whereby the stiffer the aorta, the faster the pulse wave. However detecting a clear and reliable 
femoral pressure wave using this technique can be difficult in participants with metabolic syndrome 
or obesity (Laurent et al., 2007). Additionally, as the distance between measurement sites is needed 
to assess the blood distance travelled, individuals with abdominal obesity (particularly men) or large 
breast size may introduce additional error into these measurements (Laurent et al., 2007). As the 
participants in our study were likely to have one or more of these limitations, PWV was assessed 
between the carotid and radial arteries. 
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Figure 14: Pulse wave analysis assessed using the augmentation index at the radial artery 
The above waveform was captured using radial tonometry. The speed at which the pressure wave 
travels through the arterial system determines where the forward moving wave (Peak 2) interacts 
with the reflected wave (Peak 1). In the above example, taken from a sedentary middle-aged 
participant, the reflected pressure wave has interacted with the forward moving wave near the 
systolic peak which has resulted in a reasonably high augmentation of the pressure wave. The 
augmentation index is the ratio between the augmentation pressure and the pulse pressure (%). For 
example, in the wave form above, the augmentation index is: (156-140)/(156-80) *100 = 21.1% 
Following palpation to detect the region of strongest pulse, pressure waves at the carotid and radial 
sites were recorded sequentially using a high-fidelity tonometer. The ‘foot’, or the steep rise of the 
pressure wave at the end of diastole, of each pressure pulse was used as the locus for the pulse to 
pulse measurement. The R wave of a simultaneously recorded ECG (using a lead II configuration on 
the participant’s wrist and ankle) provided a timing reference. At least 2 ½ screens of a clear ECG and 
tonometry recording was required for each site. The mean time of the distance between the R wave 
of the ECG and the foot of the carotid pulse minus the time between the R wave of the ECG and the 
foot of the radial pulse was used to determine transit time. The distance covered by the pressure 
wave was estimated by using a tape measure to measure the distance between the measurement 
site at the radial artery and the suprasternal notch, and the supersternal notch and the measurement 
site at the carotid artery (to the nearest mm). Pulse wave velocity is equal to the distance covered 
over the mean difference in time (Laurent et al., 2007, AtCor Medical, 2008). Diastolic blood 
pressure/Mean arterial pressure was used to correct the data.  
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5.3.6 Assessment 3: Anthropometric, SBP, HRV and Cardiovascular fitness  
Athropometric data 
Upon entering the exercise lab, participants were assessed for height (Mechanical Stadiometer, 
Surgical & Medical Products, Mentone, Australia) and body composition (InBody230, Biospace Co. 
Ltd., Seoul, South Korea), including total body fat percentage and lean muscle mass.  
Blood pressure.  
Resting blood pressure was assessed during the supine rest period of the HRV analysis. To ensure an 
accurate average resting blood pressure recording was captured, the average of two blood pressure 
(Omron, HEM-907XL, Matsuzaka City, Japan) measurements, one min apart were taken following 10 
min, and 16 min of supine rest respectively. The reported systolic blood pressure was the average of 
the 10 and 16 min recordings. 
Heart rate variability analysis.  
Heart rate variability is the assessment of the beat – to – beat variation between the R – R intervals 
(RR interval) of a heart rate (HR) recording, and reduced HRV has been correlated with impaired 
health or risk of future cardiovascular disease (Tsuji et al., 1996). An analysis of this beat-to-beat 
variation reflects the influence of the parasympathetic and sympathetic branches of the autonomic 
control of the heart rhythm. A lower variation (or lower HRV) reflects more sympathetic activity, and 
higher variation (or higher HRV) reflects greater parasympathetic activity, or sympathetic withdrawal 
(Task Force of The European Society of Cardiology and The North American Society of Pacing and 
Electrophysiology, 1996). Details regarding the measurement and assessment of HRV have been 
reported in detail in the previous chapter, and therefore will not be repeated here.  
Briefly, alterations in the RR intervals were detected using a Polar transmitter belt (Wearlink W.I.N.D, 
Polar Electro Oy, Kempele, Finland) applied with contact electrode gel (Signa Crème®, Electrode 
cream, Parker Laboratories Inc. Fairfield, New Jersey, USA) to improve skin contact, and relayed and 
stored on a HR watch (RS800CX, Polar Electro Oy, Kempele, Finland).  
The participant rested in a supine position for 10 min while they breathed freely, followed by 6 min 
of paced breathing (12 breaths.min-1 or 0.2 Hz). As the heart rate recording was started as the 
participant began the rest period, minutes 5 to 10 of the recorded trace were used as the 
spontaneous breathing HRV data. The 5 min portion 30 s following the start of the controlled 
breathing period was selected for analysis. Selected heart rate data were filtered for ectopic beats 
(‘moderate filter power’, minimum protection zone of 6 beatmin-1 and ‘remove spikes’ selected) and 
analysed using Polar ProTrainer software (Version 5.40.172). Parasympathetic activity was measured 
using the root mean square of successive differences (rMSSD) and the RR interval (Task Force of The 
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European Society of Cardiology and The North American Society of Pacing and Electrophysiology, 
1996) under spontaneous and controlled breathing. Unfortunately an insufficient number of 
participants (10 in IHE3 + Ex, but only 6 in Ex) were able to breathe in time to the metronome 
satisfactorily (breathing frequency of 12  1; and a standard deviation for the breathing frequency of 
< 1.5) on more than 2 occasions and therefore the paced results were not analysed. The standard 
deviation of all normal-to-normal beats (SDNN, R-peaks can be referred to normal, or N peaks 
following editing procedures to denote the differences between filtered and unfiltered data). Low 
frequency (LF) and high frequency data were also reported to enable greater comparability with 
other studies. However as we have found these measurements to be less reliable in the population 
under investigation, these are not used as primary indicators of HRV alteration in the pre- and post- 
intervention discussion. 
The median absolute deviation (MAD) method was used to detect outliers (Leys et al., 2013) from the 
combined groups in order to eliminate inflated HRV results that may be related to recording error 
(Wallén et al., 2012). The MAD method for outlier detection is more resistant to the effects of 
outliers  than protocols relying on the mean  SD (Wilcox, 2010). All data 2.5 X the SD as estimated 
from the median were considered outliers and were removed from the dataset (Leys et al., 2013).  
Cardiovascular fitness.  
Maximal oxygen uptake assessments were conducted using an incremental treadmill test to 
exhaustion. Two additional stages were added to the Standard Bruce Protocol to cater for the older, 
more sedentary population in this study. The protocol for this Modified Bruce Protocol (MBP) is 
outlined in Table 13.  
Table 13: Modified Bruce Protocol 
Stage Time (min) Elevation (degrees) Speed (km/h) 
1 1 - 3 0 2.7 
2 4 – 6 2.8 2.7 
3 7 – 9 5.7 2.7 
4 10 – 12 6.8 4 
5 13 – 15 7.9 5.5 
6 16 – 18 9.1 6.8 
7 19 – 21 10.2 8 
Every three minutes the workload was increased until the participants reached voluntary exhaustion. 
The third stage of the Modified Bruce Protocol corresponds to the first stage of the standard Bruce 
Protocol, thereafter the protocols are identical. 
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Maximal oxygen consumption was assessed using a metabolic cart (MetaMax® 3B; Cortex Biophysik, 
Leipzig, Germany) which was calibrated daily for volume (Hans Rudolph 5530 3 L syringe; Kansas City, 
MO, USA), and between each testing period for gas composition (15% O2 and 5% CO2). The oxygen 
sensor was calibrated against ambient air prior to each participant’s testing session. Participants 
were fitted with leak proof face masks (Hans Rudolph, Kansas City, MO, USA) with a small dead space 
(approximately 70 mL) that allowed breathing through the nose or mouth. Expired breath was 
directed to the volume and gas analysers which were housed in plastic fitting attached to the face 
mask. The same Polar HR monitor and belt used in the HRV assessment were used to record 
maximum HR during the fitness assessment. The participant was supervised continuously throughout 
the MBP and the test was stopped immediately if any contra-indications to exercise, as outlined in 
the American College of Sports Medicine guidelines for exercise testing and prescription,  became 
evident  (Thompson et al., 2010). Maximal exertion was achieved when the participant satisfied 2 or 
more of the following criteria: HR > 90% of age-predicted HR max (220 – age); respiratory exchange 
ratio of >1.15; a rating of perceived exertion of 19 or 20 on the Borg Scale, or the participant wished 
to stop due to exhaustion. A 5 min warm down at Stage 1 intensity followed. Participants were 
supervised until the researcher was satisfied that they had recovered sufficiently.  
All breath – to – breath data were collected and exported to an excel spreadsheet for analysis. The 
last 30 s prior to maximal exhaustion were used to determine V˙ O2peak (mlmin
-1kg-1). Time to 
exhaustion was measured as the taken from the start of Stage 1 to voluntary exhaustion (min). 
Determination of cardiovascular risk 
Cardiovascular risk was assessed using 2 different risk profiling assessments. The first was assessed 
using the New Zealand Guidelines Group 5- year risk stratification. In this analysis systolic blood 
pressure, TC, HDL, age, diabetes status and sex were used to determine each participant’s overall 5 –
year cardiovascular risk (See Appendix E). Following the risk assessment, participants were divided 
into 4 different categories:  
 >2.5 % chance in the next 5 years 
 2.5 – 5 % chance in the next 5 years 
 5 – 10 % chance in the next 5 years 
 10 – 15 % chance in the next 5 years 
The second analysis used the Framingham overall cardiovascular risk assessment to determine 10 
year risk. In this assessment, each risk factor is awarded either positive (for adverse health 
measurements such as high blood pressure) or negative points for beneficial health indicators (such 
as low blood pressure). The overall points accumulated are then associated with a percentage risk for 
general cardiovascular disease in the next 10 years (D’Agostino et al., 2008). Risk factors included in 
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the Framingham Risk Assessment include age, sex, TC, HDL, SBP (and whether this is treated or not) 
diabetes status and smoking status.  
5.3.7 10 week intervention.  
All participants attended 3 exercise sessions per week. Exercise sessions included a mix of aerobic 
and strength training and typically included a 10 minute warm-up ( 65 – 70 % of HR maximum as 
assessed during the V˙ O2peak assessment), followed by another 15 - 20 minutes of walking or jogging  
at 70 – 80% of maximum HR in Week 1, and thereafter at 75 – 80% of maximum HR. Participants 
then completed 20 minutes of strength training which targeted major muscle groups and included 
free weights (bicep and tricep curls, anterior and lateral raises) resistance bands (as an alternative to 
free weights), lunges, calf raises, sit-ups, back extension exercises; lateral, front and back straight leg 
raises, and stepping up and down on a step. Where participants had physiological restrictions to 
prescribed exercises, alternative exercises were provided. The exercise sessions were concluded with 
10 minutes of light aerobic activity and stretching. All exercise sessions were supervised and the 
participants were encouraged to communicate with the lead researcher regarding any injury, or 
discomfort experienced in any of the prescribed training exercises or intensities.  
In addition to the above training programme, half of the participants completed 2 – 3 simulated 
altitude training sessions per week using the IHE protocol of 5 min hypoxia alternated with 5 min 
normoxia for 1 h. Hypoxic air was delivered through a hand-held face mask (QuadraLite Facemask, 
Intersurgical, Intermed, Auckland, New Zealand) fitted with an antibacterial filter (HMEF Clear-therm, 
Intersurgical, Intermed, Auckland, New Zealand). Each participant had their own face masks and 
antibacterial filter, and all facemasks and filters were discarded at the end of the intervention period. 
Hypoxic air (Era®-II Hypoxic Air Generator, GO2Altitude, Biomedtech, Victoria, Australia) was 
delivered to a main control computer which allowed the researcher to control the fraction of inspired 
oxygen (FiO2). Hypoxic dose was monitored using SpO2 measured at the finger with a pulse oximeter 
(Nonin Pulse Oximeter, Plymouth, Minnesota). The FiO2 was progressively lowered to yield the 
following SpO2 targets: Week 1: 90%, Week 2: 85%, and Week 3 - 10: 80%. 
5.3.8 Statistical analyses.  
A mixed modelling procedure (Proc Mixed) was used to analyse the repeated measures (Statistical 
Analysis System, v. 9.3, SAS Institute, Cary, NC). To reduce the effects of non-uniformity of error, the 
natural logarithm of each dependent variable was used in the data analysis (Hopkins et al., 2009). 
Fixed effects were the time points (Baseline, Post, 4-wk, 8-wk) and the group (IHE3 + Ex and Ex) and 
their interaction. Dependent variables included, SBP, V˙ O2peak, Time to exhaustion, PWV, PWA, HDL, 
TC, and HDL:TC ratio and Framingham Risk Assessment Score. Random-effects parameters, or 
 132 
variance components, were also included in the model as covariance components, and were 
estimated using the restricted maximum likelihood (REML) method. A mixed (including both fixed 
and variance components) linear model was then fitted to the data which allowed greater statistical 
inference that is resistant to unbalanced data (SAS Institute Inc., 2008).  
Effect estimates and p-values were then converted to magnitude-based inferential statements using 
a spreadsheet (Hopkins, 2007). Changes from baseline to Post, 4-wk and 8-wk in the IHE3 + Ex group 
were compared to changes in Ex only using the smallest worthwhile change identified by Cohen 
(1988), that is, 0.2 multiplied by the between subject SD at baseline.  
Clinical assessments were performed in parameters that have a direct effect on health or 
performance, which included all variables except HRV in this study. As the outcome of the clinical 
parameter will have a direct effect on health, the risk of harm was considered after the likely range 
of the true value (90% confidence interval) had been estimated. Results were only considered 
beneficial when the potential for benefit was substantially greater than the risk of harm. In this way 
avoiding the risk of harm, rather than neglecting to use a beneficial effect was prioritised (Hopkins et 
al., 2009, Hopkins, 2007). For this study a benefit: harm ratio of > 66% was considered acceptable. 
Where the clinical effect was unclear, but there was a clear mechanistic outcome, the mechanistic 
outcome was reported in brackets. 
Heart rate variability was included as a mechanistic variable as changes in this measurement can 
relate to stimuli unrelated to risk stratification. Unlike the clinical assessments, the mechanistic 
inference simply relates to where the likely range of the true value lies relative to the smallest 
worthwhile change (Batterham and Hopkins, 2006), and does not consider the potential for harm.  
No statistical analyses were performed on the ordinal categorical data retrieved from the 2 groups 
across the 3 time points from the New Zealand Guidelines risk assessment chart. Instead the 
outcomes of these analyses have been presented in pie charts to clearly represent changes between 
risk categories at each assessment.  
For both the clinical and mechanistic assessments, the likely range of the true value is expressed 
using the percentage change (from the natural logarithm) ± 90 % confidence interval, and the 
percent chances for substantially increased / trivial / decreased outcomes (Hopkins, 2007).  Where 
the confidence interval spanned all three possibilities (increased, trivial and decreased), the result 
was deemed unclear. In all other cases (the confidence interval spans either 1, or a maximum of 2 
possibilities, i.e. increased/trivial, or decreased/trivial), a clear outcome was reported and a 
qualitative assessment of the magnitude of the change was given. To determine the qualitative 
outcome the following scale was used: < 0.5% = most unlikely; 0.5 – 5% = very unlikely; 5 – 25% = 
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unlikely; 25 – 75% = possibly; 75 – 95% = likely, or 95 – 99.5% = very likely, > 99.5% = most likely). For 
clinical analyses, the descriptors “Beneficial”, “trivial”, “harmful” were used, and for mechanistic 
analyses, the descriptors, “Increased”, “trivial” or “decreased” were used. Results are presented as: 
mean % change (from the natural log)  90% confidence interval; % chance that the change 
substantially increased/trivial/decreased; followed by the qualitative outcome.  See Table 14 for an 
overview of participants excluded from analyses and the motivations for exclusion. 
5.4 Results 
Food and activity diaries were examined following the 10-week intervention, and participants did not 
deviate substantially from their habitual food intake and physical activity. Raw data (mean  SD) are 
presented in Table 24 in Appendix D. Results for anthropometric data (body fat % and muscle mass) 
are presented in Table 12. Independent risk factors (PWV, PWA, and cardiovascular fitness, blood 
lipids, SBP and overall cardiovascular risk) have been presented in Table 15. HRV changes have been 
reported in Table 16, while changes in fat and muscle mass have been reported in Table 17. Changes 
in cardiovascular risk category are presented in Figure 15. 
 
Figure 15: 5-year cardiovascular risk assessed using the New Zealand Guidelines chart 
Pie graphs representing the percentage of participants in pre-defined risk categories as defined by 
the New Zealand Guidelines Group. Striped portions indicate <2.5% risk; White portions indicate 
between 2.5 – 5% risk of cardiovascular disease in the next 5 years; Grey portions indicate 5 – 10% 
risk; and Black portions indicate 10 – 15% risk of cardiovascular disease in the next 10 years. 
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Table 14: Number of participants excluded from respective analyses 
 IHE3 + Ex 
(n) 
Ex 
(n) 
Reason for exclusion 
Anthropometric data 
Body fat (%) 0 0  
Muscle mass (kg) 0 0  
Arterial Health 
Pulse wave velocity (ms) 6 3 Unavailability at the time of recording: 
PWV & PWA: IHE3 + Ex: n = 4; Ex: n = 1  
PWV: > 2 Inconclusive results:  
IHE3 + Ex: n = 2; Ex: n = 4 
PWA > 2 Inconclusive results:  
IHE3 + Ex: n = 1; Ex: n = 5 
Pulse wave analysis (AIx) 5 3 
Heart rate variability 
RR interval (ms) 1 4 RR- Interval & rMSSD: Unclear recording: 
IHE3 + Ex: n = 1; Ex: n = 4. 
rMSSD (ms)     
Cardiovascular fitness 
V˙ O2peak (mlmin
-1kg-1) & 1 
 
3 
 
Test terminated due to hypertension:  
IHE3 + Ex: n = 1; Ex: n = 2 Time to exhaustion (min) 
Blood lipids 
TC, HDL & TC:HDL 1 
 
3 
 
Elected not to have blood samples drawn: 
IHE3 + Ex: n = 1; Ex: n = 3.  An additional 2 
(forgot/ not available) in Ex and 5(2 
excluded due to lipid lowering drugs 
between measurements, 3 forgot/not 
available) in IHE3 + Ex were unable to 
submit blood samples at the 8-wk follow 
up. 
Systolic blood pressure 
SBP 1 1 On hypertension medication but BP 
fluctuated substantially between time 
points: IHE3 + Ex: n = 1; Ex: n = 1  
Cardiovascular risk 
NZGG & Framingham 
assessments 
1 4 Missing either SBP and / or blood sample 
All data are reported as a mean change from baseline in IHE3 + Ex relative to the Ex group (i.e. IHE3 + 
Ex – Ex at each time point). IHE3 + Ex: Group receiving intermittent hypoxic exposure and exercise 
during the intervention period. Ex: Group receiving exercise only during the intervention period. 
PWA: pulse wave analysis; PWV: Pulse wave velocity; RR interval: average distance between R – R 
peaks; rMSSD: root mean square successive difference; V˙ O2peak: peak oxygen uptake during exercise 
to exhaustion; TC: Total cholesterol; HDL: High density lipoprotein; TC: HDL: Total cholesterol to high 
density lipoprotein ratio; SBP: Systolic blood pressure; NZGG assessment: 5 – year risk assessment 
according to the New Zealand Guidelines Group. 
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Table 15: Baseline, Post, 4-wk and 8-wk analyses for independent risk factors and overall 
cardiovascular risk  
 Mean change (%)  
 90% confidence 
interval 
Chances of increase/ 
trivial /decrease 
Qualitative outcome 
Arterial Health 
Pulse wave velocity (ms)   
Post – baseline  -0.25  11.2 47 / 3 / 50 Unclear 
4-wk – baseline -4.2  11.5 26 / 2 / 72 Unclear 
8-wk – baseline  -8.1  12.1 13 / 1 / 86 Unclear 
Pulse wave analysis (AIx)   
Post – baseline  -6.1  18.4 24 / 11 / 65 Unclear 
4-wk – baseline 11.8  18.4 82 / 7 / 11  Likely harmful 
8-wk – baseline  24.8  19.7 97 / 1 / 2 Very likely harmful 
Cardiovascular fitness 
V˙ O2peak (mlmin
-1kg-1)   
Post – baseline  3.1  7.7 65 / 17 / 18  Unclear 
4-wk – baseline 9.4  8.0 95 / 3 / 2 Very likely beneficial 
8-wk – baseline  7.9  8.3 90 / 6 / 4 Likely beneficial 
Time to exhaustion (min)   
Post – baseline  3.8  6.3 81 / 5 / 13 Unclear   
4-wk – baseline -1.3  6.5 33 / 8 / 59 Unclear  
8-wk – baseline  5.0  6.8 87 / 4 / 9 Unclear 
Blood lipids 
Total cholesterol    
Post – baseline  4.4  6.5 86 / 2 / 12 Likely harmful 
8-wk – baseline  6.5  7.2 93 / 1 / 6 Likely harmful 
High density lipoprotein   
Post – baseline  8.0  8.0  95 / 0 / 5 Likely beneficial 
8-wk – baseline  10.0  8.5 97 / 0 / 3 Very likely beneficial 
Total cholesterol: High density lipoprotein ratio  
Post – baseline  -77.2  50.5 1 / 0 / 99 Very likely beneficial 
8-wk – baseline  -24.7  52.4  21 / 1 / 78 Unclear 
Systolic blood pressure 
SBP (mmHg)    
Post – baseline -3.4  3.4 0 / 43 / 57 Possibly beneficial 
4-wk – baseline  0.5  3.5 12 / 83 / 5 Possibly trivial 
8-wk – baseline  -3.5  3.7 0 / 42 / 58 Possibly beneficial 
Cardiovascular risk 
Framingham assessment   
Post – baseline  -3.1  15.1 30 / 13 / 57 Unclear 
8-wk – baseline  6.6  16.9 69 / 10 / 21 Possibly harmful 
All data are reported as a mean change from baseline in the group receiving exercise and 
intermittent hypoxic exposure relative to the group receiving exercise only. Post, 4-wk and 8-wk: 
measurements taken immediately, 4-wk and 8-wk following the intervention compared to baseline 
assessments; AIx: Augmentation index; V˙ O2peak: peak oxygen uptake during maximal exercise; SBP: 
Systolic blood pressure. 
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Table 16: Changes in HRV between baseline and post - intervention measurements 
 Mean change (%)  
 90% confidence 
interval 
Chances of increase/ 
trivial /decrease 
Qualitative outcome 
Heart rate variability  
RR interval (ms)    
Post – baseline  3.1  5.1 0 / 100 / 0 M: Most likely trivial 
4-wk – baseline 0.03  5.3 0 / 100 / 0 M: Most likely trivial 
8-wk – baseline  3.4  5.4 0 / 100 / 0 M: Most likely trivial 
rMSSD (ms)    
Post – baseline  18.0  24.0 87 / 5 / 8 M: Unclear 
4-wk – baseline 14.0  25.2 78 / 7 / 15 M: Unclear 
8-wk – baseline  13.0  25.6 76 / 7 / 17 M: Unclear 
SDNN (ms)    
Post – baseline  1.7  23.1 48 / 12 / 39 M: Unclear 
4-wk – baseline -9.9  23.9 20 / 10 / 70 M: Unclear 
8-wk – baseline  0.9  24.9 46 / 12 / 42 M: Unclear 
HF (ms2)    
Post – baseline  52.7   50.0 69 / 31 / 0 M: Possibly increased 
4-wk – baseline 31.1  52.9 41 / 57 / 2 M: Possibly trivial 
8-wk – baseline  31.7  53.1 42 / 56 / 2 M: Possibly trivial 
LF (ms2)    
Post – baseline  -11.0  51.5 4 / 81 / 15 M: Likely trivial 
4-wk – baseline 27.9  54.2 31 / 67 / 2 M: Possibly trivial 
8-wk – baseline  7.4  54.9 14 / 80 / 6 M: Unclear 
LF:HF    
Post – baseline  -86.4  56.2 0 / 1 / 99 M: Very likely decreased 
4-wk – baseline -15.0  58.3 23 / 22 / 55 M: Unclear 
8-wk – baseline  1.3  59.6 40 / 23 / 37 M: Unclear 
Data are mean change from baseline in IHE3 + Ex relative to the Ex group (i.e. IHE3 + Ex – Ex at each 
time point; Post, 4-wk, 8-wk: Measurements taken immediately after, 4- and 8-wk following the 
intervention; M: mechanistic inference; RR interval: average distance between R – R peaks; rMSSD: 
root mean square successive difference; SDNN: Standard deviation of normal to normal peaks; HF: 
high frequency; LF: low frequency; LF:HF: low frequency: high frequency ratio (LF/HF*100) 
 
Table 17: Changes in body fat % and muscle mass between baseline and Post, 4-wk and 8-wk  
 Mean change (%)  
 90% confidence interval 
Chances of increase/ 
trivial /decrease 
Qualitative outcome 
Muscle mass (kg)    
Post – baseline  1.4  1.5 56 / 43 / 0 Possibly beneficial 
4-wk – baseline 1.2  1.5 46 / 53 / 0 Possibly beneficial 
8-wk – baseline  0.6  1.5 23 / 75 / 2 Unclear 
Fat mass (kg)    
Post – baseline  -0.7  3.9 12 / 59 / 29 Unclear 
4-wk – baseline 2.3  3.9  56 / 21 / 3 Possible harmful 
8-wk – baseline  4.1  4.0 81 / 18 / 1 Likely harmful 
All data are reported as a mean change from baseline in IHE3 + Ex relative to the Ex group (i.e. IHE3 + 
Ex – Ex at each time point; Measurements taken immediately after, 4- and 8-wk following the 
intervention.  
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5.5 Discussion 
The purpose of this study was to assess whether a small number of IHE sessions per week (2 – 3) over 
10-week period would supplement an exercise training programme and yield greater reduction in 
independent cardiovascular risk factors and overall risk of cardiovascular disease than exercise alone. 
Contrary to our expectations, while there was a tendency for an increase in rMSSD in the IHE3 + Ex 
group compared to the Ex only group, there was no clear ‘additive’ effect of IHE on HRV. The key 
findings from this study are the greater improvements in HDL, SBP and V˙ O2peak following IHE3 + Ex 
when compared to exercise only. However, while the arterial stiffness as assessed using the 
augmentation index appeared to decrease slightly compared to Ex immediately post-intervention, 
there was a likely and very likely increase at the 4-wk and 8-wk follow up. While this could have been 
due to a decrease in the pulse pressure (attributed to the decrease in SBP in IHE3 + Ex) relative to the 
augmentation pressure, more research is needed on the long-term effects of IHE on vascular health 
before hypoxic-based intervention can be described as ‘safe’. 
5.5.1 Cardiovascular risk parameters and overall cardiovascular risk profile 
Changes in the overall cardiovascular risk profiles were subtle. The proportion of participants in 
different risk categories (presented in pie graphs in Figure 15) suggest that both the Ex and the IHE3 
+ Ex groups demonstrate greater effectiveness in the ‘middle’ risk categories. That is, in the IHE3 + Ex 
group, there was a small change between the 2.5 – 5% category (increased) and the 5 – 10% category 
(decreased) at Post which persisted to the 8-wk assessment but there were no changes in portion 
size in either the 10 – 15% or the >2.5% categories following the 10-week intervention. Additionally, 
there were no changes in the Ex group between Post and Baseline, but there was an increase in the 
<2.5% risk portion, and a decrease in the 2.5 – 5% portion. Based on these observations, it appears 
that the 10-week intervention had a negligible effect on the most (<2.5% risk) and least (10-15% risk) 
healthy participants, but a possibly beneficial effect on those between the 2.5 and 10% risk 
categories. It is likely that below 2.5% risk, there is little more that can be done to improve overall 
risk (due to non-modifiable risk factors such as age and sex), and at higher risk, perhaps a more 
aggressive intervention is required before health benefit is observed. However, the sample size for 
each group were relatively small (IHE3 + Ex: n=15; and Ex: n = 14) and so each one person represents 
approximately 7%. Therefore caution should be used when drawing meaning from the pie charts. 
These results should be repeated in a larger cohort before conclusive statements can be made. 
The absence of more substantial changes in the overall cardiovascular risk assessments is likely due 
to the magnitude of the changes needed before a change in risk category is observed (see Figure 31 
in Appendix E). For example, each SBP increment in the New Zealand Guidelines chart spans 20 
mmHg, and HDL:TC changes in 1 mmol/L increments. Indeed as the risk categories can include 
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several increments of HDL:TC and SBP, the 5-year risk assessment chart is unlikely to have been 
sensitive enough to detect smaller changes in overall cardiovascular risk as a result of a relatively 
short intervention. 
Changes in 10-year risk of cardiovascular disease as determined using the Framingham study 
indicated no clear benefit of one intervention over the other at Post-intervention, but there was a 
possibly harmful effect of using IHE3 + Ex in the 8-wk follow up. On closer inspection of the data, this 
increased risk score in the IHE3 + Ex group was primarily due to the increase in total cholesterol. As 
discussed below, the increase in total cholesterol was due to the increase in high density lipoprotein 
in the IHE3 + Ex group compared to Ex, and therefore, the relevance of the “possible harmful” 
outcome is limited. 
Systolic blood pressure 
The greater decrease in SBP at Post in the IHE3 + EX group compared to Ex supports earlier research 
by our lab where we have reported a tendency for a decrease in SBP following a 5-week IHE 
intervention (without additional exercise training).  The decrease in SBP in our study may be related 
to several of the other findings in this study, particularly the tendencies for decreased PWV and 
increased rMSSD.  
The close relationship between SBP and PWV has long been investigated (Gribbin et al., 1976), with 
conventional wisdom suggesting that increased SBP is the cause and the correlated increase in PWV 
is simply the reflection of the arterial dysfunction associated with the sustained strain on the arterial 
system (Franklin, 2005). As highlighted by Franklin (2005), the longitudinal study by Dernellis and 
Panaretou (2005), and the more recent study by Najjar et al. (2008) have challenged this assumption 
by indicating that the increase in PWV may precede the increase in SBP. The predictive ability of 
increased PWV in normotensive individuals suggests that PWV is the risk factor, rather than the risk 
marker. Therefore, the unclear decrease in PWV in the IHE3 + Ex group in the current study may have 
contributed to the decrease in SBP in the same group. Alternatively, both the lowered SBP and PWV 
may be related to the tendency towards an increase in the parasympathetic component (rMSSD), or 
sympathetic withdrawal in the autonomic nervous system (Franklin, 2009, Palatini and Julius, 2004). 
That is, as both SBP (Guyenet, 2006) and arterial compliance (Grassi et al., 1995, Boutouyrie et al., 
1994) are subject to autonomic control. The contribution of sympathetic activity on both the SBP and 
the PWV was recently demonstrated in patients with resistant hypertension who underwent renal 
sympathetic denervation (Brandt et al., 2012). Following the renal denervation, patients 
demonstrated substantial reductions in both blood pressure and arterial stiffness. Therefore, the 
tendency towards improved sympathovagal balance (unclear increase in rMSSD) in the IHE3 + Ex may 
also have attributed to the lower SBP in the IHE3 + Ex group. While the improvements in rMSSD and 
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PWV were unclear, the combined interaction of these variables likely contributed to the clear 
improvement in SBP in the IHE3 + Ex group compared to Ex.  
Total cholesterol and high density lipoprotein 
Tin'kov and Aksenov (2002) posit that the modification of blood lipid profile by IHE is attributable to 
greater oxidation in the monooxygenase pathway in cholesterol biosynthesis. To support this claim, 
these authors report an increase in the activity of 7-α-hydroxylase, an important initiating and rate 
limiting enzyme in the catabolism of cholesterol into bile salts (Russell, 2009).  However, no data 
other than changes in HDL, TC, low and very low density lipoprotein and triglycerides were reported. 
Contrastingly, Johnson (2008) outlines a possible inhibiting action of hypoxia on cholesterol 7-α-
hydroxylase in patients with obstructive sleep apnoea. Johnson (2008) suggests that the shift to 
glycolytic metabolism in response to the repeated hypoxic intervals associated with obstructive sleep 
apnoea promotes an increase in nicotinamide adenine dinucleotide + hydrogen (NADH) which has an 
inhibitory effect on Sirtuin. In turn, the inhibitory action of Sirtuin decreases active proliferator-
activated receptor-ɣ co-activator-1 α which is needed for co-activation of cholesterol 7-α-
hydroxylase. In this view, IHE would result in a decreased expression of cholesterol 7-α-hydroxylase 
and inhibition of the conversion of cholesterol into bile salts. However, there are several 
physiological responses to obstructive sleep apnoea that appear reversed following shorter, 
controlled periods of IHE, such the increase in SBP associated with obstructive sleep apnoea (Møller 
et al., 2003), but not with IHE (Serebrovskaya et al., 2008). The differences in responses are usually 
thought to be due to an adaptive response to the short term stress (in the case of IHE), rather than 
maladaptation to long-term distress (in obstructive sleep apnoea). Therefore, it is unclear whether 
the pathway described by Johnson (2008) would have a negative effect on cholesterol metabolism 
following IHE, or a short term inhibition of cholestrol catabolism following IHE, followed by a 
compensatary ‘catch up’ during recovery. 
At first glance, the increase in the HDL in the IHE3 + Ex (0.1 mmol/L increase at Post which was 
sustained at 8-wk follow up, compared to no change in Ex) appears to support the findings of Tin'kov 
and Aksenov (2002) who reported an increase of 0.08 mmol/L following 22 days of 3 h hypoxic 
exposure intervals, with a further 0.05 mmol/L increase at the 3 month follow up. However, upon 
closer examination of the TC:HDL results in the present study, a different conclusion can be reached 
for our participants. That is the overall decrease in TC in Ex was substantially higher than IHE3 + Ex 
(0.3 mmol/L immediately following the intervention in the Ex group of the present study, and a 
further decrease of 0.1 mmol/L at the 8-wk follow up, compared to no change in IHE3 + Ex at Post 
and a decrease of 0.1 mmol/L at 8-wk follow up). Therefore, it appears that the likely proportion of 
non-HDL cholesterol was lower in the Ex group compared to the IHE3 + Ex group following the 
intervention, and more supportive of the inhibitory mechanism proposed by Johnson (2008). As 
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Tin’kov and Aksenov (2002) did not use a control group, it is possible that the decrease in TC and 
increase in HDL that these researchers observed was due to normal fluctuations in blood lipid profile 
associated with a change in season (Ockene et al., 2004) rather than the influence of hypoxia. 
However, in the current controlled study, participants in the IHE3 + Ex group demonstrated a likely 
beneficial increase in HDL at the Post-intervention assessment, compared to no change in the Ex 
group. As these participants were traversing the seasons simultaneously, it appears that IHE may 
indeed facilitate an increase in HDL. It is likely that this increase in HDL was also responsible for the 
‘possibly harmful’ response in TC, and the very likely beneficial response in the TC:HDL ratio.  
It is important to note that there were a number of participants in this study who were unable to 
complete the 8-wk follow up (5 in the IHE3 + Ex group and 2 in the Ex group). This was either due to 
missing or erroneous data, see Table 14. 
While a modelling-based statistical analysis was utilised to reduce the impact of missing values, there 
is no doubt that the integrity of a full dataset is lacking. Therefore the results of the 8-wk follow up 
may not reflect the true change between groups. In this regard, the results of this study do not help 
to clarify whether there is a beneficial long-term effect of IHE on blood lipid profile as proposed by 
Tin'kov and Aksenov (2002), or a negative response as proposed by Johnson (2008). 
5.5.2 Arterial stiffness 
While pulse wave velocity and pulse wave analysis (specifically, the augmentation index), are both 
measures of arterial stiffness, they cannot be used interchangeably. Pulse wave velocity is a measure 
of the speed of the pressure wave along the artery (measured as the distance (mm) divided by the 
transit time (s)). The PWV reflects the stiffness of the segment of the artery that has been measured 
(so, as the brachial artery was assessed in the current study, we can only make inferences regarding 
the arterial stiffness of the upper body), and is inversely related to the arterial distensibility (Van 
Bortel et al., 2002). An increase in the arterial stiffness is usually caused by an increase in collagen, a 
decrease in elastin and endothelial dysfunction which can occur with increases in inflammation or 
arterial pressure (Zieman et al., 2005, Wang et al., 2008). On the other hand, the augmentation index 
is a composite measurement (derived using the ratio of the pulse pressure and the augmentation 
pressure) that reflects systemic arterial stiffness. Therefore, the augmentation index is influenced by 
both the central arteries which influence the speed of the pulse wave (i.e. the PWV), and factors 
influencing the peripheral conduit arteries (which then alter the reflected wave) such as peripheral 
vascular tone (Kelly et al., 2001).  
Several researchers have reported an improvement in arterial stiffness (using PWV) following 
exercise in a hypoxic environment compared to normoxic exercise (Nishiwaki et al., 2011, Shi et al., 
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2013) which suggests that a hypoxic stimulus enhances the effect of exercise alone on arterial health. 
In the presence of hypoxia, HIF-1α triggers an increased expression of endothelial NO synthase 
which, via several steps, initiates a vasodilatory response (Beall et al., 2012). The exogenous 
application of glyceryl trinitrate (which is metabolised to NO in the vascular wall) has also been found 
to decrease PWV (Wilkinson et al., 2002b). Conversely, inhibition of NO synthase (via the 
vasoconstrictor L-NG-monomethyl arginine) has resulted in increased PWV and AIx (Wilkinson et al., 
2002a). As endothelial function (and thus endothelium- derived NO control) is strongly correlated to 
arterial stiffness  (McEniery et al., 2006), it is possible that NO plays an important role in arterial 
stiffness. Therefore, the intermittent up-regulation of NO during the hypoxic exposure is likely to 
have had a beneficial effect on arterial compliance. Indeed, the vasodilatory effects of NO during 
hypoxic intervals may also account for the improvement in flow mediated dilation observed in the 
group training in hypobaric hypoxia compared to normobaric normoxia reported by Nishiwaki et al. 
(2011).  
Pulse wave velocity in the current study 
Pulse wave velocity decreased in both groups following the 10- week intervention. While the IHE3 + 
Ex group demonstrated a seemingly lower PWV at the 4-wk and 8-wk follow up testing period, there 
were no clear differences between IHE3 + Ex and Ex. This is contrary to other researchers who have 
reported a decrease in PWV in post-menopausal women (Nishiwaki et al., 2011) and in healthy men 
(Shi et al., 2013). The differences in the outcomes between our study and that of Nishiwaki et al. 
(2011) and Shi et al. (2013) could be due to either differences in the measurement sites or the 
hypoxic dosage.  
Regarding the PWV measurements, both Nishiwaki and colleagues and Shi et al. (2013) used 
brachial–ankle PWV to assess arterial stiffness, compared to the carotid – radial PWV in our study. As 
the carotid-radial PWV reflects the arterial compliance of the upper body (specifically the brachial 
artery) and that the majority of the training completed by the participants in this study involved the 
lower limbs (walking and running in addition to leg strength, compared to arm strength exercise 
only), a clearer decrease in PWV may have been observed using a brachial – ankle PWV assessment. 
Alternatively, the intensity of the hypoxic stimulus may be responsible for the different PWV 
outcomes between the current study and those by Nishiwaki and colleagues, and Shi et al. (2013). In 
the current study supplementary passive IHE was included in addition to a traditional normoxic 
exercise programme while the studies by Shi and colleagues and Nishiwaki and colleagues used 
exercise in a hypoxic environment. As exercising in hypoxia would provide a higher stress stimulus, 
the passive exposure to normobaric hypoxia for 1-h may have been insufficient to induce clear 
changes to endothelial function, or collagen and elastin regulation. Indeed, the differences and 
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similarities between these 3 studies meant that we can tease out some of the effects of the 
intervention length, hypoxic dosage and participants recruited on the relative effect of the simulated 
altitude on the PWV outcome. For example, the current study was a 10-week intervention with a 1-h 
passive hypoxic exposure which yielded an unclear PWV outcome in sedentary middle-aged 
participants. On the other hand, the participants in the study by Shi and colleagues used a 4-week 
intervention period in healthy young men, and while the exercise prescription was similar to the 
current study, it was completed in hypoxia followed by an additional 30 min of passive hypoxic 
exposure. The participants in the study by Nishiwaki et al. (2011) had arguably the highest dose of 
hypoxia and was run over a similar period of time to the current study (10-weeks in the current 
study, and 8-weeks in the study by Nishiwaki and colleagues) and with similar participants to the 
current study. In the intervention by Nishiwaki and colleagues, a combination of exercise in 
hypobaric hypoxia with an additional 90 min of passive hypobaric hypoxic exposure for an 8-week 
intervention period was used. Taken together, these differences suggest that the hypoxic dosage, 
rather than the intervention length (longer than 4 wk) has a greater influence on the PWV.  
Augmentation index in the current study 
Immediately following the 10-wk intervention there was a qualitatively unclear decrease in the 
augmentation index in the IHE3 + Ex group compared to the Ex. It is possible that an increase in 
vascular endothelial growth factor in response to HIF-1α activation resulted in angiogenesis and 
therefore increased absorption of the pressure waves, and an associated reduction in AIx. However, 
Geiser et al. (2001) only reported an increase in capillary length density  (length of capillary in 1 mm3) 
following high intensity exercise in hypoxia, and not in moderate-intensity exercise (let alone passive 
hypoxic exposure). Therefore, it is unlikely, that angiogenesis would be responsible for the reduction 
in the post-intervention AIx, and the actions of NO (as discussed above) provide a more likely 
explanation for any alterations in vascular compliance. 
However, in the 4- and 8-wk follow up assessments, the augmentation index was reversed (i.e. 
increased) in the IHE3 + Ex group compared to Ex suggesting a possible mal-adaption to the hypoxic 
intervention. These results are intriguing as they appear to conflict with the other measured 
responses to IHE (such as the decrease in SBP and unclear improvements in rMSSD and PWV in the 
IHE3 + Ex compared to Ex). 
It is possible that the increase in augmentation index could be due to a stiffening of the smaller 
arterioles resulting in a larger intensity of the reflected wave (Kelly et al., 2001). Speculatively, an up-
regulation of the endothelial NO synthase pathways during the intervention may have resulted in 
down-regulation of endothelial NO synthase activity in the post-intervention phase, and 
subsequently increased arterial vasoconstriction. Kelly et al. (2001) suggest that as the central 
 143 
arteries are predominantly elastic, acute increases in vascular tone may not be readily detected with 
PWV, but would increase the intensity of the reflected wave and in so doing, increase AIx. As such, 
while the immediate effects of IHE on arterial stiffness are promising, future research should 
examine the longevity of changes associated with arterial health (particularly regarding the AIx) that 
are associated with IHE or hypoxic exercise. In addition PWV measurements should be tailored to the 
primary segment involved in the intervention-based training (i.e. carotid-radial in upper-body 
interventions, and carotid-ankle for lower-body intervention, or carotid-femoral for risk 
stratification) to get a better indication of overall changes in vascular health.  
5.5.3 Heart rate variability 
Earlier research by our lab detected improvements in HRV following a 4- and 5-week IHE 
intervention. In these studies we suggested that the increase in parasympathetic activity 
demonstrated by the participants receiving IHE treatments was due to improved stress tolerance 
conferred via the repeated parasympathetic withdrawal and reactivation between hypoxic intervals. 
Therefore, we expected that the addition of IHE to an exercise programme would have an additive 
effect on the post- intervention HRV compared to the group receiving exercise only. However, while 
rMSSD did appear to increase in the IHE3 + Ex group more so than Ex immediately post- intervention, 
this was effect was unclear.  
The absence of any clear advantage of IHE +Ex compared to Ex on HRV may be related to the small 
dosage of hypoxia. Indeed, in our earlier 5-week study, the improvement in HRV in the group 
receiving IHE 2 – 3 times per week was only evident under controlled breathing conditions. As 
exercise has also been known to increase the RR interval and rMSSD (Jurca et al., 2004, Sandercock 
et al., 2005a), the exercise stimulus may have out-weighed any clear additional benefit of IHE to the 
parasympathetic activity of the nervous system. 
It is also important to consider the wide variability associated with HRV, particularly in individuals 
with compromised health (Sandercock et al., 2005b). To address this variability, recent research has 
demonstrated far clearer and more reliable results when the HRV is measured over the course of a 
week and reported as a weekly average, rather than using a single measurement (Le Meur et al., 
2013, Plews et al., 2013). Therefore, future research regarding the use of IHE in a sedentary 
population should consider using the average of a week’s worth of HRV data, rather than a single 
measurement, in order to elucidate any beneficial (or harmful) effects of IHE on HRV. 
5.5.4 Cardiovascular fitness 
The IHE3 + Ex group showed a small increase in V˙ O2peak at each of the time points (except at the 8-wk 
follow up where V˙ O2peak returned to baseline). On the other hand, the Ex group remained unchanged 
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between Baseline and Post, increased at 4-wk follow up but then decreased to below the baseline 
value at the 8-wk follow up. We had anticipated a larger increase in the V˙ O2peak in both groups as a 
result of the combined action of the intervention (Murias et al., 2010) and the seasonal change from 
winter to spring (Ingemann-Hansen and HalkjÆr-Kristensen, 1982). Additionally, the decrease to 
below baseline in the 8-wk assessment was also surprising and is difficult to account for as any 
alterations in environmental or testing conditions would have also affected the IHE3 + Ex group. One 
would anticipate a decrease in V˙ O2peak following a time interval of more than 2 weeks of inactivity 
(Neufer, 1989) but this detraining effect is typically halted at approximately baseline values. One 
possible explanation for the substantially lower V˙ O2peak in the Ex group could be attributed to 
participant motivation (or lack thereof). For example, Andreacci et al. (2002) demonstrated an 
increase in V˙ O2peak of approximately 5 mlkg
-1min-1 when participants were given frequent verbal  
encouragement compared to when they received no or infrequent encouragement. Despite an effort 
to maintain frequent and similar encouragement for all participants during all maximal exercise tests 
in the current study, if the participants in the Ex group were intrinsically less motivated at the final 
follow up assessment, this could explain the lower V˙ O2peak. The counter-argument to this explanation 
is that there was not an associated decrease in the time taken to complete the test, which means 
that motivation as an explanation for the decrease in V˙ O2peak in the Ex group is unsatisfactory. 
Nevertheless, the difference between the groups, while small, indicates an additive effect of the IHE 
on peak oxygen uptake compared to exercise alone. The improvement in V˙ O2peak in the IHE3 + Ex 
group could be attributed to haematological adaptation, such as an increase in haemoglobin, acting 
to increase the oxygen-carrying capacity of the blood, as has been reported following other IHE-
based interventions (Burtsher et al., 2004) and in our earlier study (following 5 IHE sessions per week 
for 5 weeks, see Chapter 4, Study 2). While there were no clear increases in haemoglobin in the 
participants attending 2-3 IHE sessions per week in our earlier study, the inclusion of exercise into 
the current study may have produced sufficient oxidative stress to induce erythropoiesis in the IHE3 
+ Ex group. Despite the statistically beneficial outcome of the IHE3 + Ex on V˙ O2peak, there were no 
clear changes between groups in the time taken to complete the exercise tests. The absence of a 
clear change in time to complete the test questions the practical benefit of the relative V˙ O2peak 
increase in the IHE3 + Ex group. 
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5.5.5 Fat mass and muscle mass 
When one is exposed to hypoxia, oxygen sensors such as HIF-1α act to reduce the dependency of the 
body on oxygen-dependent systems such as oxidative phosphorylation. This requires a metabolic 
shift to anaerobic glycolytic pathways that do not require the break-down of fats for energy 
provision. In addition, the active cellular switch to glycolysis avoids the accumulation of excessive 
levels of reactive oxygen species that occur under oxidative stress (Semenza, 2009). Additionally, 
exposure to hypoxia up-regulates the leptin gene which is associated with appetite suppression 
(Ambrosini et al., 2002). The alteration in metabolism and the propensity for reduced caloric intake 
has prompted several researchers to assess the effects of exercise training in hypoxia on body 
composition (Haufe et al., 2008, Netzer et al., 2008, Wiesner et al., 2010). One of these studies, like 
the current study, assessed the effect of passive IHE in conjunction with exercise (Balykin et al., 
2004). All of the above-mentioned studies have reported greater improvements in body fat mass 
reduction following exercise in hypoxia compared to normoxic exercise.  
While both groups decreased body fat mass over the course of the 10-week intervention, and 
continued to decrease until the 4-wk follow up, the declines in body fat were substantially greater in 
the Ex group than the IHE3 + Ex group. Additionally, the IHE3 + Ex group had returned to baseline 
levels at the 8-wk follow up whereas the Ex group continued to decrease. Therefore, unlike (Balykin 
et al., 2004) the participants in the IHE3 + Ex group did not demonstrate greater body composition 
improvement with hypoxia and exercise compared to exercise alone. This difference in result could 
be attributed to the differences in population groups. Balykin’s participants were all young (19 y) 
overweight males, whereas the current participants were older (56 y) and heterogeneous (being 
overweight was not required for inclusion, nor were overweight or obese excluded based on their 
body composition). It is possible that individuals with more fat mass (and therefore greater scope for 
improvement in body composition) or who are younger (potentially greater sensitivity to hypoxia) 
may demonstrate greater responsiveness to hypoxic interventions. 
Unlike the changes in fat mass, the IHE3 + Ex groups demonstrated likely beneficial improvements in 
muscle mass. The findings from this study support previous findings from our research group who 
demonstrated an increase in muscle cross-sectional area following 5 weeks of either blood occlusion 
or inspired hypoxia during strength training in female netball players (Manimmanakorn et al., 2013). 
These increases in CSA were attributed to an earlier switch in the recruitment pattern from the 
lower-powered aerobically fuelled Type I fibres to the greater force-generating, anaerobic Type II 
muscle fibres with the hypoxic stimuli during exercise (Manimmanakorn et al., 2013).  As the 
participants in the current study received a passive dose of hypoxia, it is unlikely that the increase in 
muscle mass in our participants was due to this reason. Instead, perhaps, the shift to glycolytic 
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metabolism, and associated increases in lactate production during the IHE sessions facilitated 
accelerated improvements buffering capacity allowing for greater exertion during the strength 
training portion of the exercise intervention. 
One limitation of the body composition analysis in the current study was the use of bioelectrical 
impedance to estimate muscle and fat mass, rather than a more reliable measurement such as 
hydrostatic weighing. As the changes between the groups were reasonably small, caution should be 
applied when interpreting the results.  
5.5.6 Limitations 
Given the timeframe of the study, there was a considerable change in the ambient conditions from 
the mid-winter baseline temperatures to the summer 4- and 8- week follow up temperatures. It is 
possible that this seasonal variation may have had an impact on some of the results.  However, as 
this was a controlled trial, we would expect any variation in seasons to affect both groups equally. 
The participants in the study were all sedentary and middle aged when they were recruited into the 
study. However, despite being sedentary, the participants were in good health. It is possible that a 
‘ceiling effect’ of sorts limited the effectiveness of the prescribed intervention and that a greater 
change in cardiovascular risk factors would have been evident in a population with a greater severity 
of cardiovascular risk.   
In any maximal tests, particularly in fitness assessments, motivation to continue will pay a substantial 
role in the drive to continue exercising to exhaustion and attaining a true V˙ O2peak. Additionally, the 
length of a maximal fitness assessment should be <10 min (Astorino et al., 2004, Yoon et al., 2007). 
However, given the wide range of fitness abilities, and the fixed protocol of the MBP, some 
participants took considerably longer than this, and therefore the V˙ O2peak results in the current study 
may be under-estimated for some participants. While this makes it difficult to compare the absolute 
V˙ O2peak with other studies, the results should still demonstrate changes in fitness in the individual as 
the protocol was kept consistent between time points. 
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5.6 Conclusion 
The inclusion of IHE into a traditional exercise programme resulted in slightly bigger improvements in 
SBP, V˙ O2peak and HDL compared to exercise alone. While there was some indication of increased 
resting parasympathetic activity (assessed using rMSSD) in the IHE3 + Ex group compared to the Ex 
group, none of these changes were clear. Additionally, there were no clear differences between the 
groups in the time taken to complete the maximal exercise test. Importantly, while the immediate 
arterial response to IHE3 + Ex seems to improve augmentation index, the longer term effects of IHE3 
+ Ex on arterial stiffness demonstrated an opposite, increase in augmentation index.  It is possible 
that this increased augmentation index was simply the result of a reduction in the pulse pressure 
without an associated decrease in the augmentation pressure. Still, further research should test the 
long-term effects of hypoxic exposure on vascular health before IHE can be considered a safe 
intervention in a sedentary population. Finally, the inclusion of IHE into a traditional exercise 
programme may benefit some independent cardiovascular risk parameters, but the protocol we have 
used is unlikely to improve the overall cardiovascular risk profile or exercise capacity more so than 
exercise alone in a our sedentary middle-aged participants. Furthermore, when the additional time 
and travel costs of the participant are considered, the practical application of IHE as an effective 
supplement to exercise must be questioned. 
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 Chapter 6
Final discussion and Conclusion 
Regular exercise plays a vital role in both maintaining and improving health. Active individuals 
demonstrate lower risk of coronary heart disease (Tanasescu et al., 2002), reduced blood pressure 
(Whelton et al., 2002), improved glycemic control in diabetics (Thomas et al., 2006), and lower levels 
of depressions and other metal illness (Stathopoulou et al., 2006). Indeed, the adage attributed to 
the late Robert Butler, former Director of the National Institute on Aging, that “if medicine was a pill, 
it would be the single most widely prescribed and beneficial medicine in the nation” elequently 
encapsulates the medical importance of regular physical activity. However, for those for whom 
exercise is not a possibility, or for those who can only exercise in limited doses –such as those with 
arthritis, injuries or illness, an alternative intervention is lacking. The overarching thesis statement 
was to determine the effects of intermittent hypoxic exposure on cardiovascular risk factors in a 
sedentary population. To address this, the following aims were defined:  
1) Identify gaps in the literature regarding the use of simulated altitude for health improvement. 
(Addressed in Chapter 2) 
2) Informed by findings in the literature review, determine the effects of simulated altitude on 
selected cardiovascular disease risk factors in a sedentary population. 
(Addressed in Chapters 3 and 4) 
3) Informed by findings in the literature review, determine whether simulated altitude is effective 
as an accompaniment to exercise on selected cardiovascular disease risk factors in a sedentary 
population 
(Addressed in Chapter 5) 
Following an extensive literature review, the following gaps in the literature regarding the use of 
simulated altitude in a sedentary population were identified: 
I. Further investigation to support or challenge the reports of improved sympathovagal balance 
in the autonomic nervous system (primarily through increased vagal activity), vascular 
health, and blood lipid profile associated with simulated altitude. Additionally, a full 
cardiovascular risk profile, rather than individual risk factors should be used to detect 
improvement in cardiovascular health. 
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II. Few studies report the participant’s subjective response to the simulated altitude 
treatments.  
III. Despite promising reports of health improvement, only a small portion of simulated altitude 
research is focussed in a clinical or sedentary population. 
IV. No research has assessed the effects of different frequencies of simulated altitude sessions 
per week on health (assessed via modulation of cardiovascular risk factors). 
V. More research should be conducted on the effects of passive simulated altitude in 
conjunction with exercise (versus exercise alone or exercise in hypoxia) in a sedentary, 
middle-aged group. 
Informed by these gaps in the literature, three studies took place to address the 2nd and 3rd aims, that 
is, the effects of simulated altitude without, and with exercise on cardiovascular risk factors in a 
sedentary population.  
6.1 What are the effects of simulated altitude (without the use of exercise) 
on selected risk factors in a sedentary population? 
The first and second studies (in chapters 2 and 3 respectively) sought to contribute to this question. 
In doing so, research gaps II, III and IV were addressed, as was the effect of simulated altitude on the 
sympathetic and parasympathetic contribution to autonomic cardiac variation as indicated in 
research gap I. The novel findings in this portion of the thesis research relate to the improvements in 
HRV. While several studies have investigated the instantaneous response of HRV to hypoxic 
exposure, this is the first research that has demonstrated an improvement in the parasympathetic 
contribution to HRV following 4 or 5 weeks of IHE in a sedentary, middle-aged population. 
Additionally, this is the first time the effects of different weekly frequencies of IHE were measured on 
independent cardiovascular disease risk factors.  
Based on the findings of studies 1 and 2, IHE has potential to increase resting HRV, primarily through 
an increase in the indicator for parasympathetic activity, rMSSD. While 2 – 3 IHE sessions per week 
yielded a small increase in rMSSD, these changes were only detectable under paced breathing. The 
impact of IHE on rMSSD was most clearly observed following 4 or 5 IHE sessions per week (in both 
controlled and spontaneous breathing conditions).  
There were no substantial improvements following IHE on submaximal exercise efficiency. While 4 
IHE sessions per week seemed to improve submaximal exercise tolerance as indicated by a lower 
heart rate at the same exercise intensity at post-intervention compared to baseline (Study 1, Chapter 
2), this was not evident following either 2-3 or 5 IHE sessions per week (Study 2, Chapter 3). There 
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were some differences between these studies that compromise the ability to directly compare 
changes in submaximal exercise between groups. For example, the submaximal exercise intensity in 
Study 2 was controlled by heart rate (therefore it was relative to the individual) whereas in Study 1, 
an absolute submaximal intensity of 50 W was used. This HR-defined submaximal workload remained 
consistent between baseline and post-intervention submaximal exercise assessments and was set at 
40 - 50% heart rate reserve. It is possible that 40 – 50% heart rate reserve would have been too high 
to detect changes in submaximal efficiency, compared to the lighter 50 W workload. Given the 
absence in any worthwhile changes in V˙ O2submax following any frequency of IHE per week (2 – 5), it is 
unlikely that IHE on its own had a beneficial influence on moderate, submaximal exercise efficiency in 
the participants in the current study. 
The effects of IHE on maximal exercise capacity are more difficult to interpret. While 2 – 3 IHE 
sessions per week (Study 2, Chapter 3, possibly Study 3, Chapter 4) increased  V˙ O2peak, there were no 
changes in V˙ O2peak following 4 (estimated V
˙ O2peak, Study 1) or 5 (measured V
˙ O2peak, Study 2) IHE 
sessions per week. While no improvements in V˙ O2peak were observed following 5 IHE sessions per 
week, participants receiving this dosage took longer to complete the exercise test, and tolerated a 
higher maximum workload, suggesting improved tolerance to maximal exertion. This improvement in 
high intensity exercise tolerance is possibly due to improvements in buffering capacity (Gore et al., 
2007) or a shift to glycolytic energy pathways (Semenza, 2001). 
Changes in SBP were unclear in Study 1, but did demonstrate a tendency to decrease with IHE in 
Study 2. Furthermore, when IHE was included in an exercise programme, there was a possibly 
beneficial effect on SBP compared to exercise alone. Therefore the effect of IHE on SBP warrants 
further attention in a larger cohort, receiving a dosage of 3 - 5 IHE sessions per week for a minimum 
of 4 weeks. (Participants in the IHE group in Study 1 effectively received IHE for 3 weeks, as the first 
week was a very mild dose of hypoxia and primarily used to familiarize participants and facilitate 
blinding). 
Overall, the participants tolerated the hypoxic exposures well, with only one participant 
demonstrating moderate side effects across all 3 studies.  
6.2 Does IHE enhance the cardio-protective effects of a traditional exercise 
programme compared to exercise alone? 
The final study (Study 3 in Chapter 4) addressed the effectiveness of IHE as an accompiament to 
exercise for the purpose of reducing cardiovascualr risk factors. In doing so, Research Gap V was 
prioritised. Additionally, the participants recruited into each of the studies were all sedentary and 
middle-aged and therefore contributed to Research Gap III. Finally, the effects of IHE and exercise 
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were measured against changes in arterial stiffness, blood lipids (limited to high density lipoprotein 
and total cholesterol) and overall cardiovascualr risk profile, thus informing Research Gap I.   
Overall, neither the exercise only nor the exercise with IHE groups had a substantial effect on overall 
cardiovascular risk (as assessed using the New Zealand Guidelines 5 – year cardiovascular risk 
assessment chart, and the 10 – year Framingham assessment) immediately following the 10-week 
intervention. While there was a possibly harmful outcome at the 8-wk follow up in the IHE3 + Ex 
group compared to Ex, this was caused by an increase in total cholesterol (which was inflated due to 
an increase in high density lipoprotein). Additionally, the absence of a full dataset at the 8-wk follow 
up owing to missing blood sample data (either not collected or excluded due medication that would 
have altered the lipid profile between the post and 8-wk time points), further compromised the 
accuracy of the 8-wk follow up overall cardiovascular risk profile. 
Regarding the independent risk factors, the group receiving IHE in addition to exercise demonstrated 
increased high density lipoprotein and maintained V˙ O2peak (compared to a decrease in Ex only) at all 
post-intervention measurements. Additionally, there was a tendency for lower pulse wave velocity 
(particularly at 4- and 8-wk post) and increased HRV (increased rMSSD, at all post-intervention time 
points) in the exercise and IHE group compared to exercise only, however none of these changes 
were clear. If these findings become clearer in a larger study, these adaptations may suggest superior 
caridioprotective adapation with IHE and exercise compared to exercise only in a sedentary 
population.  
However, while the indicator for systemic arterial stiffness, the augmentation index, appeared to 
decrease immediately post-intervention, there was a likely and very likely harmful outcome in the 4- 
and 8-wk follow ups. Because the augmentation index is a ratio between the augmetation pressure 
and the pulse pressure (SBP – diastolic blood pressure), the increase in the AIx could have been 
caused by a decrease in the pulse pressure with a smaller decrease, no change, or increase in the 
augmentation pressure.  It is also possible that the increase in AIx is a side effect of the repeated up-
regulation of the endotheial NO systhase activity during the hypoxic intervals resulting in a down-
regulation following the hypoxic exposure. The down-regulation of the endothelial NO synthase 
activity would result in increased vascular tone and a greater reflected waves. Therefore, until 
further research can disqualify any long-term vascular maladaptation to IHE, this protocol should not 
be recommended for beneficial health application in a sedentary population. 
6.3 Possible side effects 
The participants receiving IHE 5 times per week in Study 2 demonstrated a likely trivial increase in hs-
CRP. While this increase was not sufficient to change the risk category of the participants, it is worth 
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investigating further. Additionally, when IHE was included in an exercise programme, the participants 
in the IHE3 + Ex group initially demonstrated an unclear decrease in the augmentation index 
suggesting an improvement in arterial compliance. However at the follow up assessments, the 
augmentation index had increased substantially at 4 and 8-wk respectively. Whether the slightly 
elevated hs-CRP noted in Study 2 was related to the delayed increase in arterial stiffness in noted in 
the IHE3 + Ex group in Study 3 is uncertain. 
Before IHE can be freely recommended as a useful tool for improving cardiovascular health, a greater 
understanding of the long-term effects of IHE on arterial health and systemic inflammation is 
required. Future research should probe further into this potential side-effect in a healthy young 
cohort, or possibly in animal models, and avoid using sedentary, middle-aged participants to prevent 
any possible further declines in vascular health that participants in this population are likely to have. 
The findings of potentially increased systemic inflammation and a delayed increase in arterial 
stiffness noted in Studies 2 and 3 may challenge the ‘safe’ description of IHE as a potentially 
therapeutic intervention.  
6.4 Proposed mechanisms behind adaptations observed with IHE in Studies 
1, 2 and 3.  
Many of the adaptations observed in the 3 studies completed can be related back to adaptations 
associated with HIF-1α and peripheral chemoreceptor activity (particularly the carotid bodies). Figure 
16 attempts to resolve the research outcomes from the current studies with the adaptations known 
to occur with the HIF-1 α and peripheral chemoreceptor activation in hypoxia. As no direct measures 
of HIF-1 α activity, such as vascular endothelial growth factor, erythropoietin or carbonic anhydrase 
concentrations were taken, these are all hypothesised mechanisms for the observed changes that 
have been based on research by others. There are some questions that arise, and seeming conflicts 
between this proposed model and some of the adaptations.  
Figure 16 demonstrates the stimulation of genes associated with up-regulating erythropoiesis and 
carbonic anhydrase, as well as stimulating alterations in vascular tone and an active cellular shift to 
glucose metabolism (Semenza, 2001). From these, improvements in in oxygen carrying capacity; 
carbon dioxide, bicarbonate ions and hydrogen transport to the lungs (Geers and Gros, 2000); 
vascular compliance (Wilkinson et al., 2002a, Wilkinson et al., 2002b) is produced. One important 
consequence of the shift to glycolysis is the increase in nicotinamide adenine dinucleotide + 
Hydrogen which (following several steps) inhibits 7-α-hydroxylase, a rate limiting enzyme in the 
conversion of cholesterol to bile salts (Johnson, 2008) which cause an increase in plasma cholesterol.  
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Figure 16: Integration of adaptations associated with IHE interventions to the actions associated with HIF-1 α and peripheral chemoreceptor activation
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Upon cessation of the hypoxic stimulus and reversion to oxidative phosphorylation the relatively 
higher cholesterol concentration in the blood may then trigger an up-regulation of 7-α-hydroxylase 
resulting in an overall decrease in cholesterol. The point of interest, however, is that the IHE3 + Ex 
group in Study 3 demonstrated an increase in high density lipoprotein while total cholesterol 
remained stable over the course of the study (and subsequently decreased at the 8-wk follow up). In 
comparison, the Ex group decreased total cholesterol throughout the study and at the 8-wk follow 
up, but had no change in the high density lipoprotein. It seems, then that the effect of the IHE 
treatments may have been more related to the increase in high density lipoprotein, than the 
decrease in non-high density lipoprotein.  
There are a few ‘puzzle pieces’ that don’t seem to fit in the diagram outlined in Figure 16. For 
example, while an increase in V˙ O2peak was observed in both studies using IHE 2 – 3 times per week 
(the IHE3 group in Study 2 and the IHE3 + Ex group in Study 3), there was no increase in estimated or 
measured V˙ O2peak following 4 or 5 IHE sessions per week (the Hyp group in Study 1 and IHT5 group in 
Study 2 respectively). Additionally, it is possible that the short term influence of the increased 
endothelium nitric oxide activity (the unclear decrease in pulse wave velocity, and augmentation 
index) may have long-term mal-adaptations such as an increase in augmentation index and hs-CRP. 
The effect on an increase in sympathetic nervous activity associated with hypoxia on vascular health 
is complicated. For example, despite an increase in the sympathetic innervation to skeletal muscle 
arteries (which would typically be associated with an increase in vasoconstriction), there is a 
vasodilatory response in the skeletal muscle arteries (Hudson et al., 2011). This may suggest that 
other, local factors (possibly due to metabolic alterations) may play a larger role on vascular 
augmentation than the increase in sympathetic innervation. 
6.5 Practical lessons 
Part of the aims outlined in the first study in Figure 1: Decision making process for research 
progression” in Chapter 1 was to assess the best ways of running the studies, specifically regarding 
participant recruitment, management and testing scheduling. The following practical and invaluable 
learnings through the research have been gathered through the research process.  
When it comes to recruitment, any form of personal communication was more effective than 
notices. For example, most of the participants were successfully recruited following information stalls 
at Farmers Markets (most effective), or presentations at community groups such as Rotary Clubs. 
Information drops in mail boxes, posters on community notice boards or small notices in the 
newspaper were not as effective.  
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Regarding participant management, it was difficult to find the balance between giving the 
participants enough information so that they were fully informed, but not too much so that they 
‘switched off’ and did not read the information packs. Having a clear and concise summary at the 
beginning of the information pack was helpful. Reminding participants of their medical and testing 
appointments the day before the appointment, including any preparatory detail (such as avoiding 
caffeine and strenuous exercise etc.) improved the flow of the testing procedure. 
Having a full run through and familiarization of the baseline testing procedures made a substantial 
difference to the quality of the baseline data. For example, in the HRV analyses in Study 2, there 
were considerably fewer outliers detected in the baseline testing session compared to the 
familiarization. Unfortunately, due to logistical and time restrictions, a full familiarization was not 
conducted in Studies 1 and 3, and participants were familiarized with the testing procedures for 
approximately 30 min prior to baseline collection. It is unclear what effect this would have had on 
the baseline values in these studies. 
6.6 Practical considerations regarding the use of IHE as a means of reducing 
cardiovascular risk factors 
The findings of this thesis demonstrate several cardio-protective responses to an IHE intervention. 
However, it is important to recognise the considerable time and travel commitments that are also 
required and therefore one should consider the time cost to health benefit trade-off when 
recommending the use of an IHE treatment. It is likely that a similar or improved cardiovascular risk 
response can be achieved by a moderate exercise intervention. In this regard, IHE may not be 
appropriate for individuals who are able to exercise for the government-recommended time of 30 
minutes on most days of the week, even if the exercise dose is mild. The use of IHE as a tool for 
cardiovascular risk reduction may be best suited for those who are unable to exercise sufficiently or 
at all.  
6.7 Future research 
The most pressing area for investigation is to investigate the long-term effects of IHE on vascular 
health. In particular, future research should focus on markers of inflammation, such as hs-CRP or 
measures of arterial compliance such as the augmentation index which may indicate mal-adaptation 
to the repeated hypoxic intervals. As the group receiving 2 -3 IHE sessions per week did not 
demonstrate any change in hs-CRP following the 5-week intervention, mediating the potentially 
harmful effects of IHE may have to do with the dosage. Therefore, research investigating different 
intensities of hypoxia (for example, reducing SpO2 to 90 - 85% instead of 80%), or using a lower 
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frequency of IHE sessions per week may avoid the observed increases in hs-CRP and delayed increase 
in arterial stiffness. 
Should a safe mode of IHE be established, additional research, in a larger cohort should examine the 
effects of simulated altitude (4 – 5 times per week, for 4 weeks) on changes in systolic blood 
pressure. Finally, other methods of simulated altitude, such as the live high, train low protocol using 
altitude tents, or IHT should be investigated for their influence on reducing cardiovascular risk factors 
in a sedentary population. 
6.8 Conclusion: The effect of IHE on cardiovascular risk factors in a sedentary 
population 
The use of IHE either alone, or accompanying exercise may prove to be a useful intervention for 
improving HRV, high intensity exercise tolerance, increasing high density lipoprotein and possibly 
reducing systolic blood pressure. Additionally, the findings of this research suggest an IHE 
intervention 4 or 5 times per week, for 4 weeks (at the target SpO2) is the dosage most likely to result 
in health improvement. However, potential side effects, such as increased hs-CRP and the long-term 
effect on arterial stiffness following IHE need to be investigated further before IHE can be described 
as ‘safe’. Given the additional intervention hours required by the participants in the IHE3 + Ex group, 
the time commitment required for IHE may be better spent engaging in physical activity more 
regularly in a healthy population. However, should the concerns regarding the long-term effects of 
IHE on vascular health and systemic inflammation be unfounded, IHE may be a useful intervention 
for individuals for whom additional exercise is not an option. Target populations could include those 
in surgical or injury rehabilitation programmes, or even those new to exercise training.   
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Appendix A  
A beginner’s guide to heart rate variability  
Heart rate variability (HRV) is a widely used tool in the assessment of the autonomic control of the 
heart. However, there is little practical guidance regarding the measurement of HRV. The aim of this 
guide is to try and fill this gap by providing some practical steps and considerations in the 
measurement of HRV using a Polar heart rate monitor and software. While there are a number of 
ways to measure HRV, this guide will focus on short term (5 minutes), time and spectral domain 
analyses measured using a polar heart rate monitor (HRM), measured in a laboratory setting. The 
authors welcome any further contribution by other researchers, particularly those with experience in 
longer term (24 hours) or alternative methods of HRV (e.g. geometric, fractal, course graining 
spectral analyses etc.).  
A.1 What, exactly, is heart rate variability (HRV)? 
Heart rate variability is how much the interval between each of your heart beats vary from one to 
another (Task Force of The European Society of Cardiology and The North American Society of Pacing 
and Electrophysiology, 1996). While heart rate measures an average of the number of times your 
heart beats in one minute, HRV lets us know how uniform the time interval between each of the 
beats was. The more uniform the time intervals, the lower the heart rate variability.  For example, in 
the graph below (from a 3-lead ECG, recorded using Beatscope software), notice that none of the 
intervals between the heart beats are exactly the same. This is because your body is always 
responding to both internal and external stimuli by up-regulating (sympathetic stimulation increase 
and/or parasympathetic withdrawal) or down-regulating (increased parasympathetic stimulation via 
the vagal nerve and/or sympathetic withdrawal) the autonomic nervous system to maintain 
homeostasis (Porges, 1992).  
 
Figure 17: Fluctuations in heart beat intervals 
 
The fluctuations between up- and down-regulation occur at different frequencies. For example, the 
fastest fluctuation would be related to your respiratory sinus arrhythmia – when your heart beat 
speeds up as you breathe in, and then slows down as you breathe out. The purpose of the 
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respiratory sinus arrhythmia is to increase the amount of blood sent to your lungs while there is fresh 
oxygen available (while inhaling), and reduces the amount of blood sent to your lungs while there is 
little fresh oxygen available (while exhaling) (Yasuma and Jun-ichiro, 2004). The extent to which your 
heart rate speeds up and slows down during your respiratory sinus arrhythmia is controlled by your 
parasympathetic nervous system via the vagus nerve (Porges, 1992), and as it fluctuates with every 
breath, it occurs at a high frequency (Task Force of The European Society of Cardiology and The 
North American Society of Pacing and Electrophysiology, 1996). 
In 1996 a taskforce (The European Society of Cardiology and the North American Society of Pacing 
and Electrophysiology) was established to describe the various HRV techniques, define the correct 
nomenclature, and to standardise the best practice for the measurement of HRV. The Taskforce 
guidelines (Task Force of The European Society of Cardiology and The North American Society of 
Pacing and Electrophysiology, 1996) explain the interaction of the ANS and HRV very well (See 
guidelines p. 366)  
 
 
 
 
 
A.2 What the abbreviations mean 
As mentioned above, the focus of this guide is on short term time and spectral domain heart rate 
variability measured using Polar heart rate monitors. Therefore, only the time and frequency domain 
parameters  are reported in Table 18.  
Pinna et al. (2007) have compiled an excellent review on the reliability, repeatability and estimated 
samples sizes needed to detect changes in these variables.  
  
Figure 18: Excerpt from the Taskforce Guidelines (1996) explaining the interaction 
between sympathetic and vagal activity 
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Table 18: The abbreviations, full titles and meanings of some of the time and spectral domain HRV 
analyses 
Time 
domain 
Units  Unabbreviated  What it measures 
RR interval ms. The average time interval 
between R-peaks.  
Much like heart rate, it gives an overall 
indication of the SNS/PNS balance. Just as a 
lower heart rate indicates higher PNS, higher 
RR interval indicates higher PNS. Always report 
this in your studies. 
SDNN ms Standard Deviation of 
Normal – Normal intervals. 
(intervals between normal 
QRS complexes)  
Because overall variance = overall power, 
SDNN measures overall cyclic power of the 
variability. The length of the SDNN recording 
greatly affects the SDNN value, so ensure the 
recording length is consistent (Task Force of 
The European Society of Cardiology and The 
North American Society of Pacing and 
Electrophysiology, 1996) 
    
rMSSD  ms Root mean square 
successive difference 
Parasympathetic component (largely related to 
the respiratory sinus arrhythmia). rMSSD 
reflects cardiac vagal activity. 
 
PNN50 % The proportion of the 
number of pairs of 
adjacent NN intervals that 
are greater than 50 ms in 
the total number of NN 
intervals recorded. 
Parasympathetic component 
Frequency 
domain 
Units  Unabbreviated What it measures 
TP ms2 Total power  Overall variance of the 5 minute segment. 
HF ms2 High frequency  
(0.15 – 0.4 Hz) 
Parasympathetic component (via respiratory 
sinus arrhythmia) 
LF ms2 Low frequency  
(0.04 – 0.15 Hz) 
Sympathetic and parasympathetic (some 
respiratory sinus arrhythmia, also blood 
pressure related changes) 
VLF ms2 Very low frequency (0.003 
– 0.04 Hz) 
Unsure – do not use this in short term 
recordings. 
HF or LF  n.u. High frequency and low 
frequency expressed in 
normalised units 
Measuring HF and LF in normalised units (nu) 
allows the researcher to see the proportion of 
each out of 100%. (When expressed in nu, the 
values added together will equal 100%). This 
allows the researcher to see whether the SNS 
or PNS was more dominant. (Task Force of The 
European Society of Cardiology and The North 
American Society of Pacing and 
Electrophysiology, 1996)  
LF/HF  Low frequency to high 
frequency ratio 
Dominance of SNS 
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A.3 Using the right tool for the job 
Each of the different HRV measurements is used to draw different conclusions. Therefore, it is 
important to decide which is the most useful ‘tool’ or measurement before you start to ensure you 
are able to answer the research question effectively. By selecting specific variables you avoid 
conflicting results and avoid using in-appropriate measurements for your study.  
Spectral methods have been recommended for short term recordings (Sandercock et al., 2005b, Task 
Force of The European Society of Cardiology and The North American Society of Pacing and 
Electrophysiology, 1996). However, some researchers suggest that spectral analyses can be less 
reliable than time domain analyses (Al Haddad et al., 2011), while others report that no one measure 
is more reliable than the others (Sandercock et al., 2005b). The rMSSD appears to be the most 
reliable time domain measure that reflects vagal activity and, importantly, does not appear to be 
influenced by breathing patterns (Penttilä et al., 2001). 
The HF and LF measurements can give a better insight into the interplay between the sympathetic 
and parasympathetic systems. The HF component is a good reflection of the parasympathetic 
nervous system and represents short term fluctuations on the sinus node. Because the LF component 
is a mix of both parasympathetic and sympathetic nervous systems interpreting the cause of the 
change in LF is somewhat more challenging and the LF can be difficult to interpret. 
A.4 How does the polar HRM compare to an ECG 
The Polar HRMs have been validated against 2 lead (Gamelin et al., 2006), 12 lead ECG (Porto and 
Junqueira Jr, 2009) (amongst others) and have been accepted as a good, non-invasive means of 
detecting HRV. Still, ECGs remain the gold standard and should be used where possible. 
A.5 How to set up the equipment 
Electrode Gel on the HRM belt 
To improve the contact of the HRM belt to the participant’s skin, it is recommended that you use 
some electrode cream under the belt of the HRM strap.  
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Figure 19: Apply some electrode gel to the electrodes of the HRM belt to improve contact with the 
skin 
 
Recording frequency on the watch 
Ensure that the Polar HRM watch is set to record the RR Intervals (check box is ticked, see image 
below). The RR Interval function measures the variation in heart beats to within 1 ms (Polar Electro 
Oy, 2008). If you find that the memory is filling up too fast, you can set the recording rate to 5 
seconds instead of 1 second. Just make sure you keep it consistent between participants. 
 
Figure 20: Ensure that the HRM watch is set to record the RR interval. Use the top right button (A) 
to scroll through options and the bottom red button (B) to select an option. Use the 
bottom left button to return to the previous menu (C) 
A.6 How to take the measurement 
Supine, Sitting, Standing or during exercise 
This will depend entirely on what you’re trying to measure. For example, if you wanted to measure 
whether an intervention altered the normal resting state of the participant, you would position your 
participant such that the SNS stimulation is reduced, and the parasympathetic component is 
enhanced (a supine position in a quiet, ‘safe’ space). While supine rest appears to be the most 
commonly used posture for the collection of HRV data, some researchers suggest adopting a seated 
posture. The Task Force of The European Society of Cardiology and The North American Society of 
Pacing and Electrophysiology (1996) guidelines do not specify a posture, only that it is consistent.  
As the parasympathetic contribution is measured primarily using the respiratory sinus arrhythmia, 
the participant should not talk during the measurement as this alters breathing frequency and 
A 
C B 
Make 
sure this 
box is 
ticked 
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therefore the respiratory sinus arrhythmia. The participants should be encouraged to breathe as 
normally as possible. 
Measuring HRV during exercise is very difficult for a couple of reasons. 
a) For an accurate measurement of HRV, the recording needs to be taken during a physiological 
stable state (unless you’re measuring HRV during the Valsalva manoeuvre or head tilt and so 
on – I have not used these methods, so cannot comment here). Achieving a steady state 
during exercise over a period of 5 minutes can be difficult, particularly in a sedentary, 
middle-aged population. The HR stationarity can also become compromised in protocols that 
require a consistent workload (as is required in most ramp protocols). Completing such 
measures on athletes is probably easier but its best to try things out in a pilot study first.  
b) There are a lot of non-neural stimuli that affect HRV during exercise, so the accuracy of the 
HRV measurement using time and spectral domain analyses is compromised (coarse graining 
spectral analyses and non-linear methods may be more appropriate) (Sandercock and Brodie, 
2006). 
c) Short-term HRV recordings should be 5-minutes long, as recommended by the guidelines 
(Task Force of The European Society of Cardiology and The North American Society of Pacing 
and Electrophysiology, 1996), so that the results of your study can be compared with other 
studies. The length of the HR recording influences the HRV value, so if the recording length is 
shorter or longer than this, it cannot be compared to other research or even different 
recording lengths between participants in the same study. (Task Force of The European 
Society of Cardiology and The North American Society of Pacing and Electrophysiology, 
1996)). Recordings shorter than 5 minutes are also considerably less reliable than the 5-
minute recommendation (Schroeder et al., 2004).  
A.7 Using Paced / Controlled breathing or spontaneous breathing? 
Controlled breathing can improve the clarity and reliability of the heart rate recording (Pinna et al., 
2007); however, spontaneous breathing can also produce reliable data, particularly if you’re using 
the rMSSD (Penttilä et al., 2001). The participants should rest for 5 minutes prior to the 5 minutes 
HRV recording to ensure the participants are relaxed.  
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Figure 21: Spontaneous and controlled breathing on HR 
 
Measuring controlled HRV can present a few practical issues for the researcher to consider: 
a) People have a wide range of natural breathing frequencies, so they may find the ‘set’ 
breathing frequency uncomfortable. The participants can also hyperventilate if they breathe 
too deeply or too fast, so it’s important to encourage the participants to breathe as normally 
as possible. 
b) Even if you set the metronome to a frequency similar to the participant’s natural breathing 
rate, it is often still uncomfortable for the participant to breathe at a controlled pace for an 
extended period of time.  
c) It is difficult to monitor adherence to the controlled breathing protocol.  
d) After already lying supine for 5 - 10 minutes, the continuous metronome can put the 
participants to sleep. As soon as the participants fall asleep, their breathing rate changes, 
and their HRV is also altered between sleep and wake states (Shinar et al., 2006). 
The use of a metronome in conjunction with a visual cue of sorts may reduce the tendency for the 
participant to fall asleep. A seated position might keep the participants awake better while only 
introducing a small increase in the sympathetic component (Chan et al., 2007). 
A.8 Rest time, lighting and noise. 
Related to section 3.2 above, a 5 minute rest period can provide the participant with some time to 
‘unwind’ from the stress of getting to the lab (possibly rushing to do so), getting set up with possibly 
intimidating equipment, and being in an unfamiliar place. However, a rest period of longer than 5 
minutes may increase the likelihood of the participant falling asleep. Practically, while many 
researchers recommend the use of a quiet, semi-dark room, a room that is too quiet, dark and 
comfortable readily induces sleep, and therefore keeping the lights on and not removing all white 
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noise may be beneficial. Sudden or sharp noises will increase the participant’s heart rate suddenly 
and should be avoided. 
A.9 How to analyse the data using Polar Protrainer5 
Which sample to select? 
The 5 minutes of rest (to reduce the impact of any initial white coat syndrome or elevated HR due to 
unfamiliar equipment or rushing to the exercise laboratory) immediately followed by the 5 minutes 
of recording means that the participant will be resting for a period of 10 minutes. If you have started 
your HRM as the participant starts their rest period, you should select the last 5 minutes of the 10 
minute rest period for your HRV analysis as this is the most reliable way of collecting data. Before 
actually testing this (unpublished preliminary research), we assumed that selecting the ‘most 
consistent’ or ‘tidiest’ 5 minutes of data in the 10 minute period would be best. However, by doing 
this, you are selecting unusually ‘high/low/unvaried’ data which actually reduces the repeatability of 
the measurement.  
A.10 How to select your sample 
After the HR data are uploaded into Polar Protrainer5TM it will need to be filtered for ectopic beats.  
 
 
 
 
 
 
 
 
 
 
 
 
 
After filtering the data, you will need to select the portion that you wish to analyse. To do both of 
these, you will need to select the relevant portions of data. By right clicking on the y-axis, you can 
choose to display the RR interval instead of HR. This gives you an inverted HR graph. This is entirely 
personal preference and will not affect the outcome of the data. 
The blue bar at the bottom of the trace indicates which data has been is selected. To remove the 
selection, right click under the graph. To add a selection, left click and drag over the interval you wish 
to analyse. The HRV analyses will only work when there is only one piece of data selected. If there 
are no values when you display the HRV data (see section A.12 below) it might be because you have 
accidently selected more than one interval for analysis. 
Figure 22: Selecting the data 
Likely ectopic 
Blue bar indicating 
selected HR data 
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A.11 Filtering your data 
To filter the data, select the full segment (the full segment should be selected when you open the file 
for the first time). Right click anywhere on the graph and select “error correction”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Use the default settings of “moderate filter power”; “minimum protection zone” of 6 beatmin-1; and 
make sure that the scissors tick box has been selected. Click preview to see the changes, and then 
click OK.  
 
Figure 24: Filter the data 
The purple line is the filtered trace. Notice that the tall peak as the participant started exercising (in 
the above figure) will be removed following filtering.  
A.12 Measuring HRV 
After the data have been filtered, remove the blue selection bar under the graph by right clicking 
under the graph. Select the portion of data you wish to analyse by left clicking and dragging 
underneath the X-axis of the graph over the required portion. If you are using spontaneous 
breathing, this portion should be the 5 minutes following your 5 minute rest interval. If you are using 
controlled breathing, use the 5 minute interval shortly after the start of the metronome (or whatever 
you are using to control breathing frequency).  
For example, in the graph used in Figure 22 - Figure 25 the participant rested for 5 minutes, HRV 
under spontaneous breathing conditions was then recorded for 5 minutes, followed by controlled 
Figure 23: Choose the "error correction" function 
Ensure all data are 
selected for error 
correction 
This peak will be 
removed following 
filtering 
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breathing for 5 minutes. The participant then started the exercise portion of the fitness assessment. 
The start of each new period was separated using the ‘lap’ function on the heart rate watch. When 
the function is pressed, it creates a small vertical line and number on the X-axis when after the HR 
has been downloaded. For example, to analyse the controlled breathing portion, clear the selection 
by right clicking under the graph, and select the data shortly after the ‘2’ marker by dragging the 
curser over the following 5 minutes. 
Once you have selected the portion for analysis, right click anywhere on the graph and select 
“Selection Info…” This will bring up a table of the HRV results which can be copied and pasted into an 
Excel Spreadsheet.  
 
Figure 25: Perform HRV analysis using the "Selection Info..." option 
 
A.13 How to improve the accuracy of the data.  
Our research group has found rMSSD to be the most reliable measurement (unpublished preliminary 
data) in a sedentary, middle-aged population. The HF spectral recording is also reasonably reliable, 
but the typical error associated with this reading is large, so you need to interpret your data carefully 
(Al Haddad et al., 2011).  If your data are within the typical error of measurement, consider plotting 
the change scores from Time 1 and Time 2 to see if there’s a general trend. Ensure that you mention 
the high typical error in your discussion.  
5 minutes of 
‘controlled’ 
breathing have 
been selected 
Lap markers 
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Figure 26: The use of change scores to illustrate the change in HRV 
 
The data in the above graphs are an excerpt from a study conducted in November 2009 by our lab. 
The pre/post-intervention changes in rMSSD indicate a more uniform result in the test group 
compared to the control group.  
A.14 Dealing with outliers 
Unfortunately, the Polar ProTrainer5 may not pick up non-sinus originating beats (which would be 
excluded in an ECG) which can result in inflated HRV values (Wallén et al., 2012). The use of outlier 
detecting methods can be useful in deciding whether an inflated HRV result is likely to be ‘normal’. 
Importantly, the outlier detection strategy should be resistant to the effects of outliers. For example 
while including all data that are 2 standard deviations (SD) from the mean is a common form of 
outlier detection (Leys et al., 2013), it is flawed in that the technique itself is susceptible to the effect 
of the outlying data. The use of the median absolute deviation (MAD) or Interquartile range methods 
to detect and remove outliers are two robust techniques that are resistant to the effects of outlying 
data (Wilcox, 2010) . Unfortunately there has not yet been a study that directly assesses whether 
outlier removal improves the reliability of the results. However, it is not unusual to receive some 
particularly high HRV recordings (see Figure 27 below). Some reasons why the high value could be 
false include: the belt losing contact with the skin; mis-interpreting components of the QRS complex 
(Gamelin et al., 2006); or incorrect  automatic filtering for ectopic or non-sinus originating beats 
(Wallén et al., 2012). Regardless of whether the outlier removal improves reliability, it is likely to 
improve the integrity of the data.  
How you detected the outliers, the number of outliers detected and removed, and possibly what the 
outliers were should be noted in your publication. 
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For more information on outlier detection and removal, read:  Wilcox, R. R. 2010. The normal curve 
and outlier detection. In Fundamentals of modern statistical methods: Substantially improving power 
and accuracy. New York: Springer. 
 
Figure 27: Outliers detected by visual inspection (a), Median Absolute Deviation (b), and 2X SD (c) 
methods of outlier detection (interquartile range not shown) 
 
While one of the outlying data points were selected by the 2 X SD method, the MAD method was 
slightly more sensitive and picked up a data point at 60 ms (a, b), where most of the data for this 
population were below 40 ms. However the data are analysed, it is essential that an objective and 
consistent approach is used in the data filtering process.  
A.15 When to use the natural logarithm  
Some authors recommend always using the log transformed data as the nature of HRV 
measurements, particularly the rMSSD, is usually skewed (Plews et al., 2012).  
If you are doing a repeatability study, and your data are heteroscedastic or follows a non-normal 
distribution, you’ll need to log transform the data before you analyse it. 
A.16 What is the advantage of Kubios?  
Kubios is free software that can assist with the assessment of HRV. Kubios, unlike the Polar software 
can also produce Poincare plots (rather than just the SD1 and SD2 values returned by the 
PolarProTrainer5 software). The Kubios software can be download from: http://kubios.uef.fi/. A 
registration with the developers of the software is required. Following registration, an activation link 
for the download will be emailed. The registration field requires a valid email address and it appears 
after selection of the appropriate software version (Linux or Windows) of Kubios has been made. 
There is very little difference in the HRV reports between the two software programmes when 
identical strips of heart rate data (recorded from a Polar device) are analysed Kubios and ProTrainer. 
Kubios may be more relevant for other heart rate monitors that are not compatible with 
PolarProTrainer5, or ECG recordings that have been converted into a text file. 
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A.17 Practice measurements  
Full ‘practice’ measurements can minimise the number of outliers and improve the quality of HR 
recordings. The improvement in the quality of the data could be due to: 
a) The participants being more relaxed and more comfortable with the researcher, the lab, and 
the equipment. 
b) The researcher will be more relaxed, have a better understanding of how the timing between 
participants will work, what each of the participants requires, and (importantly) how to 
explain the session to the participants. 
A.18 Using the average of several recordings 
Plews et al (2013) recommends using the average of HRV measurements taken every day for one 
week, rather than just one measurement on one day (Plews et al., 2013, Plews et al., 2012). While 
this is a useful means of improving the sensitivity of the data, it might not be practical for larger 
studies. Schroeder et al (2004) noticed that taking multiple 1-minute recordings during one rest 
period vastly improves reliability (Schroeder et al., 2004). More research to assess whether taking 
the average of 2 or 3 5-minute recordings improved reliability, or whether HRV recordings several 
times per week (rather than every day) improve reliability. 
A.19 Are there normal values?  
Nunan et al (2010) have recently published some normative values of HRV (Nunan et al., 2010). 
However, one must be careful when trying to decide whether your population demonstrate ‘normal’ 
data as reliability and HRV values vary considerably across different populations (Sandercock et al., 
2005b). For example, we have consistently found that our middle-aged, sedentary participants who 
are usually on some form of stable medication, have lower HRV values (and reliability) than the 
averages reported by Nunan et al (2010).  
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Appendix B 
Repeatability and outlier detection of HRV measurements 
The purpose of this paper was to assess the variability of HRV measurements. However, there were 
several important drawbacks with this research that prevented us using the assessed variations in 
the current research. The main drawbacks of the current research include are the small sample size 
(n = 19), and the variation and length long between measurements (1 – 2 weeks). 
B.1  Abstract:  
Background: While recommendations exist regarding the appropriate usage, filtering and analysis of 
heart rate variability (HRV) data, there are no recommendations regarding the selection of 
appropriate data segments or outlier detection. Aim: Determine whether subjectively selected 
(‘most stable’), predefined (‘last 5 minutes’), or ‘controlled breathing’ 5-minute data segments 
produce the highest HRV reliability in a sedentary population. Method: Eight males (age: 56.3  4.6; 
BMI: 26.4  4; on medication: n=6) and 11 females (age: 55.5  6.7; BMI: 26.8  5.6; on medication: 
n=6; mean  standard deviation) attended 2 measurements 1 - 2 weeks apart. Supine resting HRV 
(Polar RS800CX) was assessed during spontaneous breathing (10 minutes) and controlled breathing 
(6 minutes). Visual inspection, the Median Absolute Deviation, and 2X Standard Deviation were 
considered for outlier detection. Results: The ‘last 5 minutes’ demonstrated the best relative 
reliability in heart rate (HR: 0.82 (0.58 – 0.92 intraclass correlation coefficient and 95% confidence 
limits)), root mean square successive difference (rMSSD: 0.82 (0.56 – 0.93)), high frequency (HF: 0.76 
(0.43 – 0.91)) and low frequency (LF: 0.42 (-0.08 – 0.75). The standard deviation of NN intervals 
(SDNN: 0.57 (0.13 – 0.82)) was most relatively reliable in the ‘most stable’ segment. The ‘controlled 
breathing’ and ‘most stable’ data segments produced best absolute reliability for HR (5.0 (3.8 – 7.5) 
coefficient of variation (95% Confidence Limits)) and LF (56.4 (37.8 – 109.3)); and SDNN (28.4 (20.4 – 
46.3)) and HF (61 (41.7 – 111.9)) respectively. The ‘last 5 minutes’ produced the best absolute 
reliability for rMSSD (24.4 (17.5 – 40.2)). Discussion: High frequency and rMSSD were sufficiently 
reliable in this population.  However, the typical error is still large, and results, (especially SDNN, LF 
and HF) should be interpreted with caution. Conclusion: The rMSSD from the last five minutes of a 10 
minute resting period during spontaneous breathing is recommended for this population.  
Key words: Polar heart rate monitor, median absolute deviation, rMSSD, inactive   
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B.2 Introduction: 
Heart rate variability (HRV) has been used in both health and sports science contexts as it is a simple 
means of estimating the contributions of the parasympathetic and sympathetic contributions to the 
autonomic control of the heart period (Task Force of The European Society of Cardiology and The 
North American Society of Pacing and Electrophysiology, 1996). While the variation in the RR peaks 
has traditionally been detected using ECGs, the use of commercial devices such as the Polar heart 
rate monitors and automatic error correction functions provides a far more convenient means of 
measuring HRV. The use of these devices to detect RR intervals has been validated against 2 
(Gamelin et al., 2006) and 12 lead ECGs (Nunan et al., 2008).  
Although heart rate monitors have been validated against traditional ECGs, some researchers have 
debated their accuracy. Gamelin et al. (2006)  identified the two highest causes of error in the heart 
rate monitor when compared to ECG recordings  include missing  beats (resulting in much longer RR 
intervals), or detecting  too many beats (resulting in smaller RR intervals). The authors suggest that 
these errors could be caused by the heart rate monitor belt either lifting away from the skin, 
resulting in a missed beat, or the heart rate monitor belt misinterpreting a T-wave or P-wave for an 
R-wave and effectively doubling a beat (Gamelin et al., 2006). In this regard, it is essential that the 
raw HR data are corrected prior to HRV analysis. However, the automatic error correction with the 
Polar ProTrainer5TM is not always sufficient in detecting these errors, or other non-sinus originating 
beats (Wallén et al., 2012). These errors result in higher HRV measurements (Wallén et al., 2012) and 
HRV parameters that differ from those derived from traditional ECG recordings (Nunan et al., 2008). 
This emphasises the responsibility of the researcher to carefully examine the data post-filtering for 
instances where data may be erroneous. It is thus important that a robust and objective outlier 
detection method is employed to identify any potential outlying data points.  
Since the HRV Guidelines were published (1996), several authors have made recommendations to 
improve the repeatability and reliability of the HR data. For example, Penttilä et al., (2001) 
recommends using the root mean square of successive difference (rMSSD) rather than spectral 
analyses. Others recommend that if one is unable to use the recommended 5 minute recordings 
(Task Force of The European Society of Cardiology and The North American Society of Pacing and 
Electrophysiology 1996), the average of multiple 10 second or 2 minute recordings rather than single 
ultra-short recordings substantially improves reliability (Schroeder et al., 2004).  Plews et al (2013) 
has recently advocated the use of the average of HRV parameters recorded daily over approximately 
one week to improve the reliability. Finally, Nunan et al (2008) recommends that, where possible, 
ECGs should be used instead of Polar devices.  
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Breathing frequency also has a substantial effect on the spectral measures of HRV. For example, a 
particularly low breathing frequency (less than 6 breaths/min) will shift the ‘respiration’ peak, or HF 
band, into the LF range (0.04 – 0.15 Hz). Conversely, a particularly high breathing frequency (above 
24 breaths per minute) may shift the HF peak outside of the typical HF range (0.15 – 0.4 Hz) (Penttilä 
et al., 2001). In order, to minimise the influence of different breathing patterns, the use of controlled 
respiration, typically between 12 – 15 breaths per minute, has become commonplace.  
While several reliability studies have emerged in recent years, most of these have been conducted in 
reasonably young, healthy, and physically active populations (Gamelin et al., 2006, Guijt et al., 2007, 
Pinna et al., 2007). For example, the average age in Pinna et al.’s (2007) study was 38 years (ranging 
from 26 – 56 years) and all the participants were free from medication and chronic disease (Pinna et 
al., 2007).  However, as there is a high prevalence of sedentary behaviour and medication use in the 
general population (Bertoldi et al., 2006), the findings from this study may not be representative of a 
typical middle-aged, sedentary population. In addition, Pinna et al (2007) used custom-designed 
software as opposed to readily available commercial equipment to detect and analyse the RR 
intervals. Consequently, the findings of their study may not translate well for commercially available 
equipment. Therefore, the aim of this research is to determine the reliability of various short term 
HRV measurements in a slightly older, sedentary population. To make the results as reflective of the 
population as possible, we minimised exclusion based on medication or medical conditions. We also 
used readily available equipment (Polar RS800CX) and analysis software (Polar Protrainer5TM) to 
improve the relevance of the results of the study to other researchers. In addition to this, we aimed 
to determine whether there are alternative means of increasing the reliability of the HRV recording. 
For example, if HRV is recorded over a 10 minute resting period, would it be better to select an 
objectively pre-defined 5 minute interval (for example, the last 5 minutes of the 10 minute HR 
recording), or use researcher discretion to select the clearest, ‘most stable’ 5 minute portion in the 
10 minute HR recording? 
B.3  Method 
Following a medical examination, 19 participants from the local community (8 males, 11 females) 
were recruited into the study. Participants were aged between 45 – 70 years, and sedentary (did not 
meet the guidelines of 30 minutes of planned physical activity on most days of the week (Garber et 
al., 2011)). Exclusion criteria included any current cardiovascular disease or a history of cardiac 
events, and any uncontrolled medical condition such as hypertension, or cholesteraemia. Most 
(n=12) of the participants were on medications however these medications were stable and were 
unlikely to change over the course of the study thereby reducing the influence of a change in 
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medication or dosage on HRV. All participants signed a written informed consent prior to 
participation and this study was approved by the Lincoln University Human Ethics Committee. 
Table 19: Anthropometric data for HRV reliability study 
 Male (n=8) Female (n = 11) 
Age (y) 56.3  4.6  55.5  6.7 
Weight (kg) 76.9  11.5 73.2  14.7 
Height (cm) 170.8  6.8 165.4  6.6 
BMI 26.4  4 26.8  5.6 
Body fat (%) 24.5  6.6 35.3  10.7 
SBP (mmHg) 114.1  15.5 109.9  16.5 
DBP (mmHg) 77.1  12.9 69.1  69 
Medications n(%) 6 (75) 6 (54.5) 
Medications were for asthma (Ventolin (1M), Flixotide (2F) and Serevent (1F)); Cholesterol 
(Atorvastatin (1M, 1F) and Simvastatin (1M)). Other medications included Esterin cream (1F), 
Thyroxine (1F), Asprin (1M), Betaloc (1M), Cilazapril (1M), CPAP (1M), Ropinirole (restless legs, 1M), 
Radiaodine (1F), Prednisone (1M), Panadeine (1M), Codeine (1F), Paracetamol (1F) and Citalopram 
(1F). Medications exclude supplements (2 females, 1 male) and occasional medication (such as for 
migraines, 1 female). (M: male; F: female). Results are mean  standard deviation, unless otherwise 
specified. 
 
Participants were advised to avoid caffeine, alcohol or strenuous exercise for 24 hours, and any large 
meals 2 hours prior to the assessments. Participants were allowed to book their appointments at any 
time convenient to themselves, provided the follow-up appointment was at the same time of day, 1 
– 2 weeks following the first assessment. Upon arrival at the testing laboratory, the protocol was 
explained and the participants were familiarised with the equipment and the metronome-controlled 
breathing protocol. Height (Mechanical Stadiometer, Surgical & Medical Products, Mentone, 
Australia), weight and body composition (InBody230, Biospace Co. Ltd., Seoul, South Korea) were 
then measured.  
Participants were fitted with a Polar transmitter belt (Wearlink W.I.N.D, Polar Electro Oy, Kempele, 
Finland) applied with contact electrode gel (Signa Crème®, Electrode cream, Parker Laboratories Inc. 
Fairfield, New Jersey, USA) to optimise the contact between the electrodes of the transmitter belt 
and the skin. Heart rate data were recorded and stored on a Polar heart rate watch (RS800CX, Polar 
Electro Oy, Kempele, Finland) set to capture RR interval data with an accuracy of 1ms. A facemask 
(Hans Rudolph, Kansas City, MO, USA) was placed over the participant’s nose and mouth to monitor 
adherence to the controlled breathing interval. Respiration data were analysed using a breath-by-
breath gas analysis system (MetaMax® 3B; Cortex Biophysik, Leipzig, Germany). All equipment was 
calibrated as per manufacturer instruction. 
Participants rested in a supine position in a semi-dark room while resting heart rate and heart rate 
variability were recorded continuously for 16 minutes. For the first 10 minutes, participants breathed 
spontaneously. Participants were then instructed to breathe in time to a metronome set at 12 
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breaths per minute (inhale and exhale for 4 seconds each) for an additional 6 minutes. No attempt 
was made to control tidal volume, participants were simply asked to breathe as normally as possible.  
HR data were uploaded to the Polar ProTrainer5TM (Version 5.40.172) interface. All data were 
automatically filtered for ectopic beats using the “error correction” function in the Polar 
ProTrainer5TM software (using default settings: moderate filter power, minimum protection zone of 6 
beatmin-1, and ‘cut’ peaks in the data). Three different 5-minute segments of the HR trace were 
selected for HRV analysis (Figure 28Error! Reference source not found.). The 3 segments included: 
the most ‘stable’ segment (determined visually by the researcher), the last 5 minutes of the 10 
minute spontaneous breathing resting period, and 5 minutes of the controlled breathing period, 
starting 30 seconds after the start of the metronome.  
 
Figure 28: 5 minute selections for HRV analysis 
Three 5-minute heart rate segments were extracted from the 16 minute heart rate recording. During 
the first 10 minutes participants breathed spontaneously, followed by 6 minutes of breathing in time 
to a metronome at 12 breaths per minute. The Three 5 minute segments included the ‘most stable’ 5 
minutes during the 10 minute spontaneous interval, the ‘last 5 minutes’ of the 10 minute 
spontaneous breathing interval and 5 minutes starting 30 seconds in to the controlled breathing 
period. 
 
Time domain analysis included the root mean square of successive differences (rMSSD), and the 
natural logarithm of this measure (Ln rMSSD), as well as the standard deviation of the NN interval 
(SDNN). Spectral analyses included both high  (HF, 0.15 – 0.4 Hz) and low frequency (LF, 0.04 – 0.15 
Hz). 
Statistical analyses 
To determine the most appropriate means of detecting outliers, the initial data from Time 1 of the 
‘most stable’ dataset was scrutinised for outliers using three different methods. The first was a visual 
inspection of the data. In this method, the researcher plotted the data in a scatter graph, and 
selected data that appeared outside the normal range or grouping of the other observations (i.e. 
data that appeared to be outliers). The advantage of this method is that is a simple and convenient 
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method of identifying and removing erroneous data. However, the technique is highly subjective 
(and thus may vary from researcher to researcher), and it may be difficult to make a decision 
regarding some borderline data points. 
The second method used to inspect the data for outliers is based on the Standard deviation (SD) as 
estimated from the median value, namely the Median Absolute Deviation (MAD) (Wilcox, 2010). In 
this method the raw data are ranked, and the median is determined. Each observation is then 
subtracted from the median value. The absolute values of the differences between the observation 
and the median are then ranked again, and the median of the absolute differences is the MAD. The 
MAD divided by the constant 0.6745 is used to estimate the population standard deviation (SD) 
(Wilcox, 2010). (This constant is sometimes written as MAD X 1.4826 (Leys et al., 2013) which is 
simply 
 
      
)). Based on the work of  Miller (1991), Leys et al (2013) recommends using an outlier 
threshold of 2.5 X estimated population SD. This creates a moderate level of conservativeness which 
reduces the chances of excluding a true value (which is more likely when multiplying by 2), while 
reducing the risk of including erroneous data (which is more likely when multiplying by 3) (Leys et al., 
2013). Thus in our sample, an outlier was identified if: 
|   |     
   
      
 
Where   is the individual observation,  is the population’s median value,    is the absolute 
difference between the observation and the median,        is the constant applied to estimate the 
sample mean, and where data falling within 2.5 times the estimated sample mean are accepted. 
(Variations using 2 and 3 X estimated population median SD is also presented in Figure 29. Because 
this method is centred on the median rather than the mean, it is highly tolerant of outliers, and thus 
has a very high level of resistance before the method breaks down. That is, more than 50% of the 
data would have to be spurious before the median is affected. The limitation of the method is that 
using the median to estimate the population mean is not as accurate as the true mean and standard 
deviations of a normally distributed population (Wilcox, 2010). 
The third method is based on the standard deviations from the mean, and is one of the most 
frequently used means of reporting outliers (Leys et al., 2013). In this method, data that are outside a 
pre-defined number of standard deviations (usually 2 - 5) is excluded. As 2 times the SD appears to 
be the minimum number of standard deviations used to detect outliers, this is what we have used in 
our analysis.  While this method is quick and easy to apply, the biggest limitation is that the method 
itself is subject to the influence of the outlying data.  
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Figure 29: Outliers detected by visual analysis, MAD and SD methods (using the most consistent 5 
min dataset) 
To determine the closest, objective outlier detection, the HRV data were initially screened by 3 
different methods. A) Visual inspection of the data, outliers detected using this method are indicated 
by the symbol “a”. B) Median Absolute Deviation (MAD) which detects outliers based on their 
proximity to the median value (2, 2.5 or 3 times the standard deviation (SD) estimated by the 
median) “b” denotes outliers detected at all three strengths, “b# #” denotes observations detected as 
an outlier only at the 2.5 and 2 X SD range, and # denotes observations that were only detected at 
the 2 X SD range). C) Outliers detected if they were more than 2 SD from the sample mean. Outliers 
detected by this method are denoted as “c”. SDNN: Standard deviation of NN intervals; (Ln) rMSSD: 
(natural logarithm of the) Root mean square successive difference; HF: High frequency; LF: Low 
frequency; LF/HF: low frequency to high frequency ratio; HRV: heart rate variability   
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Results were filtered for outliers using the MAD method (which was the most sensitive to outlying 
data), and erroneous data were removed prior to further analysis. Each dataset, i.e. ‘most stable’, 
‘last 5 min’ and ‘controlled breathing’ were analysed individually and data excluded from one data 
set were not necessarily excluded from the other. If an rMSSD observation was highlighted as an 
outlier, the corresponding Ln rMSSD measurement was also removed. As the absolute HF and LF 
measurements were measured, as opposed to the normalised units, the exclusion of one did not 
exclude the other.  
Bland Altman plots were then constructed where by the difference between the Time 1 and Time 2 
measurements were plotted against the mean of the 2 measurements (Figure 30). This is a useful 
method for qualitatively displaying the agreement between the two time measurements, and to 
determine whether there is any relationship between mean measurement and the differences 
between the two time measurements (Bland and Altman, 2010).  
Reliability can be assessed in both a relative and an absolute manner. For example, relative reliability 
is used to assess how much a participant varies in their measurement relative to the rest of the 
participants and is usually measured using an intraclass correlation coefficient, (ICC) (Hopkins, 
2000b). On the other hand, absolute reliability informs us how much that individual’s measurement 
fluctuates in repeated measurements under consistent conditions. Absolute reliability is usually given 
as the standard error of measurement (SEM) or typical error (Hopkins, 2000b), or coefficient of 
variation (CV) (Atkinson and Nevill, 1998, Hopkins, 2000b)). 
However, because the typical error and ICC calculations and are based on the assumption that the 
difference in time 1 and time 2 recordings is random (homoscedastic) (Hopkins, 2000b, Atkinson and 
Nevill, 1998), and as the 95% limits are based on the assumption of normality (Bland and Altman, 
1999), the data needed to be tested for heteroscedasity and non-normality. The differences between 
the two measurements were assessed for normality using a spreadsheet designed by Guth (2006) to 
display a normal quantile plot. Normality was rejected if the correlation coefficient (r) between the Z 
score and the observation was less than the critical value of α = 0.05.  
To assess for heteroscedasity, the absolute difference in the measurements was plotted against their 
mean, and the correlation coefficient was calculated. If the heteroscedasticity correlation is close to 
zero, we can assume the data are homoscedastic (or normally distributed). However, even if a weak 
relationship exists, it is beneficial to log transform the data prior to analysis (Atkinson and Nevill, 
1998). 
Spreadsheets designed by (Hopkins, 2000b) were used to calculate the ICC (as a measure of relative 
reliability) and the typical error (as a measure of absolute reliability and given as a coefficient of 
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variation). As there are several ways of determining the ICC, each of which giving slightly different 
answers (Atkinson and Nevill, 1998), it is valuable to state how data were analysed. In this study, ICC 
was determined as follows: 
    
       
   
 
Where     = between-subject standard deviation, and the     is the within-subject standard 
deviation (Hopkins, 2000b). We have added slightly to categories defined by Pinna et al. (2007) used 
to interpret the strength of the ICC. Based on the recommendations of several authors, Pinna et al 
(2007) identified ICC > 0.8 as good - excellent, and ICC > 0.6 as substantial. Based on these categories, 
the following interpretation of the ICC will be used: ICC > 0.9: Excellent; ICC > 0.8: Good; ICC > 0.7 
substantial; ICC > 0.6: Reasonable; ICC <0.6: Poor  
Typical error was calculated as follows:  
             
√ 
 
All data were log transformed, so the coefficient of variance (CV) was derived from the typical error 
and was expressed as a percent. The 95% upper and lower confidence limits were also determined. 
The confidence limits represent the likely range of the systemic change (Hopkins, 2000b). To assess 
the magnitude, or appropriateness of the typical error, the normal fluctuations of the HRV 
parameters were determined in a subset of 10, randomly selected participants. In these participants, 
the 2 successive 5-minute intervals from the 10 minute spontaneous breathing period were selected 
and analysed using the Polar ProTrainer5TM software. The typical error of the log transformed data 
were determined. This gave the expected percentage fluctuation of the assumedly ‘steady state’ 
recording. If the typical error for the Time 1 and Time 2 recordings fell within the expected 
fluctuation of the first 5 minute and second 5 minute measurement, the typical error was considered 
‘ideal’, if it fell within 2X the expected fluctuation, it was considered ‘good’, and if it fell within 3X the 
expected fluctuation it was considered ‘acceptable’.  
The RR interval and heart rate are highly correlated, thus, heart rate was reported instead of the RR 
interval to increase the relevance of our findings to studies not using HRV parameters. While the RR 
data will not be presented explicitly in this paper, it can be extrapolated by using the relationship 
between frequency and period (     ) where   is period and   is frequency. (Period is used to 
solve for the RR interval).  
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As HR is measured in beatmin-1, the frequency is thus  
  
  
, and since the RR interval (in ms) = T (in 
seconds) *1000, this equation resolves to: 
            (
  
  
)       
As HR is rounded off to a whole number, results using this formula for HR < 100 beatmin-1 will be 
accurate up until the last digit (when the RR interval is expressed in ms). 
B.4 Results  
Outlier detection 
A comparison of the outcomes for the different methods of detection is displayed in Figure 29 and 
the outlier values are given in Table 20. The MAD method was the most sensitive, followed by visual 
inspection, and the 2XSD method. The MAD method was selected as the method for outlier 
detection for the remainder of the conditions. There were approximately twice as many outliers 
detected from the Time 1 dataset as there were from the Time 2 dataset. A considerable number of 
HF and LF data points were highlighted as outliers which left an insufficient number of high and low 
frequency pairs to compare the reliability of the LF: HF ratio. 
Normality and homoscedasity 
While most of the differences in Time 1 and Time 2 measurements followed normal distributions 
(HR, rMSSD, Ln rMSSD, HF in all conditions, and LF in controlled breathing only), most of the data 
were heteroscedastic (see Table 21), and required log transformation prior to analysis. Since it would 
be redundant to report the log transformed data twice, only the SDNN and rMSSD data are reported 
(omitting the Ln rMSSD). Heteroscedasity was also evident in the Bland Altman plots (Figure 30) 
where most of the HRV measures exhibit an increasing difference with an increasing mean 
measurement (see especially the spectral analyses). 
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Table 20: Outlier values 
 Most stable 
spontaneous  
Last 5 minutes 
spontaneous 
Controlled 
breathing 
SDNN (ms) 
Time 1 (n; outlier value(s)) 2(90.31; 116.42) 2 (138.62; 174.13) 0 
Time 2 (n; outlier value(s)) 0 0 0 
    
rMSSD (ms) 
Time 1 (n; outlier value(s)) 2 (54.71; 882) 3 (55.71; 68.03; 92.52)  1 (65.71) 
Time 2 (n; outlier value(s)) 1 (52.004) 0 0 
    
Ln rMSSD (ln ms) 
Time 1 (n; outlier value(s)) 1 (4.482) 1 (4.532) 0 
Time 2 (n; outlier value(s)) 0 0 0 
    
HF (Hz) 
Time 1 (n; outlier value(s)) 4 (524.595; 823.394; 
906.931; 2406.862) 
4 (857.694; 989.741; 
1258.293; 2229.292) 
3 (568.444; 656.465; 
1765.471) 
Time 2 (n; outlier value(s)) 1 (1083.314) 1 (864.234) 1 (1057.564) 
    
LF (Hz) 
Time 1 (n; outlier value(s)) 5 (1072.846; 1278.561; 
1319.97; 1398.968; 
5157.832) 
2 (5335.083; 
7143.112) 
4 (783.185; 877.287; 
1286.98; 1691.251) 
Time 2 (n; outlier value(s)) 3 (572.47, 574.376, 
739.955, 1669.798) 
1 (1669.798) 2 (553.68; 578.137) 
    
Superscript numbers (1 –8) indicate data from one participant. In the ‘most stable’ dataset, it is 
possible that the ‘most stable’ data were indeed the last five minutes, which is why, for example, 
there are identical LF outliers in both the ‘last 5 min’ and ‘most stable’ data sets. For the data 
analysis, if data were considered an outlier both the participant’s Time 1 and Time 2 observations 
were removed. This table ignores this rule and examined Time 1 and Time 2 datasets independently. 
There were no outliers detected for heart rate. Time 1: measurement taken during the first 
assessment; Time 2: measurement taken during the second measurement at the same time of day 
but 1 - 2 weeks following the first measurement; SDNN: Standard deviation of NN interval; (Ln) 
rMSSD: (natural logarithm) root mean square successive difference; HF: high frequency; LF: low 
frequency  
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Table 21: Heteroscedasity correlation coefficient 
 HR SDNN rMSSD Ln rMSSD LF HF 
 
Most stable -0.13 0.40 0.39 0.12 0.81 0.84 
Last 5 min -0.25 0.50 0.24 -0.13 0.53 0.56 
Controlled 
breathing 
0.43 0.44 0.30 -0.36 0.60 0.49 
Heteroscedasity was assessed by plotting the (Time 1 – Time 2) difference against the mean of the 
two measurements and then determining the correlation coefficient of the relationship between the 
two. The closer the correlation is to zero, the more homoscedastic (random) the change in the 
variables is. As you can see from the above table, all of the HRV measurements has at least a weak (in 
the case of Ln rMSSD and HR) and in some cases a strong (HF in the most stable condition) 
correlation, which indicates heteroscedasity, or some relationship between the magnitude of the 
difference between the Time 1 and Time 2 measurement and the mean. HR: heart rate; SDNN: 
Standard deviation of NN interval; (Ln) rMSSD: (natural logarithm) root mean square successive 
difference; HF: high frequency; LF: low frequency 
 
Relative and absolute reliability  
The results from the ICC and the typical error (expressed in percent as CV) are presented in Table 22. 
The typical error in HRV parameters from the two successive 5-minute analyses are as follows: HR: 
1.4%; SDNN 20.8%; rMSSD 10.9%; LF: 33.6%; HF: 27.2%. Thus, if the typical error was less than or 
equal to the above mentioned typical value for the respective measurement, the reliability was 
considered ‘ideal’. The typical error was considered ‘reasonable’ if it was between “ideal” and 2 X 
this value, and “acceptable” if the typical error was within 2 – 3 X this value. Typical errors greater 
than 3X the expected fluctuation during one measurement were considered “poor”.  
All participants breathed in time with the metronome during the controlled breathing segment. That 
is, participants maintained an average breathing rate of 12  0.5 breaths per minute, with an 
individual standard deviation of less than 1 breath per minute). Breathing frequency data are as 
follows: Time 1 (12.11  0.12, mean  SD), Time 2 (12.14  0.19). 
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Table 22: A table comparing the relative and absolute reliability of the various HRV parameters 
 Most stable 
spontaneous  
Last 5 minutes 
spontaneous 
Controlled 
breathing 
HR (beatmin-1) 
Time 1 (mean  SD) 64.3  8.6 64.9  8.3  65.2  7.2 
Time 2 ( mean  SD) 65.6  7.7 65.1  7.1  65.3  7.0  
n 19 19 19 
ICC (95% CL) 0.76 (0.48 – 0.9) # 0.82 (0.58 – 0.92)* 0.81 (0.58 – 0.92)* 
Typical error as CV (95% CL) 6.7 (5.0 – 10.1) 5.6 (4.2 – 8.3) 5.0 (3.8 – 7.5)  
SDNN (ms) 
Time 1 (mean  SD) 32.8  13.6 41.0  18.6 35.0  16.5 
Time 2 ( mean  SD) 34.0  12.1 37.3  11 31.8  8.8 
n 17 17 19 
ICC (95% CL) 0.57 (0.13 – 0.82) 0.48 (0.01 – 0.77) 0.49 (0.06 – 0.77) 
Typical error as CV (95% CL) 28.4 (20.4 – 46.3) $ 32.3 (23.2 – 53.2) $ 33 (24.0 – 52.4) $ 
rMSSD (ms) 
Time 1 (mean  SD) 18.7  8.1 21.3  9.8 20.2  9.1 
Time 2 ( mean  SD) 20.5  9.6 23.7  11.6 22.4  8.8 
n 16 16 18 
ICC (95% CL) 0.78 (0.48 – 0.92) # 0.82 (0.56 – 0.93)* 0.73 (0.41 – 0.89) # 
Typical error as CV (95% CL) 24.8 (17.8 – 40.8) ^  24.4 (17.5 – 40.2) ^  26.5 (19.3 – 42.3) ^ 
HF (Hz) 
Time 1 (mean  SD) 140.2  98.4 181.5  133  192.5  147.0 
Time 2 ( mean  SD) 190.7  167.4 245.3  202.6 272.7  196.9 
n 15 15 16 
ICC (95% confidence limit) 0.74 (0.39 -  0.91) # 0.76 (0.43 – 0.91) # 0.64 (0.23 – 0.86) ‡ 
Typical error as CV (95% CL) 61 (41.7 – 111.9) ^ 63.5 (43.3 – 117.1) 
^ 
65.0 (44.7 – 117.0) 
^ LF (Hz) 
Time 1 (mean  SD) 199.3  159.4 434  358.4 175.8  148.0 
Time 2 ( mean  SD) 217.3  125.1 349.2  222.8 165.8  106.8 
n 13 16 14 
ICC (95% confidence limit) 0.21 (-0.36 – 0.67) 0.42 (-0.08 – 0.75) 0.64 (0.16 – 0.87) ‡ 
Typical error as CV (95% CL) 68.1 (45.1 – 135.8) ^ 84.5 (57.2 – 158) ^ 56.4 (37.8 – 109.3) 
$ Relative absolute reliability was categorised as follows: *Good relative reliability (ICC >0.8); 
#Substantial relative reliability (ICC > 0.7); ‡ reasonable relative reliability (ICC > 0.6). Absolute 
reliability was categorised relative to the naturally occurring typical error as measured from 
consecutive 5 minute HR recordings. Absolute reliability is categorised as follows:  $good absolute 
reliability (within 2 X naturally occurring typical error); and ^acceptable absolute reliability (within 3 X 
naturally occurring typical error). HR: heart rate measured in beats per minute; Time 1: 
measurement taken during the first assessment;  Time 2: measurement taken during the second 
measurement at the same time of day but 1 - 2 weeks following the first measurement; SD: standard 
deviation; ICC: intraclass correlation coefficient; CV: coefficient of variation; CL: confidence limit;  
SDNN: Standard deviation of NN interval; (Ln) rMSSD: (natural logarithm) root mean square 
successive difference; HF: high frequency; LF: low frequency  
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Figure 30: Bland Altman plots of the HRV measurements across the different conditions 
The Bland Altman plot is used to detect any relationship between the difference in the 2 time 
measurements and their mean. The HR and Ln rMSSD are homoscedastic, while SDNN, LF and HF 
(particularly under the ‘most stable’ condition are heteroscedastic). Time 1: measurement taken 
during the first assessment; Time 2: measurement taken during the second measurement at the 
same time of day but 1 - 2 weeks following the first measurement; SD: standard deviation; SDNN: 
Standard deviation of NN interval; (Ln) rMSSD: (natural logarithm) root mean square successive 
difference; HF: high frequency; LF: low frequency. 
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B.5 Discussion 
We expected that selecting the 'most stable’ 5 minute interval of spontaneous breathing HR would 
improve the relative reliability when compared to the fixed ‘last 5 minutes’, and display results 
similar to those of the controlled breathing period. Therefore, we found it surprising that the ‘most 
stable’ 5 minute segment was very similar, but slightly less relatively reliable than the ‘last 5 minutes’ 
in HR, rMSSD, HF and LF, with the ‘most stable’ 5 minutes only more reliable in SDNN (however, LF 
and SDNN both had poor relative reliability). Interestingly, the last 5 minutes was also more relatively 
reliable than the controlled breathing period in the HR, rMSSD, and HF measurements. Controlled 
breathing improved LF (reasonable relative reliability) and SDNN (poor relative reliability). Both the 
LF and SDNN are markers that are sensitive to both sympathetic and parasympathetic contributions. 
In contrast, HF and rMSSD specifically reflect parasympathetic innervation (Task Force of The 
European Society of Cardiology and The North American Society of Pacing and Electrophysiology, 
1996). As the vagal response is far quicker than the sympathetic response, the poor reliability in 
SDNN and LF may be a function of the relatively short time interval. 
To assess the absolute reliability, we compared the typical error to the naturally occurring typical 
error associated with the measurement, rather than using pre-defined arbitrary criteria. For example, 
if the measure under investigation is a highly dynamic measurement, such as the LF and HF 
measures, it would be reasonable to expect a wide ‘normal’ range of resting measures, and a higher 
typical error. On the other hand, if a measurement is typically a very stable measurement, such as HR 
or the RR interval, even a small deviation from the normal range could be considered a large or 
meaningful change. To this end, the typical error was assessed for two consecutive 5 minute 
measurements during one uninterrupted 10 minute resting period. By basing the acceptability of the 
typical error from Time 1 to Time 2 on the ‘normal steady state fluctuations’ of the consecutive 5 
minute intervals, we were able to get relative indices of acceptability for the absolute reliability of 
the HRV parameters. While this improves our ability to gauge the repeatability of the measurements, 
the researcher must be aware that changes derived from inherently dynamic variables in the 
assessment of intervention-based change must be interpreted with caution.  
By using the above described absolute reliability assessment criteria, HR was not considered 
absolutely reliable under any of the conditions even though it had the lowest typical error. The SDNN 
component was the most absolutely reliable time domain component, which was surprising when 
considering its low relative reliability. This dichotomy is probably due to the high naturally occurring 
typical error associated with the SDNN, which likely improved the repeatability description but also 
resulted in reduced relative reliability.  
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Controlled breathing improved the typical error of the LF to within 2X the steady state typical error 
which indicates good reliability. All of the other spectral domain measures exhibited an acceptable 
(3X the steady state) typical error. However, as the typical errors for the spectral domain analyses 
were large, even though the result is reliable, the researcher should interpret changes in this value 
with caution. Unlike the relative reliability, selecting the ‘most stable’ 5 minutes and using controlled 
breathing improved the absolute reliability.  For example, the typical error was lowest for HR and LF 
under controlled breathing, and the typical error for SDNN and HF were lowest when the ‘most 
stable’ data were selected.  
While controlled breathing improved reliability (both absolute and relative) in the low frequency 
measurements, it did not exhibit a substantially different response in other measurements. These 
findings are similar to those of Penttilä et al (2001) who demonstrated no change in rMSSD with 
controlled breathing but did report alterations in the spectral domain (although these researchers 
used a breathing frequency of 15 breaths per minute, rather than the 12 breaths per minute in our 
study). However, when compared to the improved relative reliability under the ‘last 5 minutes’, 
these differences in absolute reliability, do not seem big enough to warrant the use of either 
controlled breathing, or selecting the most stable 5 minute period instead of using the pre-defined 
last 5 minutes. Thus, regarding the segments of data to be analysed from the overall HR trace, our 
data support the use of the last 5 minutes of a 10 minute resting period for the analysis of HRV, 
particularly for HR, (Ln) rMSSD, and HF. The LF data were most reliable under controlled breathing, 
and SDNN was most reliable when the most stable 5 minute segment was selected, however in both 
these measurements the reliability was poor. 
While using the average rMSSD taken over one week as suggested by Plews et al. (2013) may 
considerably improve reliability, a lack of time and resources may not make this possible in large 
studies. However, it would be worth investigating whether the average of 2 or 3 consecutive 5 
minute HRV analyses extracted from one 15 minute HR recording would improve relative and 
absolute reliability in test – retest protocols. For example, Schroeder et al (2004) demonstrated 
substantially improved reliability in ultra-short HR recordings when the average of several ultra-short 
HRV recordings were used, when compared to poor reliability when just 1 measurement was taken.  
Our data confirms the findings of Pinna et al. (2007)  who reported large typical error measurements, 
particularly in the spectral domain. However, our study reports a much lower repeatability than 
Pinna et al (2007) which is likely due to both the population sampled (younger, medication-free 
individuals compared to sedentary, unhealthy older adults), and measurement technique (ECG and 
manual editing versus polar heart rate monitor and automated error correction). 
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The MAD method of outlier detection appeared to be the most sensitive, and 2 SD of the mean did 
not identify clearly outlying data. While some data points rejected as outliers by MAD were not 
identified as outliers by visual inspection, as soon as the outlying data were removed and the axes 
readjusted, the initially accepted points were quite clearly different from the rest of the data. This 
was particularly evident in the spectral analyses. For example, in the LF analysis (using the ‘most 
stable 5 min’ dataset, Figure 29) one outlying data point extended the axes to up to 6000  ms2 while 
most of the data were less than 200 ms2. Thus when the extreme observation was removed, the 
initially accepted data points at 1000 ms2 were considered likely erroneous. We recommend, 
however, that when data are excluded, a list of the identified outliers is made available. 
Limitations 
The test re-test protocol did not include a full protocol before the two measurements were taken, 
and so a substantial proportion of the variability in the 2 measurements could be due to 
familiarization and systematic bias associated with mental stress (Bernardi et al., 2000) rather than 
by random error association with true equipment and biological variation (Atkinson and Nevill, 1998, 
Hopkins, 2000b).  
B.6 Recommendations: 
The number of outliers detected was approximately halved in the Time 2 dataset. This is possibly due 
to the participant feeling more comfortable with the equipment and procedures and was more 
relaxed during the measurement. This suggests that having a full practice assessment prior to the 
baseline measurements substantially improves the quality of recording in this population, and should 
be included in any test-retest protocol. 
Regarding outlier detection, the Median Absolute Deviation (MAD) may provide a reasonable and 
objective method of identifying outliers. However, we would recommend using this method in 
association with visual inspection to determine whether to use 2, 2.5 or 3 X 
   
      
. For example, 
where a relatively small change is expected (such as in changes in resting values), a coefficient of 2 
might improve reliability, however, when larger changes are possible, a more conservative threshold 
for exclusion might be necessary and a coefficient of 3 might be more appropriate.  
The results of this study recommend the use of rMSSD (and/or the natural logarithm of the rMSSD 
signal) as the most reliable measure of HRV in short term recordings in a sedentary, middle-aged 
population. High Frequency (absolute units) in the spectral domain can be also be used, but the 
researchers should be aware that although the relative reliability is reasonable (0.76 (0.43 – 0.91)), 
the absolute reliability is unclear (65% (43.3 – 117.1), Typical error as CV, 95% confidence interval). 
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Measurements sensitive to both parasympathetic and sympathetic innervation such as SDNN and LF 
should be avoided in this population in short term recordings. 
The findings of this study also recommend the use of a fixed, rather than selected 5 minute period 
for the analysis of HRV. 
B.7 Conclusion 
While the HRV indices in our sedentary, older population with various medical complaints was 
somewhat less reliable than the reliability reported in younger, healthy, active cohorts, the absolute 
and relative reliability for rMSSD, Ln rMSSD and HF was still acceptable. We recommend the use of 
rMSSD or Ln rMSSD in the assessment of HRV in this population. Researchers should be aware that 
the typical error associated with all HRV measurements is reasonably high, particularly regarding 
spectral measures. As such, interpretation of intervention-related changes in HRV using HF and LF 
measurements should be assessed with caution. The median absolute deviation (MAD) method of 
outlier detection is a robust, sensitive and objective means of outlier identification. 
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Appendix C 
Raw data for Study 2: The minimum dosage of intermittent hypoxic exposure per week for health 
improvement in sedentary, middle-aged individuals. 
Table 23: Raw baseline and post-intervention data for Study 2 
 C IHE3  IHE5  
 Baseline Post Baseline Post Baseline Post 
Anthropometric data 
Age (y) 54.8  5.4  57.0  5.9  55.7  5.0  
M/F 3M6F  4M6F  5M5F  
Height (cm) 168.7  3.5  171.4  10.2  163.7  6.8  
Weight (kg) 79.5  11.5 79.2  11.4 81.6  20.2 80.9  19.9 76.2  13.7 76.4  13.8 
BMI 27.9  4.1 27.8  4.0 27.6  5.2 27.4  5.2 28.5  5.6 28.7  5.7 
Body fat (%) 34.3  7.0 34.2  7.1 31.8  11.4 30.4  12.4 32.9  10.4 32.5  11.3 
Muscle mass (kg) 28.8  3.9 28.9  4.2 30.7  8.5 29.7  8.7 28.6  5.6 28.2  4.7 
HRV: Spontaneous breathing 
RR interval (ms) 928 ± 114 927 ± 123 966 ± 61 942 ± 74  986 ± 67 984 ± 76  
rMSSD (ms) 23.3 ± 10.7 20.9 ± 11.6  26.2 ± 14.8  23.9 ± 10.9 26.4 ± 7.3  29.6 ± 10.0  
SDNN (ms) 40.4  11.2 34.8  13.0 32.7  9.8 30.6  9.1 37.2  9.5 35.2  13.1 
HF (ms
2
) 277.5  247.0 155.0  194.0 237.5  220.6 228.3  177.9 233.8  107.7 296.5  135.8 
LF (ms
2
) 258.3  105.7 143.1  107.2 278.2  257.7  228.1  166.6 297.7  209.4 181.3  68.3 
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 C IHE3  IHE5  
 Baseline Post Baseline Post Baseline Post 
HRV: Controlled breathing 
RR interval (ms) 938 ± 123 913 ± 125 970 ± 43 967 ± 36 970 ± 63 992 ± 75 
rMSSD (ms) 21.9 ± 9.9 18.1 ± 10.2  23.2 ± 11.1 23.6 ± 8.1  26.4 ± 5.1 31.3 ± 10.1 
SDNN (ms) 32.2  7.3 30.1  6.2 27.5  9.8 31.4  8.5 35.8  8.9 39.0  12.4 
HF (ms
2
) 281.9  250.3 223.5  238.3 313.1  329.6  299.0  260.1 390.8  154.4 443.9  235.6 
LF (ms
2
) 144.9  24.1 147.1  174.1 119.2  89.17  226.7  145.8 212.4  147.8 246.2  126.6 
Resting BP 
SBP (mmHg) 110.4 ± 17.2 110.6 ± 15.8 122.7  18.4 113.11  15.5 114.2  23.1 109.00  23.9 
Blood Samples 
Hb (g/L) 139.3  14.9 138.4  13.8 137.6  8.3 138.1  10.3 142.2  13.2 144.7  11.4 
Hs-CRP (mg/L) 1.6 ± 2.6 1.6 ± 2.1 1.5 ± 1.5 1.6 ± 1.2 2.1 ± 2.3 2.6 ± 3.0
 
Hs-CRP (quintiles) 4 4 4 4 4 4 
Submaximal exercise 
HRsubmax (beatmin
-1
) 105.5 ± 5.6 106.9 ± 7.7 108.1 ± 7.3 108.1 ± 10.0 106.8 ± 7.5 107.5 ± 9.3 
V
˙
O2submax (mlmin
-1
kg
-1
)  15.5 ± 2.3 14.7 ± 14.7 15.6 ± 3.0 15.5 ± 3.1 17.1 ± 3.9 15.9 ± 3.2 
SBPsubmax (mmHg) 148.8 ± 23.2 141.6 ± 14.0 157.4 ± 24.1 151.1 ± 15.7 140.6 ± 23.7 134.9 ± 26.5 
Maximal exercise 
V
˙
O2peak (mlmin
-1
kg
-1
) 26.8 ± 3.3 24.8 ± 3.9 23.7 ± 6.0 24.5 ± 5.7 27.2 ±7.5 25.3 ± 7.5 
Timeex (min) 5.4 ± 1.2 5.0 ± 2.3 5.0 ± 1.8 5.2 ± 2.3
†
 5.1 ± 1.4 5.8 ± 1.7 
Resmax (watts) 146.4 ± 26.7 142.9 ± 40.1 142.5 ± 29.0 142.5 ± 33.4 136.1 ± 28.3 147.22 ± 29.2 
Values are mean ± SD; C: Control group; IHE3: Group attending 2 – 3 IHE sessions / week; IHE5: Group attending 5 IHE sessions/week; Baseline: measurement taken at baseline; 
Post: measurement taken within 1 week of the last IHE session; M: male; F: female; BMI: Body mass index; RR interval: average time interval between R to R peaks; SDNN: 
standard deviation of normal to normal heart beat intervals; HF: high frequency; LF: low frequency; SBP: Systolic blood pressure; Hb: haemoglobin; Hs-CRP: highly sensitive C-
Reactive protein;  HRsubmax: Average heart rate taken over the last 5 minute of the steady state exercise period; V
˙
O2submax: oxygen uptake during submaximal exercise; SBPsubmax 
systolic blood over the steady state submaximal exercise period; V
˙
O2peak: oxygen uptake over the last 30 seconds of peak physical exertion; Timeex: Time from the end of 
submaximal steady state exercise to exhaustion; Resmax: maximum sustained (for at least 30 sec) resistance.  
 190 
Appendix D 
Raw data for Study 3: Does IHE enhance the cardioprotective effect of exercise in a sedentary population? 
Table 24: Raw baseline, post, 4-wk and 8-wk data for Study 3 
 
 IHE + Ex Ex  
 Baseline Post 4-wk 8-wk Baseline Post 4-wk 8-wk 
Anthropometric data 
Age (y) 56.7  6.4    56.4  6.5    
M/F 6M10F    5M13F    
Height (cm) 168.0  8.8    167.3  8.4    
Weight (kg) 78.6  12.4 78.5  12.1 79.5  11.8 79.7  11.4 81.2  15.9 81.0  16.1 79.3  15.5 80.4  15.4 
Body fat (%) 32.3  8.9 31.3  8.7 31.2  8.3 31.9  8.8 35.9  8.0 35.2  8.4 34.7  8.6 34.2  9.4 
Body fat (kg) 25.3  8.5 24.5  8.3 24.7  25.3 25.3  8.1 29.5  5 29.0  11.6 27.8  10.9 28.0  11.7 
Muscle mass (kg) 29.8  7.1 30.3  6.9 30.7  6.8 30.5  7.0 28.8  6.0 28.9  6.0 28.6  6.3 29.2  6.0 
Arterial health 
PWV (ms) 7.91  1.0 7.5  1.4 7.3  0.8 7.2  1.3 7.8  1.3 7.3  1.3 7.4  1.1 7.8  7.7 
PWA  20.7  8.7 17.2  6.6 21.3  7.5 23.2  8.0 27.7  7.1 26.0  5.3 27.3  5.9 26.5  6.7 
Heart rate variability 
RR interval (ms) 903.6  106.1 993.2  148.3 943.5  128.9 1019.2  137.5 981.1  109.3 1032.9  159.1 1033.4  129.6 1034.0  157.0 
rMSSD (ms) 21.7  9.4 32.2  13.7 30.6  15.7 31.0  16.3 28.9  9.8 33.4  13.3 32.5  16.9 33.6  15.3 
SDNN (ms) 37.3  10.9 43.7  14.2 40.3  14.1 44.0  11.5 37.3  11.8 43.2  14.5 45.1  17.0 45.4  16.5 
HF (ms
2
) 240.7  208.2 462.4  342.6 311.0  248.8 430.8  369.7 269.3  173.3 392.4  213.9 258.0  141.1 374.0  241.1 
LF (ms
2
) 342.7  229.6 493.2  316.6 531.8  294.0 418.2  218.8 311.1  213.8 490.7  273.8 407.0  273.5 454.1  265.6 
LF:HF ratio 103.0  50.5  79.4  39.2 156.6  108.8 130.8  74.1 105.9  58.9 151.2  69.7 158.4  72.4 130.1  80.7 
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 IHE + Ex Ex  
 Baseline Post 4-wk 8-wk Baseline Post 4-wk 8-wk 
Cardiovascular fitness 
V
˙
O2peak (mlmin
-1
kg
-1
)   29.5  6.8 29.8  7.8 30.1  5.7 29.3  8.0 26.9  5.7 26.9  6.4  27.4  6.4 25.5  6.8 
Time to exhaustion (min) 14.0  1.9 16.0  1.9 15.7  1.4 16.7  2.3 14.0  2.3 15.5  2.5 16.5  1.8 16.1  2.2 
Systolic blood pressure 
SBP (mmHg) 125.3  11.9 121.9  13.4 120.8  13.9 122.7  12.0 124.7  17.6 125.4  18.1 121.0  15.8 125.0  15.5 
Blood Samples 
Total cholesterol 5.8  1.2 5.8  1.3  5.5  1.0 5.9  0.7 5.6  0.9  5.5  1.1 
HDL 1.3  0.3 1.4  0.3  1.5  0.4 1.3  0.2 1.3  0.2  1.3  0.3 
TC: HDL  ratio 4.6  1.4 4.5  1.5  3.9  1.2 4.7  1.4 4.6  1.1  4.4  1.2 
Cardiovascular risk 
Framingham risk  9.6  7.2 9.6  7.5  9.9  7.9 10.6  7.9 10.0  7.1  10.0  6.9 
Values are mean ± SD; IHE + Ex: Group receiving intermittent hypoxic exposure treatments in addition to 3 exercise sessions per week; Ex: Group receiving 3 exercise sessions per 
week. Baseline, Post, 4-wk and 8-wk: Measurements taken immediately before, immediately after and then 4 and 8 weeks following the 10-week intervention respectively; M/F: 
Male and female participants included in the study; PWV: Pulse wave velocity; PWA: Pulse wave analysis; RR interval: Average time interval between R peaks; rMSSD: Root mean 
square of successive differences in the heart’s beat-to-beat intervals; SDNN: Standard deviation of all normal to normal R intervals; HF: High frequency; LF: Low frequency;  
V
˙
O2peak:oxygen uptake during the last 30 seconds of maximal exertion; SBP: Systolic blood pressure; HDL: High density lipoprotein; TC:HDL ratio: The ratio between total 
cholesterol to high density lipoprotein; Framingham risk assessment protocol estimating an individual’s 10 year risk of cardiovascular disease.  
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Appendix E 
New Zealand Guidelines Group: 5-year risk assessment chart 
 
 
 
  
Figure 31: New Zealand 5 Year Risk Assessment Chart 
Source: New Zealand 
Guidelines Group: New 
Zealand Cardiovascular 
Guidelines Handbook: A 
summary resource for 
primary care 
practitioners. 2nd ed. 
Wellington: New 
Zealand Guidelines 
Group; 2009. 
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Appendix F 
Explaining the code used to assess qualitative outcomes in clinical 
analyses using spreadsheets designed by Will Hopkins 
IF(benefit to harm ratio>66,value if true: IF(smallest important harmful change > 0, value if true: use 
the qualitative outcome from the substantially negative block, value if false: use the qualitative 
outcome from the substantially positive block) and add the descriptor" beneficial", value if false: 
IF(smallest important harmful change>0, value if true: IF(percent chance for a substantially negative 
outcome >minimum chance of benefit (25%) , value if true: IF(percent chance for a substantively 
positive outcome <Maximum chance of harm (50%), value if true: insert the qualitative outcome for 
the substantially negative (beneficial) response and add the descriptor" beneficial", value if false: 
insert "unclear; get more data"), value if false: IF(percent chance for substantially positive 
outcome>25, value if true: insert the qualitative outcome from the substantially positive block and 
add the descriptor " harmful", value if false: use the qualitative outcome from the trivial block and 
add the descriptor " trivial")), value if false: IF(the percentage for a substantially positive 
outcome>minimum chance of benefit (25%), value if true: IF(the percent chance for a substantially 
negative outcome <maximum risk of harm (50%), value if true: use the qualitative outcome from the 
substantially positive block and add the descriptor " beneficial", value if false: "unclear; get more 
data"), value if false: IF(the percent chance for a substantially negative outcome >25, value if true: 
insert the qualitative outcome from the substantially negative block and include the descriptor " 
harmful", value if false: use the qualitative outcome from the trivial block and add the descriptor “ 
trivial")))) 
Basically, what this means is: 
IF the odds ratio is greater than 66: 
Use the substantially beneficial qualitative outcome and add the word “beneficial” 
IF the odds ratio is less than 66: 
And the chances of benefit are greater than 25%: 
AND the percent for a substantially harmful outcome is LESS than the maximum risk of harm of 50%, 
then use the qualitative outcome from the substantially beneficial block and add the word 
“beneficial" 
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BUT the percent for substantially harmful outcome is MORE than the maximum risk of harm of 50% 
display the words "unclear; get more data" 
And if the chances of benefit are less than 25%: 
AND the value for a substantially harmful outcome is greater than 25, use the qualitative outcome 
from the substantially harmful block and add the word “harmful". 
BUT the value for a substantially harmful outcome is less than 25, use the trivial block’s qualitative 
outcome and add the word “trivial" 
(The rest of the formula is repeated for a smallest important harmful change of <0) 
For example, after an intervention, the differences in total cholesterol were 86 / 2 / 12 for percent 
chances of increase / trivial/ decrease at Post – intervention, and then 93 / 1 / 6 at the 8-wk follow 
up.  
Because of the wide overlap in beneficial and harmful outcomes, a mechanistic outcome would 
return a qualitative outcome of “unclear”. On the other hand, the clinical assessment considers the 
extent of benefit (it must be at least 25% beneficial) and harm (the maximum risk of harm should be 
less than 50%) and therefore a clear statement can be made. In both these situations, the potential 
for benefit is less than 25% and the risk of harm is greater than 50% and therefore the qualitative 
outcome is “likely harmful” for both time points. 
The qualitative outcome is based on the following scale:  
< 0.5% = most unlikely 
0.5 – 5% = very unlikely 
5 – 25% = unlikely 
25 – 75% = possibly 
75 – 95% = likely 
95 – 99.5% = very likely 
 > 99.5% = most likely 
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Appendix G 
Further publications arising from this thesis 
This paper has been submitted to the Medicine and Science in Sports and Exercise Journal and is 
currently under review. 
Title: Does arterial health affect V˙ O2peak and muscle oxygenation in a sedentary cohort? 
Authors: Lizamore, Catherine Anne1, Stoner, Lee2, Lucas, Samuel John Edwin. 3, 4, Lucero, Adam2, 
Hamlin, Michael John1 
Affiliations: 1Lincoln University, Christchurch, New Zealand; 2Massey University, Wellington New 
Zealand; 3University of Otago, Dunedin, New Zealand; 4University of Birmingham, Birmingham, 
United Kingdom 
Corresponding Author: Dr. Mike Hamlin 
Running title: Relationship between AIx, V˙ O2peak and TOI 
Disclosure of funding: The lead researcher receives a Doctoral Scholarship from the National Heart 
Foundation of New Zealand  
Conflicts of interest: None. Results of this study do not constitute endorsement by ACSM.  
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G.1 ABSTRACT 
Purpose: An association between peak oxygen consumption ( O2peak) and arterial health has been 
demonstrated, however little is known about how arterial health influences muscular oxygenation 
during exercise. The purpose of this study therefore, was to gain insight into the relationships 
between arterial health, O2peak and muscle oxygenation in a sedentary population. Methods: Radial 
augmentation index (AIx; via Pulse Wave Analysis) of 21 sedentary, middle-aged participants (15 
females, 6 males; age: 54.7  5.4 years; BMI: 29.0  4.7, mean  SD) was assessed, and on another 
day (<7 days) participants completed a Modified Bruce Protocol (MBP). Using near infra-red 
spectroscopy, total oxygenation index (TOI) of the left flexor carpi ulnaris and the left vastus lateralis 
was monitored throughout the MBP. Individual and average (arm + leg) percentage decrease in TOI 
between stage 1 of the MBP and at maximal exertion (TOIdiff) was calculated. Changes between 
dependent variables were correlated using Pearson product-moment correlations; interpreted as: 
r>0.5: strong, 0.5>r>0.3: Moderate; r<0.3: weak. Results: We observed a moderate negative 
correlation between AIx and O2peak (r = -0.34, -0.63 to -0.03; Pearson correlation, 90% Confidence 
Limits), and a strong negative correlation between AIx and average TOIdiff (r = -0.58, -0.78 to - 0.27). 
The O2peak and average TOIdiff were strongly correlated (r= 0.55, 0.23 to 0.77). Individual arm and leg 
correlations were similar to the combined average, but slightly smaller. Conclusion: Arterial health 
appears to be an important determinant of muscle oxygenation during exercise. In turn, the muscle 
oxygenation during exercise is strongly related to the O2peak.  Developing training modalities to 
prioritise arterial health outcomes may be a useful way of improving O2peak in this population. 
Keywords  
Near infrared spectroscopy, total oxygenation index, augmentation index, exercise capacity  
V˙  
V˙  
V˙  
V˙  
V˙  
V˙  
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G.2 Introduction 
The process of aging is usually associated with various decrements in cardiovascular health (Lakatta, 
2002) and physical performance (Rogers et al., 1990). For example, aging is associated with increased 
arterial and ventricular stiffening (Redfield et al., 2005) and a steady decline in peak oxygen uptake 
(V˙ O2peak) (Astrand et al., 1973). However, the deleterious effects of aging on V
˙ O2peak and arterial 
stiffness are reduced with healthy lifestyle habits such as regular physical activity (Rogers et al., 1990, 
Tanaka et al., 1998, Lee et al., 1999). This associated decline in V˙ O2peak and increased arterial stiffness 
with age and concurrent improvement with healthy lifestyle habits have led to several investigations 
aimed at determining whether arterial stiffness and V˙ O2peak are related. For example, it is possible 
that the decline in arterial health is linked to the decline in V˙ O2peak as an impaired vascular system 
would limit the capacity to deliver oxygenated blood to the working muscle. To assess the arterial 
stiffness, researchers have used the augmentation index (AIx), which provides a systemic assessment 
of arterial health based on the augmentation of the pressure wave generated during systole (Stoner 
et al., 2012). Indeed, researchers have noted an inverse relationship between V˙ O2peak and arterial 
stiffness (Vaitkevicius et al., 1993, Binder et al., 2006). For example, Binder et al. (2006) noted a 
decrease of 1 mL/min/kg for every 10% increase in arterial stiffness (2006).  
However, in addition to an efficient oxygen delivery system, enhanced V˙ O2peak also requires adequate 
pulmonary, circulatory, tissue, and mitochondrial diffusion of oxygen (2003). While the previously 
reported inverse relationship between arterial stiffness and V˙ O2peak provides some insight into the 
relative importance of the oxygen delivery network to overall V˙ O2peak, the relative importance of 
oxygen diffusion to V˙ O2peak is unknown in this sedentary, middle-aged population. Furthermore, it is 
unknown whether the health of the blood vessels is related to oxygen uptake in muscle tissue.  
Therefore, the purpose of this study was to determine the relationship between muscular oxygen 
uptake, arterial stiffness and V˙ O2peak. We hypothesise that an increase in oxygen uptake from the 
capillaries to the muscle will be strongly associated with an increase in V˙ O2peak. In addition, we 
hypothesise that improved arterial health will be associated with greater oxygen uptake at the 
muscle. The findings of this study will provide insight into currently unexplored downstream effects 
of changes in arterial health associated with a sedentary lifestyle. 
G.3 METHODS 
Participants.  
Twenty-one middle-aged participants who were not actively engaged in planned physical activity 
were recruited from the local community (see Table 25 for anthropometric data). Exclusion criteria 
included the presence of any overt or uncontrolled cardiovascular disease, smoking or uncontrolled 
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medical condition such as undiagnosed hypertension. All participants were screened by a medical 
practitioner prior to the study, and all participants provided written informed consent. This study 
was approved by the Lincoln University Human Ethics Committee. 
Table 25: Anthropometric data for participants 
 Participant data 
Total n (M/F) 21 (6 M / 15 F) 
Age (years) 54.7  5.4 
Height (cm) 167.5  8.4 
Weight (kg) 80.9  11.9 
BMI (average) 29.0  4.7 
Body fat (%) 34.9  8.9 
SBP (mm Hg) 121.1  11.9 
DBP (mm Hg) 71.8  7.0 
Resting HR (beats·min-1) 64.4  9.2 
HRmax (beats·min
-1) 166.0  12.7 
O2peak (ml·min
-1·kg-1) 28.1  6.0 
AIx (%) 24.2  8.9 
Values are mean ± SD. Total n: final number of males and females included in the study, BMI: body 
mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; Resting HR: heart rate taken 
during 16 min of rest; HRmax: Average heart rate over last 30 seconds of maximal exertion; V˙ O2peak: 
peak oxygen consumption during maximal exertion; AIx: augmentation index normalised to a heart 
rate of 75 beats·min-1 
 
Protocol. 
Participants attended two sessions. The first session included the collection of anthropometric and 
arterial stiffness data and was conducted in a quiet, temperature controlled room (18 - 25°C). 
Anthropometric data included body composition, height, total mass, body fat percentage 
(InBody230, Biospace Co. Ltd., Seoul, South Korea) and body mass index (BMI). Blood pressure was 
recorded using an automated machine (Omron, HEM-907XL, Matsuzaka City, Japan) following 20 
minutes of supine rest. The average of two recordings was used, with a third measure taken if 
readings differed by >5 mmHg. In this case the average of the closest two readings was used. 
Session two was completed within one week of session one, and included assessments of peak 
oxygen uptake (using a metabolic cart) and skeletal muscle oxygen uptake (using near infrared 
spectroscopy) during a maximal treadmill protocol. Participants were asked to refrain from caffeine 
or alcohol for 12 hours, and eating for 4 hours prior to the assessment. 
 
 
V˙  
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Augmentation Index.  
Pulse wave analysis (SphygmoCor, AtCor Medical, Sydney, Australia) was used to measure the 
augmentation index (AIx) as an assessment of systemic arterial stiffness (Oliver and Webb, 2003, 
Mackenzie et al., 2002). All measurements were taken on the radial artery with a tonometer 
following 20 minutes of undisturbed supine rest (Stoner et al., 2013). The AIx is the augmentation 
pressure (maximum systolic peak of the pulse wave minus the pressure at the inflection point) 
expressed as a percentage of the central pulse pressure (Laurent et al., 2007) and was derived using 
the integrated software (SCOR Px 7.1, AtCor Medical, Sydney, Australia). As AIx is influenced by heart 
rate (Wilkinson et al., 2000) all AIx data were normalised to a heart rate of 75 beats per minute 
(AIx@75) prior to analysis. Two recordings were taken; if AIx differed by 4% between the two 
recordings a third recording was taken, and the average of the closest two measurements was used. 
Recordings were assessed for quality and were only considered acceptable if they were within the 
default setting specifications (average pulse height: 80 units, Pulse height variation: 5 %, Diastolic 
variation: 5 %, and quality index: >80 %). 
Peak Oxygen Uptake.  
After being fitted with the required equipment, participants rested for 16 minutes while baseline 
oxygen uptake and muscle oxygenation were recorded. Following the rest period, participants 
transferred to the treadmill (Rodby™, RL 1600E, Enhorna, Sweden) for the fitness assessment. 
Maximal oxygen uptake assessments were conducted using a Modified Bruce Protocol (MBP). Two 
stages were added to the beginning of the standard Bruce protocol to cater for older or less fit 
individuals (the third stage corresponded to the first stage of the standard Bruce Protocol). The 
workload was increased every three minutes either by increasing the gradient and/or the speed of 
the treadmill until maximal exertion. 
Breath by breath analysis was used to determine maximal oxygen consumption (MetaMax® 3B; 
Cortex Biophysik, Leipzig, Germany); and was calibrated for volume and gas composition (15% O2 and 
5% CO2) prior to all testing sessions. Expired breath was directed to the volume and gas analyses 
through a leak-free face mask (Hans Rudolph, Kansas City, MO, USA) with small dead space 
(approximately 70 mL) that minimised restriction to breath via the nose or mouth. A heart rate (HR) 
monitor (RS800CX, Polar Electro Oy, Finland) and belt (Wearlink W.I.N.D, Polar Electro Oy, Finland) 
were used to record HR and determine maximal HR (HRmax). The test was stopped if there were any 
exercise-related contra-indications as outlined by the American College of Sport Medicine guidelines 
(Thompson et al., 2010). Maximal exertion was achieved when the participant met one of the 
following criteria: HR >90% of age-predicted HRmax (220 – age); respiratory exchange ratio of > 1.15; 
or a rating of perceived exertion of 19 or 20 on the Borg Scale (Borg, 1982). Participants then walked 
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at a low intensity for 5 minutes to warm down. All data were collected and exported to an excel 
spreadsheet for analysis. The average of the last 30 seconds of the respective datasets associated 
with the maximal assessment was used to determine V˙ O2peak and HRmax. 
Total Oxygenation Index.  
To measure skeletal muscle oxygen uptake, we monitored the change in the total oxygenation index 
(TOI) in the flexor carpi ulnaris of the forearm and in the vastus lateralis of the thigh. The 
participant’s skin was prepared for the NIRS assessment by removing any excess hair, exfoliating and 
sterilizing the probe sites. A set of NIRS probes consisting of a light emitting laser diode, and a light 
detecting photodiode were then placed over the belly of the participant’s flexor carpi ulnaris (5 cm 
distal from the lateral epicondyle), and vastus lateralis (6 cm proximal of the midway point between 
the lateral condyle and the lateral border of the patella), following the line of the muscle fibres. All 
NIRS measurements were conducted using a commercially available NIRS system (NIRO-200; 
Hamamatsu Photonics KK; Hamamatsu, Japan). The emitting laser diode and the light detecting 
photodiode were 5 cm apart to ensure adequate penetration in to skeletal muscle (Yoxall and 
Weindling, 1997) and were housed in a black casing and covered with tape to minimize extraneous 
light (Lucas et al., 2012). The NIRO-200 uses a modified Beer-Lambert method and spatially resolved 
spectroscopy to calculate changes in oxy- and deoxygenated haemoglobin (oxy-Hb and Hb 
respectively), and total haemoglobin from the light attenuation at three different wavelengths 
(Hamamatsu Photonics K.K., 2005, Boushel et al., 2001, Lucas et al., 2012) in real time (see Figure 
32). The TOI is determined as follows: TOI % = oxy-Hb/t-Hb x 100 (Lucas et al., 2012). 
To assess the TOI during rest and exercise, either 30-second or 5-second bins were used (refer to 
Figure 32). The average of two 30-second intervals at rest in a supine position was taken (after 10 
minutes and 16 minutes supine rest, respectively) to assess inactive, resting tissue TOI. During 
exercise, 30-second intervals were used during steady state conditions (the first 3 stages of the 
Modified Bruce Protocol, and 2 and 5 minutes into the recovery following maximal exertion), or 
where there was a large amount of noise in the signal (during the 4 consecutive 30-second 
recordings in the 2 minutes immediately before maximal exertion). Five-second intervals were used 
to elicit the TOI at peak exercise, and then the last 5 seconds every 10 seconds for the first minute of 
recovery.  
Near infrared spectroscopy is better suited to monitoring a change rather than the absolute value of 
the chromophores (Yoxall and Weindling, 1997). In addition to this, because irrelevant, but 
unavoidable physiological differences, such as the thickness of the adipose tissue (McCully and 
Hamaoka, 2000), have a profound effect on the NIRS measurement, data were normalised to a 
change score (TOIdiff) from a baseline value rather than using an absolute TOI value. The participant’s 
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TOI during the last 30 seconds of the first stage of the Modified Bruce protocol was used as the 
baseline exercising reference as the signal position of the NIRS probe can shift and therefore alter the 
measurement as participants change position (McCully and Hamaoka, 2000)  such as from supine 
rest to treadmill walking. To determine TOIdiff, the percentage drop in the TOI between the last 30 
seconds of the first stage of the Modified Bruce Protocol and the 5-second maximal exertion 
recording between the forearm and thigh was determined for each participant.  The arm TOIdiff and 
the leg TOIdiff were independently correlated with AIx and V
˙ O2peak. In addition to this, as both the        
V˙ O2peak and AIx are ‘whole body’ measures, the average of the forearm and thigh TOIdiff were used as 
an estimate of the systemic change in TOI. 
 
Figure 32: Continual measurement of total oxygenation index in the forearm and thigh of a 
participant 
 
Statistical analyses.  
Pearson product-moment correlation coefficients were used to assess the relationship between 
TOIdiff, V
˙ O2peak and arterial stiffness (AIx), and AIx and TOIdiff. As BMI, age, heart rate and height have 
demonstrated strong relationships with AIx (Binder et al., 2006), an additional partial correlation 
controlling for these variables was also conducted. Results are recorded as the r score  90% 
confidence interval. A correlation of r > 0.50 was considered strong; the correlation was considered 
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‘moderate’ if 0.5 > r  > 0.3, and weak if r < 0.3 (Hopkins, 2000a). Correlations were analyses using SAS 
9.3 software (SAS Institute, Cary, North Carolina, USA). 
The change in the TOI in the arm and the leg during Stage 1 (S1: last 30 seconds) and at maximal 
exertion (M: 5 seconds at maximal exertion) of the Modified Bruce Protocol, and at minutes 2 and 5 
of the recovery period (R2 and R5, 30 seconds respectively) was also measured (see Figure 33). The 
differences in these time points were converted to their natural logarithms to avoid any effects of 
non-uniformity of error, and were then assessed using magnitude based inferences (Hopkins, 2006, 
Hopkins, 2007, Batterham and Hopkins, 2006). The likely range of the change in the true value 
(expressed as the 90% confidence interval) between time points (S1 – M; S1 – R2; S1 – R5) were 
measured against the smallest meaningful change using Cohen’s standardised units (change in mean 
divided by 0.2 of the between subject SD at baseline) (Cohen, 1988). The descriptors: increased, 
trivial or decreased were used to describe the direction of the change. Where the confidence interval 
spanned all three possibilities (increased, trivial and decreased), the result was deemed unclear. In all 
other cases, such as no overlap, or an overlap between 2 possibilities (trivial and increased, or trivial 
and decreased) a clear result was achieved. Finally, the magnitude or probability of the change was 
assessed using a qualitative scale defined as:  < 0.5 %: almost certainly not; < 5 %: very unlikely; < 25 
%: unlikely/probably not; 25 – 75 %: possibly, possibly not; > 75 %: likely, probably; > 95 %: very 
likely; and > 99.5 %: almost certainly. 
Results are expressed using the percentage change (from the natural logarithm) ± 90 % confidence 
limit, the % chance the variable has increased / is trivial / has decreased followed by the qualitative 
outcome.   
G.4 RESULTS 
Participant characteristics are summarised in Table 25.  
Arm and leg oxygenation during exercise.  
The TOI decreased substantially between stage 1 (S1) and maximal exertion of the MBP in both the 
arm (-22.8%; CL: -30.5 to -14.2%, 0 / 0 / 100, most likely decreased) and the leg (-14.0%; CL: -22.1 to -
5.2%, 0 / 4 / 96, very likely decreased, Figure 33). In the arm, there was a slight increase in the TOI at 
2 min (R2) and 5 min (R5) into the recovery compared to S1 (arm R2: 4.5%, CL: 1.2 to 7.9%, 26 / 74 / 0, 
possibly increased; R5: 6.4%, CL: 3.0 to 10.0%, 64 / 36 / 0, possibly increased). However, there was 
little difference in the TOI in the leg at S1 compared to R2 (leg: 3.7%, CL: 1.0 to 6.4%, 20 / 80 / 0, likely 
trivial) and R5 (leg: 3.0%, CL: -0.2 to 6.2%, 14 / 86 / 0, likely trivial, see Figure 33). 
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Figure 33: Total oxygenation index of the arm and the leg during rest, exercise and recovery 
 
Correlations between AIx, O2peak, and TOIdiff.  
The arm and leg TOIdiff were both independently correlated to AIx and V
˙ O2peak (See Table 26). 
However, average (arm + leg) TOIdiff demonstrated an even stronger correlation with AIx and O2peak 
(See Table 26, Figure 34A and Figure 35). The AIx was moderately correlated to V˙ O2peak (r = -0.34; CL: -
0.63 to 0.03; see Figure 34B).  
Table 26: Independent arm and leg correlations with VO2peak and AIx 
Correlation between r 90% Confidence  
Limits  
Qualitative  
Outcome 
O2peak and    
Arm TOIdiff 0.41  0.05 – 0.68 Moderate 
Leg TOIdiff 0.41 0.05 – 0.68 Moderate 
Average (Arm + Leg) TOIdiff  0.55 0.23 – 0.77 Strong 
    
AIx and    
Arm TOIdiff -0.38 -0.66 – -0.02 Weak/moderate 
Leg TOIdiff -0.49 -0.73 – -0.15 Moderate/strong 
Average (Arm + Leg) TOIdiff  -0.58 -0.78 – -0.27 Strong 
Qualitative outcome was assessed as: r>0.5: strong, 0.5>r>0.3: Moderate; r<0.3: weak;  
O2peak was measured over the last 30 seconds of maximal exertion (using a Modified Bruce 
Protocol), TOIdiff: change in total oxygenation index between stage 1 of the Modified Bruce Protocol 
and maximal exertion, measured in the flexor Carpi ulnaris (Arm TOIdiff) and vastus lateratis (Leg 
TOIdiff) independently and averaged over both sites (Average (Arm + Leg) TOIdiff); AIx: Augmentation 
index normalised to a heart rate of 75 beats·min-1 
 
V˙  
V˙  
V˙  
V˙  
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Figure 34: Correlations between (A) AIx and  V˙ O2peak and (B) AIx and average (arm + leg) TOIdiff 
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Figure 35: Correlation between the average (arm and leg) decrease in total oxygenation index 
(TOIdiff) and peak oxygen consumption (V˙ O2peak) 
 
Accounting for BMI, age, resting HR and height in the analysis slightly weakened the correlation 
between average (arm + leg) TOIdiff and V
˙ O2peak from a strong to a moderate relationship (r = 0.40, CL: 
0.04 to 0.67), while the correlation between average (arm + leg) TOIdiff and AIx became stronger (r = -
0.63, CL: -0.81 to -0.34) after controlling for these variables. The correlation between AIx and V˙ O2peak 
remained similar to the unadjusted correlation (r = -0.31, CL: -0.61 to 0.07).  
G.5 DISCUSSION 
While several authors have examined the relationship between arterial stiffness and peak oxygen 
consumption, to our knowledge, this is the first study that has investigated the relationship between 
arterial stiffness, muscle oxygen uptake, and peak oxygen consumption (V˙ O2peak). Our results support 
those of previous studies which have found a negative correlation between arterial health and           
V˙ O2peak (Binder et al., 2006, Tanaka et al., 1998, Vaitkevicius et al., 1993). The novel finding in this 
study was that arterial health also appears to play an important role in the extent to which oxygen 
dissociates from haemoglobin, and thereby may be an important determinant in the uptake of 
oxygen by the skeletal muscle in a sedentary, middle-aged, but otherwise healthy population.  
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V˙ O2peak and AIx.  
The results of our study support the findings of Vaitkevicius et al. (1993), Tanaka et al. (1998) and 
Binder et al. (2006), who all found an inverse relationship between the AIx and V˙ O2peak  in sedentary, 
middle-aged individuals (Binder et al., 2006, Tanaka et al., 1998, Vaitkevicius et al., 1993). The 
moderate correlation between AIx and V˙ O2peak in our study (r = -0.34)  was somewhat lower than the 
strong correlation reported by Vaitkevicius et al. (1993) who reported r = -0.54 for men and r = - 0.74 
for women. The participants in the Vaitkevicius et al. (1993) study, although sedentary and of a 
similar age to the participants in this study, were screened for any forms of cardiovascular disease or 
severe hypertension (blood pressure >160/95), and none of the participants were on any 
cardiovascular medication. Likewise, Tanaka et al. (1998) demonstrated a strong correlation between 
carotid AIx and V˙ O2peak of   r = -0.53 in their cohort of (combined) active and sedentary middle-aged 
women. Similar to Vaitkevicius and colleagues’ study, the participants in the Tanaka et al. (1998) 
study were free of any overt cardiovascular disease, and aside from hormone replacement, did not 
take any regular medications. We suspect that the lower correlation in our study could be due to a 
possibly more heterogeneous cohort. By increasing participant diversity, factors in addition to 
vascular function may be responsible for limiting the physiological capacity to deliver, take up and 
use oxygen. In this regard, our population was more like the sample of Binder et al.(2006), which 
consisted of sedentary middle-aged men and included participants who smoked, were hypertensive 
and who were on medications such as statins, insulin and oral hypoglycaemic agents (2006). While 
none of our participants were smokers or had uncontrolled medical conditions, we did not exclude 
participants who were on hypertension or cardiovascular-related medication. Following adjustment 
for age, heart rate, height and body mass index, Binder et al (2006) reported a correlation of r = -0.22 
between AIx and V˙ O2peak. The correlation in our study and the health profiles of our participants fit 
between the healthier groups tested by Vaikevicius et al. (1993) and Tanaka et al (1998) and the 
more diseased participants tested by Binder et al. (2006).  
It is possible that the site of the AIx measurement could have played a role in the sensitivity of the 
relationship between AIx and V˙ O2peak. That is, both Vaitkevicius et al (1993) and Tanaka et al. (1998) 
used the carotid artery as the measurement site for AIx, while the present study and that of Binder et 
al. (2006) measured AIx at the radial artery. The radial site requires use of generalized transfer 
function to estimate the pressure waveform at the level of the aorta, while the carotid artery is 
closer to the aorta and does not require a transfer function (Laurent et al., 2006). However, the 
technical differences between the sites are unlikely to explain the lower correlation in our study as 
the AIx at each of these sites has been previously reported to infer similar information (Sugawara et 
al., 2007, Sugawara et al., 2008).  
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While the nature of a correlation study does not lend itself to causality, the ability of the arterial 
system to dilate and facilitate blood flow to skeletal muscle is likely to be related to oxygen uptake 
(Vaitkevicius et al., 1993). Accordingly, as the arteries stiffen the ability of the blood vessels to deliver 
oxygen to working skeletal muscle becomes impaired, which would contribute to the V˙ O2peak decline  
TOI and AIx.  
In the current study, TOIdiff was used to indicate the oxygen taken up by the musculature (change in 
TOI between light and maximal exercise). A strong negative relationship was found between AIx and 
TOIdiff. Additionally, both the arm and the leg independently demonstrated negative correlations 
between AIx and TOIdiff. The strength of the correlation between AIx and TOIdiff became progressively 
stronger as the included musculature increased. That is, the correlation between the AIx and arm 
TOIdiff was weaker than the correlation between AIx and leg TOIdiff, both of which were weaker than 
the correlation between the AIx and the average (arm + leg) TOIdiff.  
In older adults, there is progressive stiffening of the central arteries, while the peripheral arteries 
remain relatively stable (Mitchell et al., 2004, Safar et al., 2003). The increased central stiffness as 
compared to the peripheral vasculature results in later reflection sites, and more of the pulsatile 
energy of the forward wave being transferred to the microcirculatory vessels, potentially damaging 
these structures (Mitchell et al., 2004, Mitchell, 2008). This disruption to the microvascular structure 
and/or function appears to occur independently of traditional cardiovascular risk factors (Mitchell et 
al., 2005) and therefore may have already been present in our sedentary but otherwise healthy 
population. While skeletal muscle tissue may be less sensitive to the pulsatile energy increases 
(Mitchell, 2008), the minor microcirculatory damage may be sufficient enough to reduce oxygen 
uptake. That is, the conduit arteries may be able to deliver oxygenated blood to the active skeletal 
muscle, but damage to the microvasculature may impede the process of diffusion from the capillary 
to the site of the skeletal muscle cells, thereby limiting oxygen diffusion and aerobic metabolism.  
Alternatively, the correlation between AIx and TOIdiff could be a spurious relationship. That is, both 
the decline in the magnitude of the TOIdiff, and apparently associated increased AIx could be caused 
by a third variable such as physical (in)activity. For example, the absence of regular physical activity 
in our participants could have resulted in a decline in the oxidative properties of the mitochondria 
(2001, Layec et al., 2012), which would result in a reduced capacity to utilize oxygen. Therefore, while 
increased arterial stiffness and decreased mitochondrial function are both manifestations of a 
sedentary lifestyle, it may be that mitochondrial function, not arterial stiffness is explaining impaired 
V˙ O2peak. 
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TOI and V˙ O2peak.  
There was a strong positive correlation between the average (arm + leg) TOIdiff and V
˙ O2peak, (this 
correlation was ‘moderate’ and identical in the arm and leg independently) which indicates that the 
capacity of the muscle to take up and use oxygen (a-vO2diff) is an important determinant of V
˙ O2peak. 
Interestingly, the contribution of the average TOIdiff to the V
˙ O2peak in our study (r
2 = 0.30)  is similar to 
the estimation by di Pampero (2003) that 25 – 30 % of the V˙ O2peak  is attributable to the muscle and 
mitochondrial ‘resistors’ to oxygen diffusion (di Prampero, 2003).  
Most of the oxygen desaturation (TOIdiff) is due to the decrease in capillary and venous 
oxyhaemoglobin (Belardinelli et al., 1995). With continuous exercise above the lactic acid threshold, 
increases in H+ (increased PCO2 from aerobic metabolism and the bicarbonate ion buffering of lactic 
acid) and consumption of bicarbonate ions (increased lactic acid) lowers the pH and shifts the 
oxyhaemoglobin dissociation curve to the right (Stringer et al., 1994). In addition, an increase in 
muscle temperature during heavy exercise also acts to promote oxygen dissociation from 
haemoglobin (Severinghaus, 1966), however the effect of temperature on the oxyhaemoglobin 
dissociation curve is comparatively small compared to the decrease in pH (Stringer et al., 1994). As 
NIRS measures the change in absorption by chromophores rather than the oxygen molecules per se 
(Yoxall and Weindling, 1997), this results in a lower TOI. Therefore, it would be expected that 
participants with a greater lactate tolerance (and therefore lower pH at maximal exertion) would also 
demonstrate lower TOIdiff. 
TOI during rest and exercise.  
There were considerable differences between the TOI measured in the forearm and in the leg (see 
Figure 33) whereby the arm demonstrated lower TOI throughout the measurement period when 
compared to the leg. During whole body exercise, particularly where the legs provide the primary 
musculature activity, sympathetically-mediated vasoconstrictor signals act to oppose the metabolic 
vasodilatory stimuli in the arms and prioritise blood flow to the legs (Calbet et al., 2007). This 
enhanced vasoconstrictor response results in reduced vascular conductance in the arms and forces 
maximal oxygen uptake in the available blood (Calbet et al., 2007). As the TOI reflects the proportion 
of oxyhaemoglobin in the blood, rather than the absolute volume of oxygen taken up by the 
musculature, this vascular restriction may account for the considerably lower TOI in the arms 
compared to the legs during exercise. In addition, reduced vascular conductance as reported in other 
studies (Calbet et al., 2007, Volianitis and Secher, 2002) likely impeded lactate clearance in the arms, 
further reducing local pH and facilitation of oxygen dissociation from haemoglobin (Volianitis and 
Secher, 2002). 
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During recovery the TOI in the arms increased to beyond the recorded levels during light exercise, 
while the legs returned to a slightly elevated (but only trivially) TOI. The reversal of the 
sympathetically mediated vasoconstriction in the arms at the end of maximal exercise, and return of 
the metabolically driven local vasodilation may account for this enhanced recovery in the arms 
compared to the legs.  
Limitations.  
The small sample size of the current population (n = 21) increases the risk of Type 1errors whereby a 
trivial or meaningless relationship is assessed as significant. To this end, further research is needed to 
validate and further explore the relationships between arterial health, oxygen uptake and V˙ O2peak in a 
sedentary population. As our sample was inclusive of a wide age range of heterogeneous participants 
(i.e. we did not exclude based on ongoing medication) we also increase the chance of any change, or 
correlation being attributed to a spurious variable. However, as our findings are consistent with 
those of others (Binder et al., 2006, Vlachopoulos and O'Rourke, 2000) these results are likely to be 
reliable.  
In this study, we used the TOI to estimate oxygen uptake and utilisation. There are several limitations 
with the conclusions we can draw from this assumption, for example, as the TOI represents a ratio 
between oxyhaemoglobin and total haemoglobin, we cannot make any inferences regarding the 
volume of blood flow of the volume of oxygen dissociated from haemoglobin. By using the average of 
arm and leg TOI we likely reduced the impact of volume discrepancies in the arm and leg, however 
more research specifically examining the relationship between arterial health and blood flow, blood 
volume and changes in oxy haemoglobin volumes is needed to explain our preliminary findings.  
Finally, this is a cross-sectional study which does not lend itself to causal conclusions and caution 
must be used when interpreting the data, as such, further research is needed to establish these 
causations via longitudinal and/or intervention-based studies. 
G.6 CONCLUSIONS 
The ability to monitor oxygen saturation continuously during exercise offers a unique opportunity to 
observe the oxidative demand of skeletal muscle tissue. We observed a strong relationship between 
the augmentation index and the average percentage decrease in total oxygenation index, indicating 
that arterial health may have an important role in the uptake of oxygen by working skeletal muscle. 
Arterial health was also negatively related to the V˙ O2peak. However, this relationship was not as 
strong. Oxygen uptake at the muscle appears to be an important determinant for V˙ O2peak, the 
contribution of which is similar to di Pampero’s estimation of 30 % (di Prampero, 2003). Further 
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research should determine the relative contributions of global arterial health, microvascular supply 
and mitochondrial capacity to V˙ O2peak in this cohort. 
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